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Human Immunodeficiency Virus (HIV) is the causative agent of AIDS, a disease which 
affects over 24 million people globally and for which there is neither curative treatment 
nor vaccine available. As an intracellular pathogen that encodes only 15 proteins HIV-1 
is highly dependent upon its host's cellular machinery in order to complete its life cycle. 
Host-directed therapy thus represents a potentially lucrative strategy for the 
development of novel anti-HIV therapies. microRNAs (miRNAs) are short noncoding 
RNA molecules that function as part of the endogenous RNA interference system which 
governs post transcriptional gene regulation. Current knowledge has placed miRNAs at 
the crux of HIV-host interactions, yet the functional relevance of the majority of the 
human miRNAome with regards to HIV replication has remained unknown. A 
microscopy-based high content screening (HCS) approach was thus developed to 
systematically evaluate the significance of augmenting or inhibiting the function of 
individual host miRNAs on the replication dynamics of HIV. A bespoke image analysis 
and data mining pipeline recovered 56 host miRNAs associated with suppressed HIV 
replication and 28 host miRNAs associated with enhanced HIV replication. Notably, the 
HIV-modulating potential of 80 of these miRNAs was previously unknown. Furthermore, 
HCS  also uncovered a novel role for the miR-200 family in the modulation of HIV 
replication.  In silico miRNA target identification and pathway enrichment analysis 
identified 24 pathways associated exclusively with suppressed HIV replication, 10 
pathways associated exclusively with enhanced HIV replication and 38 functional 
pathways enriched for both enhanced and suppressed viral replication. These included a 
number of pathways previously implicated in HIV replication such as the PI3K, MAPK, 
TNF and WNT signalling pathways but also revealed novel functional associations 
including that of the Hippo signalling pathway. Intriguingly pathway analysis revealed an 
enrichment for host factors associated with viral carcinogenesis and a convergence on 
host processes and functional targets classically associated with chemotherapy 
including host DNA damage repair, cell cycle and tyrosine kinase receptor-mediated 
signalling. Experimental validation confirmed that HIV replication induced an aberrant 
cell survival phenotype in response to chemically induced DNA damage but this effect 
was reversed when DNA damage was induced prior to HIV exposure. A series of 
compound-based validation screens were thus undertaken in order to verify the 
functional associations recovered by miRNA screening. A targeted collection of 293 
small molecule inhibitors, including a number of FDA-approved chemotherapeutics, were 
screened for HIV modulating activity. Novel anti-HIV activity was recovered for over 40 
compounds including a number of FDA-approved therapies. Compound-target 
enrichment analysis revealed a strong concordance with functional associations initially 
described by miRNA-based HCS including EGFR-mediated signalling and DNA damage 
repair. Concordant HIV-suppressive activity was also recovered for miRNAs and 
compounds with common functional targets. The outcomes of this study thus represent a 
significant and novel contribution to current knowledge on HIV-host interactions. 
Furthermore, these findings have characterised novel miRNA and small molecule 
candidates for the treatment of HIV and have successfully demonstrated the utility of 
miRNA-based HCS for novel-drug discovery and drug repositioning. 
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Chapter 1: Introduction  
 
1.1 HIV/AIDS : A brief history and current epidemiology 
 
Acquired immunodeficiency syndrome (AIDS) is a disease characterised by the 
depletion of a specific subset of immune cells which express the cell surface cluster 
differentiation 4 (CD4) receptor. The consequence of CD4+ cell depletion is a diminished 
immune system, which renders afflicted individuals highly susceptible to opportunistic 
infections and various forms of cancer (Gottlieb, 1981; Engels, 2006). The first 
documented case of AIDS was reported in 1981 when a number of homosexual men in 
the United States of America (USA) presented with cases of Kaposi’s Sarcoma and 
pneumonia, which had previously only been seen in individuals with severely impaired 
immune systems (CDC, 1981; Gottlieb, 1981). In 1982 AIDS was recognised as an 
infectious disease which is transmitted by bodily fluids including blood, and by 1983 the 
first cases of hetereosexual transmission of AIDS were recorded by the CDC (CDC, 
1982 and 1983). A French research group at Institut Pasteur, led by Luc Montagnier, 
was the first to isolate a novel retrovirus from an at-risk AIDS patient, while a separate 
group led by Robert Gallo became the first to demonstrate that this retrovirus was in fact 
the causative agent of AIDS (Barre-Sinoussi, 1983; Gallo, 1984). Three years after it 
was first identified, this virus became known as the Human Immunodeficiency Virus 
(HIV; Coffin, 1986). 
 
Since its discovery HIV/AIDS has become one of the most significant infectious 
pandemics in human history, inflicting a devastating effect on global health (UNAIDS, 
2014). The Joint United Nations programme on HIV and AIDS (UNAIDS) was piloted in 
1996 in response to the global pandemic, and its findings reported an estimated 22.6 
million infections worldwide and 6.4 million estimated AIDS related mortalities since the 
onset of the pandemic (UNAIDS, 1996).  By 2006 the number of HIV/AIDS related 
mortalities had risen to ~25 million with an estimated 40 million infected individuals 
globally (UNAIDS, 2006). The latest global UNAIDS report revealed that as of December 
2013, there were an estimated 35 million infected individuals worldwide, 24.7 million of 
which were accounted for by the Sub-Saharan Africa region (UNAIDS, 2014). There 
were also 2.1 million new infections in 2013, 70% of which were recorded in Sub-
Saharan Africa (UNAIDS, 2014; WHO, 2014). HIV/AIDS is now estimated to have 
resulted in 39 million deaths since 1981, with 1.5 million deaths recorded in 2013 alone 
(WHO, 2014). Strikingly only 38% of the infected adults and only 24% of infected 
children worldwide had access to life saving antiretrovirals (ARVs) in 2013 (UNAIDS, 
2014). More than 30 years since it was first discovered, HIV remains a globally relevant 
health issue, especially in Sub-Saharan Africa. Despite the success of ARV therapies in 
prolonging the lifespan of afflicted individuals, HIV infection remains a disease for which 
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there is still no cure and only limited availability of treatment, especially in countries that 
carry the majority of the global HIV/AIDS burden.  
 
1.2 HIV origins and diversity  
 
 
HIV has evolved from multiple zoonotic transfer events of Simian Immunodeficiency 
Virus (SIV) from non-human African primates to humans (Santiago, 2005; Keele, 2006; 
D’arc, 2015). These distinct transmission events, along with the high mutation rate 
associated with HIV replication, have given rise to the vast genetic heterogeneity that 
belies the name “HIV” (Figure 1.1.). Firstly, there are two different strains of HIV: HIV-1 
and HIV-2. Despite possessing a similar genetic structure, these strains have been 
demonstrated to exhibit up to 45% variability in their nucleotide sequences, and up to 
65% variability in their amino acid sequences (Motomura, 2007). HIV-2 originated from 
the cross-species transfer of SIV from Sooty Mangabeys (Cercocebus atys) to humans, 
and was first described in West African individuals afflicted with AIDS in the mid 1980s 
(Clavel, 1986; Santiago, 2005). HIV-2 infections are principally confined within West 
Africa and are associated with inferior rates of virulence and transmission compared to 
HIV-1 (Pepin, 1991; Kanki, 1994; Marlink, 1994; Marchant, 2006). The origin of HIV-1 
has been traced to distinct zoonotic transmission events between chimpanzees (Pan 
troglodytes) or gorillas (Gorilla gorilla) and humans, thus resulting in broad heterogeneity 
within the HIV-1 classification (Keele, 2006; D’arc, 2015). HIV-1 can be divided into 4 
phylogenetically distinct groups M, N, O, and P. While groups N, P and O infections are 
generally rare or endemic, group M viruses are recognised as the main protagonists of 
the global AIDS pandemic (Leys, 1990; Mauclère, 1997; Simon, 1998; Plantier, 2008; 
Vallari, 2011; Sharp, 2011). HIV-1 group M viruses can be further differentiated into 
subtypes A-K and circulating recombinant forms (CRFs) based on variations in the 
nucleotide sequences encoding the viral envelope protein (env) and(or) other regions of 
the viral genome (Hemelaar, 2004). In addition to geographically distinct distribution 
patterns, these HIV-1 group M subtypes have also been linked to variable rates of 
disease progression and varied responses to antiretroviral therapy, suggesting that the 
genetic variability within HIV-1 viruses may contribute to variations in the molecular 
pathology of HIV infection (Kanki, 1999). For the purpose of this thesis all future 




Figure 1.1. Phylogenetic diversity of HIV.  
HIV is comprised of two genetically distinct strains: HIV-1 and HIV-2. These strains originated 
from distinct zoonotic transfer events traced to Chimpanzees (Pan troglodytes) and Gorillas 
(Gorilla gorilla) for HIV-1 and Sootey mangabeys (Cercocebus atys) for HIV-2. HIV-1 is the most 
widespread strain and can be divided into 4 phylogenetically distinct groups (M, N, O, P). Group 
M viruses are responsible for the global HIV pandemic and these can be further divided into 
genetically distinct subtypes (A-J) and circulating recombinant forms (CRFs).  
 
1.3 Natural history of infection  
 
A single HIV-infected CD4+ T cell is estimated to be capable of producing 5 x 104 virions 
per day with a half life of ~1.6 days (Perelson, 1996; De Boer, 2010). A single infection 
event is thus sufficient to catalyse a graduated de-regulation of the host immune 
response, which is characteristic of HIV pathogenesis (Coffin, 2013). The eclipse phase 
occurs within the first 2 weeks of infection, and is characterised by asymptomatic 
replication and dissemination of the virus within specific lymphoid tissues, thus 
establishing stable reservoirs of infection (Coffin, 2013). The next phase, the acute 
phase, generally occurs 2-4 weeks following initial infection and is characterised by a 
peak in viral replication and a corresponding depletion of the circulating CD4+ T cell 
population (Little, 1999). Additionally, patients may exhibit flu-like symptoms,  consistent 
HIV-1 HIV-2 
Gorilla gorilla Cercocebus atys 
A RFs 
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with the production of antibodies against HIV proteins (seroconversion), and mobilisation 
of CD4+ T cell populations that facilitate further spread of the virus (Gurunathan, 2009). 
Viral infection next progresses into a chronic phase of variable length  (~10 years) and is 
preceded by a sharp decline in viral load and partial recovery of the CD4+ T cell 
population (Coffin, 1995; Coffin, 2013). During this phase, a set point of viral load is 
established along with a balance between restricted viral replication and gradual CD4+ T 
cell decline, which is maintained by a functional host immune system (Pantaleo, 1993; 
Coffin, 2013).   
 
Rapid depletion of CD4+ T cells to levels below ~200 cells per cubic millimeter (mm3) of 
blood, and subsequent failure of the host immune system characterise this final stage 
and progression to an AIDS phenotype. Intriguingly, while the HIV replication cycle itself 
ultimately results in the death of productively infected cells, massive depletion of the 
global CD4+ T cell population is largely attributed to non-productive infection events 
within bystander cells (Finkel, 1995; Doitsh, 2014; Monroe, 2014).  In response to the 
rapid CD4+ T cell decline, steady production of new virus is predominantly supported by 
productively infected macrophage populations, which are comparatively long lived 
(Coffin, 2013). During this stage, unrestricted viral replication and CD4+ T cell decline 
lead to immunodeficiency rendering the afflicted individual highly susceptible to 
opportunistic infections that result in mortality in the absence of ARV intervention (Coffin, 
2013).   
 
1.4 HIV genome and structure 
 
The complete sequence of the HIV-1 genome was first described in 1985 and contains a 
long terminal repeat region preceding 9 open reading frames (ORFs) that encode 15 
viral proteins (Ratner, 1985; Wain-Hobson, 1985). The viral genes env, pol and gag 
encode proteins that undergo a post-translational cleavage process to produce shorter 
functional products, while the remaining genes encode the accessory proteins Nef, Rev, 
Tat, Vif, Vpr and Vpu (Figure 1.2.). Cleavage of the env-derived polyprotein (gp160) 
gives rise to gp41 and gp120 proteins (McKeating, 1989). The protein product of pol 
produces the viral enzymatic proteins integrase (IN), reverse transcriptase (RT) and 
protease (PR), which are three of the major targets of current ARVs (Jacks, 1988). Gag-
derived polyprotein cleavage results in the production of capsid-associated structural 
proteins p24 (CA), p17 (MA), p7 (NC) and p6 (Göttlinger, 1989). Two copies of the 
single-stranded, positive sense RNA genome, along with selected viral proteins, are 
encapsulated within a conical inner core (CA), which lies within a protein matrix (MA) 
surrounded by an outer coat consisting of host cell-derived plasma membrane and viral 
proteins gp120 and gp41 (Figure 1.3.). The inner viral core is estimated to be roughly 
119 x 60 nm in size while the complete mature virion is reported to have an average 
diameter of 145 nm with projections extending ~7.5 nm from the surface of the outer 
membrane (Briggs, 2003). These outer projections consist of trimeric gp120 molecules 
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anchored by transmembrane gp41 heterodimers and constitute the effector molecule of 
the receptor-mediated entry step in the replication cycle of HIV-1 (McKeating, 1989; 





Figure 1.2. Structure of the HIV genome.  
The HIV genome is roughly 9.7 Kb in length and contains 9 genes encoding 15 proteins, flanked 
on either end by a long terminal repeat sequence (LTR). The gag, pol and env genes encode 
polyproteins that undergo enzymatic cleavage to produce the structural elements  p17 (MA), p24 
(CA), p7 (NC), p6; the viral enzymes Protease (PR), Reverse transcriptase (RT) and Integrase as 
well the envelope proteins gp120 and gp41. The HIV genome also encodes 2 regulatory proteins, 
Tat and Rev as well as the accessory proteins Nef, Vif, Vpr and Vpu. 
 
LTR gag vif LTR 
pol 
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Figure 1.3. Structure of a mature HIV virion. 
The HIV virion is ~145 nm in diameter and consists of 3 layers, the first is a host-derived outer 
membrane that contains the viral envelope proteins gp120 and gp41. The second structural layer 
is comprised of the viral matrix protein (p17) that protects and stabilizes the 3rd structural 
element, the viral core. The viral core is a conical structure made up by the viral capsid protein 
(p24), and houses the two positive RNA strands that constitute the viral genome bound to p7 
(NC) along with specific viral factors (RT, IN, Vif, Vpr).    
 
1.5 HIV replication cycle  
 
Successful completion of the HIV replication cycle relies on a series of spatially and 
temporally coordinated interactions between host and pathogen, culminating in the 
production of infectious virions (Figure 1.4.). The last 30 years of HIV research have 
dramatically enhanced our understanding of the dynamic nature of the viral life cycle and 
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Figure 1.4. The HIV replication cycle.  
1) Host cell receptor engagement.:The gp120 trimers on the surface of a mature virion bind the 
host cell surface receptor CD4 promoting a conformational change in gp120 and the binding of a 
co-receptor (either CXCR4 or CCR5). 2) Membrane Fusion: Coreceptor binding triggers the 
gp41 mediated fusion of the viral and host membranes thus introducing the viral capsid into the 
cytosol 3) Intracellular trafficking: The viral capsid proteins engage the host microtubule 
network in order to promote the trafficking of the viral core toward the nuclear membrane 4) 
Reverse transcription: HIV RT begins to convert the viral RNA genome into a DNA intermediate 
via reverse transcription 5) Uncoating and Nuclear entry: The docking of the capsid at the NPC 
results in the disassembly of the viral core and capsid mediated interactions with NPC proteins 
then facilitates the nuclear import of fully reverse transcribed viral preintegration complex (PIC) 6) 
Integration: The PIC-NPC-LEDGF association facilitates proviral integration into transcriptionally 
active regions of host chromatin via the activity of HIV integrase 7) Transcriptional activation: 
Tat mediated transactivation of the HIV LTR promoter results in the stabilized transcription of viral 
genes 8) Transcript processing and nuclear export: Transcripts undergo 5’ capping and 3’ 
polyadenylation steps, Rev mediated nuclear export is utilised by unspliced transcripts and the 
canonical host mRNA export pathway utilised by spliced transcripts  9) Translation of viral 
proteins: Translation of viral products is completed by the host ribosomal machinery 10) Virion 
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assembly and budding: The newly synthesized viral proteins, predominantly polyprotein 
precursors, are localised to the host cell membrane by the Gag precursor which also recruits full 
length RNA transcripts that serve as the viral genome, Env is expressed at the cell surface via the 
endogenous secretory pathway and the budding of new virions is initiated by Gag-mediated 
subversion of the host ESCRT machinery 11) Maturation: The cleavage events induced by HIV 
protease results the liberation of functional protein units from the polyprotein complexes and the 
subsequent rearrangement of these units to form a 3 layered structure (Figure 1.3) results in the 
maturation of the now infectious virion. Currently available ARVs are able to target specific 
stages of the viral life cycle, namely, receptor engagement (1), the fusion step (2), the reverse 




The gp120 subunits of HIV Env have a high affinity for the CD4 receptor, which is 
expressed by a number of cell types specifically associated with cell-mediated immunity 
including macrophages, antigen-presenting dendritic cells and T lymphocytes. The 
binding of gp120 to its primary receptor CD4 results in a conformational change in the 
variable loop regions of gp120, thereby exposing a secondary binding domain for a 
chemokine coreceptor (Kwong, 1998). Depending on the tropism of the virus this can 
either be a CXCR4 or CCR5 receptor, while dual tropic viruses are able to utilize either 
receptor (Connor, 1997; Keele, 2008).  
 
The fusion of viral and host membranes is catalysed by gp41, which undergoes a 
conformational change in response to gp120 coreceptor engagement (Herold, 2014). 
This conformational change results in exposure of the gp41 fusion domain and its 
subsequent insertion into the target host membrane, thus creating a membrane fusion 
pore (Chan, 1998). Formation of the membrane fusion pore facilitates the  injection of 
the viral core into the cytosol, thus completing the entry process (Figure 1.4; Chan, 
1998). There are currently a number of ARVs within the drug development pipeline that 
function as either inhibitors of viral fusion or antagonists of receptor binding (Arts, 2012). 
Maraviroc, an antagonist of the CCR5 coreceptor, was the first host-directed anti-HIV 
therapy approved for use by the FDA in 2007, while Enfuvirtide, a gp41-binding peptide, 
was the first fusion inhibitor approved for use in 2003 (Arts, 2012). 
 
1.5.2 Reverse transcription and uncoating 
 
The processes of reverse transcription and nuclear import are tightly coupled to viral 
capsid degradation (uncoating). Studies utilizing various p24 (CA) stabilisation mutants 
have demonstrated that either delayed or premature uncoating can negatively impact the 
reverse transcription process (Arhel, 2010a; Hulme, 2011; Ambrose, 2014). This 
relationship is further validated by the antiviral activity of the non-human primate cellular 
restriction factor tripartite motif 5-alpha (Trim5-α). Trim5-α, was initially identified as a 
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key determinant of HIV-1 resistance in monkey cells as a result of its ability to promote 
rapid and premature degradation of the HIV-1 capsid both ex vivo and in vivo (Anderson, 
2008; Stremlau, 2004; Stremlau, 2006).  
 
Following entry into the cytoplasm, viral capsid proteins are able to engage the 
microtubule network in order to promote cytoplasmic shuttling of the capsid structure 
towards the nuclear membrane (Gaudin, 2013). During the transit phase to the nuclear 
membrane, the viral capsid may remain fully intact or become partially degraded, but 
eventually plays a role in the downstream nuclear import process (McDonald, 2002; 
Arhel, 2007; Yamashita, 2009; Matreyek, 2013). The reverse transcription process is 
completed prior to complete dissociation of the capsid, and molecular rearrangements 
within the capsid resulting from reverse transcription may contribute to the uncoating 
processing (Arhel, 2007; Hulme, 2011). HIV RT possesses both DNA polymerase and 
RNase-H functionality, which it utilises to convert the single stranded viral RNA genome 
into a double-stranded DNA intermediate (Furfine, 1991; Sarafianos, 2008; Hu, 2012). 
This process occurs within the nucleoprotein structure known as the Reverse 
Transcription Complex (RTC) and is dependent on a host transfer RNA (tRNA) primer 
(Lys3) along with the recruitment of deoxynucleoside triphosphate molecules (dNTPs) to 
the viral RNA template (Furfine, 1991; Kleiman, 2002; Sarafianos, 2008).  
 
Reverse transcription is estimated to occur over a 10 hour period following viral entry 
and culminates in conversion of the RTC into the preintegration complex (PIC) (Arts, 
2012; Hu, 2012). It is during this time frame that the virus is susceptible to therapeutic 
intervention using reverse transcription inhibitors (RTIs) and ~50% of all currently 
approved anti-HIV therapies are comprised of RTIs (Pincus, 1990; Klarmann, 2000; Arts, 
2012). RTIs (Figure 1.4) can be divided into two classes of molecules, nucleoside 
reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). In the absence of RTI intervention, the newly formed PIC, 
comprised of a full-length viral DNA genome bound to MA, Vpr and integrase, is primed 
for nuclear entry (Vandegraaff, 2006; Al-Mawsawi, 2007).  
 
1.5.3 Nuclear import 
 
The nuclear pore complex (NPC) is a highly structured multiprotein assembly that 
functions as a selective barrier to bidirectional nuclear transport (Allen, 2000). The size 
of the PIC naturally precludes it from passively traversing through the nuclear membrane 
but HIV has acquired the ability to actively transport the PIC through nuclear pores 
(Pante, 2002; Matreyek, 2013). The ability to traverse an intact nuclear membrane 
permits HIV to efficiently infect terminally differentiated and non-dividing cells types like 
macrophages and dendritic cells, in addition to T lymphocytes (Yamashita, 2009; 
Lahaye, 2013; Rasaiyaah, 2013). The nuclear trafficking process is largely mediated by 
the viral capsid protein and is initiated by the interaction of the HIV capsid with the 
cytoplasmic extensions of the NPC protein Nup358 (Yamashita, 2009; Di Nunzio, 2012; 
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Matreyek, 2013). The CA-Nup358 interaction permits docking and subsequent 
disassembly of the viral capsid at the nuclear pore and likely facilitates a series of 
downstream interactions with various NPC-associated components localized along the 
nuclear pore channel. Nup98 which is present in both the cytoplasmic and nuclear 
domains of the channel likely functions as an intermediary binding partner between the 
cytoplasmic nucleoporins and the intranuclear and chromatin-associated proteins like 
Nup153 and Nup155 (Lee, 2010; Ambrose, 2014). These PIC-nucleoporin interactions 
result in translocation of the PIC through the mesh-like filaments that constitute the 
central domain of a nuclear pore (Walther, 2002; Di Nunzio, 2012; Matreyek, 2013). 
Specific interactions between CA and host proteins have also been identified as key 
determinants of NPC cofactor selection. The interaction of CA and Cyclophilin A (CypA) 
in addition to stabilising the cytosolic capsid, has been identified as a mediator of 
downstream interactions with Nup358, Nup153 and TNPO3 (Schaller, 2011; Rasaiyaah, 
2013; Ambrose, 2014). Likewise, a functional cleavage and polyadenylation specificity 
factor 6 (CPSF6) binding domain on CA has also been identified as a determinant of 
nucleoporin usage (Nup358, TNPO3) as well a requirement for the infection of non-
dividing cell types (Lee, 2010; De Iaco, 2013; Shah, 2013). 
     
1.5.4 Integration   
          
Following nuclear entry, the HIV PIC must integrate into the host cell’s DNA in order to 
complete the next stage of the viral replication cycle. A number of studies have 
demonstrated that the site of HIV integration is not entirely random and that HIV 
preferentially integrates into transcriptionally active regions of host chromatin (Schroder, 
2002; Wang, 2007; Sherrill-Mix, 2013; Marini, 2015). CA-NPC interactions along with the 
lens epithelium-derived growth factor (LEDGF/p75) function as a critical determinants of 
HIV integration site selection (Ciuffi, 2005; Shun, 2007; De Rijck, 2010; Lee, 2010; 
Schaller, 2011; De Iaco, 2013; Matreyek, 2013). Following nuclear entry the sustained 
interaction between the PIC and NPC brings the PIC into close proximity with structurally 
relaxed and transcriptionally active chromatin regions (Marini, 2015). HIV integrase is 
then directed to specific transcriptionally active recognition sites by its interaction with 
LEDGF, which functions both as a molecular tether and guide during the integration 
process (Maertens, 2003). Integration is initiated by a 3’ processing event where 2 
nucleotides are removed from each 3’ end of the viral DNA genome (Craigie, 2001). The 
3’ processing event exposes a pair of 3’-hydroxyl groups on the viral DNA which are 
required for a subsequent strand transfer step. During the DNA strand transfer step, the 
exposed hydroxyl groups on the viral DNA attack a pair of phosphodiester bonds in the 
proximal host DNA resulting in a covalently bound viral/host DNA intermediate (Craigie, 
2001). The 3’ resectioning and strand transfer events are mediated by HIV integrase but 
the subsequent events of strand repair and ligation are completed by the host DNA 
repair machinery (Craigie, 2001; Espeseth, 2011). Integrase inhibitors interact with both 
the viral DNA and integrase thereby disrupting the integrase active site via magnesium 
ion sequestration (Figure 1.4; Grobler, 2002).      
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1.5.5 Transcriptional activation  
 
The integrated HIV genome (referred to as the provirus) serves as a template for 
transcription of viral genes. The 5’ HIV LTR functions as the main viral promoter while 
the 3’ LTR plays a role in termination of transcription and subsequent polyadenylation 
events (Pereira, 2000; Gilmartin, 1995). The 5’ and 3’ LTR sequences are identical and 
comprised of 3 domains, a unique 3’ end (U3), a repeat domain (R) and a unique 5’ end 
(U5) (Figure 1.5; Pereira, 2000). The U3 domain contains an extensive number of host 
transcription factor binding sites and can be further differentiated into a modulatory 
region, an enhancer region and a core promoter region (Rittner, 1995; Pereira, 2000; 
Krebs, 2001). Notably the enhancer region contains two NFKβ binding sites, while the 
modulatory region encodes binding sites for constitutive and inducible transcription 
factors including SP1 and NFAT respectively (Krebs, 2001).  A TATA box is located 25 
base pairs (bp) upstream of the transcriptional start site (TSS) within the core promoter 
region of U3 (Garcia, 1989).  The TSS is present at the junction between the U3 and R 
domains, and the first 60bp of the R domain following the TSS contains the 
transactivating responsive (TAR) element (Pereira, 2000). The TAR element encodes a 
nuclease-resistant stem looped RNA transcript (TAR RNA) which is present at the 5’ end 
of all viral transcripts and functions as a molecular scaffold and regulatory signal 
(Berkhout, 1989; Selby, 1989). Of particular importance to the viral transcription process, 
TAR RNA serves as a recruitment signal for the HIV transactivating protein (Tat), which 
facilitates stabilized proviral transcript elongation (Sodroski, 1985; Feinberg, 1991).  
 
LTR-mediated transcription is initiated by assembly of the transcriptional pre-initiation 
complex at the core promoter region. Briefly, TFIID, which contains the TATA box 
binding protein (TBP), is first recruited to the promoter followed by TFIIA and TFIIB, 
which function to stabilize the interaction between TFIID and the promoter DNA (He, 
2013).  RNA polymerase II (RNAPII) is then recruited to the growing complex along with 
TFIIF (He, 2013). Subsequent recruitment of TFIIE and TFIIH completes assembly of the 
pre-initiation complex, which then facilitates targeting of RNAPII to the TSS, 
transcriptional initiation and promoter clearance  (Matsui, 1980; Goodrich, 1996; Roeder, 
1996). In the absence of Tat, restricted RNAPII activity (in part due to inhibition by the 
negative regulator of elongation NELF) results in a high number of abortive or truncated 
transcripts (Zhou, 2000; Williams, 2006; Zhang, 2007). This low level of transcriptional 
activity is however sufficient to produce the viral proteins Tat and Rev. Following its 
translation and nuclear localisation, recruitment of Tat to TAR RNA loop structures 
results in an interaction between Tat, the positive transcription elongation factor complex 
(pTEF-b) and the TAR RNA scaffold (Dingwall, 1990; Wei, 1998). The pTEF-b complex 
is composed of a catalytic cyclin dependent kinase (CDK) 9 subunit and a regulatory 
cyclin T1 subunit (Marshall, 1996; Wei, 1998).  
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Tat is able to directly bind cyclin T1 and the T loop of CDK9 thus recruiting pTEF-b to the 
TAR RNA structures on nascent viral transcripts (Tahirov, 2010). Tat binding results in a 
conformational change and constitutive activation of CDK9 (Zhou, 2000; Tahirov, 2010).  
The Tat-activated pTEF-b complex then executes a series of phosphorylation events, 
including phosphorylation of the RNAPII subunit Rbp1, at serines 2 and 5 of the carboxy 
terminal domain, as well phosphorylation and inactivation of NELF (Fujinaga, 1998; Kim, 
2002; Zhou, 2000). Stabilisation of RNAPII activity and interaction of the TAR complex 
with additional host coactivators like ELL2 then dramatically enhances proviral 
transcription (Kim, 2002; He, 2010). High levels of proviral transcription create a positive 
feedback loop of Tat-mediated transactivation, which can result in a nearly 100 fold 
increase in transcript elongation capacity (Feinberg, 1991). Tat-mediated transcription is 
still however highly dependent on host transcriptional initiation processes, and conditions 
that may perturb global transcription (such as cellular quiescence) have a knock-on 
effect of diminishing Tat availability. Reduction of Tat levels below a critical threshold 
can result in halted proviral transcription and a transition into a dormant state referred to 
as latency (Karn, 2011). Latency represents the primary obstacle to curative treatment of 
HIV and a conserved survival strategy employed by HIV where stochastic gene 
expression from the HIV LTR during the early stages of infection functions as 
determinant of latency (reviewed by Weinberger, 2015).  
 
 
Figure 1.5. Structure of the HIV LTR.  
The HIV  LTR is ~640 bp in length and can be divided into 3 distinct domains: the unique 3 (U3) 
region, the repeat domain (R) and the unique 5 domain (U5). The U3 domain can be further 
segmented into the Modulatory Element  region (ME), the enhancer region and a core promoter 
region. Key landmarks within the LTR include Sp1 transcription factor binding sites in the ME and 
core promoter regions, an NFAT binding site in the ME, pairs of NFKβ binding sites in the 
enhancer region and R domain respectively, a TATA box in the core promoter region, a 
transcriptional start site (TSS) located at the junction of the U3 and R domains, a TAR sequence 
within the first 60 bp of the R domain, and an AAUAAA polyadenylation signal in the R domain.  
#I Spl 
• NFAT-1 
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1.5.6 RNA processing and nuclear export of viral transcripts 
 
Much like their host counterparts, HIV transcripts also undergo post-transcriptional 
processing in order to enhance stability and facilitate their nuclear export and 
downstream functions (Gilmartin, 1995; Gontarek, 1996; Yedavalli, 2010).  Post-
transcriptional processing may involve 3 main modifications: i) 5’ capping (Gu, 2005; 
Ghosh, 2011; Picard-Jean, 2013), ii) 3’ polyadenylation and iii) splicing (Colgan, 1997). 
The 5’ cap is acquired during transcription and subsequently functions to regulate 
nuclear export, confer immunity to ribonuclease cleavage and eventually serves as a 
recognition element for protein translation and mRNA turnover (Gu, 2005; Ling, 2011; 
Topisirovic, 2011).. The polyadenylation process is initiated by recruitment of host 
polyadenylation machinery to the polyadenylation signal (AAUAAA) encoded within the 
R domain of the HIV 3’ LTR (Gilmartin, 1995; Millevoi, 2010). Identical signals are 
present in both 5’ and 3’ LTR sequences, and HIV has thus evolved a number of 
regulatory mechanisms to ensure preferential use of the 3’ LTR signal and silencing of 
its 5’ counterpart (Ashe, 1995; Gilmartin, 1995; Das, 1999; Valente, 2009). The poly(A) 
modification plays an important role in transcript stabilization and translation, and is 
critical to nuclear export of fully spliced HIV transcripts which utilise the endogenous 
mRNA nuclear export pathway (Bilodeau, 2001; Millevoi, 2010; Stewart, 2010; Katahira, 
2012).  
         
HIV exploits the host’s endogenous spliceosome machinery in order to produce a 
diverse selection of RNA variants from a limited viral genome (Schwartz, 1990a; Purcell, 
1993; Stoltzfus, 2006; Ocwieja, 2012). These RNA species can be differentiated into 3 
categories i) unspliced, ii) partially spliced and iii) completely spliced. The transcripts that 
encode the Gag-Pol polyprotein also serve as full-length genomic RNA for new virions 
and remain unspliced at ~9 kb (Schwartz, 1990a; Purcell, 1993). The transcripts that 
encode Env, Vif, Vpr and Vpu are partially spliced to produce ~4 kb products, and Tat, 
Rev and Nef are translated from ~1.8 kb fully spliced RNA transcripts (Schwartz, 1990b; 
Purcell, 1993). Rev binds and then oligomerises at  the RRE present in unspliced and 
partially spliced HIV transcripts  (Zapp, 1991; Daugherty, 2008). This precludes viral 
transcripts from interacting with the spliceosome and also facilitates their nuclear export 
(Hadzopoulou-Cladaras, 1989; Felber, 1990; Gontarek, 1996). Rev oligomer-bound 
transcripts are able to interact with the karyopherin exportin-1 (XPO1), also known as 
chromosomal maintenance 1 (CRM1), thus facilitating nuclear export of these transcripts 
via the NPC (Wolff, 1997; Daugherty, 2010). The Rev-RRE complex dissociates upon 
cytoplasmic entry and released Rev monomers are then transported back into the 
nucleus (Henderson, 1997). The intranuclear Rev concentration thus functions as a 





Eukaryotic translation is initiated by recognition of the 5’ cap structure by the eukaryotic 
initiation factor 4E complex (eIF4E) and subsequent interactions with eIF4G, eIF4A, 
eIF4B and poly(A) binding protein (PABP) (reviewed by Jackson, 2010 and Hinnebusch, 
2014). Despite the fact that HIV has acquired mechanisms such as 5’ capping and 3’ 
polyadenylation, which allow it to effectively utilise the host translational machinery, 
there are still a number of unique requirements for successful translation of viral 
transcripts (Schwartz, 1990b; Purcell, 1993). Structures produced by the TAR sequence, 
poly(A) loop, tRNA primer binding site and the RNA packaging signal (ψ) naturally 
preclude the translation initiation process. However, HIV has evolved a number of 
strategies to circumvent this (Schwartz, 1990a; Purcell, 1993; Lu, 2011). The use of an 
internal ribosome entry site (IRES) allows HIV to bypass the canonical cap-dependent 
initiation process and 5’ UTR scanning, while the TAR loop secondary structure present 
in all HIV transcripts functions as a docking site for the pre-initiation machinery (Brasey, 
2003; Plank, 2014). Additionally  HIV is able to regulate the production levels of specific 
proteins like Env and Gag by selectively utilising ribosomal shunting (Schwartz, 1990b; 
Krummheuer, 2007) and ribosomal frameshifting respectively (Parkin, 1992; Dulude, 
2006; Namy, 2006).  
 
1.5.8 Assembly, budding and maturation 
 
The Env precursor (gp160) is heavily glycosylated and processed into gp120 and gp41 
subunits by the host protease Furin as it traverses the golgi complex (Decroly, 1994; 
Moulard, 1999). Env is ultimately integrated into lipid raft domains within the host cell 
membrane by the endogenous secretory pathway (Campbell, 2001). Gag precursors 
(p55) undergo a myristoylation step which directly targets them to the cell membrane 
along specific viral and host factors bound by Gag (Frankel, 1998; Freed, 2001; Ono, 
2004; Saad, 2006). The ψ packaging signal is present upstream of gag in unspliced full 
length viral transcripts and is recognised by the RNA binding domain of Gag thus 
facilitating the inclusion of full length viral RNA into budding virions (Lu, 2011; Chen, 
2014a). Gag monomers and dimers are trafficked through the cytoplasm to the cell 
membrane but extensive Gag multimerization only occurs at the cell membrane with 
Gag-bound RNA serving as points of nucleation (Jouvenet, 2009). Viral mediated 
subversion of endosomal sorting complexes required for transport (ESCRT) machinery 
facilitates membrane remodelling and fission processes that are required for virion 
release (Usami, 2009; Carlson, 2010; Hurley, 2010; Peel, 2011). Budding occurs with 
the release of an enveloped virion containing a spherical array of Gag molecules bound 
to two RNA genomes, host and viral proteins and Gag-Pol precursors (Bell, 2013). Virion 
maturation occurs post-release and is dependent on an initial autocatalytic cleavage 
event which liberates the HIV PR to then produce MA, CA, NC, p6, IN and RT (Hill, 
2005; Bell, 2013). Pharmacological inhibition of HIV Protease cleavage inhibits virion 
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maturation and protease inhibitors are designed to competitively bind and sequester the 
active sites of HIV PR molecules (Figure 1.4; Brik, 2003).  
 
1.6 Viral accessory proteins 
 
The accessory proteins expressed by HIV are able to exert a broad range of effects 
which ultimately synergise to create a favourable intracellular environment for viral 
replication via inhibition of specific host restriction factors and subversion of essential 




The human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3 
(APOBEC3) family is comprised of 7 cytidine deaminases which function as  innate 
cellular restriction factors of retroviral infection (Munk, 2012). The APOBEC3G protein in 
particular has a well characterised ability to suppress HIV replication (Malim, 2009). 
APOBEC3G molecules are able to localise within HIV virions by binding viral and host 
RNA transcripts that are readily bound by HIV Gag (Cen, 2004). The cytidine deaminase 
activity of  APOBEC3G promotes hypermutation of the HIV DNA genome within virions, 
resulting in a replication-deficient virus (Malim, 2009). However, this restriction 
mechanism is effectively countered by the activity of HIV viral infectivity factor (Vif) 
during the natural course of infection (Sheehy, 2002). Vif is able to significantly deplete 
intracellular levels of APOBEC3G thus dramatically reducing the chance that 
APOBEC3G molecules might be packaged within budding virions (Mangeat, 2003; 
Zhang, 2003). Cellular depletion of APOBEC3G is achieved both by suppressing 
translation of APOBEC3G mRNAs, and by directly targeting cellular reservoirs of 
APOBEC3G for ubiquitin-mediated degradation (Stopak, 2003; Yu, 2003). Additionally 
Vif has recently been demonstrated to suppress the cytidine deaminase activity of 
APOBEC3G in a degradation-independent manner within nascent virions (Wang, 2014). 
In combination with the observation that Vif-deficient viral strains exhibit a severely 
impaired ability to produce infectious virions (Strebel, 1987; Sheehy, 2002), Vif is clearly 
an indispensable tool within the HIV replication process.      
    
Vpu  
 
HIV viral protein U (Vpu) functions as the viral countermeasure to the host restriction 
factor bone marrow stromal antigen 2 (BST-2) also known as tetherin (Neil, 2008). 
Tetherin is a transmembrane  lipid raft-associated protein, which prevents release of 
mature virions from virus-producing cells resulting in their attachment to the cell surface 
(Neil, 2008). Therefore, while tetherin may suppress the cell-free spread of HIV, it has 
been demonstrated to have little effect on cell-to-cell transmission of HIV and thus may 
not significantly impact viral replication kinetics (Terwilliger, 1989). The exact mechanism 
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by which Vpu is able to antagonise tetherin remains unclear but one school of thought 
suggests that Vpu may facilitate deregulation of tetherin recycling, thus reducing its 
availability at the cell membrane (Dube, 2011). Additionally a direct interaction between  
Vpu and CD4 within the ER results in the rapid degradation of nascent CD4 protein, 
thereby suppressing its expression at the cell surface and enhancing viral release and 




Viral protein R (Vpr) has been identified as the effector of a diverse set of molecular 
processes that are required during the early stages of HIV infection (Guenzel, 2014). 
This is further supported by the fact that Vpr is actively recruited into budding virions via 
its interaction with Gag (Bachand, 1999). Vpr activity has been described to be 
particularly relevant for efficient replication of HIV within macrophages via its roles in 
nuclear import, stabilisation of reverse transcription and enhancement of integrase-
independent integration (Connor, 1995; Eckstein, 2001; Chen, 2004; Koyama, 2013). 
Additional functions of Vpr have been reviewed extensively and include induction of DNA 
damage, subversion of host DNA repair machinery, regulation of HIV-mediated 
apoptosis, and transcriptional regulation (Guenzel, 2014). Furthermore, Vpr activity has 
long been implicated in HIV-associated G2 cell cycle arrest in proliferating cell types, 
and recent findings have demonstrated that Vpr-mediated activation of the 
endonuclease regulatory complex (SLX4) promotes cell cycle arrest in addition to its 
primary purpose of masking non-integrated viral DNA from innate immune sensors 





The HIV negative effector factor (Nef) has been implicated as a master coordinator of 
cell surface receptor localization and stability, as well as downstream receptor-mediated 
signaling processes (Landi, 2011). Nef is thus able to mediate a wide array of molecular 
effects within different cell lines. Notably, interaction of Nef with adapter proteins 1 and 2 
(AP-1 and AP-2) facilitates clathrin-mediated endocytosis of CD4, CD8 and major 
histocompatibility complex  (MHC) receptors (Roeth, 2004; Jin, 2005). Enhanced 
endocytosis of CD4 serves to complement Vpu-mediated degradation of nascent CD4 
proteins, restrict superinfection, promote virion release and also suppress T cell 
activation signals in response to infection (Zhou, 2003; Michel, 2005). Likewise, down-
modulation of MHC and CD8 proteins at the cell surface retards the antigen-presenting 
capability of infected cells and masks them from cytotoxic immune cells, thus subverting 
the host immune response to infection (Landi, 2011). In addition to its ability to sequester 
target proteins from the cell surface, Nef also promotes enhanced stability of gp41 and 





1.7 Current treatment strategies 
 
Current classes of ARV drugs are able to target different stages of the viral replication 
cycle (Figure 1.4). Diversification of therapeutic targets is essential for the success of 
current anti-HIV treatment regimes, which consist of a combinatorial ARV (cARV) 
approach that was first pioneered in 1997 as ‘highly active antiretroviral therapy’ 
(HAART; Autran,1997; Delaney, 2006). In the absence of therapeutic intervention, 
diagnosis with AIDS is typically followed by mortality within 2 years (Osmond, 1994; 
Crum, 2006). A canonical HAART regimen consists of 2 NRTIs in combination with 
either a protease or integrase inhibitor, and is usually initiated following the decline of 
CD4+ T cell levels to ~350 cells per mm3 of blood (Lederman, 1998; Arts, 2012). The 
successful implementation of HAART results in a significant suppression of viral 
replication and subsequent reconstitution of the host immune system (Autran,1997; 
Komanduri, 1998; Lederman, 1998). The advent of HAART and improved diagnostics 
have thus dramatically reduced global AIDS-related mortality and improved the life 
expectancy of afflicted individuals (Palella, 1998; Nakagawa, 2013). However, despite 
the many benefits of HAART there are still a number of caveats that exist within the 
current treatment strategy.  
 
The HIV genome evolves at a rapid rate with an estimated 1-10 mutations introduced 
during each replication cycle (O'Neil, 2002; Abram, 2010). This high rate of viral 
evolution results in tremendous levels of viral heterogeneity within infected individuals, 
and has major implications for drug resistance (Coffin, 1995). Indeed early HIV 
treatments that utilised a monotherapy-based approach, including the first anti-HIV drug 
AZT, resulted in rapid treatment failure due to the emergence of drug-resistant viral 
variants (Larder, 1989; St Clair, 1991). The high rate of viral evolution has thus 
necessitated use of a 3 pronged cARV approach in order to increase the barrier to viral 
escape by mutagenesis (Autran,1997; Arts, 2012). Alarmingly, a number of HIV variants 
resistant to frontline components of cARV treatments continue to emerge and remain 
transmitted in response to ongoing treatment (Wittkop, 2011). These drug-resistant 
variants have the greatest prevalence in regions such North America and Europe where 
cARV treatments were first introduced, suggesting that continued use of the current 
cARV strategy will ultimately drive diversification and dissemination of drug-resistant 
viral variants across the globe (Frentz, 2012). Additionally, the prolonged use of cARV 
treatments have also been linked to a number of adverse side effects, including an 
increased risk of heart disease, diabetes and osteoporosis to name a few (Visnegarwala, 
1997; Brinkman, 1998; Henry, 1998; Tebas, 2000). The lifelong use of ARVs, which is 
required to suppress HIV replication, may therefore also negatively impact of the quality 
of life for people receiving cARV therapy. Furthermore, the complete eradication of HIV 
remains beyond the reach of current ARV therapies and is antagonised by low levels of 
34 
viral replication and cellular reservoirs of infection that persist even during active cARV 
treatment (Sharkey, 2001; Palmer, 2003; Alexaki, 2008).  
 
The most well characterized reservoir of infection is comprised of a small populations of 
latently infected resting CD4+ T cells which are established during the early stages of 
infection prior to the initiation of cARV treatment (Chun, 1998; Dahabieh, 2013). Latency 
can be established via a number of molecular mechanisms, such as activation or 
differentiation state of the cell, transcription factor dynamics, specific host restriction 
mechanisms, as well repressive chromatin states (reviewed extensively in Alexaki, 2008; 
Siliciano, 2011). Latently infected cells harbour integrated proviral DNA which is 
transiently silenced and thus effectively ‘hidden’ from viral protein targeting drug 
regimens (Alexaki, 2008; Siliciano, 2011). The extended longevity of these latent 
reservoirs in combination with their sporadic activation in response to environmental 
cues perpetuates the lifetime persistence of HIV even in individuals receiving functional 
cARV treatment (Siliciano, 2003; Strain, 2003). The problem of latency may be further 
compounded by the prevalence of HIV infectable cell types within anatomical 
compartments that are poorly accessible to ARVs, such as the central nervous system 
(CNS) and lymphoid tissues  (Vyas, 2006; Schnell, 2009; Alexaki, 2008; Fletcher, 2014). 
These compartments harbour cell types such as  tissue-resident macrophages and 
CNS-fated immunogenic cells which may also facilitate low levels of viral replication 
thereby sustaining latent reservoirs even during active cARV treatment (Schnell, 2009; 
Fletcher, 2014). The cellular reservoirs established by HIV thus necessitate a lifelong 
treatment programme with a rebound in viral replication reported to occur within a matter 
of weeks after the cessation of cARV treatment (Davey, 1999). The lack of a viable cure 
in combination with unsuccessful vaccine efforts and inadequate availability of treatment 
in many countries portend the continued persistence of the global HIV pandemic 
(Pitisuttithum, 2006; Burton, 2012; UNAIDS, 2014). As the current state of HIV treatment 
remains imperfect, it warrants the development of more robust therapeutics in order to 
surpass the limitations of the traditional virocentric approach to ARV drug discovery.  
 
1.8 HIV-host interactions 
 
As an obligate intracellular pathogen with a seemingly limited arsenal of effector 
proteins, HIV is highly dependent on the function of certain host factors in order to 
complete its life cycle (reviewed by Arhel, 2010b and Friedrich, 2011). On the other hand 
the virus also requires the deregulation of a number of host processes that may prove 
restrictive to viral replication (Strebel, 2013). Host factors thus serve as critical 
determinants of the fate of HIV replication as either HIV dependency factors (HDFs) or 
suppressive viral restriction factors (VRFs). The comprehensive identification and 
characterization of all host factors that fall into either of these functional classes is 
therefore of great significance to our fundamental understanding of HIV, as well as the 
effective exploitation of these host factors for therapeutic gain. VRFs may be exploited 
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by mimicking or enhancing their restrictive properties as in the case of chimeric Trim5-α 
variants, while the functional silencing of HDFs via pharmacological or molecular means 
may likewise be utilised as in the case of the CCR5 antagonist, Maraviroc (Dorr, 2005; 
Stremlau, 2006; Anderson, 2008).  
 
Indeed host factors present very attractive targets for ARV development as their 
inherently low mutation rates compared to viral proteins precludes the rapid emergence 
of drug resistance that has been characteristic of viral targeted therapies (Schwegmann, 
2008; Abram, 2010). Furthermore, therapies directed towards HDFs that cannot be 
circumvented by HIV’s flexible use of host factors, may also serve as impermeable 
barriers to viral escape via simple mutagenesis (Schwegmann, 2008; Arts, 2012). The 
challenge with host-directed therapy however is twofold. Firstly it requires the 
identification of specific host factors that can be utilised or modulated to suppress HIV 
replication. This requirement alone is no simple task when considering the vast number 
of functional products encoded by the ~3.2 billion bp human genome compared to its ~9 
700 bp viral counterpart. Secondly the effective utilisation of host-directed therapy 
requires the exclusion of host factors that are essential for normal cellular function and 
whose inhibition or modulation may result in undesired effects (Schwegmann, 2008). 
 
The identification and  characterization of HDFs and VRFs have traditionally emanated 
from the interrogation of HIV-host interactions by focusing on host factors that directly 
associate with viral proteins and those that are differentially expressed or modulated 
during infection (Greene, 2007). It has been estimated that the 18 protein products 
encoded by HIV are able to directly interact with 435 different host proteins, and there 
are currently also thousands of host factors that are differentially regulated in response 
to infection (Bosinger; 2004; Jager, 2012; Ako-Adjei, 2015). While still informative, these 
data do not directly provide functional roles for those host factors during the HIV 
replicative process. As functional relevance is critical to the identification of 
therapeutically useful HDFs and VRFs (Friedrich, 2011), this represents a key area of 
ongoing HIV research. 
 
1.9 Natural restriction of HIV 
 
Scrutinisation of host factors in order to guide ARV development is further justified by the 
prevalence of unique disease progression phenotypes within ARV-naive subsets of the 
human population (Okulicz, 2009; Gurdasani, 2014). Rapid progressors (RPs) are 
generally characterised as individuals who exhibit a CD4+ cell count below 100 cells per 
µL within the first year of seroconversion and who go on to rapidly develop AIDS within 
3-5 years post infection without cARV intervention (Oslon, 2014; Gurdasani, 2014). Long 
term non progressors (LTNPs) on the other hand are individuals who, in the absence of 
ARVs, are still capable of maintaining CD4 counts above 500 cells per µL of blood for at 
least 10 years following HIV infection thus delaying the natural progression to AIDS 
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(Mikhail, 2003; Westrop, 2009; Gurdasani, 2014). Elite controllers (ECs) constitute a 
very rare subset (< 1%) of the HIV infected population who are characterised by their 
ability to spontaneously restrict viral replication (<50 copies per mL) for at least 1-10 
years following infection in the absence of cARV treatment (Okulicz, 2009; Walker, 
2013). While all of these phenotypes represent intriguing models for the evaluation of 
host resilience and susceptibility to HIV, delineation of the mechanisms of viremic control 
in such stratified patients hold great promise for the development of more robust 
therapies (Baker, 2009; Walker, 2013; Gurdasani, 2014).  
 
A number of host and virological factors have been canonically associated with the 
natural control of HIV (Blankson, 2010; Poropatich, 2011; Walker, 2013). The exact role 
of virological factors in viremic control however remains tenuous (Bailey, 2008). While a 
number of early data points had suggested that LTNPs and ECs may be infected with 
attenuated viral strains with reduced fitness, recent findings have demonstrated that it is 
more likely the host response which drives restriction of viral replication as well as 
emergence of attenuated viral variants (Bailey, 2008; Poropatich, 2011).  
 
Enhanced cell-mediated immunity is essential for sustained elite control of HIV 
(Blankson, 2010). EC-derived CD8+ cytotoxic T cells  effectively suppress HIV replication 
in CD4+ T cells via the recognition of HIV Gag and EC-characteristic polyfunctional 
activity that includes improved cytotoxicity, proliferation and autocrine secretion (Walker, 
2013). Specifically, the host transcription factor TBX21 has been associated with an 
increased production of cytotoxic enzymes like perforin and granulysin in EC-derived 
CD8+ T cells, which also exhibit augmented secretion of interleukin-2 (IL-2; Blankson, 
2010; Walker, 2013). The exact role of CD4+ T cells in ECs remains less clear although it 
has been suggested that they support antiviral activities of HIV-specific CD8+  T cells via 
secretion of cytokines such as IL-2 and IL-21 (Blankson, 2010; Walker, 2013). 
Furthermore, macrophages derived from ECs are recalcitrant to productive infection by 
HIV, but the molecular mechanism behind this phenotype is not yet understood (Saez-
Cirion, 2011).  
 
The results from a number of genome-wide association studies to identify known single 
nucleotide polymorphisms (SNPs) in viremic controllers and RPs have also revealed that 
SNPs within the human leukocyte antigen (HLA) class I locus are preferentially 
associated with extreme progression phenotypes (Walker, 2013). Furthermore, the 
expression of specific HLA  alleles, including HLA B*57, HLA B*27 and HLA B*13, 
have been demonstrated to be relevant to viremic control in some EC populations but 
not others thus further highlighting the heterogeneity of possible viremic control 
mechanisms (Poropatich, 2011; Walker, 2013). Additionally, the CDK inhibitor p21, has 
also been described to contribute to viremic control as a putative viral restriction factor 
(VRF). An innate and significant upregulation of p21 was observed in CD4+ T cell 
populations derived from two distinct groups of ECs (Yu, 2011). Elevated p21 expression 
was demonstrated to inhibit CDK9-dependent viral transcription within one EC group, 
and subsequent suppression of p21 expression by small interfering RNAs (siRNAs) 
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rendered EC-derived CD4+ T cells susceptible to viral replication (Yu, 2011). However, 
direct association of p21 upregulation to viremic control in only one of the two EC groups 
suggests that p21 activity alone may not be enough to elicit the observed control 
phenotype, and that additional restriction mechanisms may be at work (Saez-Cirion, 
2011). The physiological manifestation of viremic control therefore likely results from the 
prevalence of specific combinations of favourable host determinants which are able to 
restrict viral replication on both a molecular level and at the level of the immune 
response against HIV. While the exact mechanisms remain poorly characterized, the 
ability to recapitulate these natural restriction phenotypes within HIV infected or HIV 
naive individuals still represents the “holy grail” of HIV-directed therapy.  
 
Polymorphisms in a number of chemokine coreceptors and their ligands (CCR5, CCR2, 
CX3CR1 CXCR4) have also been associated with protective HIV phenotypes 
(Poropatich, 2011). The most well characterised of these is a 32 base deletion in the 
gene encoding the chemokine coreceptor CCR5 (CCR5 Δ32; Liu, 1996). Briefly, the 
CCR5 Δ32 mutation is most common in individuals of eastern european descent and 
results in a nonfunctional protein product (Liu, 1996; Zimmerman, 1997). CCR5 Δ32 
homozygosity confers a high degree of immunity against R5 tropic viral variants that 
dominate transmission events (Liu, 1996; Zimmerman, 1997). This protective 
homozygous phenotype was further shown to be transferable via stem cell-mediated 
transplantation resulting in the long term control of HIV within a previously infected and 
naturally progressing individual (Hutter, 2009). CCR5 Δ32 heterozygosity was also 
initially reported to result in a delayed onset of AIDS, but this phenotype has more 
recently been called into question (Zimmerman, 1997; Liu, 2012). Likewise the 
prevalence of a mutation in the promoter region of CCR5 (CCR5P1/P1) which results in 
increased surface expression of CCR5 was shown to account for 10-17% of all rapid 
progressor (RP) phenotypes, thus further validating the potential of chemokine 
coreceptors as therapeutically relevant HDFs (Martin, 1998).   
 
1.10 RNAi as a tool to understanding HIV-host interactions 
 
 
Sequencing of the human genome and subsequent advances in RNA interference 
(RNAi) and its application within mammalian models facilitated the advent of a new era 
in functional genomics (Elbashir, 2001; Hannon, 2004). The ability to readily and 
systematically achieve functional silencing of specific mRNA species by siRNAs or short 
hairpin RNAs (shRNAs) has provided researchers with a means to evaluate the 
functional relevance of individual human genes against a backdrop of complex cellular 
processes using cell-based readouts (Hannon, 2004). In the case of HIV, RNAi was 
readily adopted to suppress viral replication in cellular models by targeting specific viral-
specific RNAs, and known HDFs such as CD4, CXCR4 and CCR5 (Novina, 2002; 
Anderson, 2003). The combination of RNAi with high throughput (HT) experimental 
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design lead to the ability to timeously perform functional screening at a genomic scale. A 
related seminal study  utilized a library of siRNAs targeted to 510 human kinase genes, 
in order to identify specific modulators of TNF-related apoptosis-inducing ligand (TRAIL)-
mediated apoptosis in HeLa cells (Aza-Blanc, 2003). This pilot study established the 
utility of large-scale RNAi screening in mammalian cell models and since then a 
multitude of functional genome-wide RNAi screens have led to  delineation of countless 
endogenous processes, identification of novel host determinants of pathogenesis and 
improved drug discovery (Cherry, 2009; Mohr, 2014).  
 
Specific to HIV, the first genome-wide RNAi screens were undertaken in 2008 by 3 
independent research groups (Brass, 2008; Konig, 2008; Zhou, 2008). All 3 of these 
pioneering screens utilised commercially available synthetic siRNA libraries in 
combination with cell-based measures of viral replication and cellular toxicity in order to 
identify host factors that could significantly affect HIV replication without negatively 
impacting cell viability (Pache, 2011). Studies by the Brass and Zhou groups assessed 
host factors that may contribute to all stages of the viral life cycle, from entry to 
production of infectious virions, in Hela-derived cell lines (Brass, 2008;  Zhou, 2008). 
Konig and colleagues on the other hand only evaluated the impact of host factor 
depletion on viral replication from a post-entry stage until the point of stable proviral 
transcription, using the HEK293T human embryonic kidney cell line. (Konig, 2008). 
These screens each interrogated ~20 000 human genes and collectively were able to 
identify over 800 host factors relevant to HIV replication (referred to as ‘hits’), the 
majority of which were novel potential HDFs (Bushman, 2009). There were however only 
3 genes identified as hits by all three screens and only 31 other genes identified as hits 
in at least 2 screens (Table 1.1). The poor concordance between hits was determined to 
be largely attributable to major differences in both the experimental and analytical 
parameters utilised by each research group including differences in cell types, viral 
variants, assay readouts and hit selection criteria, to name a few (Pache, 2011).  
 
Despite the diverse experimental conditions across the three studies, there was still a 
strong enrichment of host factors previously implicated in HIV replication (Table 1). This 
finding further strengthened confidence in the newly identified HDFs and implied that the 
replicative requirement for these specific host factors was likely inflexible and highly 
conserved by viral evolution, thus making these hits prime candidates for drug 
development (Bushman, 2009). Notably, members of the Mediator complex protein 
family were for the first time implicated as potential HDFs that regulated proviral 
transcription, while TNPO3 was identified as a regulator of PIC nuclear import, and the 
cytosolic trafficking of HIV was associated with MAP4, MID1IP1 and CAV2 (Bushman, 
2009). Additionally a number of semi-concordant hits with poorly described endogenous 
functions (DMXL and IDH1) were also uncovered, although they mediate unknown 
aspects of HIV replication (Bushman, 2009). Meta analysis of the screen hits in 
combination with databases of known HIV-host and host-host protein interactions was 
able to further reveal a prevalence of distinct protein interaction clusters that correlated 
with proviral transcription, molecular chaperoning, splicing and the cellular immune 
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response (Bushman, 2009). Therefore, in spite of the issues surrounding concordance, 
these 3 pioneering screens were able to successfully demonstrate the tremendous 




Table 1.1 The 34 hits identified by at least of 2 of 3 genome-wide siRNA screens 




MED6 ✔ ✔ ✔  
MED7 ✔ ✔ ✔  
RELA ✔ ✔ ✔ ✔ 
ADRBK1  ✔ ✔  
AKT1  ✔ ✔ ✔ 
ANAPC2 ✔  ✔  
ANKRD30A  ✔ ✔  
CAV2  ✔ ✔  
CCNT1  ✔ ✔ ✔ 
CD4  ✔ ✔ ✔ 
CHST1 ✔  ✔ ✔ 
CTDP1 ✔ ✔  ✔ 
CXCR4  ✔ ✔ ✔ 
DMXL1 ✔ ✔   
DDX3X  ✔ ✔ ✔ 
HMCN2 ✔  ✔  
IDH1 ✔ ✔   
JAK1  ✔ ✔ ✔ 
MAP4 ✔ ✔   
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MED4  ✔ ✔  
MED14 ✔ ✔   
MED19 ✔  ✔  
MED28  ✔ ✔  
MID1IP1 ✔ ✔   
MRE11A ✔  ✔  
NUP153 ✔ ✔  ✔ 
RAB28  ✔ ✔  
NUP358 ✔ ✔   
RNF26  ✔ ✔  
RGPD8  ✔ ✔  
TCEB3  ✔ ✔ ✔ 
TNPO3 ✔ ✔   
TRIM55 ✔ ✔   
WNK1  ✔ ✔  
 
Subsequent to the initial three siRNA-based screens, Yeung and colleagues undertook a 
genome-wide screen targeting ~54 000 human transcripts in clonal T cell lines that were 
stably transduced with shRNA-expressing lentiviral vectors (Yeung, 2009). This shRNA-
based screen identified and validated 5 host factors NRF1, STXBP2, NCOA3, PRDM2, 
and EXOSC5 as potential HDFs from a primary hit list of 252 candidates (Yeung, 2009). 
A different shRNA-based screen targeted to >800 human kinases and phosphatases 
was further able to identify 14 novel HDFs that were dispensable for normal host cell 
function but essential for viral replication (Rato, 2010). The activities of the majority of 
these host factors was demonstrated to restrict viral replication at stages prior to proviral 
integration, and were mapped to the ERK, JNK and MAPK signalling cascades as well 
as host DNA repair and vesicular transport processes (Rato, 2010). Using a combination 
of ultra high throughput screening via printed siRNA arrays and multidimensional image 
based profiling, Genevesio and colleagues identified 56 HDFs that exhibited a visual 
infection phenotype similar to CD4 depletion in a HeLa-derived GFP reporter cell line 
(Genovesio, 2011). Eleven of these host factors were previously associated with HIV 
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replication while the remaining 45 factors represented novel HDFs (Genovesio, 2011). 
The Non-homologous end-joing (NHEJ) -associated DNA repair factor Ku70, along with 
RNAseH2A and PAK1 were selected for further validation and their depletion was shown 
to significantly inhibit HIV replication in a Jurkat T cell line (Genovesio, 2011). A more 
focused siRNA-based screen was also published in the same year where a library of 232 
siRNA pools was utilised to uncover novel HDFs specifically associated with the DNA 
repair process (Espeseth, 2011). The base excision repair (BER) pathway was found to 
be the mostly highly enriched within the 35 total hits identified by the screen, while 
Homologous repair (HR) -mediated repair proteins were almost as highly represented. 
Depletion of the BER-associated hits MUTYH, NTHL1, NEIL3, XRCC1, LIG3, and POLB 
resulted in a >40% inhibition of viral replication, which could be rescued by re-
expression of these factors.  
 
Taken together, the advent of large scale RNAi based screening has had a great impact 
on delineation of the global HIV-host interaction landscape (Bushman, 2009; Yeung, 
2009; Rato, 2010; Espeseth, 2011; Genovesio, 2011). This statement is even more 
relevant when we consider that RNAi-based experiments have led to the 
characterisation of over 1200 potential HDFs thus far, which accounts more than a 
quarter of all host genes currently implicated in HIV infection (Ako-Adjei, 2015). While 
much of the early focus on host pathogen interactions rested on the coding region of the 
host genome, the last decade has ushered in a dramatic shift in this paradigm with the 
noncoding component of the human genome becoming more relevant across all 
disciplines of biology, including HIV-host interactions (Barichievy, 2015). Notably, the 
long noncoding RNAs (lncRNAs) lincRNA-p21 and NEAT-1 are co-opted by HIV to 
facilitate deregulation of the host apoptotic response and the nuclear export of viral 
transcripts respectively (Barichievy, 2015; Zhang, 2013). While the current number of 
lncRNA-HIV interactions appears modest, the emerging role of lncRNAs as critical 
mediators of gene expression in response to pathogenic stress suggests that many 
more HIV-specific interactions may be uncovered in the years to come. Furthermore 
small non-coding RNAs have emerged as major regulators of post-transcriptional gene 
expression. Within this class, host microRNAs (miRNAs) that constitute the backbone of 
the endogenous RNAi system, are most interesting as they represent a potentially 
significant resource for the delineation of HIV-host interactions and the development of 




miRNAs are short non-coding RNA molecules ~ 22 nucleotides in length that were first 
described in C.elegans when two small RNA transcripts derived from the gene lin-4, a 
known negative regulator of lin-14, were revealed to exhibit homology to a repeated 
sequence encoded within the 3’ UTR of mRNAs encoding lin-14 (Lee, 1993). The 
subsequent discovery of the endogenous RNAi pathway and the role of dsRNA in post-
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transcriptional gene regulation heralded a new era in RNA biology, and two decades of 
research have placed miRNAs at the centre of this exciting field of research (Fire, 1998; 
Elbashir, 2001; Salmena, 2011). miRNAs have now been identified in a multitude of 
organisms from worms to humans, where they function as molecular guides that direct 
the endogenous RNAi machinery to specific targets (Bartel, 2009). Additionally a number 
of miRNAs and their target transcripts are highly conserved across different species, 
suggesting a strong selection pressure for miRNA-mediated gene regulation throughout 
evolution (Friedman, 2009). Recent advancements in deep sequencing technologies 
have bolstered miRNA discovery and there are currently over 2500 miRNAs species 
identified in humans alone, which is more than double the number of human miRNAs 
annotated only two years ago (Kozomara, 2014). While miRNAs may exhibit similar 
functional properties to other small non-coding RNA families like PIWI- interacting RNAs 
(piRNAs) and siRNAs, they are also readily distinguished by their unique biogenesis 
(Figure 1.6.) and constitute the dominant class of small non-coding RNAs in most human 






Figure 1.6. Canonical miRNA biogenesis and function. 
1) miRNAs are actively transcribed by RNAPII to produce pri-miRNA molecules. 2) Pri-miRNAs 
are cleaved by the Drosha-DiGeorge microprocessor complex to produce pre-miRNAs 3) which 
are ~70 nt long stem loop structures that contain  a 2 nt 3’ overhang. 4) An alternative route of 
miRNA biogenesis results in pre-miRNA structures known as mirtrons that are produced directly 
as a result of splicing events 5) Both pre-miRNAs and mirtrons are actively transported into the 
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cytoplasm by Exportin-5. 6) Cytosolic pre-miRNAs are bound by a DICER-TRBP complex. 7) The 
pre-miRNA-DICER complex is bound by AGO-HSP90 thus forming a RISC loading complex 
(RLC) 8) The RLC cleaves the pre-miRNA to produce a ~22 nt RNA duplex. 9) The mature 
miRNA duplex is loaded onto AGO and detaches from the RLC 10) The mature single stranded 
guide RNA bound to AGO and GW182 form the core RISC complex (miRISC). 11) miRISC target 
recognition is determined by sequence homology and miRISC binding predominantly results in 
translational repression of a target mRNA which may be followed by the degradation of the target 
transcript. 12) mRNA degradation is initiated by deadenylation of the target mRNA by CCR4-NOT 
and is followed by removal of the 5’ cap by decapping enzymes DCP1 and DCP2. 13) The 
unprotected mRNA transcript is degraded by the exonuclease XRN1. 
 
1.11.1 microRNA biogenesis 
 
The genetic sequences encoding miRNAs can occur within intergenic, intronic or exonic 
regions, where the majority of non-intergenic human miRNAs are located within the 
introns of coding and noncoding transcripts (Rodriguez, 2004). miRNAs can either be 
expressed directly by RNAPII-mediated transcription, or indirectly via transcription of 
another host gene (Cai, 2004). miRNA expression is therefore subject to many of the 
same regulatory mechanisms that govern canonical gene expression, and is tightly 
regulated by epigenetic factors such as histone modifications and DNA methylation 
signatures, as well the activity of specific transcription factors including p53, ZEB1 and 
MYC (reviewed  by Krol, 2010 and Ha, 2014). These factors contribute to cell and tissue-
specific miRNA expression profiles, and are further augmented by autoregulatory miRNA 
feedback circuits that govern the expression of specific miRNAs (Kim, 2007; Tsang, 
2007). Canonical miRNA biogenesis results in the RNAPII-dependent expression of 
primary miRNAs (pri-miRNAs) which undergo both 5’ capping and 3` polyadenylation, 
are generally over 1 kb in length and are comprised of ~33-35 bp stem-loop structures 
flanked by single stranded RNA (ssRNA; Ha, 2014). These stem-loop structures are 
liberated from the pri-miRNA structure by a microprocessor complex in order to produce 
precursor miRNA (pre-miRNA) molecules  (Krol, 2010).  
 
The microprocessor complex is comprised of the RNAseIII endonuclease Drosha and 
the double stranded RNA (dsRNA) binding complex, DiGeorge syndrome critical region 
8 (DCGR8) (Ha, 2014). DCGR8 directly interacts with both Drosha and the pri-miRNA 
structure to stabilize Drosha-mediated cleavage (Ha, 2014). The two RNAseIII domains 
of Drosha function as a processing centre and are directed to a cleavage site ~11 bp 
upstream of the juncture between the ssRNA and dsRNA loop structure (Ha, 2014). 
Drosha first cleaves the 3’ strand of the pri-miRNA stem loop and then the 5’ strand, to 
release a hairpin structure with a 2 nucleotide overhang at the 3’ end (Ha, 2014). This 
hairpin molecule is ~70 bp in length and is referred to as a pre-miRNA (Krol, 2010). An 
alternative route of miRNA biogenesis results in production of pre-miRNA molecules via 
intronic splicing, and these are known as mirtrons (Lee, 2004; Sibley, 2011).  
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Nuclear export of pre-miRNA molecules is facilitated by a nuclear transport complex 
comprised of exportin 5 (XPO5) and RanGTP (Yi, 2003). RanGTP-bound XPO5 is able 
to specifically recognise and bind both the dsRNA stem and 2 nucleotide 3’ overhang of 
pre-miRNA molecules (Ha, 2014). The pre-miRNA-XPO5 interaction facilitates 
cytoplasmic trafficking of pre-miRNAs and mirtrons through the NPC and also shields 
these molecules from nuclear degradation (Yi, 2003). DICER is an RNA endonuclease 
that contains two RNAseIII domains, a helicase domain and a Piwi-Argonaute-Zwille 
(PAZ) domain (MacRae, 2006). The helicase and PAZ domains facilitate pre-miRNA 
recognition, while the dimerised RNAse domains function as a catalytic centre (Ha, 
2014). The helicase domain interacts with the terminal loop of the pre-miRNA hairpin, 
while the PAZ domain specifically binds the 2 nucleotide 3’ overhang (Ha, 2014). The 
distance between the RNAseIII domains and the PAZ domain functions as a “molecular 
ruler”, which directs cleavage at a fixed distance from the 3’ end to produce a ~22 
nucleotide long mature miRNA duplex with a 2 nucleotide 3’ overhang and 5’ phosphate 
group (MacRae, 2006). 
 
The RNA induced silencing complex (RISC) is the ribonucleoprotein effector of both 
miRNA (miRISC) and siRNA-mediated gene silencing (Ha, 2014). The core components 
of a functional mammalian miRISC complex include a single stranded RNA guide 
sequence, one of four argonaute proteins (AGO1-4) and a GW182 protein (Krol, 2010). 
Canonical miRISC assembly is therefore dependent on the loading of a DICER-
processed mature miRNA duplex onto an AGO protein. The formation of the Risc-
loading complex (RLC) comprised of DICER, AGO, TRBP and a heat shock protein 
(HSP) has been posited as a major route of miRISC assembly (Liu, 2012). In this model, 
pre-miRNAs are first bound by a  DICER-TRBP complex which then recruits an AGO-
HSP complex (Liu, 2012). DICER-mediated cleavage occurs within the RLC and transfer 
of the mature miRNA duplex to AGO occurs following a conformational change in AGO, 
mediated by HSP90 (Iwasaki, 2010). DICER-mediated cleavage and AGO-miRNA 
loading then promote release of the miRNA-AGO complex from the RLC (Liu, 2012). 
The next stage in miRISC assembly requires conversion of the miRNA duplex into a 
ssRNA guide sequence, and is mediated by AGO following its release from the RLC 
(Liu, 2012; Ha, 2014). The guide strand of the miRNA duplex is preferentially 
incorporated into AGO during loading, while the passenger strand is later removed either 
by unwinding of a mismatched RNA duplex or in rare instances by AGO2-mediated 
cleavage of perfectly paired duplexes (Ha, 2014). Strand selection is largely determined 
by  thermodynamic stability of the RNA duplex, with guide strand selection favouring 5’ 






1.11.2 Target recognition and mRNA silencing 
 
miRNA target recognition is determined predominantly by a seed region located between  
nucleotides 2-8 at the 5’ end of a guide RNA (Lewis, 2003; Bartel, 2009). This seed 
sequence adopts an A-form helix structure within miRISC in order to facilitate mRNA 
scanning for specific miRNA binding sites (Ha, 2014). The majority of functionally 
relevant human miRNA binding sites are located within the 3’ UTRs of mRNA transcripts 
and can be identified by the seed region (reviewed by Grimson, 2007 and Bartel, 2009). 
mRNAs may encode multiple binding sites specific to a single miRNA or many different 
miRNAs thereby creating a non-orthogonal relationship between miRNAs and their 
targets (Bartel, 2009). This relationship also has important functional consequences, as 
the relative concentration of specific miRNAs and the availability of their target binding 
sites can influence both miRISC target selection and the degree of suppression 
(Mukherji, 2011; Pasquinelli, 2012). miRISC target recognition and miRNA-mRNA 
binding occur via classical Watson-Crick base pairing and can result in either mRNA 
cleavage, translational repression or mRNA decay (reviewed by Fabian, 2012). While all 
RISC-loaded human AGO proteins are capable of repressing mRNA translation and 
facilitating mRNA degradation, AGO2 is the only protein that possesses the ability to 
actively cleave perfectly matched mRNA targets (Liu, 2004). The majority of miRNA-
mRNA interactions are however only partially complementary and translational 
repression therefore represents the predominant form of miRISC-mediated mRNA 
silencing (Lewis, 2003; Fabian, 2012).  
 
The exact molecular mechanisms and temporal events that govern miRNA mediated 
translational repression are not well understood and are likely constituted by 
multifaceted inhibitory processes (reviewed by Fabian, 2012). miRISC-mediated 
translational repression can result in either the transient silencing mRNAs, or their 
subsequent deadenylation, decapping and decay (reviewed by Pillai, 2005). 
Sequestration of PABP by GW182 and the recruitment of factors such as RCK/p54 can 
specifically repress 5’ cap recognition and recruitment of ribosomal machinery to target 
mRNAs (Cy, 2006; Mathonnet, 2007). Additionally, the GW182-PABP interaction may 
also function to further inhibit the initiation process by stifling eIF4G-mediated mRNA 
circularization (Fabian, 2012). miRISC can block translation following initiation by 
prompting premature dissociation of ribosomes from target mRNAs during the elongation 
process (Nottrott, 2006; Petersen, 2006). These translationally blocked mRNAs 
preferentially localise with cellular P-bodies and it is within these structures that their 
subsequent fates are determined (Pillai, 2005). mRNA destabilization is initiated by the 
CCR4-NOT and PAN2-PAN3 complexes, which facilitate deadenylation of the 3’ poly(A) 
tails of target mRNAs (Fabian, 2012). Following deadenylation, miRISC promotes 
removal of the 5’ cap from target mRNAs via recruitment of decapping factors like DCP1 
and DCP2 to target mRNAs (Nishihara, 2013). Unprotected mRNAs are then rapidly 
degraded by the 5’-3’ exonuclease, Xrn1 (Fabian, 2012). Alternatively, transiently 
repressed mRNAs may also be released from P-bodies in response to specific 
environmental cues (Bhattacharyya, 2006).  
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1.11.3 Functional relevance of host miRNAs 
 
A single mRNA transcript may be regulated by multiple miRNAs and a single miRNA 
may in turn regulate the expression levels of hundreds of transcripts to varying extents 
(Bartel, 2009). Intriguingly, mRNAs that are regulated by a common miRNA, or family of 
miRNAs, often belong to a single functional pathway or one that is closely related 
(Gennarino, 2012). The non-orthogonal nature of miRNA-mRNA interactions and the 
relaxed binding requirements for miRNA-mediated silencing thus enable the concurrent 
regulation of specific subsets of genes that are involved in functionally related 
processes. This is particularly significant when we consider that over 60% of all human 
coding transcripts are subject to miRNA-mediated regulation, and that the number of 
documented regulatory interactions between miRNAs and lncRNAs is also on the rise 
(Friedman, 2009; Jalali, 2013; Wang, 2013). It is not surprising then that miRNAs have 
been implicated in a number of complex physiological processes that require high-level 
coordination of multiple functional pathways and temporal control over the expression 
patterns of specific cohorts of genes (reviewed by Ivey 2015).  
 
In developmental biology miRNAs have been implicated in various aspects of 
embryogenesis and organ development (reviewed by Ivey 2015). Manipulation of miRNA 
expression levels can result in the reprogramming of human cells to pluripotent states, 
and likewise a number of miRNAs have also been implicated as critical determinants of 
cellular differentiation and lineage selection within pluripotent cell populations (reviewed 
by Gangaraju, 2009; Ivey, 2010; Anokye-Danso, 2011; Miki, 2015). Additionally miRNAs 
have emerged as critical regulators of cell cycle, proliferation and apoptosis thus placing 
them as critical factors in tumorigenesis (reviewed by Hwang, 2006). Briefly, deregulated  
miRNA expression may result in loss of transcriptional control over pro-oncogenic 
factors or the emergence of miRNA themselves as oncogenic molecules known as 
“oncomirs” (reviewed by Esquela-Kerscher, 2006). A number of studies have also 
documented a pivotal role for miRNAs in immunity and inflammation along with their 
associated pathologies (reviewed by Contreras, 2012 and O'Connell, 2012). Of particular 
interest, miRNAs have been implicated as crucial mediators of a diverse set of host 
responses to pathogenic challenge (reviewed by He, 2014 and Seddiki, 2014). 
 
The role of miRNA-mediated gene silencing in restriction of various forms of pathogenic 
bacteria have recently been well characterised (reviewed by Eulalio, 2012). The origin of 
host RNAi however can be linked to the intrinsic restriction of foreign dsRNAs that are 
characteristic of viral infection (reviewed by Obbard, 2009). Furthermore, a number of 
viruses have evolved sophisticated RNAi silencing suppressor (RSS) molecules, which 
suggests a prominent role for the host RNAi pathway in viral evolution (Obbard, 2009). 
Notably, ebola, hepatitis C virus (HCV) and influenza have all evolved protein-based 
RSS effectors, while adenoviruses employ an RNA-based strategy aimed at saturating 
the endogenous miRNA biogenesis pathway (reviewed by Bivalkar-Mehla, 2011). A 
number miRNAs have been identified as putative VRFs for a wide array of viruses 
(Lecellier, 2005; Lagos, 2010; Santhakumar, 2010). Alternatively, miRNAs may also 
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function as host dependency factors, such as in the case of miR-122 and HCV (Jopling, 
2005). These findings position miRNA biology at the crux of the viral-host interface and 
HIV-host interactions have proven to be no exception.  
 
1.12 Host miRNAs and HIV 
 
HIV infection has been reported to perturb global miRNA expression profiles to variable 
degrees in different studies (reviewed by Klase, 2012). Like many other viruses, HIV has 
evolved a number of strategies to both evade host miRNA-mediated repression, and 
selectively subvert the host miRNA network in order to promote a cellular environment 
conducive to viral replication (reviewed by Swaminathan, 2014). Furthermore, a number 
of specific host miRNAs have been identified as potential VRFs that act either by directly 
targeting viral transcripts, or indirectly by repressing endogenous targets that function as 
HDFs (Klase, 2012). Conversely, a small number of miRNAs, which themselves may 
function as putative HDFs, have also been recently uncovered (Swaminathan, 2014). 
The relationship between HIV and the host miRNA network is thus characterised by a 
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Figure 1.7. Host miRNAs that modulate HIV replication.  
Specific host miRNAs can either positively or negatively regulate HIV replication. miRNAs that 
negatively regulate HIV (red) do so either by directly targeting viral products, or via translational 
inhibition of specific HDFs required for viral replication. Likewise, miRNAs that positively regulate 
HIV replication (green) do so by suppressing potential VRFs.  
 
1.12.1  Perturbed miRNA expression in response to infection by HIV 
 
Perturbation of the host miRNA expression profile in response to HIV was noted by a  
seminal study that utilized a microarray-based approach to evaluate the relative 
expression of 312 host miRNAs in HeLa cells transfected with an infectious clone of HIV, 
pNL4-3 (Yeung, 2005). Not a single host miRNA was found to be significantly 
upregulated in response to HIV infection, while 43% of the interrogated miRNAs were 
downregulated (Yeung, 2005). This observation led to the hypothesis that HIV infection 
may exert a unilaterally suppressive effect on the expression of host miRNAs. This 
notion was however called into question by a subsequent study which utilized the same 
microarray platform to evaluate the effect of HIV infection in Jurkat cells and patient-
derived peripheral blood mononuclear cells (PBMCs; Triboulet, 2007). This latter study 
demonstrated  upregulation of 11 host miRNAs and specific downregulation of the miR-
17-92 family  in response to infection.  Additionally miR-122, miR-370, miR-373* and 
miR-297 were found to be exclusively expressed in HIV-infected cells but not in 
uninfected controls (Triboulet, 2007). These early findings thus alluded to a potential cell 
type-specific miRNA response to HIV, and the prevalence of a multifaceted effect on 
host miRNA expression following HIV infection (Yeung, 2005; Triboulet, 2007).  
 
Indeed, subsequent studies have suggested that the effect of HIV infection on miRNA 
expression may be highly selective and ‘purposely orchestrated’. A microarray-based 
evaluation of miRNA expression levels across 3 different cell types revealed miR-21, 
miR-26a, miR-155, miR-29a, miR-29b and miR-29c to be significantly downregulated 
following infection in PBMCs,  while miR-223 was found to be significantly upregulated 
(Sun, 2011). Changes in miRNA expression levels were more modest in CEM and 
Jurkat cell lines with only miR-29 and miR-155 found to downregulated following 
infection, while miR-223 was again shown to be upregulated (Sun, 2011). The 
differential expression of 21 host miRNAs in HIV-infected PBMCs was correlated with 
the differential expression of 444 host genes that mediate specific aspects of the 
apoptotic, MAPK, T cell receptor and Wnt signalling cascades (Gupta, 2011). All of these 
pathways have been previously associated with HIV replication thus implying that HIV 
may modulate the expression levels of specific miRNAs in order to subvert specific 
functional processes (Gupta, 2011). In addition, selective modulation of miRNA 
expression by HIV may also be temporally coordinated within infected cells (Chang, 
2013). Fifteen host miRNAs were observed to be differentially expressed at 5, 12 and 24 
50 
hours post infection (hpi) in SupT1 cells using small RNA sequencing (Chang, 2013). 
Furthermore, miRNAs that were differentially expressed at early infection time points 
were shown to revert back to their basal expression levels after 24 hours (Chang, 2013).  
These observations further support the the idea that HIV may selectively modulate 
specific host processes by regulating the expression levels of distinct subsets of host 
miRNAs.      
 
Two of the miRNAs (miR-143-3p and miR-10a-5p) previously identified to be 
differentially expressed at 24 hpi (Chang, 2013) were also observed to exhibit a similar 
trend 72 hpi in another study (Whisnant, 2013). A comparison the of miRNA expression 
profiles between 3 cell types (TZM-bl, C8166 T cells and PBMCs) infected with R5-tropic 
(BAL) and X4-tropic (pNL4-3) viral variants revealed that HIV infection only perturbed the 
expression levels of a few host miRNAs 72 hpi (Whisnant, 2013). Notably, a single 
miRNA miR-30b-5p, was found to be upregulated in PBMCs infected with BAL but not 
those infected by pNL4-3, while the miR-17-92 miRNA family was not differentially 
expressed (Whisnant, 2013). These findings contradict previous reports that described a 
more diverse perturbation of host miRNA expression in response to HIV infection, and 
further contribute to the poor concordance that has plagued expression-based 
evaluations of the host miRNA response to HIV (Klase, 2012).   
 
Despite the many contradictions within expression-based datasets, some robust yet 
subtle HIV-host interactions are clear. Notably, perturbation of miRNA expression 
following HIV infection is suggested to be highly selective and temporally coordinated. 
This level of control over the host miRNA network can facilitate viral modulation of 
discrete functional pathways at distinct stages of viral replication. The very nature of 
miRNA-based repression however, as determined by variable functional thresholds, 
makes extrapolation of functional significance from miRNA expression data alone very 
challenging (Mukherji, 2011). Additionally, discrimination between host and viral-driven 
changes in miRNA expression levels in infected cells requires further investigation in 
order to accurately interpret the significance of observed deviations. Thus while 
delineation of specific miRNA expression signatures relevant to HIV may serve to advise 
biomarker development and provide valuable correlative information on potential HIV-
host interactions, the identification of therapeutically relevant viral restriction factors 
(VRFs) and host dependency factors (HDFs) requires a more functional approach.  
 
1.12.2 The role of miRNAs in host and cell susceptibility to HIV 
  
The role of host miRNAs in natural viremic control phenotypes has been a subject of 
great interest but unfortunately one that has also not yielded much clinically relevant 
data. Comparison of miRNA expression profiles between patient samples from elite 
controllers and infected and uninfected normal progressors revealed miR-31 and miR-
31* to be suppressed in elite controller samples along with miR-125b and miR-150 
(Witwer, 2012). These latter miRNAs were also suppressed in infected normal 
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progressor samples thus implying that a common host or viral response related to miR-
125b and miR-150 expression still persists even under viremic control (Witwer, 2012). 
Plasma miRNA expression levels from samples of elite controllers, chronically infected 
patients and healthy uninfected donors revealed that 16 miRNAs were differentially 
expressed in chronically infected individuals, and miR-29b-3p, miR-33a-5p and miR-
146a-5p were significantly upregulated in elite controllers (Reynoso, 2014). Notably, elite 
controller and healthy donor groups showed no significant differences in plasma miRNA 
expression patterns, suggesting that HIV susceptibility may be closely linked to the 
expression levels of specific host microRNAs in response to infection.   
 
Susceptibility is also connected to the differentiation or activation state of HIV-infectable 
cell types. Activated T cells are more permissive to HIV replication compared to resting 
CD4+ T cell populations were HIV replication can be arrested in a latent state (Tyagi, 
2010). Additionally, while macrophages are susceptible to HIV infection, their monocytic 
progenitors are highly recalcitrant to permissive HIV replication (Bergamaschi, 2010).  A 
number of host miRNAs that regulate the differentiation or activation states of target cells 
have been implicated as putative mediators of HIV replication (Swaminathan, 2014). 
These miRNAs modulate cell susceptibility either by directly targeting viral transcripts or 
via their regulation of specific HDFs, and examples of each are presented in the 
following section.  
 
1.13 miRNAs as viral restriction factors 
 
A number of host miRNAs have been described to suppress HIV replication by directly 
targeting viral transcripts via miRISC-mediated translational repression (Hariharan, 
2005; Huang, 2007; Ahluwalia, 2008). A seminal study demonstrated the utility of an in 
silico prediction tool to identify putative host miRNA binding sites within HIV transcripts 
(Hariharan, 2005). Binding sites for miR-29a and miR-29b were found to be conserved 
within HIV Nef transcripts across multiple clades of HIV, while conserved binding sites 
for miR-149, miR-378 and miR-324-5p were identified in transcripts encoding Vpr, Env 
and Vif respectively (Hariharan, 2005). In a follow up study,  exogenous expression of 
miR-29a but not miR-29b downregulated Nef protein levels in Jurkat cells (Ahluwalia, 
2008). These findings were however later contradicted by the observation that miR-29b 
was one of 5 host miRNAs that could negatively regulate HIV transcripts in 42CD4 cells 
(Houzet, 2008). Likewise, overexpression of miR-29b-3p and miR-33a-5p, but not miR-
29a, could suppress HIV replication in both the MT2 cell line and primary CD4+ T cells 
(Reynoso, 2014). Photoactivatable ribonucleoside-enhanced cross-linking and 
immunoprecipitation (PAR-CLIP) analysis revealed 4 potential miRNA binding sites 
within the HIV genome that corresponded to miR-423, miR-301a, miR-29a and miR-155 
(Whisnant, 2013). While miR-423, miR-301a and miR-155 were observed to directly 
associate with and negatively regulate viral transcripts, miR-29a overexpression did not 
have a significant  effect on viral protein levels (Whisnant, 2013).  In accordance with 
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initial predictions (Hariharan, 2005) and in partial disagreement with prior findings 
(Reynoso, 2014; Whisnant, 2013) overexpression of both miR-29a and miR-29b 
significantly suppressed HIV replication and HIV Nef transcripts in a HeLa-derived cell 
line (Sun, 2012). Additionally miR-15a, miR-15b, miR-16, miR-24 and miR-150 were also 
predicted to target Nef transcripts, although these have not been functionally validated 
(Sun, 2011).  
         
In addition to miRNAs that target HIV transcripts involved in active replication, miRNAs 
that mediate HIV-resistance and latency have also been identified. miRNAs that were 
upregulated in resting CD4+ T cells were compared to conserved miRNA binding sites in 
HIV transcripts to identify those which potentially regulated viral latency (Huang, 2007). 
In functional assays, these miRNAs were shown to be within a cluster comprised of miR-
28, miR-125b, miR-150, miR-223 and miR-382, and were demonstrated to actively 
suppress viral transcripts in CD4+ T cells, thus implicating them in the maintenance of 
viral latency (Huang, 2007). The role of this miRNA cluster in monocyte and macrophage 
susceptibility to HIV replication has also been evaluated (Wang, 2009). Interestingly, 
repression of miR-28, miR-150, miR-223 and miR-382 by synthetic inhibitors enhanced 
HIV replication in patient-derived samples, presumably via relief of HIV-directed 
translational repression (Wang, 2009). In addition, these miRNAs were significantly 
down-regulated during monocyte to macrophage differentiation, and furthermore 
transfection with of synthetic mimics of these miRNAs recapitulated monocyte-like 
resistance to HIV in cultured monocyte-derived macrophages (MDMs; Wang, 2009). 
Together, these data suggest miRNAs targeted to viral transcripts regulate HIV activity 
and ‘inactivity’ in the case of latency.  
 
A novel mechanism of viral restriction was recently described whereby overexpressed 
RISC-free miR-146a and miR-888, bound directly to HIV Gag and antagonised its 
multimerization at the cell membrane (Chen, 2014a). The nonspecific association 
between HIV Gag and both host and viral mRNAs promotes Gag multimerization and 
virion assembly (Jouvenet, 2009). Thus, saturation of Gag RNA binding domains with by 
unbound small RNAs species like miRNAs, perturbed Gag stabilisation and 
internalization at the cell membrane (Chen, 2014a). In addition, depletion of AGO2 
recapitulated this restrictive phenotype, probably due to a consequential accumulation of 
RISC free miRNAs (Chen, 2014a). However, as AGO2 has been implicated in virion 
packaging and is known to associate with Nef (Aquil, 2013), the significance of these 
relationships in context of an AGO2-depletion phenotype, remains unclear. Furthermore, 
characterisation of host miRNAs that are able to reproducibly target viral transcripts 
across different viral variants and experimental conditions has proven challenging 
(Klase, 2012). While pursuit of these potential VRFs has uncovered valuable knowledge 
regarding miRNA-specific escape strategies and cell susceptibility to HIV, any miRNA-
based therapy that directly targets viral transcripts is inherently susceptible to the same 
inadequacies as treatments. miRNAs that function as VRFs via suppression of host 




Less than 20 putative miRNA-HDF regulatory associations have been characterised to 
date. This number appears far too modest when we consider the hundreds of potential 
HDFs already characterised by RNAi screening, and the critical role of the human 
miRNA network in the regulation of virtually every aspect of cellular biology. The HDF, 
p300-Creb binding protein associated factor (PCAF), is negatively regulated by miR-17-
92-associated miRNAs  in Jurkats and PBMCs (Triboulet, 2007). PCAF-mediated 
acetylation of Tat promotes Tat-mediated viral transcription and overexpression of both 
miR-17-5p and miR-20a specifically suppress PCAF translation in Jurkat cells (Triboulet, 
2007). The purine-rich element binding protein alpha (Pur-α) has been identified as a 
miRNA-regulated HDF, which serves as a transcriptional co-activator of HIV Tat (Shen, 
2012). Host miRNAs miR-15a, miR-15b, miR-16, miR-93 and miR-106b antagonise Pur-
α translation in HIV-restrictive monocytes, but this regulation is lost following 
differentiation into HIV-permissive monocyte-derived dendritic cells (MDDCs; Shen, 
2012). Ectopic application of synthetic mimics of these miRNAs was able to suppress 
HIV replication in MDDCs, while the same synthetic inhibitors relieved the restriction on 
HIV replication in monocytes (Shen, 2012).  
 
Cyclin-T1 is another well characterised Tat-associated HDF, which may be subject to 
active miRNA-mediated repression under certain conditions. In HIV-restrictive monocytic 
cell lines, Cyclin-T1 proteins are repressed by miR-198-mediated silencing and this 
phenotype is lost following monocyte to macrophage differentiation (Sung, 2009). 
Ectopic expression of miR-198 via synthetic mimics suppressed upregulation of cyclin-
T1 in differentiating monocytes,  and inhibited HIV transcription in monocytes transfected 
with an HIV proviral plasmid (Sung, 2009). In addition, miR-27b, miR-29b, miR-150 and 
miR-223 restricted HIV replication in resting CD4+ T cells via the suppression of Cyclin-
T1 (Chiang, 2012). While miR-27b and miR-29b are able to suppress Cyclin-T1 
transcripts directly, miR-150 and miR-223 suppress Cyclin-T1 indirectly by an unknown 
mechanism (Chiang, 2012).   
 
Activation of Toll-like receptor 3 (TLR3) can impede HIV replication in MDMs 
(Swaminathan, 2012). This restriction has further, in part, been attributed to RISC-
associated activity of miR-155, which is upregulated in response to TLR activation 
(Swaminathan, 2012; Seddiki, 2014). The mechanism of miR-155-mediated restriction 
occurs via  suppression of the known HDFs ADAM10, TNPO3, Nup153 and LEDGF/p75, 
which have all been implicated in HIV nuclear import (Friedrich, 2011; Swaminathan, 
2012). Furthermore, a recent study also implicated miR-155 as a pro-latency factor that 
suppresses the HIV activator protein, TRIM32 (Ruelas, 2015). The human Vpr binding 
protein (VprBP) mediates interaction of Vpr with specific host cell cycle-associated 
factors (Belzile, 2007). The host miRNA miR-1236 negatively regulates VprBP 
expression in HIV-restrictive monocytes but not MDDCs (Ma, 2014). In addition, both 
ectopic expression of miR-1236, and siRNA-mediated suppression of VprBP, similarly 
inhibited HIV replication in MDDCs only in the presence of Vpr-expressing viral variants 
(Ma, 2014).    
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Current knowledge on miRNA-HDF interactions, while limited,  has highlighted some 
interesting prospects that warrant further attention. Notably, four miRNAs that reportedly 
suppress HIV replication by directly targeting viral transcripts,  also reportedly do so 
indirectly via repression of HDFs (miR-150, miR-155, miR-223 and miR-29b). This 
observation would suggest that specific subsets of host miRNAs may potentially exert 
multiple modes of repression against HIV, and warrants a comprehensive 
characterisation of these potentially therapeutically relevant miRNAs. In addition, a 
number of host miRNAs have been identified as significant determinants of host cell 
susceptibility and latency, suggesting that continued investigation of HIV-miRNA 
interactions may also yield valuable insights into novel mechanisms that govern both 
innate viral restriction and HIV latency.      
 
1.14 RNAi evasion strategies utilised by HIV 
RNA silencing suppressor activity  
 
HIV reportedly utilises a diverse set of RSS effectors including Tat, Vif, Vpr, Nef and viral 
TAR RNAs. The prevalence of these diverse RSS strategies thus suggests an important 
role for the host miRNA pathway in the evolution of HIV (Bennasser, 2006; Coley, 2010; 
Hayes, 2011).  Similar to the RSS activity of adenoviral-encoded VA1 RNAs, TAR RNA 
structures encoded by HIV have been proposed to exert a broad disruptive effect on 
miRNA biogenesis by binding TRBP (Bennasser, 2006). Specifically, association of 
TRBP with TAR RNAs preclude its association with DICER, thereby affecting 
stabilisation of DICER protein levels (Bennasser, 2006). The RSS potential of Tat was 
first brought to light when a group of researchers stumbled upon the observation that 
exogenous Tat was able to suppress shRNA-mediated knockdown in cultured cells 
(Bennasser, 2005). A series of systematic validation experiments eventually mapped this 
phenotype to Tat-mediated suppression of DICER activity (Bennasser, 2005). The RSS 
function of Tat was further demonstrated to be independent of its transcriptional activity, 
but sensitive to a specific lysine to alanine point mutation in the RNA binding domain of 
Tat (TatK51A;Bennasser, 2005). The RSS-deficient TatK51A viral variant was 
subsequently demonstrated to have only a modest effect on naturally progressing HIV 
replication, while significantly sensitising viral replication to shRNA-mediated silencing of 
viral transcripts (Bennasser, 2005). The role of Tat as an RSS was further supported in a 
subsequent study (Qian, 2009), although in contrast to the earlier findings, the TatK51A 
mutation significantly retarded HIV replication, and Tat-mediated RSS activity was 
shown to occur downstream of DICER processing (Qian, 2009). Significantly, Tat-RSS 
activity was also proposed to selectively regulate specific host miRNAs as opposed to 
having a global effect on miRNA biogenesis (Qian, 2009).   
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Infection assays utilising Nef and Vpr-deficient viral variants resulted in attenuated 
antagonisation of DICER activity, thus implying that both Vif and Vpr may possess RSS 
activity (Coley, 2010). This hypothesis was further strengthened by observations that 
ectopic Vpr expression downregulated DICER protein levels, and that Nef could 
suppress RISC-mediated cleavage via its association with AGO2 (Coley, 2010; Aqil, 
2013). Comparison of miRNA expression levels between T cell lines infected with either 
a wildtype HIV variant or an RSS-deficient Tat variant, revealed that only a discrete 
subset of 19 host miRNAs were differentially expressed in response to attenuated Tat 
RSS activity (Hayes, 2011). Likewise only 5 host miRNAs were found to be differentially 
expressed in T cells infected with a Vif/Vpr deficient virus compared to those infected 
with wildtype virus (Hayes, 2011). Each of these discrete subsets represented only a 
small fraction of the 170 host miRNAs that were observed to be differentially expressed 
in infected T cells compared to uninfected control cells (Hayes, 2011). These findings 
thus strongly support the idea that each of the individual RSS effectors encoded by HIV 
are able to selectively antagonize distinct subsets of host miRNAs. Furthermore these 
findings imply that large scale dysregulation of host miRNA expression reported by some 
studies may represent a cumulative effect of multiple RSS effectors and  host-driven 
responses.  
 
Secondary structure of viral-encoded RNAs 
 
The notion that complex secondary structures within HIV RNAs can render them 
refractory to RNAi-mediated suppression was first documented many years ago 
(Westerhout, 2005). Stable expression of a siRNAs targeted to viral transcripts was 
initially found to effectively suppress HIV replication, although suppression was 
subsequently lost following emergence of viral escape variants that had either acquired 
nucleotide substitutions within siRNA binding sites, or occluded siRNA binding sites 
within altered secondary RNA structures (Westerhout, 2005). This evasive strategy has 
also been noted in models of miRNA-mediated viral suppression where increased RNA 
secondary structure complexity negatively correlated with miRNA-mediated suppression 
(Sun, 2011). Briefly, ectopic expression of synthetic mimics of miR-29a and miR-29b 
both only modestly suppressed a full-length Nef-luciferase reporter transcript (Sun, 
2011). Interestingly  suppression was significantly improved (up to 80%) when a shorter 
reporter transcript, unable to form loop structures, was used (Sun, 2011). Addition of 17 
extra base pairs to the short reporter transcript permitted formation of stem-loop RNA 
structures and resulted in attenuation of miR-29-mediated suppression (Sun, 2011). 
PAR-CLIP data also revealed that while HIV transcripts constitute a major fraction of the 
RNA population within infected cells (up to 50%), these viral transcripts are also a 100 
times more refractory to miRISC binding than their host counterparts (Whisnant, 2013). 
Cumulative knowledge thus suggests that prevalence of complex secondary structures 
within HIV transcripts represents a highly effective strategy to mitigate miRNA-mediated 
regulation of these transcripts. However, the question of whether these structures have 
evolved specifically for this purpose or some other function remains to be determined. 
Additionally these findings may also have important implications for the use of reporter 
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constructs in miRNA target validation, as constructs that do not take the secondary 
structure of endogenous RNAs into consideration may generate phenotypes that are not 
physiologically accurate.    
 
1.15 miRNAs as potential host dependency factors 
 
Recently, exploitation of miR-122 as an indispensable HDF during Hepatitis C Virus 
(HCV) replication, has led to clinical success and fueled a great interest in characterising 
a similar relationship for HIV (Jopling, 2005; Janssen, 2013). miR-217 has been put forth 
as a potential HDF due to its translational repression of SIRT-1, which was previously 
described to disrupt Tat-mediated transcription (Zhang, 2012). Exogenously added Tat 
upregulated miR-217 expression in a HeLa-derived reporter cell line (MAGI), while 
modestly suppressing SIRT-1 protein levels (Zhang, 2012). in addition, suppression of 
miR-217 by a synthetic inhibitor only resulted in a 34% reduction in LTR transcriptional 
activity (Zhang, 2012). miR-132 was found to be highly upregulated in activated CD4+ T 
cell populations, and augmentation of miR-132 expression with a synthetic mimic 
enhanced viral replication in Jurkats by potently reactivating latent proviral transcription 
(Chiang, 2013). These findings place miR-132 as an intriguing positive regulator of HIV 
replication. Perplexingly however, the effect of inhibiting miR-132 activity on HIV 
replication was omitted from this study, thus excluding an important control and leaving 
the potential of miR-132 as a therapeutically relevant HDF unknown (Chiang, 2013). A 
more recent study identified let-7c, miR-34a and miR-124a as potential HDFs that are 
also upregulated following infection in T lymphocytes and a HeLa-derived cell line 
(Farberov, 2015). let-7c suppressed translation of the putative VRF, p21, following 
infection, while miR-124a and miR-34a were shown to target TASK (also known as 
KCNK3), which has been previously implicated as a target of Vpu-mediated degradation 
and in virion release (Farberov, 2015). Subsequent suppression of these miRNAs was 
found to inhibit viral replication as well as in vitro dissemination of HIV (Farberov, 2015) 
 
There are currently only 5 host miRNAs that have been proposed as potential HDFs and 
unfortunately none of these relationships appear to be as robust as the one described 
for HCV and miR-122. Nevertheless, considering that functional relevance with regards 
to HIV interactions, for the majority of the host miRNome is unknown, there is still hope 
for identification and characterisation of a more ‘miR-122/HCV-like’ phenotype. 
Furthermore, positive regulation of HIV replication by specific host miRNAs succinctly 
demonstrates how HIV can ‘hijack’ the host miRNA network to subvert specific host 




1.16 Aims of this study 
 
A decade of research has placed host miRNAs and its associated miRNA pathway as 
critical determinants in the etiology of HIV-host interactions (reviewed by Klase, 2012 
and Barichievy, 2015). This dynamic relationship is now understood to be characterised 
by both host and viral-driven changes in cellular miRNA expression, subversion of 
specific subsets of host miRNAs in order to promote viral replication, and a diverse set of 
viral strategies to counter a select contingent of host miRNAs that may suppress viral 
replication. It must also be noted that much of the miRNA/siRNA-HIV research field is 
also littered with examples of poor concordance and inconsistencies between various 
bodies of work. Although these shortcomings are present in virtually all areas of HIV-
related research, they are perpetuated by varying experimental parameters, and are 
confounded by the highly complex and tissue-specific nature of miRNA functionality. In 
contrast to a wealth of information available on functional relevance of the entire human 
coding genome with regards to HIV, current knowledge regarding functional significance 
of all host miRNAs covers only a small fraction of the human miRNome. Intriguingly, 
even this limited knowledge has proven more than sufficient to posit that the human 
miRNome is a valuable tool in delineating  HIV-host biology. Clearly, the absence of 
large-scale functional miRNA data, similar to the seminal siRNA-HIV screens (reviewed 




The host miRNome has been identified as a critical mediator of host-pathogen 
interactions in the context of HIV replication. There is however a large gap in current 
knowledge regarding the functional relevance of each host miRNA within this 
relationship. The primary aim of this thesis was thus to address this shortcoming by first 
establishing and then utilising a high-content screening approach to characterise the 
functional relevance of host miRNAs during HIV replication.  
Objectives  
 
1) Establishment of  a robust high-content screening workflow  
 
The miRNA screens reported in this study represent the first large-scale, high-
throughput RNAi screens conducted within the Gene Expression and Biophysics Group, 
and thus a considerable amount of time was dedicated to the optimisation of specific 
cellular assays, and evaluation of technical requirements essential to the establishment 
of a robust high-content image-based screening platform. These optimisations and 
technical requirements were divided to into the following sub-categories: 
 
i) The rational design of a preliminary HCS experimental workflow  
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-Establishment of best practices for effective management and utilisation of reagent 
libraries, experimental plate design 
 
ii) Validation of a suitable HCS assay for the quantification of HIV replication by image 
based screening 
 
iii) Optimisation of experimental conditions for screening of miRNAs in microwell plates 
 
-Optimisation of cell seeding densities, transfection conditions, infection conditions, 
validation of experimental controls  
 
iv) Establishment  and validation of an effective image acquisition, image analysis and 
data management pipeline 
 
-Optimisation of imaging parameters for HCS, optimisation of image analysis 
parameters,  development and implementation of appropriate quality control measures, 
optimisation of data processing and hit selection criteria 
 
2) To utilize the screening workflow established in objective 1 in order to screen a 
commercial library of 1239 synthetic miRNA mimics and 1245 miRNA inhibitors in 
duplicate to identify host miRNAs, whose functional modulation, results in either 
enhanced or suppressed  HIV replication phenotypes 
 
3) To utilise a bioinformatics-based approach to identify putative functional targets of the 
miRNAs identified by objective 2 as well as specific regulatory pathways enriched for 
these targets  
 
4) To utilise the HCS approach established by objective 1 to screen a library of small 
molecules in order to validate the functional relevance of the pathways/functional targets 











Chapter 2: General materials and methods 
 
All optimisation and experimental procedures were undertaken at the Council for 
Scientific and Industrial Research (CSIR) site in Pretoria within the laboratories of the 
Gene Expression and Biophysics Group led by Dr. Musa M. Mhlanga (UCT/CSIR).  
 
2.1 Mammalian cell lines and culture conditions  
 
All tissue culture and cell culture based experimental steps were conducted within class 
II, type A2 biological safety cabinets (Labconco, USA) using standard aseptic 
techniques, and cell cultures were maintained within water-jacketed Forma™ Direct 
Heat CO2 incubators (Thermo Fisher Scientific, USA). Additionally these experiments 
were conducted within a dedicated biosafety level II (BSL II) tissue culture facility. 
Standard CO2 incubator conditions of 37 °C and 5% CO2 were maintained for routine 
culture and experimental conditions. Adherent cell lines were passaged using 1x 
TrypLE™ Express dissociation reagent (Thermo Fisher Scientific, USA). GHOST(3) 
X4/R5 cells, referred to as GHOST(3) cells, were obtained from the National Institute of 
Health (NIH) AIDS reagent programme (catalogue # 3942). GHOST(3) cell lines were 
cultured in phenol red-free Dulbecco's Modified Eagle's Medium (DMEM; Thermo Fisher 
Scientific, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; 
Merck Millipore, USA), 2 mM Gibco® GlutaMAX™ (Thermo Fisher Scientific, USA) and 
an antibiotic selection cocktail comprised of 10 µg/mL Hygromycin B (Thermo Fisher 
Scientific, USA), 1 µg/mL Puromycin (Thermo Fisher Scientific, USA) and 300 µg/mL 
Geneticin (G418) (Thermo Fisher Scientific, USA). HEK293T cell lines were cultured in 
phenol red-free DMEM (Thermo Fisher Scientific, USA) supplemented with 10% heat-
inactivated FBS (Merck Millipore, USA) and 2mM Gibco® GlutaMAX™ (Thermo Fisher 
Scientific, USA). TZM-bl cell lines were obtained from the NIH AIDS reagent database 
(catalogue # 8129) and maintained in the same media as HEK293T cells.  
 
2.2 Plasmids and plasmid purification 
 
An expression plasmid containing an Env-deficient PSG3-derived clone of HIV along 
with an ampicillin resistance (AmpR) cassette (PSG3ΔEnv) and another plasmid containing 
an R5-tropic HIV BAL-derived Env protein (pBAL-Env-AmpR) were kindly provided by the 
Aptamer Research Group at CSIR Biosciences. A full length molecular clone of X4 
tropic, pNL4-3-derived HIV (HIV Gag-iGFP) was also obtained from the NIH AIDS 
reagent programme (catalogue # 12457). Plasmids received from the NIH AIDS reagent 
programme were recovered from filter paper in Tris-EDTA (TE) buffer at pH 8.0 and the 
recovered DNA was quantified using a NanoDrop® ND-1000 UV-Vis spectrophotometer 
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(Thermo Fisher Scientific, USA). Plasmid stocks were amplified by propagation within 
stable DH5-α bacterial cultures under the relevant antibiotic selection. Briefly, an aliquot 
of competent DH5-α bacterial cells (50 µL in a microcentrifuge tube) was removed from 
the -80 ˚C freezer and thawed on ice. The cells were mixed gently in a circular motion 
using a pipette tip without aspirating any of the cell mixture and by using aseptic 
techniques. A total of between 10-50 ng of plasmid DNA was pipetted onto the thawed 
cell mixture and gently mixed using a pipette tip. The DNA-cell mixture was left 
submerged in ice for 30 minutes and then incubated at 42 ˚C for exactly 30 seconds in 
an AccuBlock™ digital dry bath (Labnet International Inc., USA) before being submerged 
in ice for 2 minutes. A 250 µL volume of antibiotic-free luria-broth (LB) media, pre-
warmed to 37 ˚C, was added to the bacterial cells and the bacterial cell mixture was then 
placed in a shaking incubator for 1 hour. A volume of 100-200 µL of the bacterial culture 
was spread over LB-agar plates containing the relevant antibiotic. The plates were 
allowed to dry at room temperature for ~ 20 minutes, then inverted and incubated at 37 
˚C overnight. Bacteria were harvested from a single colony on agar plates for 
propagation and plasmid purification using the Nucleobond® Xtra Maxi plasmid 
purification kit (Macherey-Nagel GmbH & Co.KG, Germany) as per the manufacturer's 
guidelines. Bacterial plates were sealed with parafilm and stored at 4 ˚C for up to 3 
weeks. Glycerol-stocks of all bacterial cultures were prepared during the early stages of 
the plasmid purification process and stored at -80 ˚C.   
 
2.3  Virus production 
  
HEK293T cells were co-transfected with PSG3ΔEnv and pBAL-Env plasmids using 
Fugene 6 lipid-based transfection reagent (Promega, USA) in order to produce single-
cycle infectious BAL-pseudotyped PSG3 virions (PSG3BAL). Briefly HEK293T cells were 
seeded in 23 mL of standard cell culture media within T-150 vented tissue culture flasks 
(TPP, Switzerland) at ~5000 cells/ flask 24 hr prior to transfection. On the day of 
transfection, 120 µL of Fugene 6 reagent was added directly to 3080 µL of serum-free 
basal DMEM media (SFM) within a sterile tube. The solution was gently mixed and 
incubated at room temperature for 5 minutes. 13,3 µg of pBAL-Env and 26,7 µg of 
PSG3ΔEnv  plasmid were added to the diluted Fugene 6 solution, mixed gently and 
incubated at room temperature for ~ 25 minutes. The transfection mixture was added to 
the horizontally oriented  flask in a dropwise manner and the flask was gently rocked to 
evenly distribute the transfection mixture. The transfected flask was then placed into a 
CO2 incubator for 6-8 hr. Approximately 6-8 hr post transfection the media was replaced 
with 30 mL of standard cell culture media and the flask was returned to a CO2 incubator 
for 48 hrs. The supernatant from the transfected flask was then harvested, 
supplemented with an extra 10% of FBS, filtered through a 0.45 micron (um) filter and 
subsequently aliquoted and stored at - 80 °C. HIV Gag-iGFP virions were produced in a 
similar manner except that HEK293Ts were transfected with 30 µg of a single HIV Gag-






The approximate number of infectious HIV virions per mL of viral stock (viral titre) was 
determined using an end point dilution assay based on the calculation of the 50% tissue 
culture infectious dose (TCID50) in TZM-bl cells (Kappes, 2005; reviewed by Richards, 
2006). TZM-bls are a HeLa-derived cell line that stably express CD4, CXCR4 and CCR5 
receptors as well as a Tat-sensitive reporter construct that drives co-expression of firefly 
luciferase and β-galactosidase (Kappes, 2005). Briefly, 150 µL of standard cell culture 
medium was added to all wells of a flat bottom 96-well tissue culture plate. Two viral 
stocks from separate harvests were incubated at 37 °C until fully thawed and 50 µL of 
thawed viral solution from each aliquot was added to each of the first 4 wells, or last 4 
wells of column 1 respectively of the 96-well plate. A 4-fold serial dilution was prepared 
by repeated mixing of the contents within each well of column, and 50 µL of virus 
containing media was then transferred from the wells in column 1 to those in column 2 
and sequentially on from column 2 to column 11, with 50 µL discarded from each well in 
column 11. The wells in column 12 of the plate were used as uninfected control samples. 
TZM-bls were seeded into all 96 wells at a density of 10 000 cells/per well, in 100 µL of 
standard cell culture media containing 7.5 mg/mL DEAE dextran. Following 48 hours of 
incubation at at 37oC and 5% CO2, 100 µL of supernatant was removed from each well, 
replaced with 100 µL of Bright-Glo™ luciferase assay substrate (Promega, USA) and 
incubated at room temperature for 2 minutes to allow cell lysis. The contents of each 
well were mixed by repeated pipetting and 150 uL was then removed from each well and 
transferred to a corresponding well on a black Corning costar® 96-well luminometer 
plate (Corning, USA). Luciferase activity within each well was recorded as a relative light 
unit (RLU) value using a FLx800™ multi-detection microplate reader and the 
accompanying Gen5 software package (BioTek®, USA). The RLU values were then 
used to determine the 50% endpoint dilution (TCID50 /mL) of each viral stock using the 
Reed-Muench method of TCID50 calculation  
(http://www.hiv.lanl.gov/content/nab-reference-strains/html/TCID501.xls). These titres 
were generally used as a point of reference and the infectivity of viral stocks  were 
always evaluated in the relevant cell line (e.g GHOST(3) cells) before use. 
 
2.4 RNAi transfection  
 
All miRNA mimic, miRNA inhibitor and siRNA transfections were carried out using 
Lipofectamine® RNAiMAX (Thermo Fisher Scientific, USA) as per the manufacturer's 
guidelines. Approximately 5000 cells were seeded in 80 µL of cell culture media per well 
of a 96 well plate 24 hours prior to transfection. On the day of transfection 0.15 µL of 
RNAiMax transfection reagent was added to 9,85 µL of SFM in a sterile microcentrifuge 
tube, and 2,5 µL of a 1 µM siRNA/miRNA mimic/miRNA inhibitor stock solution was 
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added to 7,5 µL of SFM in a separate tube. Each microcentrifuge tube was mixed gently, 
and then combined. The transfection mixture was incubated at room temperature for ~ 
20 minutes and all 20 µL of the transfection mixture was then added to the culture media 
to give a 25 nanomolar (nM) final concentration of siRNA/miRNA mimic/miRNA inhibitor, 
unless otherwise stated. Cells were cultured for 48 hour post transfection before 
downstream analysis. Transfection reactions were scaled according to the 
manufacturer's guidelines for the transfection of cells seeded in larger multiwell plates 
and flasks.  ON-TARGETplus (OTP) siRNA pools, a non-targeting dye-labelled siGLO 
green transfection control, all miRIDIAN miRNA mimic and inhibitor non-targeting 
controls and a Dy547-labelled non-targeting miRNA mimic transfection control were all 
purchased from Dharmacon™ (GE Healthcare, USA) 
 
2.5 HIV infection assays 
 
Viral stocks were thawed to 37 °C before use. Thawed virus was diluted in prewarmed 
(37 ˚C) infection media (IM), comprised of basal DMEM (Thermo Fisher Scientific, USA), 
2mM Gibco® GlutaMAX™ and 20 ng/mL of Polybrene® (Sigma-Aldrich®, USA), 
according to the required multiplicity of infection (MOI). An MOI of 0.5 (1 virion for every 
2 cells) was generally used for imaging based analyses and an MOI of 1 was used for all 
population based assessments including, qPCR and western blot analyses.   
 
2.6 RNA purification 
 
Total RNA was purified from cultured cells using TRIzol® lysis reagent (Thermo Fisher 
Scientific, USA) as per the manufacturer's instructions. Briefly, for adherent cells grown 
in a 35 mm tissue culture dish, culture media was removed and replaced with 1 mL of  
TRIzol® lysis reagent within an active fume hood. The  TRIzol® lysis reagent was then 
repeatedly pipetted several times using a 1 mL pipette tip to ensure cell detachment and 
lysis. Cell lysates were incubated at room temperature for 5 minutes to facilitate 
dissociation of nucleoprotein structures, transferred to a sterile microcentrifuge tube and 
200 µL of ≥99% anhydrous Chloroform (Sigma-Aldrich®, USA) was added directly. The 
microcentrifuge tube was vigorously shaken by hand for 15 seconds resulting in a milky 
pink solution that was then incubated at room temperature for 3 minutes. The solution 
was then centrifuged at 12 000 x g for 15 minutes at 4 °C in a Microfuge 22R 
refrigerated benchtop microcentrifuge (Beckman Coulter Incorporated, USA).  
 
Following centrifugation the solution separated into three distinct phases including a 
lower red phase containing protein, a gelatinous intermediate phase containing DNA and 
a clear upper phase containing RNA. The upper RNA-containing aqueous phase was 
carefully transferred to another sterile microcentrifuge tube and 500 µL of 99.5% 
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anhydrous 2-Propanol (Sigma-Aldrich®, USA) was added, the mixture was incubated at 
room temperature for 10 minutes, and then centrifuged as before. The supernatant was 
carefully discarded so as to not disturb the RNA pellet visible at the bottom of the 
microcentrifuge tube.  Absolute ethanol (Sigma-Aldrich®, USA) was diluted to 75% in 
sterile water and 1 mL was added to the RNA pellet. The microcentrifuge tube was 
vortexed briefly to dislodge the RNA pellet and then centrifuged at 7 500 x g for 5 
minutes at 4 °C. The ethanol was carefully discarded and the RNA pellet was partially 
dried at room temperature for ~ 5-10 minutes depending on the size of the pellet. The 
RNA pellet was then resuspended in ~30 µL of sterile RNAse-free water using a 20 µL 
filtered pipette tip and repeated pipetting. The RNA solution was incubated at 56.5 °C for 
~ 12 minutes, cooled on ice and quantified using a NanoDrop® ND-1000 UV-Vis 
spectrophotometer (Thermo Fisher Scientific, USA). Only RNA samples with a 260 
nanometer (nm) to 280 nm absorbance ratio > 1.8 and < 2.2 were retained for 
downstream cDNA synthesis. RNA quality was further validated by RNA gel 
electrophoresis and samples were aliquoted and stored at -80 °C to minimize the 
number of freeze-thaw cycles per aliquot.  
 
RNA  gel electrophoresis  
 
The integrity of all RNA samples was validated by gel electrophoresis before their 
inclusion in downstream applications. RNA samples were prepared by adding the RNA 
sample to an equal volume of 2X denaturing RNA Loading Dye (Thermo Fisher 
Scientific, USA), followed by incubation at 70 ˚C for 10 minutes in an AccuBlock™ digital 
dry bath (Labnet International Inc., USA). Samples were cooled to room temperature 
and loaded onto a 3% SeaKem® LE Agarose (Lonza Group, Switzerland) 3-(N-
morpholino)propanesulfonic acid (MOPS) gel. RNA gels were run in 1x MOPS running 
buffer containing both formamide and ethidium bromide and gels were visualised under 
UV light using a Syngene G:Box gel imaging system and associated GeneSys image 
acquisition software (Synoptics Ltd., United Kingdom). 1 µg of sample RNA was loaded 
in each well and the presence of intact 18S and 28S ribosomal RNA bands were used to 
evaluate the quality of RNA samples (Appendix II, Figure A2.1). 
 




RNA samples were thawed on ice and treated using RQ1 RNAse-free DNAse (Promega, 
USA) prior to reverse transcriptase polymerase chain reaction (RT-PCR). All DNAse 
treatment reactions and cDNA synthesis reactions were prepared on ice. Briefly, a 
standard amount of 1 µg of starting RNA was used for all DNAse treatment reactions. 1 
µL of  RQ1 RNase-Free DNase 10X Reaction Buffer (Promega, USA) and 1 µL of RQ1 
RNase-Free DNase (Promega, USA) were added to 1 µg of starting RNA in a sterile 
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microcentrifuge tube and the reaction was made up to a final volume of 10 µL using 
sterile RNAse-free water (Promega, USA), followed by incubation at 37 °C for 30 
minutes using a T100™ thermal cycler (Bio-Rad, USA). 1 µL of stop solution was added 
to the reaction, followed by incubation at 65 °C for 10 minutes as before to terminate 
DNAse activity. 
 
Reverse transcription PCR 
 
RT-PCR was performed using the SuperScript® III First-Strand Synthesis system 
(Thermo Fisher Scientific, USA) as per the manufacturer's guidelines. Briefly, 1 µL of the 
supplied 50 µM oligo(dT) primer or 50 ng of random hexamer primer was added to 8 µL 
of DNAse-treated RNA solution in a sterile microcentrifuge tube followed by 1 µL of the 
supplied dNTP mix. The reaction was incubated at 65 °C for 5 minutes in a T100™ 
thermal cycler (Bio-Rad, USA). The microcentrifuge tube was submerged in ice for 2 
minutes and a cDNA synthesis mastermix was prepared in a separate sterile 
microcentrifuge tube by the sequential addition of 2 µL of 10x RT buffer , 4 µL of 25 mM 
MgCl2 , 2 µL 0.1 M Dithiothreitol (DTT), 1 µL of RNaseOUT™ and 1 µL of SuperScript® 
III reverse transcriptase enzyme. The 10 µL cDNA synthesis mastermix solution was 
then added to the chilled RNA-primer solution and depending on the primer used, the 
reactions were then subjected to different incubation steps. For oligo(dT) primer 
reactions, the microcentrifuge tube was incubated at 50 °C for 50 minutes and then at 85 
°C for 5 minutes. For random hexamer primer reactions, the microcentrifuge tube was 
first incubated at 25 °C for 10 minutes, then at  50 °C for 50 minutes and finally at 85 °C 
for 5 minutes. Microcentrifuge tubes were chilled on ice for 2 minutes and briefly 
centrifuged. 1 µL of RNase H was added to the solution and the microcentrifuge tube 
was then incubated at 37 °C for 20 minutes in order to remove  residual RNA. Reverse 
transcriptase deficient (no-RT) control reactions were prepared for each RT sample in 
exactly the same manner as described for RT samples (including DNase treatment)  
except that RT was replaced with nuclease-free water in the preparation of  the cDNA 
master mix solution. 1 µL/reaction of sample cDNA  or noRT control was utilized in all 




All primer sets  utilised in this study were purchased from Inqaba Biotechnologies™ 
(South Africa) and were designed using the NCBI primer blast online primer designing 
resource (www.ncbi.nlm.nih.gov/tools/primer-blast/). The following general criteria were 
used for primer design: Human mRNA REFseq accession numbers were used as  input 
templates for the design of primer set targeted to human transcripts. The sequence of 
relevant regions of  HIV-PSG3 viral genome were used as the input templates for the 
design of primer sets targeted to specific viral transcripts. A PCR product size range of 
between 100-1000 bp was used. Optimal primer melting temperature (Tm) was set at 60 
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˚C and the minimum and maximum Tms were set to 58 ˚C and 62 ˚C respectively. Primer 
specificity was evaluated by blasting each primer set against the Homo sapien Refseq 
RNA database. Primers were reconstituted to 100 µM stocks in nuclease free water 
(Invitrogen, USA), aliquoted at stored at -20°C. Working dilutions of 10 µM were 
prepared for each primer, and stored at -20°C. A summary of the primers utilised in this 
study are presented in Table 2.1. All individual primers were utilised at a final 
concentration of 500 nM.  
     
 
Table 2.1. Primer information 
Primer Sequence (5’-3’) PCR product size (bp) 
ß-actin forward CGAGCACAGAGCCTCGCCTTT 878 
ß-actin reverse CCACAGGACTCCATGCCCAGG 
CD4 forward CTGTGGTGGCAGGCGGAGAG 
 
143 
CD4 reverse  TGGGGCAGGGTGAGGTGGAG 
CDKN1A forward AGTCAGTTCCTTGTGGAGCC 842 
CDKN1A reverse AGGAGAACACGGGATGAGGA 
EGFR forward CTGTCCAACGAATGGGCCT 656 
EGFR reverse TGATCTTGACATGCTGCGGT 
HIV Gag forward GGCCTTCAGCCCAGAAGTAA 593 
HIV Gag reverse CTTTATGGCTGGGTCCTCCC 
 
HIV Tat forward GTGGCAATGAGAGTGACGGA 959 
HIV Tat reverse AGTGCTCTGCCTGGTCCTAT 
HPRT forward GCAGCCCTGGCGTCGTGATTA 499 
HPRT reverse CGTGGGGTCCTTTTCACCAGCA 
Lincp21 forward CAGGGAACCCCTTCAATCCC 400 
Lincp21 reverse  TTTTTGCCCACATGAGCCTG 
TP53 forward TGACACGCTTCCCTGGATTG 610 
TP53 reverse  ACCATCGCTATCTGAGCAGC 
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2.9  Conventional PCR and DNA gel electrophoresis 
 
Conventional PCR (PCR) was utilized either to identify the optimal annealing 
temperature(s) for new primer sets or for the qualitative assessment of gene expression. 
A final reaction volume of 25 µL was utilised per reaction using the Kappa HiFi DNA 
polymerase kit (Kapa Biosystems, USA) and the following cycling conditions: initial 
denaturation at 95 ˚C for 5 min followed by 35 cycles of 98°C for 20 seconds, 60°C for 
15 seconds and 72°C for 60 seconds, followed by a final extension step of 72 ˚C for 60 
seconds and a 4 ˚C hold step. The 60 ˚C annealing step was replaced with a suitable 
temperature gradient as required and all conventional PCRs were run in a T100™ 
thermal cycler (Bio-Rad, USA).  
 
DNA agarose gel electrophoresis 
 
PCR products were subjected to size-dependent separation using agarose gel 
electrophoresis. Briefly, agarose gels were prepared by diluting 2% (w/v) SeaKem® LE 
Agarose (Lonza Group, Switzerland) in 1x Tris-Borate-EDTA (TBE) electrophoresis 
buffer. Ethidium bromide (Sigma-Aldrich, USA) was added to the agarose solution at a 
final concentration of 0.5 µg/mL before the gel was cast. 6x DNA gel loading dye 
(Thermo Fisher Scientific, USA) was diluted to 1x for each PCR product and loaded into 
individual wells of the agarose gel. A DNA molecular weight marker (MWM), 
GeneRuler™ 100 bp Plus DNA Ladder (Thermo Fisher Scientific, USA) was included on 
the first and/or last lane of each gel to confirm the size of PCR products.  
 
2.10 Quantitative real-time PCR (qPCR) 
 
qPCR was utilised in order to quantify and compare the expression levels of transcripts 
of interest between specific experimental conditions. A final reaction volume of 20 µL 
and the SsoFast™ EvaGreen® Supermix (Bio-Rad, USA) was utilized for all qPCR 
reactions, and they were run in a CFX96™ real-time PCR detection system (Bio-Rad, 
USA) using the CFX Manager™ software interface. The following general protocol was 
utilized for all qPCR runs: 1) an initial denaturation step of 94 °C for 2 minutes, 2) 40 
cycles of 94 °C for 15 seconds, 60 °C for 30 seconds, 72 °C for 1 minute, a single plate 
read in the SYBR green channel, 3) a 72°C extension step for 10 minutes, and 4) a melt 
curve analysis. The melting curve analysis ranged from 50 °C to 95 °C in 0.5 °C 
increments with a plate read (SYBR-Green) for every 1 °C increment following a 5 
second hold step. The 60 ˚C annealing step was replaced with an alternative 
temperature as required by specific primer sets. The melting temperature obtained for 
each qPCR product was confirmed using DNA gel electrophoresis as described above. 
Three technical replicates of every transcript of interest and references gene(s) were 
included for each experimental condition in a single qPCR run and three experimental 
runs were performed for each set of qPCR results presented in this dissertation (n=3). 
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The quantification cycle (Cq), also known as threshold cycle or CT, values obtained for 
each reaction were then normalised using the 2 -ΔΔCT  method (Livak, 2001) in order to 
determine the relative expression levels of transcripts of interest (see below). 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT), Beta-actin (ß-actin) and 
Ribosomal Protein S12 (RPS12) were evaluated/utilised as reference genes in this 
study. 
 
2 -ΔΔCT  analysis 
 
The average Cq value of the technical replicates of each transcript of interest in each 
experimental condition were normalized against the average Cq of the internal reference 
gene for that particular experimental condition. Where possible, the geometric mean of 
the average Cq  values of multiple reference genes were utilised. These normalised Cq 
values were then normalised against the values obtained for the experimental control in 
order to determine the relative fold-change in transcript expression levels between 
experimental conditions.The statistical significance of the fold change values derived 
from 3 separate experimental runs was determined using either a two-tailed Student's T-
test or a single factor analysis of variance (ANOVA) depending on the number of 
transcripts being investigated in an experimental run. Kolmogorov-Smirnov tests were 
utilised to confirm a normal distribution of the data. All statistical analyses were 
performed using SPSS v.15.0 (IBM® Corporation, USA). Transcript expression levels 
are presented as bar graphs and error bars represent the standard error of the mean 
(SEM).  
 
2.11 Protein extraction 
 
Whole cell lysis 
 
Whole cell lysate was extracted using radio-immunoprecipitation assay (RIPA) lysis 
buffer (150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 
mM Tris pH 8.0) supplemented with cOmplete™ mini EDTA-free protease inhibitor 
cocktail (Roche, Switzerland). Cultured cells were were harvested in ice cold RIPA buffer 
using a cell scraper (TPP, Switzerland) and transferred to a pre-chilled (on ice) sterile 
microcentrifuge tube. The lysis solution was then incubated at 4 ˚C for ~ 45 minutes on 
an agitator before being centrifuged at 16 000 x g for 20 minutes at 4 ˚C in a Microfuge 
22R refrigerated benchtop microcentrifuge (Beckman Coulter Incorporated, USA). The 
supernatant (whole cell lysate) was transferred to a pre-chilled (on ice) sterile 
microcentrifuge tube and the pellet (cell debris) was discarded. Protein concentration 
was quantified by absorbance using a NanoDrop® ND-1000 UV-Vis spectrophotometer 
(Thermo Fisher Scientific, USA) and samples were snap frozen in liquid nitrogen and 




Nuclear and cytoplasmic fractionation 
 
Nuclear and cytoplasmic protein fractions were purified from cultured cells using the NE-
PER®  nuclear and cytoplasmic extraction kit (Thermo Fisher Scientific, USA) as per the 
manufacturer's instructions. All centrifugation steps were performed at 4 ˚C  in a 
Microfuge 22R refrigerated benchtop microcentrifuge (Beckman Coulter Incorporated, 
USA) and all reactions were prepared on ice. The required volumes of CERI and CERII 
buffers were supplemented with cOmplete™ mini EDTA-free protease inhibitor cocktail 
(Roche, Switzerland) prior to use. Briefly, cultured cells were harvested in ice cold 1x 
PBS buffer using a cell scraper (TPP, Switzerland ) and transferred to a sterile 
microcentrifuge tube. Cells were pelleted by centrifugation at 500 x g for 3 minutes and 
the supernatant was discarded. The pelleted cells were resuspended in CERI buffer by 
vortexing at maximum speed for 15 seconds and then incubated on ice for 10 minutes. 
An appropriate volume of CERII buffer, relative to the volume of CERI buffer used, was 
added to the resuspended cell mixture, samples were then vortexed at maximum speed 
for 5 seconds and incubated on ice for 1 minute. Samples were then similarly vortexed 
and centrifuged at 16 000 x g for 5 minutes. The supernatant containing the cytoplasmic 
protein fraction was carefully removed and transferred to a pre-chilled (on ice) sterile 
microcentrifuge tube. The remaining nuclear pellet was resuspended in 100 µL of ice-
cold NER buffer and vortexed at maximum speed for fifteen seconds. The sample was 
placed in ice and vortexed at maximum speed for 15 seconds every 10 minutes for a 
total of 40 minutes. The sample was centrifuged at 16 000 x g for 10 minutes and the 
supernatant containing the nuclear protein fraction was transferred to a sterile and pre-
chilled (on ice) microcentrifuge tube. Nuclear and cytoplasmic fractions were aliquoted 
and snap frozen in liquid nitrogen before being stored at - 80 ˚C. The protein 
concentration of specific aliquots was quantified using a NanoDrop® ND-1000 UV-Vis 
spectrophotometer (Thermo Fisher Scientific, USA) prior to use.  
 
2.12 Western Blot Analysis 
 
Rabbit anti-EGFR (ab2430), mouse anti-p24 (ab9071) and rabbit anti-Histone H3 
(ab1791) primary antibodies were purchased from Abcam plc (UK). A goat anti-Actin C-
11 (sc-1615) antibody was purchased from Santa Cruz Biotechnology® Inc. (USA). 
Horseradish peroxidase (HRP)-conjugated secondary antibodies raised against rabbit, 
mouse and goat were purchased from Rockland Immunochemicals Inc. (USA).  
 
Total cell lysates as well as nuclear and cytoplasmic protein fractions were resolved by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 10% bis-
acrylamide denaturing gels. Protein isolates were diluted in Laemmli sample loading 
buffer (Bio-Rad, USA), incubated at 95 ˚C for 5 min and cooled to room temperature 
before loading. A total of 20 µg of whole cell lysate, 40 µg of cytoplasmic protein extract 
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and 20 µg of nuclear protein extract were loaded per well and at least one lane on every 
gel was reserved for a Precision Plus Protein™ marker (Bio-Rad, USA). SDS-PAGE 
gels were run in pre-chilled (4 ˚C) Tris-glycine running buffer (25 mM Tris, 192 mM 
Glycine, pH 8.3) at 130 volts (V) for ~2 hours. Proteins were transferred to an Immun-
Blot® polyvinyl difluoride (PVDF) membrane (Bio-Rad, USA) in pre-chilled (-20 ˚C) 
transfer buffer (25 mM Tris, 192 mM Glycine, 10% Methanol, 5% SDS) at 55 V for ~ 2.5 
hours. Membranes were blocked in 5% (w/v) bovine serum albumin (BSA, Sigma-
Aldrich, USA) and 1x PBS buffer for 1 hour at 4 ˚C on a rotating shaker and then rinsed 
in 0.5 % (v/v) Tween® 20 (Sigma-Aldrich, USA) in 1x PBS buffer (PBS-T). Membranes 
were incubated at 4 ˚C overnight with primary antibodies diluted in 0.5 % PBS-T as 
follows:rabbit anti-EGFR at 1:250, mouse anti-p24 at 1:500, rabbit anti-Histone H3 at 
1:1000 and goat anti-Actin at 1:500. Membranes were washed 3 times in 0.5% PBS-T 
for 10 minutes at room temperature on a rotating shaker and incubated with an 
appropriate HRP-conjugated secondary antibody diluted in 0.5% PBS-T for 1 hour at 
room temperature on a rotating shaker. Membranes were washed three times in 0.5% 
PBS-T on a rotating shaker for 10 minutes at room temperature before being incubated 
with Clarity™ enhanced chemiluminescence substrate (Bio-Rad, USA) for 5 minutes at 
room temperature on a rotating shaker. HRP activity was visualized as immunoreactive 
bands using a ChemiDoc™ XRS+ system (Bio-Rad, USA). Blots were acquired as 





Densitometric analyses were performed using FIJI open source image analysis software 
(Schindelin, 2012) and Microsoft excel 2011 (Microsoft, USA). Briefly, the raw images 
obtained from the ChemiDoc™ XRS+ system were converted to 8-bit images and 
analysed in FIJI using the Analyze>Gels function. The profile of each lane on a blot was 
defined in order to include band(s) representing the protein of interest (e.g. EGFR) as 
well as the band representing the reference protein for that sample (e.g. Actin). The 
intensities of the bands defined by each lane were then measured and recorded as 
peaks in signal intensity. All of the recorded measurements for each lane were then 
exported to Excel for further analysis. The signal intensity value(s) for the protein of 
interest in each experimental condition was first normalised against the intensity value of 
the reference protein for that lane in order to normalise the signal intensity measurement 
against the amount of total protein loaded per lane. The normalised signal intensity for 
the protein of interest (∆ Intensity) in each experimental condition was then normalised 
again, this time using the ∆ Intensity value for the control condition in order to determine 
the relative expression level of the protein of interest in each experimental condition as 
compared to the experimental control.   
70 
 
2.13 Immunocytochemistry (ICC) 
 
Indirect immunofluorescence was utilized in order to evaluate the expression levels and 
subcellular locations of specific proteins by fluorescent microscopy. Primary antibodies 
were purchased from Abcam (UK) and ATTO dye-conjugated secondary antibodies 
were purchased from Rockland Immunochemicals Inc. (USA). Cultured cells were fixed 
in 4% Paraformaldehyde (PFA, Sigma-Aldrich®, USA) solution at room temperature for 
15 minutes. Fixed cells were washed 3 times in 1x PBS for 5 minutes at room 
temperature per wash and then permeabilized in a 0.25% (v/v) Triton X-100 (Sigma-
Aldrich®, USA) solution made up in 1x PBS for 15 minutes at room temperature. The 
permeabilization solution was removed and then replaced with a blocking solution 
comprised of 2% (w/v) BSA in 1x PBS, and cells were incubated at room temperature for 
1 hour. The blocking solution was removed and replaced with primary antibody diluted in 
antibody dilution buffer comprised of 1% (w/v) BSA and 0.15% (v/v) Triton™ X-100 in 1x 
PBS using the following dilutions: rabbit anti-EGFR (ab2430) at 1:200, mouse anti-p24 
(ab9071) at 1:100 and mouse anti-H2AX-γ phospho-serine 139 (ab1174) at 1:500. Cells 
were incubated in primary antibody solution for either 1 hour at room temperature 
(EGFR, H2AX-γ) or overnight at 4 ˚C (p24). Following the primary antibody incubation 
step, cells were subjected to three 5 minute washes in 0.2% PBS-T at room 
temperature.  
 
Cells were incubated with an appropriate dye-conjugated secondary antibody for 1 hour 
at room temperature with samples covered in aluminum foil. Secondary antibodies were 
diluted (1:1000) in antibody dilution buffer prior to use. All steps following the secondary 
antibody incubation were performed with samples shielded from light using aluminium 
foil. Following the secondary antibody incubation step, cells were subjected to three 5 
minute washes in 0.2% PBS-T and nuclei were counterstained with 2 µM Hoechst 33258 
(Sigma-Aldrich, USA) in 1x PBS for 15 minutes at room temperature. Cells were washed 
with 1x PBS and then either imaged in a suitable volume of 1x PBS (cells seeded in 
µClear® 96 well imaging plates (Greiner Bio-One International GmbH, Germany) or 
glass-bottomed tissue culture dishes (MatTek corporation, USA)) or mounted prior to 
imaging (cells seeded on coverslips were mounted onto glass slides using 
VECTASHIELD® antifade mounting medium (Vector Laboratories, USA), and the edges 
of the coverslips were sealed using clear nail polish before imaging). Antibody-specific 
negative controls were prepared in each ICC experimental set where either the primary 
or secondary antibody was excluded from the ICC process. These controls were 
included in order identify primary antibodies that were autofluorescent and secondary 







Two imaging systems were utilised for the microscopy-based experimental work 
described in this dissertation. The first was a spinning disk confocal microscope system 
(Andor Technology, UK) comprised of an Axio Observer Z1 inverted light microscope 
(Zeiss, Germany) equipped with a ProScan™ PZ100 motorized microscope stage (Prior 
Scientific, UK), a Polychrome V monochromator (TILL Photonics GmbH, Germany) with 
a 320-680 nm output range, Lambda 10-3 optical filter changers and 
SMARTSHUTTER™ control system (Sutter instrument company, USA), a CSU-X1 
spinning disk confocal scanner unit (CSU, Yokogawa electric corporation, Japan), a 
Definite Focus infra-red LED-based automatic focus unit (Zeiss, Germany), an iXONEM+ 
electron multiplying charge coupled device (EMCCD) camera (Andor Technology, UK) 
and a Revolution laser combiner 400 series (Andor Technology, UK). The following 
excitation and emission wavelengths were utilised: Hoechst/ DAPI:  405/, GFP/ ATTO 
488: 500/520, CY3/ ATTO 550: 550/570, CY5/ ATTO 647: 649/670. Images were 
acquired as 14-bit Tagged image file format (TIFF) files. The following Zeiss objectives 
were utilised: 10x Plan-apochromat (NA 0.45), 20x Plan-apochromat (NA 0.8) and 40x 
Plan Neofluar® oil (NA 1.3). Image acquisition settings (i.e exposure times, laser power, 
gain, averaging etc.) were kept constant across all samples within an experimental set 
for each channel acquired.  
 
The ImageXpress® Ultra (IXU) confocal high content screening system (Molecular 
Devices LLC, USA) was the the second imaging system utilised in this study. All of the 
image-based screens were undertaken using this closed-box point-scanning confocal 
microscope system comprised of 4 solid state lasers (405 nm, 448 nm, 532 nm, 635 
nm), 16-bit photomultiplier tube (PMT) detectors, a motorised stage, a dedicated 690 nm 
laser autofocus system, 5 self-aligning beam splitters and four Nikon objectives (Nikon, 
Japan). Images were acquired using the MetaXpress® image acquisition and analysis 
software programme (Molecular Devices LLC, USA) and were saved as individual (per 
channel/FOV) 16-bit TIFF files containing specific meta-data such as plate and well ID, 
acquisition channel information and FOV location data. Image acquisition settings (i.e 
binning, laser power, gain, averaging etc.) were kept constant for each acquisition 
channel within an experimental set and across all plates within a single screening 
replicate. Images obtained from miRNA and compound screens were acquired 
sequentially for each channel per FOV using the 20x Plan-apochromat λ objective (NA 
0.75) and 4 FOVs (100 µm apart) were acquired per well. The 10x Plan-apochromat λ 
(NA 0.45) and 40x Plan-apochromat λ objective (NA 0.95) were utilised in optimisation 
and downstream validation experiments and imaging parameters were adjusted as 




2.15 Image analysis 
 
Routine image processing for ICC and other low throughput imaging experiments was 
carried out using the open source image analysis software package, FIJI (Schindelin, 
2012). The image analysis approaches utilised for HCS are discussed in detail in 
Chapter 3. The development of bespoke MATLAB® (Mathworks Inc, USA) scripts and 
their subsequent optimisation and execution for HCS were performed by Mr. Rethabile 
Khutlang and Dr. Johnathan Warrell, members of the Gene Expression and Biophysics 
Group at CSIR.  
 
2.16 Statistical analysis and data mining for HCS 
 
HCStratomineR (HCSR) is a web based statistical analysis and data mining solution that 
was specially designed for the analysis of HCS data. HCSR was designed by a 
collaborator, Mr. Wienand Omta, at the University Medical Centre Utrecht in Holland 
(publication under review) and was utilised for all of the quality control monitoring, data 
visualization, data transformation, data reduction and hit selection steps in the HCS 
image analysis pipeline developed for this study. 
 
2.17 miRNA pathway analysis 
 
miRNA target prediction and subsequent pathway analysis was completed using an 
open source web-based miRNA pathway analysis tool, miRpath (Vlachos, 2015).  
miRpath integrates the functionality of a miRNA target prediction tool (microT-CDS), a 
database of experimentally validated miRNA-target interactions (TarBase v7.0) and the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway resource in order to 
evaluate the statistical and  hierarchical probability of miRNA-pathway interactions. 
miRNA hit lists were uploaded on the miRpath server and where available, TarBase was 
utilised as the primary miRNA target identification resource. False discovery rate (FDR) 
correction and conservative statistical analyses were applied and miRNA target data 
was merged using the pathways union option. A p-value threshold of 0.05 and a microT-
CDS threshold of 0.8 were applied.  
 
2.18 Compound-protein interaction analysis 
 
Compound interaction analyses were performed for compounds identified as screen hits 
using the online chemical-protein interaction resource, STITCH 4.0 (Kuhn, 2008). 
Compound hit lists from pre- and post- exposure drug screens were uploaded to the 
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STITCH 4.0 web page using the batch import function and protein interactions were 
predicted using the Neighbourhood, Gene Fusion, Co-occurrence, co-expression, 
Experiments, Databases and Textmining prediction options along with the requirement 
of a high confidence (> 0.7) interaction score. Gene ontology (GO) term functional and 
spatial enrichment and analyses were also applied within STITCH 4.0.  
 
2.19 miRIDIAN miRNA library  
 
The miRIDIAN miRNA library based on miRbase v.16 was purchased from 
Dharmacon™ (GE Healthcare, USA). The library was divided into two components, a 
miRNA mimic library and a miRNA inhibitor library. The miRNA mimic library comprised 
1239 synthetic dsRNA oligonucleotides that have sequences based on endogenous 
miRNAs, and are chemically modified to ensure correct guide strand selection during 
RISC programming. miRNA mimics function to augment intracellular levels and 
functional activities of specific endogenous miRNAs, leading to downregulation of the 
target mRNA species (Figure 2.1). In contrast, miRNA inhibitors are ssRNA 
oligonucleotides that are chemically modified to resist RISC-mediated cleavage, and 
exhibit secondary structures that facilitate binding to a specific host miRNA. miRNA 
inhibitors therefore function as sponges by sequestering specific miRISC complexes 
leading to suppression of specific endogenous miRNAs (Figure 2.1). The Dharmacon 








Figure 2.1 miRIDIAN miRNA library.  
miRNA mimics function as mature miRNA molecules and feed into the miRNA functional pathway 
at the point of miRISC programming resulting in an increased intracellular levels of the specific 
miRNAs, in turn promoting miRISC-target interactions and downregulation of mRNA target 
species (A). In contrast, miRNA inhibitors are able to preferentially bind and suppress the 
functional activity of specific miRISC complexes (B). Ectopic expression of a miRNA inhibitor 
therefore results in enhanced levels of mRNA species that would otherwise be negatively 
regulated by specific endogenous miRNAs. 
 
2.20 Customised compound libraries  
 
Two customised compound libraries were kindly provided by Roderick Beijersbergen 
(Netherlands Cancer Institute, Holland). The first library comprised 101 US food and 
drug administration (FDA)-approved oncology drugs (APPENDIX Table A2.1). The 
second library comprised 192 kinase inhibitors (APPENDIX, Table A2.2). Both of these 
libraries were comprised of well annotated compounds with clearly defined endogenous 
targets and form part of larger compound collections that are routinely utilized in a 
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Chapter 3: Establishment and optimisation of high 




High throughput screening (HTS) can be achieved through the miniaturization of 
experimental reactions (e.g using microplates) and improved liquid handling procedures 
(e.g. robotics, multichannel micropipettes) in order to execute a large number of 
independent experiments in a relatively short time frame (reviewed by Zanella, 2010 and 
Zhang, 2012). Cell-based HTS approaches in particular, traditionally rely on 
quantification of a single reporter readout (e.g. using a plate reader) in order to detect 
cellular changes in a biological process or molecular target of interest. While this 
approach is extremely useful in specific applications, such as generating dose response 
curves, traditional HTS approaches are not able to fully capitalise on all of the potential 
systems biology readouts that are inherent to cell-based assays (Zanella, 2010; 
Swinney, 2011). In contrast to biochemical assays, cell-based assays provide a 
considerably higher level of physiological relevance with regards to recapitulation of 
endogenous cellular responses, such as variations in cellular morphology and 
subcellular rearrangements. Traditional HTS approaches that utilise a single readout are 
therefore not able to comprehensively resolve discrete phenotypes, and are also unable 
to differentiate between heterogeneous single cell responses within a population of cells 
(Swinney, 2011).  
 
High content screening (HCS) refers to an HTS approach where not one but multiple 
measurements are extracted from each experimental reaction (Shariff, 2010; Zhang, 
2012). Cellular image-based screens in particular have become synonymous with the 
term HCS and all references to HCS within this dissertation refer to image-based HCS 
approaches. Imaging represents a robust tool for the spatio-temporal resolution of 
complex biological phenomena via the extraction and quantification of specific 
biologically relevant subcellular measurements (Zanella, 2010; Xia, 2012). Fluorescent 
proteins and fluorophore-conjugated molecular probes facilitate labelling of almost all 
cellular structures, from the scale of individual cells and nuclei, up to specific proteins, 
and even specific sequences of DNA and RNA. Such fluorescent tags allow researchers 
to label multiple subcellular structures within a population of cells and thus permit 
visualization and quantification of a number of functional and morphometric phenotypes, 
at a single cell level, using fluorescence microscopy (Zanella, 2010). Furthermore, the 
ability to differentiate between individual cells within a given population also allows 
researchers to readily differentiate between heterogenous cellular responses, and to 
monitor variations in cell number in response to specific treatments, as well as other 
functional readouts.  
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Since its inception, HCS has been widely utilised in a commercial setting in order to 
profile toxicity, efficacy and potential off-target effects of drug candidates (Zhang, 2012). 
The combination of HCS with genome-wide RNAi strategies (miRNA, siRNA, shRNA) on 
the other hand, has allowed both academic and commercial researchers to efficiently 
interrogate the functional relevance of the human proteome (~ 1 x 106 proteins) by 
screening using a relatively small number of reagents (~2000 miRNAs targeted to 25 
000 genes). This RNAi-based screening approach has been successfully utilised to 
characterise gene function in a number of biological models including stem cell 
differentiation, tumorigenesis and host pathogen interactions (Whitehurst, 2007; 
Reviewed by Brodin, 2011 and Xia, 2012).  
 
Despite the fact that recent advancements in automated microscopy, image analysis 
solutions and molecular labeling technologies have made HCS technologies more 
readily accessible, academic HCS facilities are not widely prevalent, even globally. This 
is in part due to the fact that not many research facilities possess the specialized 
technical expertise, infrastructure and funding required to establish and maintain a 
functional HCS platform (Buchser, 2004). The existing infrastructure and availability of 
specialised equipment at in Gene Expression & Biophysics laboratory thus provided an 
ideal setting to establish an HCS platform in South Africa.  
 
A major aim of this PhD project was therefore to exploit the appropriate resources within 
the laboratory to establish a functional HCS platform that could be utilized for screening 
pharmaceutically relevant compounds and RNAi reagents in cellular models relevant to 
the South African research climate. A major aim of this study was therefore to develop 
and then execute a HCS-based approach to delineate HIV-host interactions. Specifically, 
the identification of novel host factors required for successful HIV infection by using 
pharmaceutical compounds and RNAi reagents. Successful implementation and 
execution of an HCS approach is highly dependent on the development of a robust HCS 
experimental pipeline, which in turn is established through a series of rigorous 
experimental design and optimisation steps (Boutros, 2008; Johnston, 2014). These 
steps, including the development of guidelines for management of reagent libraries and 
optimisation of various experimental parameters are presented in this chapter.  
 
3.2 Automated vs. non automated liquid handling considerations 
 
One of the first steps in the design process was to determine whether screens would be 
executed using an automated liquid handling solution or by hand. The available robotics 
option was thus rigorously evaluated for its suitability to the proposed HCS workflow 
using a number of simulated liquid handling procedures. Limitations in the minimum 
volume of liquid that could be accurately transferred using the available dispensing 
arms, and the location of the instrument within a ‘clean room’ facility that was not BSL-2 
certified influenced the final decision that planned screens would instead be executed by 
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hand within a BSL-2 tissue culture facility. This decision in turn influenced the choice of 
using only a 96 well microplate format, as 384 well (and higher throughput) microplates 
are not readily conducive to non-automated screening approaches. Apart from 
reconstitution and daughtering of the miRNA libraries, all other liquid handling steps 
were executed by hand using multi or single channel micropipettes as required. A 
number of liquid handling procedures and experimental steps were therefore specifically 
adapted and optimised for use with multichannel micropipettes and screening in a 96 
well microplate format (discussed in detail below).  
 
3.3 Library management 
 
Reagent libraries generally represent one of the most valuable commodities in a HCS 
setup and should therefore be well curated. The configuration and concentration of 
reagents within reagent library plates can impact many experimental design parameters, 
and the choice of storage plate type and storage conditions are also important factors 
that can influence stability of the reagents during long term storage and transport. 
Establishment of effective library management strategies should therefore be considered 
during the early stages of the HCS design process. In the context of this thesis ‘master 
plates’ refer to the library plates in which miRNA reagents or compounds were originally 
reconstituted/diluted and ‘daughter plates’ refer to plates produced by aliquoting the 
reagents present in a master plate. The process of distributing reagents from a master 
plate to daughter plates is referred to as ‘daughtering’. The concentration and volumes 
selected for reagents in master and daughter plates, as well as configuration of these 
reagents within each plate type were important parameters that were considered during 
the development of the library management guidelines. 
  
miRIDIAN microRNA library 
 
The miRIDIAN miRNA library was shipped from the supplier in a 96 well format with a 
specific miRNA mimic or inhibitor aliquoted in each well as a 0.15nmol lyophilised pellet. 
Wells in the first and last column of each library plate were empty. A total of 33 plates, 
16 plates containing miRNA mimics and 17 plates containing miRNA inhibitors, were 
received. miRIDIAN miRNA master plates were reconstituted using aseptic techniques 
and the JANUS® automated liquid handling workstation (PerkinElmer, USA). 
Customised operating protocols were developed and optimised for the specific purpose 
of reconstituting master plates and production of daughter plates. Specifically, 
dispensing and aspiration heights and pressures were optimised for use with the library-
specific brand of 96 well plates, required pipetting volumes and required action (e.g 
mixing well contents vs. adding or removing liquid). Briefly, 96 well master plates 
containing lyophilized pellets were centrifuged at 500 x g for 5 minutes and reagents 
were resuspended in 1x Dharmacon™ siRNA buffer (GE Healthcare, USA) at a final 
concentration of 1 µM. A pipetting error-buffered volume of each reagent, suitable for 5x 
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uses, was then aliquoted into 3 daughter plates. Daughter and the master plates were 
sealed with Rotilabo® AllumaSeal II™ sterile adhesive seals (Carl Roth GmbH + Co. 
KG, Germany) and placed into storage at - 20 ˚C (A detailed version of the daughtering 
process is available in the Appendix).  
 
A number of technical parameters were considered to determine the final volume, 
concentration and configuration of reagents in both master and daughter plates. Higher 
reagent concentrations favour reagent stability during long-term storage but also 
necessitate the use of either smaller volumes of reagent or additional liquid handling 
steps in downstream applications. As the generation of daughter plates relied intimately 
on the robustness of various multichannel micropipettes, a number of simulated liquid 
transfer experiments using water were completed, and a lower volume of 2 µL was 
determined to be the minimum reproducible volume. miRNA reagents in daughter plates 
were thus maintained at a concentration of 1 µM to facilitate a downstream transfection 
reaction volume of 2.5 µL (See Transfection). Dharmacon™ recommends a maximum of 
5 freeze-thaw cycles for miRIDIAN miRNA library reagents following reconstitution. A 
volume of 15 µL of each reagent was therefore aliquoted to each daughter plate to allow 
for 5 x 2.5 µL uses as well as an extra 2.5 µL to compensate for reagent loss due to 
pipetting error. The well configuration of each master plate was maintained during 
production of daughter plates (Figure 3.1), and this was also influenced by the intended 
format of the experimental plates ( See Experimental plate selection and design).   
 
 
Figure 3.1 Configuration of reagents in miRIDIAN miRNA master and daughter plates.  





The FDA-approved oncology and kinase inhibitor libraries were each received in a 96 
well plate format. 101 oncology compounds were distributed across 2 plates while 192 
kinase inhibitors were supplied in three 96 well plates. Compounds were received as 
frozen 10 mM droplets reconstituted in DMSO, and were diluted to 1 mM stock solutions 
in 1x PBS, using the miRIDIAN library plate configuration. (Figure 3.2). Two sets of 
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at 3 concentrations i.e 100 nM, 1 µM and 10 µM. Three iterations of daughter plates 
were produced for each library from a single set of master plates in order to keep the 
volume of compound dispensed during the screening protocol constant regardless of the 
final concentration of compound used. Daughtered plates were produced at 100 µM, 10 
µM and 1 µM concentrations with a standard volume of 10 µL of reagent. Compounds 
were reported to be stable for up to 1 month at -20 ˚C following initial dilution, but 




Figure 3.2 Configuration of compound library plates.  
Master plates produced from the original compound library plates were re-configured to resemble 
the format of miRNA library plates. The reagents in columns 1 and 12 of the original library plates 








n 12** n 
A •••••••••••• • Compounds B •••••••••••• 















Master plate 1 
I I 
A o••••••••ooo * 






Master plate 2 
80 
3.4 Experimental plate selection and design 
 
Three experimental plates were evaluated for their suitability in the phenotypic screening 
workflow and 96 well µClear®  imaging plates (Greiner Bio-One International GmbH, 
Germany) were selected. Placement of control wells, the potential impact of edge effects 
and simplification of downstream liquid handling procedures were all major factors that 
influenced the design of the experimental plate layouts. Edge effects refers to the 
phenomenon whereby an increased rate of evaporation occurs within the outer wells of a 
multiwell plate as compared to the inner wells during long incubation times (Lundholt, 
2003). This differential rate of evaporation can result in skewed reagent concentrations 
and can thus bias the biological phenotypes within specific wells (Lundholt, 2003). 
Addition of high volumes of aqueous solution to either the outer wells of a multiwell plate, 
or the use of moat-like structures built into the outer edges of specialised reservoir plates 
have been described to effectively mitigate edge effects. The outer 30 wells on each 
experimental plate were thus filled with PBS prior to cell seeding and only the inner 60 
wells were utilised for experimental reactions. (Figure 3.3).  
 
The number of control wells allocated per experimental plate as well as their location are 
important parameters that influence downstream image analysis (Zhang, 2008; Bray, 
2012). Wells located in rows B and E on each experimental plate were specifically 
utilised as control wells. Thus each experimental plate included 20 control wells and 40 
experimental test wells (Figure 3.3). Experimental control rows were purposefully 
selected to be technical replicates of each other. Positioning of identical control wells 
specifically at rows B and E readily facilitated the identification of inadvertent 180 ˚ plate 
rotations, and possible edge effects or pipetting biases (Bray, 2012). Plate rotations 
occur when an experimental plate is either acquired or treated in the wrong orientation 
and both instances can occur as a result of human error. A robust experimental plate 
layout must therefore also provide a contingency that facilitates identification of such 
events (Zhang, 2008).  
 
Figure 3.3 Position of control wells on experimental plates.  
Control wells (orange) were always located in rows B and E in experimental plates utilised for 
both miRNA and compound screens. Experimental well locations are shown in black.  The outer 
36 wells (white) were filled with 1x PBS to minimise edge effects. The asymmetric layout of the 
control wells facilitated identification of inadvertent plate rotation. 
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Human error is a major concern for non-automated screening practices and 
simplification of the required liquid handling steps was thus a major focus of the 
experimental design process. The layouts selected for all plates were designed with 
‘ease-of-execution’ in mind regarding transfection, compound treatment and infection 
steps. Furthermore regardless of the type of screen, transfer of reagents from daughter 
to experimental plates was kept constant so that reagents from row A on daughter plate 
1 would always be present in row C on experimental plate 1A and reagents from row E 
would be always be present in row C in experimental plate 1B and so on (Figure 3.4). 
This design layout dramatically simplified the required liquid handling steps, and also 
maintained continuity in pipetting requirements for both miRNA and compounds screens. 
In addition, the simple layout facilitated downstream reagent identification. Based on this 
experimental plate design, a total of 63 experimental plates were generated from a 
single replicate of the miRIDIAN library (both mimics and inhibitors),  and 6 experimental 







Figure 3.4 Standardised daughter plate to experimental plate reagent transfer process. 
A single daughter plate containing 80 reagents (either miRNA or compound) generated 2 
experimental plates, using a simple, standardised transfer format. Empty wells (dark grey), 
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3.5 Development of HCS framework 
3.5.1 Characterisation of HCS assay 
 
Since a major aim of this study was to identify host factors that were functionally relevant 
to HIV replication using a miRIDIAN library in a HCS image-based approach, selecting a 
robust cell-based assay that facilitated quantification of HIV replication by fluorescent 
microscopy was essential.  A HCS assay must produce a visual phenotype that i) is 
relevant to the biological process(s) of interest, ii) can be quantified using image 
analysis, and iii) produces distinct variations that reflect significant changes in the 
biological process of interest, where these variations can also be differentiated by image 
analysis (Boutros, 2008; Zanella, 2010; Bray, 2012). With these requirements in mind, 
the infection of GHOST(3) reporter cells with a lab-adapted BSL-2/3 compliant HIV 
pseudovirus was selected as the basis of the HCS assay (Cecilia et al. 1998).  
 
The GHOST(3) X4/R5 cell line was derived from a human osteosarcoma line (HOS) 
stably transduced with a MV7neo-T4 retroviral vector containing an HIV-2 LTR promoter 
sequence driving expression of humanised GFP (hGFP). Expression of hGFP in 
GHOST(3) cells is therefore dependent on activity of the stably expressed LTR-
promoter. Following exposure to HIV, successfully infected GHOST(3) cells express viral 
Tat protein which is then able to activate the LTR-reporter construct resulting in stable 
expression of hGFP (Figure 3.5). The level of GFP expression within an infected 
population of GHOST(3) cells is thus directly proportional to the number of successfully 
infected cells within the population, as well the level of Tat production within the infected 
cells. HIV replication can therefore be both visualized and quantified in GHOST(3) cells 
using fluorescence microscopy (Figure 3.5). In addition, the GHOST(3) reporter system 
is sensitive to multiple HIV-1 subtypes, as well as HIV-2, and has previously  been 
validated as a suitable tool for the quantification of HIV-1 replication in cultured cells 
(Cecilia et al. 1998). Use of similar Tat-sensitive cellular reporter assays have also been 






Figure 3.5 GHOST(3) reporter assay.  
GHOST(3) cells stably express a Tat-sensitive GFP reporter construct.  Following exposure to 
HIV, successfully infected cells produce viral Tat protein that activates the LTR-hGFP reporter 
construct resulting in expression of GFP by infected cells. GFP expression is detected by 
fluorescence microscopy and can be used to quantify HIV replication.  
 
Having chosen GHOST(3) reporter cells for the HCS assay, it was important to 
determine if they could express GFP specifically in response to infection with HIV. 
GHOST(3) cells were transduced at different multiplicities of infection (MOIs) with the 
PSG3BAL gp120-expressing pseudovirus in order to evaluate the relationship between 
GFP reporter signal output and viral input. Cells were fixed, stained and imaged on the 
IXU 48 hours following infection and a positive correlation was observed between 
increased viral input (higher MOI) and increased GFP expression (Figure 3.6 A). These 
observations suggested that GHOST(3) cells were indeed sensitive to PSG3BAL 
infection, and also that the GFP reporter could be ‘tuned’ based on viral input. Next, an 
important control was included to ensure that PSG3BAL infection, specifically viral entry, 
was required for GFP reporter expression. GHOST(3) cells were transfected with an 
siRNA targeting CD4 (25 nM) or a non targeting control (25 nM) and 48 hours post 
transfection these cells were exposed to PSG3BAL at an MOI of 0.5. siRNA-mediated 
knockdown of CD4 prior to HIV exposure was shown to result in a significant (p <0.05) 
decrease in GFP expression, suggesting that infection was indeed dependent on CD4 
availability and represented a receptor-mediated mechanism of infection (Figure 3.6 B).  
 
The relationship between PSG3BAL infection and GFP reporter expression was further 
characterised by measuring p24 expression following infection. Based on ICC data and 
image analysis, ~90% of GHOST(3) that expressed GFP were also found to express HIV 
p24 48 hpi (Figure 3.6 C). Specificity of the p24 immunoassay was further verified by 
western blot (Figure 3.6 D), and PCR analysis confirmed that infected populations of 





GHOST(3) cells also expressed Gag transcripts at 48 hpi (Figure 3.6 E). Together, these 
observations confirmed that GFP expression in GHOST(3) cells correlated with CD4 
receptor-mediated entry of PSG3BAL pseudovirus, and that GFP reporter expression 
could be tuned based on viral input.  
 
Viral infection-mediated GFP reporter expression was key for success of the HCS assay, 
and while it had been established that GFP expression could be altered based on 
varying the viral input (MOIs), additional ways to augment GFP expression were also 
explored. Polycationic compounds have been reported to enhance viral infection by 
increasing the number of virion-cell contact events (Konopka, 1991; Hodgson, 1996). To 
test if additional virus-cell interactions led to increased GFP expression, GHOST(3) cells 
were infected with PSG3BAL media containing different concentrations of DEAE-Dextran 
(Sigma-Aldrich®), USA) or Polybrene® (Sigma-Aldrich®). Cells were fixed stained and 
imaged on the Andor confocal system 48 hpi. No significant difference was observed 
between the total GFP output in non-treated control cells and cell populations that 
received either polycationic additive. Given that GFP expression required Tat-mediated 
activation and this was in turn dependent on the timing of virus infection, the length of 
infection was also optimised to ensure maximum GFP expression.  GHOST(3) cells 
were infected for 24hr, 48 hr and 72hr at a constant MOI of 0.5 and were then fixed, 
counterstained with Hoechst and imaged on the IXU system. GFP expression was 
quantified using FIJI and and a 48 hour infection was found to be the shortest infection 
time course that produced a robust GFP readout as compared to uninfected control cells 






Figure 3.6 Experimental validation of GHOST(3) infection assay.  
A) GFP expression positively correlates with an increasing MOI, nuclei are counter stained with 
Hoechst (red) and GFP expression (green) is indicative of positive infection, cells were fixed and 
imaged 48 hpi. B) Infection of GHOST(3) cells by PSG3BAL is dependent on CD4 receptor-
mediated entry. GFP expression 48 hpi is attenuated by 65% ± 0.18 SEM  in GHOST(3) cells 
treated with siCD4 48 hours prior to infection as compared to mock transfected control wells (n=8, 
*p< 0.05). C) GHOST(3) cells expressing GFP at 48 hpi also express HIV p24 as seen in i) an 
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(white) indicate colocalization of GFP and p24-conjugated Alexa Fluor 550 signals estimated by 
image analysis to be iii) ~90% ± 1.49 SEM of infected GHOST(3) cells (n=3). D) Western Blot 
analysis of p24 protein expression in uninfected (control) and infected GHOST(3) cell populations 
48 hpi showed p24 protein only in the latter samples. E) HIV Gag is only expressed in infected 
GHOST(3) cells at 48 hpi as per gel electrophoresis of PCR amplicons. MWM = molecular weight 
marker. Scale bars = 20 um. 
 
3.5.2 Development of an HCS  experimental framework  
 
Following the characterization of the GHOST(3) reporter system as a suitable HCS 
assay that would facilitate the quantification of HIV replication by microscopy, the next 
step in the developmental pipeline was to layout a theoretical framework for each of the 
planned screens (i.e miRNA vs. compound) and to determine the number of replicates 
that would be required for each screen. Conducting multiple screening replicates can 
strengthen phenotypic classifications, reduce FDRs and improve the confidence of 
screen hits (Bray, 2012). The higher level of complexity associated with HCS assays  
suggests at least two replicates should be completed, although this also results in a 
large increase in reagent and consumable costs. This must also be weighed against the 
cost of secondary confirmation screens, which are performed at smaller scales but 
include variations in experimental conditions such as dose responses and screening 
formats. Most primary HTS and HCS studies are therefore performed in duplicate, and 
subsequent validation screens are performed with higher numbers of replicates (Bray, 
2012). The miRNA screens performed in this study were run in duplicate, and the 
compound screens in triplicate. 
 
The miRNA-based experimental workflow was designed and executed prior to 
optimisation of the compounds screens. miRNA mimics and inhibitors were only 
screened in a single experimental format, which was termed ‘pre-HIV exposure’. In this 
screening format GHOST(3) cells were first treated with miRNA mimics/inhibitors and 
then exposed to HIV  (Figure 3.7). In contrast, the compound screens were performed 
using three different screen formats, namely ‘pre-HIV exposure’ (Figure 3.8), ‘post-HIV 
exposure’ (Figure 3.8) and ‘drug only’. As with the miRNA screens, in pre-HIV exposure 
compound screens GHOST(3) cells were first treated with specific compounds prior to 
HIV exposure. In post-exposure screens, GHOST(3) cells were first exposed to HIV and 
then treated with compounds. In drug only screens, GHOST(3) cells were treated with 
compounds alone for 24hr prior to sample processing and imaging. The data derived 
from this screening format was used to establish a baseline phenotype for each 
compound treatment in terms of toxicity and compound-specific effects on the LTR-GFP 
reporter system. In addition, while miRNA screens were executed at a single 
concentration of 25 nM for miRNA mimics and miRNA inhibitors, compounds were 
screened at 3 different concentrations within each experimental format in order to 
evaluate any potential dose-response phenotypes. Optimisation of individual 
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experimental processes and parameters are discussed in subsequent sections of this 




Figure 3.7 Summary of experimental framework for miRNA screens. 
GHOST(3) cells were seeded in 96 well µClear® plates. Cells were transfected with miRNA 
mimics or inhibitors the following day. 48 hours post transfection cells were exposed to HIV. 48 
hours post infection cells were fixed and stained and experimental plates were imaged using 
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Figure 3.8 Experimental framework of ‘pre-HIV exposure’ and ‘post-HIV exposure’ 
compound screens.  
GHOST(3) cells were seeded on Day 0 for both screening formats. Compounds were screened at 
final concentrations of 100 nM, 1 µM and 10 µM. Infections were executed at an MOI of 0.5. Both 
methods fed into a common image analysis pipeline.  
 
3.5.3 Cell seeding  
 
Identifying the optimal cell seeding density is an important step in the design of a robust 
HCS workflow. The optimal seeding density for a specific biological assay may vary 
depending on the type of cells used, the experimental time course and experimental 
treatments, and should therefore be optimised for individual screening applications. Cell 
seeding density influences the number of cells in a given well at each experimental 
treatment step (e.g transfection or infection), and also impacts the number of cells 
present at the assay endpoint. The final cell count or density at the experimental end 
point is an extremely important parameter for phenotypic screening and downstream 
image analysis. High cellular densities can confound image analysis approaches that 
rely on identification of discrete objects/cells that are not in contact with each other. 
Alternatively, low cellular densities limit the amount of biological information acquired per 
field of view (FOV), and can result in toxicity following certain treatments like 
transfection. The actual cell count at the point of infection is also an important variable in 
'pre-HIV exposure' 'post-HIV exposure' 
Day 0: cell seeding 
GHOST(3) cells 
Seeded in optical 96 well plates 
Optimised seeding density 
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( Image analysis pipeline) 
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determining the MOI of an infection assay. Optimisation of cell seeding densities was 
thus essential when establishing the screening workflows utilised in both the miRNA and 
compound screens. The goal of this optimisation step was to identify a suitable cell 
seeding density range that was compatible with downstream image analyses and 
experimental treatments and to evaluate the robustness  of the selected cell seeding 
protocol.  
 
To identify the optimal cell seeding density for image analysis, multiple seeding densities 
within a range of  500-15 000 cells per well were evaluated. Cells were seeded and 
cultured for 96 hours as this was the experimental end point of the miRNA screening 
workflow. Cells were then fixed in 4% PFA and nuclei were counterstained with Hoechst 
before imaging at 20x on the IXU system. Seeding densities ≥10 000 cells/well were 
observed to negatively impact downstream analyses (Figure 3.9 i  and ii), while a 
seeding density between 5000-7000 cells/well maximised the number of cells per FOV 
without compromising image analysis (Figure 3.9 iii and iv). The same optimisation 
process was also applied to the compound screening workflow. 
 
 
Figure 3.9 The impact cell seeding density on image analysis.  
i) A cell seeding density in excess of  10 000 cells per well resulted in a large number of cell to 
cell contact events in the resultant microscopy images, and ii) cell to cell contact events 
confounded image analysis approaches by distorting the perceived boundaries of individual cells 
resulting in an inaccurate cell count. iii) A cell seeding range of 5000-7000 cells resulted in 











to be suitable to the identification of discrete cells by image analysis. Nuclei (grey) were 
counterstained with Hoechst. Scale bars= 20 µm. 
 
The proliferation rate of GHOST(3) cells was also evaluated in order to accurately  
predict the number of cells present at each experimental treatment point given a known 
seeding density. GHOST(3) cells were seeded at a density of 7 000 cells per well in a 
µClear® 96 well plate and allowed to attach overnight. The following day cells were 
transfected with a non-targeting miRNA mimic control and 48 hours later the number of 
cells present in each well was calculated using a haemocytometer. An average of  57 
500 ± 4 950 cells were present in each well (n= 60) thereby suggesting a doubling time 
of ~24 hour (Figure 3.10). This proliferation rate was utilised to estimate the number of 
cells present in each well of an experimental plate at the infection assay time point for 





Figure 3.10 Evaluation of GHOST(3) proliferation rate.  
GHOST(3) cells were seeded at a density of 7000 cells per well in a 96 well plate, transfected the 
following day with a fluorescently labelled miRNA, and then detached and counted 48 hours 
following transfection. Black lines/squares represent the expected cell counts based on a 
doubling time of 24 hours. Red blocks represent the actual cell counts from the seeding 
experiment. Cell count data corresponds to an average doubling time of ~24 hours under the 
reported culture conditions, SEM ± 4.95 x 103.   
 
To ensure that no inter-well directional biases were introduced during cell seeding, the 
fidelity of the seeding process was evaluated by comparing cell counts within the wells 
present in the first and last rows of 96 well plates. GHOST(3) cells were seeded into the 
inner 60 wells of µClear® 96 well plates using a multichannel micropipette and allowed 
to adhere overnight before being detached and counted using a haemocytometer 
(Figure 3.11). No significant differences were observed between the average number of 
cells seeded in the first (A) and last (G) rows of three test plates (Figure 3.11). In 
addition,  variability between the number of cells dispersed by individual channels of a 
multichannel micropipette were observed to be negligible, as represented by the error 
bars on each column (Figure 3.11). Inter-plate differences in cell seeding densities were 
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not a major concern as all cell count data was normalised on a per plate basis using cell 
counts from the negative control wells on each experimental plate (See HCS quality 




Figure 3.11 Fidelity of cell seeding protocol.  
No significant differences in the average cell counts were observed between experimental wells 




Optimisation of transfection conditions was a key factor in the development of a miRNA 
screening workflow. A final concentration of 25 nM was previously described to be the 
maximal concentration of miRNA-based reagent that could be used without nonspecific 
toxicity in mammalian cells (Schoolmeesters, 2009; Santhakumar, 2010). The principal 
aim of this optimisation step was thus to evaluate whether the proposed transfection 
conditions were able to produce suitable transfection phenotypes in GHOST(3) cells 
using a 25 nM final concentration of miRNA reagent. Given the lack of suitable positive 
controls to directly quantify the functional activity of miRNA reagents during the 
optimisation stage, a small interfering RNA (siRNA) targeted to CD4 was used as a 
proxy for miRNA mimic activity. The siRNA was obtained from the same vendor that 
supplied the miRNA library (Dharmacon™, USA) and was therefore subjected to the 
same chemical modifications as miRNA mimics, additionally the basic structure (short 
dsRNA) and functional activity (miRISC-mediated gene silencing) of miRNA mimics and 
siRNAs are also quite similar with the exception being that a single miRNA may have 
many molecular targets while a single siRNA is generally designed to target a single 
mRNA species. Three important transfection parameters were evaluated including the 
successful uptake of miRNA reagents by cultured cells term (uptake efficiency), the 
functional effect of the transfection process on target mRNA (transfection efficacy), and 
cell viability in response to transfection. A minimum uptake efficiency rate of 70% and a 
minimum transfection efficacy rate of 50% were set as the lower cut-off limits for 
3000 
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acceptable transfection readouts. GHOST(3) cells were seeded as previously described, 
and the following day cells were transfected with either siGLO Green or miRNA mimic 
Dy547 non-targeting transfection control reagents. Twenty-four hours later, the cells 
were washed thoroughly in 1x PBS to remove any excess transfection reagent and were 
then fixed in 4% PFA, counterstained with HCS CellMask™ blue stain and imaged on 
the Andor confocal system (Figure 3.12 A).  
 
HCS Cellmask™ stains both nuclei (strong signal) and the cytoplasm (weaker signal) of 
cells thereby allowing for visual identification of the total area occupied by individual 
cells. The acquired images were then analysed in FIJI and visual inspection. Briefly, the 
raw images acquired in the CellMask™/405 channel were processed by applying an 
automatic background subtraction and were then converted into a binary format (8-bit). 
Auto thresholding was then applied using the Li method and the resulting image was 
used to create mask/overlay in which black objects (individual cells) were defined as 
regions of interest (ROIs;Figure 3.12 B). The raw images acquired for each 
corresponding FOV in the Dy547 or siGLO Green channel were then processed 
(automatic background subtraction and despeckling), and the 405 image mask was 
overlaid (Figure 3.12 B). The total number of ROIs (cells) present in the image was 
recorded along with the number of ROIs that also contained a positive signal in the 
488/547 channel. The total number of ROIs in each image was then compared to the 
number of cells that were also positive for the dye-labeled transfection control reagent in 
order to determine the percentage of cells that had successfully taken up the 
miRNA/siRNA reagents.  
 
A 78.9% transfection efficiency rate was observed for the miRNA-Dy547 transfection 
control while a 79.7% transfection rate was observed for the siGLO Green reagent. 
Accuracy of the FIJI  transfection efficiency analysis method was evaluated using visual 
inspection (Figure 3.12 C), and the difference was negligible (< 2%) for both  miRNA-
Dy547 and siGLO-488 transfections (n=9). In addition, no significant impact on cell 
proliferation was noted in response to the transfection process. Based on these data, 
both the transfection process and the image analysis-based method of evaluating 




Figure  3.12 Optimisation of transfection efficiency for HCS.  
A) Composite images of GHOST(3) cells transfected with either miRNA DY547 (red spots) or 
siGLO Green (green spots) and counterstained with HCS CellMask™ (blue), scale bars = 10 µm. 
B) Transfection efficiency was determined by image analysis: i) raw images acquired in the HCS 
CellMask™ fluorescence channel were processed and converted to a ii) binary version, and iii)  
and a mask defining the ROIs (cells seen as black shapes) was created. iv) The same image 
acquired in the miRNA-Dy547 channel was processed and v) overlaid with the mask from iii. vi) 
Finally, a composite image was generated that overlaid the ROIs (yellow), miRNA-Dy547 signal 
(red) and HCS CellMask™ fluorescent signal (blue) from a single FOV. C) Transfection efficiency 
calculations based on image analysis suggested that both miRNA-Dy547 and siGLO 488 controls 
had an average transfection efficiency rate of ~79%. Visual inspection revealed an average 












































CD4 mRNA transcript levels were interrogated by qPCR analysis 48 hours following  
transfection of GHOST(3) cells with either siCD4 or a non-targeting siRNA control, both 
at a final concentration of 25 nM. CD4 expression levels in each treatment were 
normalised against those of the reference gene HPRT. CD4 expression was significantly 
(p<0.05) downregulated by ~70% in the siCD4 treatment as compared the control 
treatment (Figure 3.13). This finding suggested that the experimental conditions utilized 
for the transfection process were indeed effective for siRNA-mediated knockdown and 
would therefore also be effective for the transfection of miRNA mimics. A positive control 
or proxy for miRNA inhibitor activity under different transfection conditions was 
unfortunately not available at the time of optimization and this potentially important 
parameter was thus reluctantly omitted from the optimisation process in lieu of data 
suggesting that miRNA mimics and inhibitors could be used at similar transfection 




Figure 3.13 Evaluation of transfection efficacy for HCS.  
qPCR analysis revealed a ~75% knockdown of CD4 transcripts in GHOST(3) cells 48 hours post-
transfection with an siRNA targeting CD4 (n=3). CD4 expression levels in each treatment were 
normalised against those of HPRT, * p< 0.05.  
 
 
HCS transfection protocol 
 
Having established the appropriate concentrations of miRNA and transfection reagents 
to use, a protocol for doing so in a 96 well format complementary to the experimental 
plate layout was established. miRNA mimic/inhibitor transfection reactions were 
prepared in 96 well v-bottom plates (transfection plates) and transferred to experimental 
plates that had been seeded with cells as previously described (Figure 3.14). 




























µL of RNAimax per 1 mL of serum free media (SFM) and incubated while the plates 
were being prepared. For each transfection plate, 7.5 µL of SFM was added to each of 
the inner sixty wells. For each negative control well (‘natural infection’), 2.5 µL of SFM 
was added. For each non-targeting control well, 2.5 µL of 1µM working solutions of 
Dharmacon™ miRNA mimic and inhibitor non-targeting controls were added. For each 
infection control well  2.5 µL of a 1 µM working solution of siCD4 was added. Finally, 2.5 
µL of each miRNA reagent from the appropriate daughter plate was transferred to each 
transfection plate. Following this, 10 µL of the diluted RNAiMax solution was carefully 
dispensed directly into each transfection plate (Figure 3.14). Transfection plates were 
incubated at room temperature for ~20 minutes and the contents of each well were then 
transferred to  their corresponding well on the experimental plate. Experimental plates 







Figure 3.14 HCS transfection protocol. 
A) SFM was added to the inner 60 wells of a v-bottom transfection plate. B) The appropriate 
control reagents were added to each control well. C) i. Mimics/inhibitors were transferred from a 
miRNA library daughter plate to the appropriate wells in two transfection plates. ii Diluted 
RNAiMAX transfection reagent was added to each reagent well and plates were incubated at RT 
for ~20 minutes. D) The contents of each well on a transfection plate were transferred to their 
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3.5.5 Phenotypic controls  
 
As mentioned earlier, a suitable HCS assay must be able to reflect changes in a 
biological process of interest. These ‘changes’ can be purposefully engineered to create 
visually and analytically distinct phenotypes that are required for hit selection through 
image analysis, as well as to provide specific quality control steps in an HCS workflow 
(Bray, 2012: Zhang, 2012). Such engineered phenotypes are referred to as ‘phenotypic 
controls’ and include both ‘negative’ and ‘positive’ controls. Negative controls are utilised 
to define a ‘baseline’ phenotype and provide an analytical reference point for 
experimental reagents that do not elicit a significant phenotypic effect. Thus negative 
controls also function as important reference points for normalisation and 
standardisation of HCS data (Bray, 2012). Positive controls are utilised to define the 
phenotype of interest and thus provide an analytical reference point for experimental 
reagents that elicit similar phenotype(s) (Shariff, 2010). The distinction between these 
two contrasting visual control phenotypes (positive and negative) is also an important 
factor in the development of supervised machine learning based classifications (Shamir, 
2010). However, to further stratify phenotypes that may be observed during an HCS 
assay, additional controls should be included. These additional controls can monitor 
fidelity of various steps in the experimental procedure, and serve as reference points for 
the accuracy of downstream classification and analytics (Zhang, 2012).   
 
miRNA screen controls 
 
A summary of the phenotypic controls utilised in the miRNA mimic and inhibitor screens 
is presented in Table 3.1 below. Briefly, Natural infection controls were prepared by 
mock transfecting and then infecting GHOST(3) cells with PSG3BAL. Infected non-
targeting miRNA mimic/inhibitor controls were prepared by transfecting GHOST(3) cells 
with a non-targeting miRNA mimic or inhibitor at a final concentration of 25 nM prior to 
infection. The siCD4 phenotypic controls were prepared by transfecting GHOST(3) cells 
with a 25 nM final concentration of pooled siRNA 48hr prior to infection. Uninfected non- 
targeting miRNA controls were transfected with a 25 nM final concentration of non-
targeting miRNA mimic or inhibitor and cultured in ‘HIV-naive’ infection media for 48hr. 
‘Mock transfected, uninfected controls’ were mock transfected and then cultured in HIV-
naive’ infection media for 48hr. All infections were carried out using a 48hr infection time 
course. Mock transfected and uninfected controls were combined with siCD4 controls in 
image analysis to create a broader definition of a positive control (POS) phenotype for 
suppressed HIV replication. Ideally, positive controls for the functional activity of miRNA 
mimic and inhibitor reagents should also be included among the phenotypic controls 
used to monitor experimental quality, specifically the fidelity and efficacy of the 
transfection process. The quantitative assessment of the HIV- suppressive phenotype 
resulting from the efficient knockdown of CD4 by an siRNA pool (siCD4) was used in lieu 
of these miRNA reagent controls as the required reagents were not available during the 




Table 3.1 Phenotypic controls for miRNA screens 
Phenotypic Control Significance 
Natural Infection ● Negative Control (NEG) 
● Baseline phenotype for image analysis 
Infected non-targeting miRNA control ● Quality control monitoring 
● Should be classified with NEG by image 
analysis 
siCD4 ● Positive control (POS) for suppressed HIV 
replication 
● Quality control for the efficacy & consistency 
of transfection  
Uninfected non-targeting miRNA control ● Quality control monitoring 
● Should be classified with POS by image 
analysis 
Mock transfected uninfected control ● Positive control (POS) for suppressed HIV 
replication 
● Quality control for baseline GFP-reporter 
activity without treatment 
 
 
To optimise the phenotypic controls, GHOST(3) cells were prepared for each control 
condition, fixed at the relevant endpoints, counterstained with Hoechst and imaged on 
the IXU system. Images were analysed in FIJI by quantifying the average total GFP 
output for all images in each condition. Visual inspection revealed that non-targeting 
infected controls and natural infection controls were indeed similar, and this observation 
was confirmed by image analysis (Figure 3.15). In addition,  siCD4 controls, uninfected 
non-targeting controls and uninfected controls were also visually distinct from both non-
targeting infected controls and natural infection controls (Figure 3.15). Together, these 
observations confirmed that a combination of siCD4-treated and uninfected controls 
would represent suitable positive controls for image analysis, and that transfection of 
miRNA mimics/inhibitors did not have a detectable nonspecific effect on the GHOST(3) 






Figure 3.15 Evaluation of phenotypic controls for miRNA-based HCS. 
GHOST(3) cells were prepared for each phenotypic control condition, imaged on the IXU and the 
average total GFP intensity for each condition and significant differences between them were 
determined by image analysis (p < 0.05, n = 6). Mock transfected & infected negative controls 
(NEG, orange) controls and infected non-targeting miRNA reagent controls (blue) resulted in 
similar visual profiles. These were distinct from those exhibited by siCD4-treated infected controls 
(yellow) as well as uninfected mock transfected (black), and uninfected non-targeting miRNA 
reagent controls (purple). The combination of the siCD4 (yellow) and uninfected (black) 
treatments were used to define the positive control phenotype (POS).  Each image represents a 























■ ■ ■ ■ ■ 
I I 1 1 
Infected Uninfected 
■ ■ ■ ■ ■ 
■ Mock transfected & infected (NEG) 
■ Infected non-targeting controls 
■ siCD4 (POS) 
■ Uninfected non-targeting controls 
■ Mock transfected & uninfected (POS) 
99 
Compounds screen controls 
 
Similar processes were followed for optimisation of controls for the compound screens, 
although these were modified to accommodate the different screening formats used for 
the compound screens. DMSO was the solvent used to reconstitute compounds and 
DMSO treatment was thus utilised as a vehicle-control (negative) for compound 
treatments.  
 
The phenotypic controls for all compound screens are summarised Table 3.2 below. 
Natural infection controls were prepared by treating GHOST(3) with an appropriate 
dilution of DMSO either 24hr prior to infection (pre-HIV exposure screens) or 48hr post 
infection (post-HIV exposure screens). The positive control (POS) phenotype was 
created by treating GHOST(3) cells with specific ARVs (Maraviroc/ Raltegravir) prior to 
HIV exposure for both pre- and post- HIV exposure screen formats. Maraviroc inhibits 
HIV entry while Raltegravir inhibits HIV integration. Both of these ARVs were therefore 
used to obtain a broader analytical definition for suppressed HIV replication. Infected 
DMSO-naive treatments were prepared by treating cells with an appropriate volume of 
1x PBS either 24hr prior to infection (pre-HIV exposure screens) or 48hr post infection 
(post-HIV exposure screens). Uninfected controls were treated with an appropriate 
dilution of DMSO either 24hr prior to (pre-HIV exposure screens) or 48hr post (post-HIV 
exposure screens), culture with HIV-naive infection media.   All compound treatments 
were applied for 24 hours. 
 
Table 3.2 Phenotypic controls for compound screens 
Phenotypic Control Significance 
Natural Infection (DMSO-treated) ● Negative Control (NEG) 
● Baseline phenotype for image analysis 
Infected, DMSO-naive ● Quality control  
● To monitor combined  effects of DMSO 
treatment and infection on reporter activity  
Maraviroc (10 µM) ● Positive control (POS) for suppressed HIV 
replication 
● Quality control for the efficacy & consistency 
of compound treatments  
Raltegravir (10 µM) ● Positive control (POS) for suppressed HIV 
replication 
● Quality control for the efficacy & consistency 
of compound treatments 
Uninfected, DMSO-treated ● Positive control (POS) for suppressed HIV 
replication 
● Quality control for baseline GFP-reporter 






Selection of the ARVs and their respective concentrations as positive controls for 
suppressed HIV replication was determined by a dose-response experiment. Briefly, 
GHOST(3) cultures were treated with 3 different concentrations (100 nM, 1 µM and 10 
µM) of 3 different ARVs (T20, Maraviroc and Raltegravir) for 24 hours prior to exposure 
to PSG3BAL for 48 hr. Negative controls relevant to each drug concentration were 
prepared in parallel by treating GHOST(3) cells with an appropriate dilution of DMSO 
prior to infection. Cells were then fixed, counterstained with Hoechst and imaged on the 
IXU. Images were subjected to visual inspection to determine which 
ARVs/concentrations suppressed HIV replication (GFP) without broad cytotoxicity. The 
fusion inhibitor, T20, was found to be effective at suppressing HIV replication at all of the 
concentrations tested without any significant toxicity (Figure 3.16). The CCR5 
antagonist, Maraviroc as well as the integrase inhibitor, Raltegravir, were only able to 
suppress viral replication at 1 µM and 10 µM concentrations (Figure 3.16). However, due 
to limited availability of T20, Maraviroc and Raltegravir were both utilised at a final 




Figure 3.16 ARV dose response phenotypes for GHOST(3) assay.  
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GHOST(3) cells were treated with Maraviroc, Raltegravir or T20 for 24 hours prior to HIV 
infection. Cells were fixed 48hr post infection, and nuclei were counterstained with Hoechst (Blue) 
before imaging. LTR activity (GFP/Green) is indicative of HIV replication. The effect of each drug 
on HIV replication was evaluated at 100 nM, 1 µM and 10 µM concentrations. DMSO at dilutions 
equivalent to those for each ARV served as negative controls. Scale bar = 40 µm. 
 
Having established the appropriate ARV conditions, all phenotypic controls were 
evaluated in both pre- and post-exposure screening formats. In the pre-exposure format, 
GHOST(3) cells were seeded in 96 well plates and allowed to adhere overnight. The 
following day, cells were treated with appropriate compounds for 24 hours, before being 
exposed to PSG3BAL at an MOI of 0.5. Cells were fixed, counterstained with Hoechst and 
imaged on the IXU at 48 hpi. Visual inspection and image analysis revealed that DMSO-
treated and DMSO naive infected samples exhibited higher levels of GFP expression as 
compared to Maraviroc and Raltegravir-treated infected samples as well as DMSO-
treated uninfected samples (Figure 3.17). DMSO treatment prior to infection resulted in a 
slight but noticeable increase in GFP compared to DMSO-naive infected samples 
(Figure 3.17). This suggested that treatment with DMSO may either subtly influence the 
GFP reporter system or increase background signal. Thus DMSO-treated infected 
samples were used instead of untreated GHOST(3) cells as the negative control for pre-
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Figure 3.17 Pre-exposure assay format phenotypic controls. 
GHOST(3) cells were prepared for each phenotypic control condition, imaged on the IXU and the 
average total GFP intensity for each condition and significant differences between them were 
determined by image analysis (p < 0.05, n = 6). DMSO-treated infected (NEG, orange) and 
DMSO-naive infected (blue) controls resulted visual profiles (GFP expression) that were distinct 
to those of  the ARV-treated and uninfected & DMSO-treated controls. A slight increase in GFP 
was however observed for DMSO-treated versus DMSO-naive infected samples. Maraviroc 
(yellow) and Raltegravir-treated (purple) infected as well as DMSO-treated uninfected (black) 
controls produced similar visual profiles (suppressed GFP expression). Each image represents a 
single FOV acquired at 20x with multiple FOVs acquired per condition. Scale bar = 20 µm. 
 
In the post-exposure screens, GHOST(3) cells were seeded in 96 well plates and 
allowed to adhere overnight. The following day, cells were exposed to PSG3BAL at an 
MOI of 0.5 and cultured for 48 hours. The infective media was removed and cells were 
then treated with appropriate compounds for 24 hours before being fixed, stained and 
imaged on the IXU. Notably, ARV treatments were prepared as described for the pre-
exposure format, (i.e. treated then infected) as neither Maraviroc nor Raltegravir are 
effective following viral integration, and an ARV that could specifically suppress LTR 
activity within the 24 hour compound treatment time was not available. Visual inspection 
again revealed that DMSO-treated and DMSO naive infected samples exhibited higher 
levels of GFP expression as compared to Maraviroc and Raltegravir-treated infected 
controls as well as DMSO-treated uninfected samples (Figure 3.18). DMSO treatment 
following infection also resulted in increased GFP compared to the DMSO-naive infected 
samples (Figure 3.18). Again, this suggested that treatment with DMSO may either 
influence the GFP reporter system or increase background signal, thus DMSO-treated 





Figure 3.18 Post-exposure assay format phenotypic controls.  
GHOST(3) cells were prepared for each phenotypic control condition, imaged on the IXU, and the 
average total GFP intensity for each condition and significant differences between them were 
determined by image analysis (p < 0.05, n = 6). Infected & DMSO-treated (NEG, orange) controls 
and Infected & DMSO-naive (blue) controls resulted distinct visual profiles (GFP expression) in 
comparison to the ARV-treated and DMSO-treated uninfected controls. A slight increase in GFP 
readout was observed in response to DMSO-treatment following infection as compared to 
Infected & DMSO-naive samples. Maraviroc (yellow) and Raltegravir-treated infected (purple) and 
DMSO-treated uninfected (black) controls produced similar visual profiles (suppressed GFP 
expression). Each image represents a single FOV acquired at 20x with 4 FOVs acquired per 
condition. Scale bar = 20 µm. 
 
3.5.6 Sample processing 
 
Having established the optimal methodology to run each phenotypic assay, it was 
important to ensure that the processing of samples for imaging was compatible as 
certain fixatives, stabilising agents and labelling approaches have been described to 
quench fluorescent signals (Schnell, 2012). In addition, prolonged fixation may also 
negatively affect downstream experimental procedures like Fluorescent In Situ 
Hybridization (FISH) and immunochemistry (Yamashita-Kashima, 2014). The choice of 
fixative, length of fixation and general design of sample processing protocols were thus 
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important factors taken into consideration in the HCS workflow. As opposed to using live 
imaging, GHOST(3) cells were fixed in order to standardise the experimental endpoint 
used across all experimental wells and plates regardless of the order in which they were 
imaged. A nuclear stain was included to facilitate identification of individual cells and to 
monitor significant variations in cell viability. A number of different fixatives and nuclear 
stains, as well different reagent concentrations and treatment times were evaluated to 
determine which fixation and staining procedures consistently produced a strong nuclear 
readout with minimal negative impact on GFP fluorescence. A 15 minute room 
temperature fixation step using 4% methanol-free formaldehyde (pH 7.4) and nuclear 
staining using a 2 nM final concentration of Hoechst without permeabilization was found 




The choice of imaging system (Andor or IXU) as well as the imaging parameters utilized 
for both miRNA and compound screens were important factors in the HCS design 
process. A side by side comparison of both imaging systems was undertaken with a 
particular focus on image quality, acquisition time and well coverage (number of cells per 
FOV) (Table 3.3). Each microscope system was evaluated using a 20x acquisition as 
higher magnifications on the ANDOR system required oil emersion, which was not 
suitable for screening purposes. The results are summarised in Table 3.3 below. While 
the ANDOR system was able to acquire a greater number of FOVs in a shorter time 
frame, and could image in brightfield (standard light microscopy), the IXU system was 
selected for screening based on a number of criteria (Figure 3.19) including a superior 
signal to noise ratio (particularly in the GFP channel), a larger detection area, and the 
availability of an HCS-tailored software interface. Notably, the IXU system was also able 
to directly label each acquired raw image with metadata including the imaging site, well 
location, acquisition channel and the corresponding plate ID. In contrast, metadata had 
to be assigned to images acquired on the ANDOR system using a bespoke script 
designed in MATLAB®. The IXU system also exhibited a  superior level of consistency in 
well to well focusing ability across multiple 96 well plates during testing. In addition, the 
Andor system was not designed for screening multiwell plates and thus a bespoke plate 
screening protocol was developed to guide the motorised stage to 9 manually 
programmed acquisition sites within each target well. In comparison, the imaging 
settings including selection of acquisition sites, number of acquisition sites, specific wells 
to be acquired, and plate type (96 vs. 384 ) was easily manipulated using the IXU 
software. All of these factors, including that the HCS assay did not require brightfield 
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Figure 3.19  Comparison of ANDOR and IXU systems.  
A) Plate reconstruction from images acquired on the ANDOR system at 20x in the 405 channel. 9 
FOVs were acquired in each well (green square) and each FOV (red square) comprised a single 
512 x 512 pixel image. B) Plate reconstruction from images acquired on the IXU system at 20x in 
the 405 channel. 4 FOVs were acquired in each well (green square) and each FOV (red square) 
comprised a single 1000 x 1000 pixel image. The single FOV images for each system are 
depicted to scale. Scale bars = 10 µm. 
 








Acquisition settings  
 
Once a microscope system was selected, the next step was to identify optimal 
acquisition settings for the GHOST(3)-PSG3BAL HCS assay. Image resolution, well area 
coverage and acquisition time were major factors that determined the appropriate 
acquisition settings for all screens. The allocated daily imaging time on the IXU system 
was 8 hours and imaging 4 FOVs, 100 µm apart, in two channels (Hoechst and GFP) 
positioned at the centre of each well required 30-35 minutes of imaging time per plate. A 
major concern was that the use of only 4 FOVs located at the centre of each well would 
result in a biased phenotype that was not representative of the general phenotype within 
each well. In addition, while 20x acquisition had been tested in the side by side 
comparison previously, the resolution of the resulting images had not been tested using 
a downstream image analysis pipeline. To assess these imaging parameters, GHOST(3) 
cells thus were seeded into two µClear ®  96 well plates and infected with HIV at varying 
MOIs between 1 and 0.01.  One plate was acquired at 10x and 20x and the other at 20x 
and 40x (Figure 3.20 A). 
 
Nine FOVs were acquired per well during the 10x acquisition and 4 FOVs were acquired 
per well for both 20x and 40x acquisitions (Figure 3.20 B). A standard 100 µm distance 
between acquisition sites was utilised to ensure there was no overlap in cells acquired at 
each site. The average GFP intensity scores were extracted from all images acquired, at 
each magnification. The log of the average GFP scores obtained for each well were then 
plotted against the average GFP scores obtained for the same well, but at a different 
magnification. The 10x acquisition resulted in a large coverage area within each well and 
was thus used as a benchmark for the general phenotype within each well (Figure 3.20 
B). The 20x acquisition adequately recapitulated the phenotype observed at 10x (n = 30; 
Figure 3.20 C). These findings suggested that acquisition of 4 FOVs at 20x at specified 
acquisition sites, while representative of only a small area of each well, provided an 
accurate representation of the general phenotypic trend within the well. A comparison 
between 20x and 40x acquisitions revealed a similar trend (n = 16; Figure 3.20 D). This 
observation demonstrated that lower resolutions (20x acquisition) did not misrepresent 
the phenotypic trend in each well as compared to a higher resolution acquisition. Based 
on these results, the following imaging parameters were used for all screens: the 
number of averages per acquisition, laser intensity, pinhole size and exposure times 
were selected in reference to the control wells on the first plate imaged per replicate; 
four FOVs, each 100 µm apart, positioned at the centre of each well were acquired in the 





*Assuming that the same number of FOVs and channels are acquired per magnification 
 
Figure 3.20 Comparison of different acquisition parameters on the IXU system.   
A) GHOST(3) cells were infected with HIV and then imaged 48 hpi at 10x, 20x and 40x, nuclei 
(red), LTR-GFP expression (green). B) Scaled representation of FOV to well size ratios and 
coverage at different magnifications. C) A comparison of the average total GFP scores extracted 
from 9 FOVs with a high well area coverage acquired at 10x and 4 FOVs with a smaller well 
coverage acquired at 20x showed similar phenotype (n = 30). D) A similar trend occurred 
between 4 FOVs acquired at 20x and 40x. 
 
3.6 Image analysis: infrastructure and HCS pipeline 
 
HCS results in the generation of large volumes of images that are too large be efficiently 
curated manually and analysed (Shariff, 2010). Automated analysis of microscopy 
images through the integration of computer vision, pattern recognition and specialized  
data mining strategies has thus become an integral aspect of most current HCS 
approaches (Jackson, 2010; reviewed by Shamir, 2010). Such image analysis pipelines 
often require highly specialised expertise, equipment and software. Therefore, 
establishment of an image management, image analysis and data mining pipeline 
represented an important step in the development of a functional HCS workflow. A high 
level summary of the HCS image analysis pipeline is presented in Figure 3.21. Briefly, 
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bespoke image management database, parallel to this, images were processed to 
enhance signal to noise ratio, subjected to segmentation analyses and specific 
subcellular measurements (features) were then extracted from the images. The 
extracted features were used as numerical representations of the images and these 
numerical datasets were then sequentially subjected to specific quality control and  data 
transformation methods within a statistical analysis and data mining tool, 
HCStratomineR (HCSR). The transformed and validated datasets were then subjected 
to hit selection in order to identify reagents/treatments that produced predefined 
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A) Images were acquired on the IXU confocal system. B) Images were acquired in the 405 
(Hoechst) and 488 (GFP) channels. C) Images were curated in a bespoke image management 
database. D) Images were processed through automatic thresholding (i) and segmentation (ii) 
and specific numerical features were extracted from images (iii). E) Statistical analyses and data 
mining were performed in HCSR to confirm the quality of the data (i), process data for analysis 
e.g normalization (ii), data reduction was applied when needed (iii) and hits were identified using 
specific selection criteria (iv). 
 
3.6.1 Image management database  
 
The images produced by HCS should be well curated in order to efficiently locate 
specific images related to experimental plates/treatments of interest. Large scale HCS 
can result in millions of images and manually locating specific sets of images is 
cumbersome even for well organised datasets. Many HCS workflows rely on specialised 
image management solutions (Jackson, 2010; Allen, 2012) that often require specialised 
software licensed at premium prices. To circumvent this a bespoke HCS image 
management tool was designed on the open source Ruby on Rails® web framework by 
a collaborator, Dr. Juergen Helmers, following a number of consultations to determine 
the HCS needs of the project. Briefly, master and experimental plate annotations for 
each reagent library were defined within the application. Raw images acquired from 
each experimental plate were transferred to a local storage device and the location of 
each folder corresponding to a given experimental plate was then specified. The 
metadata for each image was collated and attached on a per plate basis. This resulted in 
an indexed database directly linked to all screening-related images. Furthermore, 
identification of images from specific plates, replicates and treatments was facilitated by 
a graphical user interface and search tool. In addition, the application was able to 
reconstruct images of each well at each FOV by overlaying pseudocoloured versions of 
each individual fluorescence image. This image managment system was primarily 
utilised to visually inspect screen hits and to visualize phenotypes related to specific 
reagents of interest (such as miRNAs/compounds/controls).  
 
3.6.2 Image processing, segmentation and feature extraction  
 
Computer vision is a field of research that focuses on the use of computer-aided 
methodologies to objectively interpret and classify visual datasets (Shamir, 2010; Shariff, 
2010). Within the HCS arena, images are generally preprocessed to differentiate true 
signal from background noise (Shariff, 2010). This image processing step improves 
subsequent identification of objects of interest within individual images, and increases 
the efficiency of downstream segmentation and extraction scripts. Optimisation of 
specific thresholding strategies for each dataset is therefore important. Segmentation is 
one such strategy that partitions an image into specific ROIs (cells, organelles etc.) 
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thereby reducing the total number of pixels, which in turn limits downstream analyses to 
objects of interest (Al-Amri, 2010; Zuva, 2011).  
 
Once images have been segmented, multiple subcellular measurements known as’ 
‘descriptors or ‘features’ can be extracted and these ‘feature scores’ then serve as a 
numerical representation of the visual phenotypes depicted within each image (Shamir, 
2010). The numerical scores are then processed and analysed in order to categorize 
images into distinct groups, and to visualise specific trends within a dataset/screen. A 
number of different types of features can be extracted from images including various 
descriptors of cell morphology, distribution of objects and pixels, textural descriptors and 
pixel intensity, to name a few (Haralick, 1973; Shamir, 2010). It is however very 
important that features selected for use in downstream image classification approaches 
are relevant to the HCS assay, as inclusion of irrelevant or even poorly relevant features 
can comprise both the accuracy and efficiency of downstream classifications. This is 
particularly true for supervised machine learning based approaches (Kohavi, 1994; 
Shariff, 2010).    
          
All screens presented in this thesis used image processing, segmentation and feature 
extraction scripts that were designed, optimized and executed within MATLAB® by a 
resident software engineer in the same research group. An automatic threshold was 
applied to all images on a per fluorescence channel basis, and these thresholds were re-
evaluated for each screening replicate. Initially, various segmentation parameters (object 
size, shape, distribution, etc.) and various segmentation methods were explored using 
test images obtained from simulated experimental conditions. This was done in order to 
determine the best approach for identifying individual cells within images acquired in the 
405 and 488 channels. These approaches were later refined using the data obtained 
from each screen replicate. Notably, features can either be developed de novo for a 
specific screen, or selected from large libraries of pre-existing features used in similar 
HCS assays (Shariff, 2010). In addition, there are a number of commercial and open 
source software solutions, each with their own advantages and drawbacks, that are 
capable of performing routine feature extraction (reviewed by Zanella, 2010). However 
given the available in-house expertise in computer vision and software engineering, a 
bespoke feature extraction approach was developed specifically for this study. This 
approach was implemented through MATLAB®  and 17 features were extracted from the 
images acquired during the miRNA and compound screens presented in this study 
(Table 3.4). Fifteen of the 17 features were based on an HCS study that utilized a similar 
Tat-sensitive GFP reporter model to quantify HIV replication following siRNA-mediated 
knockdown (Genovesio, 2011). Two additional features (Cell Area and Infection 






Table 3.4. Features extracted for image analysis of screen data (adapted from Genovesio, 
2011) 
Feature Description Biological relevance 
Cell area* Area of hoechst signal relative to 
size of an image  
A low value indicates cell death 
Infection efficiency * Average number of GFP expressing 
cells divided by the cell count/ cell 
area score 
A low value indicates suppressed HIV replication 
Cell number Number of cells A low number indicates cell death 
linkMinGFPAvg Average of the minimum value of 
green fluorescent protein (GFP) 
along the line going from a cell to its 
neighbour. 
A high value indicates the cell is in a syncytia 
formation 
linkMinGFPSdtdev Standard average of the minimum 
value of GFP along the line going 
from a cell to its neighbour 
A high value indicates a mix of fused cells in 
syncytia formation and non-fused cells 
linkLengthAvg Average distance between two 
neighbouring cells 
A high value means cells are spread 
linkLengthSdtdev Standard deviation of the distance 
between two neighbouring cells 
A high value means an odd dispersion of cells 
(often happens in the case of cell death) 
inTotalGFP Integration of GFP over the image 
inside the boundaries of the 
precisely fitted experiment 
A high value indicates infection measured on the 
spot 
inIntNucleiAvg Average intensity of cell nuclei 
inside the boundaries of the 
precisely fitted experiment 
An irregular sample value compared to the 
control values means cell toxicity measured on 
the spot 
inIntNucleiSdtdev Standard deviation of intensity of 
cell nuclei inside the boundaries of 
the precisely fitted experiment 
A high value means cell toxicity measured on the 
spot 
inIntGFPAvg Average intensity of GFP per cell 
inside the boundaries of the 
precisely fitted experiment 
A high quantity of reporter per cell indicates 
infection measured on the spot 
 inIntGFPSdtdev Standard deviation of GFP per cell 
on the precisely fitted experiment 
A low value indicates a well-spread infection 
measured on the spot 
outTotalGFP Integration of GFP over the image 
around the boundaries of the 
precisely fitted experiment 
A high value indicates infection on the border 
around the spot 
outIntNucleiAvg Average intensity of cell nuclei 
around the boundaries of the 
precisely fitted experiment 
An irregular sample value compared to the 
control values means cell toxicity measured on 
the border around the spot 
outIntNucleiSdtdev Standard deviation of intensity of 
cell nuclei around the boundaries of 
the precisely fitted experiment 
A high value means cell toxicity measured on the 
border around the spot 
outIntGFPAvg Average intensity of GFP per cell 
around the boundaries of the 
precisely fitted experiment 
A high quantity of reporter per cell indicates 
infection measured on the border around the 
spot 
outIntGFPSdtdev Standard deviation of GFP per cell 
around the boundaries of the 
precisely fitted experiment 
A low value indicates a well-spread infection 
measured on the border around the spot 






Image processing, segmentation and feature extraction generally represent the most 
computationally intensive processes in an HCS workflow, and require high-end 
processing systems (Shamir, 2010). While simple segmentation and feature extraction 
scripts can be executed within seconds per image (e.g. Voronoi segmentation), more 
complex approaches utilising compound or abstract features (e.g. Active contours) can 
take hours to execute on a single image (Shariff, 2010). Processing of images acquired 
in a single miRNA replicate screen and extraction of 17 features from these images 
required ~ 1 month of processing time using a communal multicore MAC system running 
OSX (Apple Inc, USA).   
 
3.6.3 Statistical analyses and data mining  
 
The sheer size of datasets in combination with a requirement for complex statistical and 
data mining functionality can represent a major challenge in HCS (Bray, 2012; Zhang, 
2012). A multitude of different approaches, strategies and software solutions have thus 
been specifically developed  to address the challenges associated with downstream 
analysis of HCS data (Jackson, 2010; Zanella, 2010). Statistical analysis, data mining 
and hit selection were initially performed within MATLAB® by a resident software 
engineer but this approach was found to be impractical for long term screening 
applications, as it was not suited to biologists who were not well versed in computer 
programing. Limiting the requirement of programming expertise to automated image 
processing and feature extraction steps enabled biologists to undertake the data mining 
and hit selection processes. To facilitate this, a collaborative relationship with the Cell 
Screening Core at the University Medical Center Utrecht was established as they had 
developed a highly relevant tool called HCStratominer (HCSR). HCSR provided an easy-
to-use interface with access to a virtual processing centre comprising >1000 cores that 
allows for on-the-fly statistical analysis, data visualization and data mining from large 
datasets. 
 
For the screens described in this thesis, design of a statistical analysis and data mining 
pipeline was based on the use of HCSR and a 3-step HCS decision matrix proposed by 
Shun and colleagues (Shun, 2011). The first step was to determine the most appropriate 
data processing methods and define specific criteria for quality assessment and hit 
selection. The next step was to utilize a graphical review process to assess the quality of 
the HCS data and apply the necessary statistical adjustments (e.g normalisation, 
standardisation). This was done from the level of monitoring inter-replicate variation to 
the gating of individual experimental wells and features that were deemed to be 
substandard. Variables that did not meet predetermined minimum standards were either 
excluded from downstream analysis or corrected using analytical strategies (Quality 
control). The final step was to apply the relevant data reduction methods (when required) 
and hit selection criteria to the validated and processed HCS data. Together, these steps 
allowed for identification of reagents that produced phenotypes of interest within HCS 
datasets (hit selection).  
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HCS quality control  
   
The large volumes of numerical data generated through HCS can be tainted by 
systematic and experimental errors thus distorting the quality of hit selection (Zhang, 
2012). While such errors are easy to identify and correct in low throughput experimental 
setups, they are exponentially more cumbersome to identify and adjust in larger HCS-
scaled datasets. Stringent quality control measures are thus required throughout the 
HCS experimental workflow (Zhang, 2008; Bray, 2012). A number of quality control 
guidelines and parameters have been described specifically for use in HTS/HCS 
(comprehensively reviewed in Zhang, 2008; Shun, 2011; Bray, 2012 and Zhang, 2012). 
The choice of quality control parameters should however be carefully considered in the 
context of each HCS assay and the available computing resources and expertise. The 
sequential stages in the quality control and data processing pipeline utilized in this study 
are discussed below.  
 
The interactive data visualization tools within HCSR were used to first evaluate the 
quality of screening datasets and the performance of the HCS assay. Graphical 
renditions (scatter plots) of unprocessed average GFP intensity (inTotalGFP) and cell 
number (Total Cell Area) feature scores were generated for each experimental well, first 
at the scale of an entire screen (all replicates) and then at the level of individual 
experimental plates. These scatter plots were used to monitor a number of quality 
control parameters by visual inspection.  
 
Firstly, the correct orientation of experimental plates was verified by confirming low GFP 
scores within well locations that corresponded to uninfected or positive control wells. 
Screen-level inTotalGFP plots were then used to confirm the consistent and significant 
separation of the major phenotypic controls (e.g NEG vs. POS) and the correct 
classification of the quality control-related phenotypic controls relative to NEG and POS 
controls (e.g. non-targeting miRNA reagent controls). Additionally the variability within 
the phenotypic distribution range of experimental treatments was also monitored at this 
stage in order to confirm that reagent-related variations in GFP-reporter activity were 
indeed prevalent within the dataset, and that a significant proportion of the experimental 
treatments had a functional impact on the HCS assay.  Likewise screen-scale scatter 
plots relevant to the cell viability indicator, Total cell area, were used to confirm that 
there were no significant variations in cell viability between the phenotypic control 
samples and that experimental treatments exhibited a suitable range of variability related 
to the functional impact of the experimental treatments.  
 
Plate level scatter plots were used for a side-by-side comparison of the phenotypic 
profiles of replicate experimental plates relative to inTotalGFP and Total cell area 
scores. Visual inspection of the variance between technical replicates on the same 
experimental plate allowed for the monitoring of possible edge effects through the 
confirmation that spatially separated technical replicates were not phenotypically distinct 
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from each other in terms of GFP-reporter activity and cell number. Controls wells that 
were found to be misclassified or outliers were excluded from downstream analysis. A 
number of different methods exist for the evaluation of HTS/HCS assay performance, 
including Z’-factor, strictly standardized mean difference (SSMD) and V-factor, to name 
a few (Bray, 2012). Of these, Z’-factor remains the most widely used, particularly in HTS. 
Z’-factor represents a statistical method to rate the performance of an HCS assay by 
evaluating how consistently, and by what margin, the positive and negative control well 
phenotypes are separated across multiple replicates of a screen. Z’-factor was 
automatically calculated for each experimental plate for both the miRNA and compound 
screens using HCSR. Z’-factor values > 0.5 are generally utilised as a cutoff for 
acceptable assay performance in HTS however due to the complex nature of phenotypic 
assays, Z’ factor values <0.5 but greater than 0 are considered acceptable for 
statistically distinct positive and negative control treatments in HCS (Bray, 2012). The 
statistical significance of the variance between the positive and negative control 
phenotypes on each experimental plate were assessed by a Z’-factor value based on 
inTotalGFP (suitable values > 0) and Total cell area (suitable values < 0).   
 
The visualization of inTotalGFP and Total cell area distributions for specific well 
locations across all experimental plates in a screen was used to monitor for specific 
positional biases (e.g row, column, well). These biases can result from defects in liquid 
handling equipment or image acquisition systems, and can result in a distorted 
representation of the data, specifically a high false discovery rate (FDR). Graphical 
representations of the average GFP intensity (inTotalGFP) and cell count scores for all 
experimental wells were also assessed on a per plate basis, to identify any non-random 
and global directional biases that might have been introduced during experimental 
procedures. These positional (well, column, row) biases can in theory be addressed 
using specialised intra-plate normalization techniques such as B-score normalisation, 
but such instances were not encountered within our datasets  (Bray, 2012). 
 
The next stage of the data processing pipeline following the inspection of the 
unprocessed data involved in the normalization of screening datasets. Normalization of 
feature scores is used to minimise the analytical noise caused by minor systematic 
errors, and to improve the detection of variations that result from experimental 
treatments by comparing them to a standardised baseline phenotype (Zhang, 2012). A 
number of different normalization methods can be applied to HCS data, including 
normalising against specific controls wells, sample wells and z-scoring (Bray, 2012). The 
choice of normalization method is dependent on the specific HCS assay, but all of these 
methods serve to improve the similarity of feature profiles for replicate experimental 
treatments located on different experimental wells/plates, and to ‘tighten’ the descriptive 
profiles of phenotypic controls across experimental plates. A number of normalization 
methods were evaluated within HSCR for each dataset and normalization against the 
negative controls was found to be the most useful approach for the majority of datasets 
tested. Normalised distribution profiles for each feature were then visualised and used to 
eliminate features that were not descriptive of the phenotypic assay or exhibited heavily 
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skewed distributions or missing values. The retained features were then either subjected 
to data reduction or utilised in a multivariate approach to hit selection. HCS generally 
results in the generation of multivariate data spread across numerous features. Data 
reduction reduces the dimensionality of this data by summarising the relationships (e.g 
through correlations) between features to create a smaller number of new and more 
relevant descriptors (Kaiser, 1958). Classical data reduction approaches used in HCS 
include principal component and factor analyses (Kaiser, 1958; Shariff, 2010). 
           
Hit Selection 
 
Identification of specific phenotypes of interest (hit selection) from numerical HCS data 
can be achieved using a number of different approaches including multivariate statistical 
analysis, machine learning based pattern recognition, and user defined selection criteria 
(Durr, 2007; Shamir, 2010). The choice of hit selection method can be limited by 
experimental design constraints and varying selection methods can in turn produce 
varying subsets of hits, even from the same dataset (Durr, 2007). For the purposes of 
this study, hit selection was focused primarily on the identification of reagents 
(miRNAs/compounds) that were able to either significantly suppress (hit class 1) or 
enhance (hit class 2) HIV replication in GHOST(3) cells, without nonspecific or 
detrimental effects on cell viability. A plethora of different combinations of hit selection 
criteria and methods were initially evaluated within HCSR using simulated test data and 
then screen data. From these, 4 methods were found to robustly facilitate the 
identification of the hit classes of interest within both the miRNA and compound 
datasets.   
 
In the most basic method, referred to as ‘GFP-ranking’, HIV-suppressive hits were 
defined as reagents that exhibited a significant decrease in the normalized, combined 
inTotalGFP score (between replicates) relative to the negative control samples and a 
predetermined threshold (e.g 50% less GFP) (Figure 4.5). Likewise, HIV-enhancing hits 
were defined as reagents that exhibited a significant increase in the combined 
inTotalGFP score relative to the negative control samples and a predetermined 
threshold. The second approach utilized automated multidimensional-scaling (MDS) 
within HCSR, where pre-determined data reduction methods were applied to the feature 
scores in order to generate a maximum of 2 factors which best summarized the 
relationships between the available features. Experimental treatments that were 
statistically (p threshold) and phenotypically distant (manhattan distance) from the 
negative control samples were then selected for further analysis. From these reagents, 
HIV-suppressive hits were defined as reagents that exhibited a significant decrease in 
the average combined inTotalGFP score relative to the negative control samples. 
Likewise, HIV enhancing hits were thus defined as reagents that exhibited a significant 
increase in the average combined inTotalGFP score relative to the negative control 
samples. This method of hit selection based on the phenotypic distance of treatments 




PCA-based data reduction, specifically the use of Kaiser criterion, Bartlett scores and a 
maximum likelihood-based extraction method was also utilised in hit selection. Following 
PCA analysis, only factors that were adequately descriptive of the variation between the 
positive and negative control samples were retained for further analysis. These factors 
were then utilised in two different hit selection methods. The first is referred to as PCA-
based on similarity to positive controls (PCA-STP) and was used to specifically identify 
reagents that were phenotypically (inverse manhattan distance) and statistically (p 
threshold) similar to the positive control phenotype. The final method relied on the use of 
the PCA-generated factors to identify experimental treatments that were phenotypically 
(manhattan distance) and statistically (p threshold) distant from the negative control 
wells. Reagents that met these criteria were then ranked by their combined inTotalGFP 
scores and HIV-suppressive or HIV-enhancing reagents were identified using specific 
cut-off thresholds as with ‘GFP ranking’. This approach was referred to as PCA-based 
distance from negative analysis (PCA-DFN). 
 
These four hit selection strategies were used in combination or isolation to identify 
reagents that produced phenotypes of interest in both the miRNA and compound 
screens presented in this study. The specific cut-off thresholds (p values, cell viability 
scores etc.) utilised for each method were selected based on individual datasets (e.g 
miRNA mimic or kinase compound library datasets). More relaxed selection criteria were 
specifically utilized in the miRNA screens to account for the high degree of complexity 
and potential variability in miRNA biology. 
 
3.7 Hit Stratification  
 
Functional HCS and HTS strategies can generate large numbers of hits with 
demonstrated functional relevance to the biological process of interest. These hit 
populations may then be stratified to identify and characterise systems biology scaled 
trends that underlie the functional phenotypes related to specific hit classes (e.g 
suppressed or enhanced HIV replication). The prediction/identification of the molecular 
targets (e.g miRNA-mRNA or chemical-protein) of reagents and the subsequent 
characterisation of specific regulatory pathways and molecular targets that are enriched 
for specific hit classes represents a general approach to HCS hit stratification that is 
used in many HCS pipelines (Brass, 2008; Genovesio, 2011). Hit stratification strategies 
specific to miRNA- and compound- based HCS are discussed below along with the 
specific hit stratification methods selected for inclusion in the HCS pipeline developed for 








The interpretation/extrapolation of miRNA screening results beyond the basic phenotypic 
readouts of cellular assays (e.g. enhanced or suppressed HIV replication) is usually 
dependent on the identification of the functional targets of the miRNAs of interest and 
their subsequent characterization through enrichment and protein interaction analyses. 
The non-orthogonal nature of miRNA-target interactions however has made the accurate 
and cost effective characterisation of miRNA-target interactions very challenging, 
especially with regards to large subsets of miRNAs (Lemons, 2013). There are currently 
a number of computational (in silico) and experimental approaches available for the 
identification of miRNA targets (reviewed by Hausser, 2014) Briefly, quantitative 
transcriptomics (Linsley, 2007) and proteomics (Bargaje, 2012) approaches have both 
been utilised to correlate changes in mRNA and protein expression levels with the 
functional modulation of a single or small subset of miRNAs. These strategies have 
proven to be extremely useful in quantifying global cellular responses associated with 
the overexpression or suppression of a given miRNA but are ultimately unable to directly 
resolve miRNA-target interactions (Linsley, 2007; Bargaje, 2012). Alternatively, various 
biochemical methods like Photoactivatable-Ribonucleoside-Enhanced Crosslinking and 
Immunoprecipitation (PAR-CLIP) and the mir-TRAP system are able to identify specific 
miRNA-mRNA interactions through a series of cross-linking, immunoprecipitation and 
sequence verification steps (Hafner, 2010; Baigude, 2012). Additionally a number of 3’ 
UTR reporter systems have also been developed in order to evaluate miRNA- target 
sequence binding efficiencies and to utilize these quantifications to verify predicted 
miRNA-target interactions (Krek, 2005). Each of these experimental methods have 
specific advantages and drawbacks but are all ultimately dependent on assaying the 
outcome of an experiment focused on a single miRNA (Hausser, 2014). These 
approaches are therefore generally not economically or practically suited to the 
identification of miRNA targets on a large scale.  
 
Computational approaches on the other hand may incur little to no financial costs and 
are also less laborious and technically challenging compared to many of the 
experimental methods described above (Hausser, 2014). Computational miRNA target 
prediction is generally based on the use of specific algorithmic criteria such as seed 
sequence complementarity and the stability of RNA-RNA interactions to infer potential 
miRNA targets (Agarwal, 2015). This approach has proven to be a useful tool for the 
large scale prediction of putative miRNA target interactions and number of miRNA target 
prediction tools are freely available as web-based applications (summarised by Lemons, 
2013). High false discovery rates and a lack biological context (e.g cell type specific 
interactions) have traditionally plagued early in silico prediction methods resulting in poor 
confidence in these methods (Alexiou, 2009). miRNA target prediction algorithms have 
however been constantly refined in order to improve their accuracy (Agarwal, 2015) and 
the integration of miRNA-prediction tools with curated databases of experimentally 
validated miRNA-target interactions and miRNA expression mapping tools have 
provided an added level of sophistication and quality to current miRNA target prediction 
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and pathway analysis tools (Vlachos, 2015). Considering that the average functional 
phenotypic miRNA screen is expected to yield between 30 and 200 hits per 900 miRNAs 
screened (Lemons, 2013) and that resources were limited for downstream validation 
experiments, an in silico miRNA target prediction and pathway analysis approach was 
implemented as part of the hit extrapolation strategy within the HCS pipeline. Specifically 
miRNA target prediction and pathway analysis was undertaken using the web-based 




The extrapolation of higher-order functional data from compound screens utilizing well 
characterised and(or) clinically prescribed compounds represents a much simpler task 
when compared to similar miRNA-based analyses. The formulation of high confidence 
protein interaction networks for compounds with characterized functional targets can be 
readily achieved using a number of computational tools. On such tool, is the online 
resource, STITCH  v.4.0. STITCH v.4.0 facilitates the construction of chemical-protein 
and protein-protein interaction networks based on published findings, online databases 
and experimental data and currently contains validated interactions for ~ 300 000 small 
molecules and 2.6 million proteins (Kuhn, 2008). STITCH 4.0 was thus chosen to serve 
as the hit stratification tool for compound screening in the HCS pipeline developed within 
this study.  
3.8 Discussion  
 
The optimisation and design principles described in this chapter were utilised to develop 
and successfully execute all miRNA and compound HCS described in this study. 
Notably, specific guidelines were established for the management of RNAi and 
compound libraries. A GHOST(3)-PSG3BAL infection assay was selected and appropriate 
phenotypic controls were validated. Transfection, cell seeding, and sample processing 
experimental procedures were also optimised for HCS. Imaging parameters were 
verified by experimental simulations, and a functional data management, image analysis 
and data mining pipeline was also successfully implemented. Furthermore validated in 
silico approaches to hit stratification for both miRNA and compound screening datasets 
were established and integrated as part of a functional HCS pipeline. 
 
The use of a Tat-sensitive reporter readout inherently limited the range of screens to 
miRNAs/compounds that affected early stages of  HIV replication, up to the point of Tat-
mediated transactivation. Thus reagents that may potentially impact later stages of 
infection (e.g Rev-dependent translation and budding) could not be resolved using this 
screening strategy. This issue was considered during the experimental design stage and 
could have been addressed by using infectious molecular clones (IMCs) that allow for 
multiple rounds of infection, in combination with a secondary infection assay similar to 
that described by Brass and colleagues (Brass, 2008). However, this was not possible 
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given the requirement of a BSL-3 facility for the use of IMCs. On a separate but related 
point, physiologically relevant cell types are best but many are not suited to HCS 
approaches (Gasparri, 2009). Primary macrophages and T lymphocytes are the most 
relevant cell types for HIV infection, however each of these cell types also present major 
challenges with regards to high content screening. T cells are generally non-adherent 
and difficult to transfect. Macrophages are more amenable to lipid-based transfection, 
however large variability and low efficiency rates with regards to macrophage infection 
render them unsuitable for phenotypic screening applications. The HOS-derived 
GHOST(3) cell line, while not as physiologically relevant as primary cell models, 
facilitated execution of RNAi-based experimental procedures with relative ease, and 
provided a cellular background that was proximal to progenitor lineages of both T cells 
and macrophages (Zhao, 2012).  
 
The data presented in this chapter represents a functional guideline for the development 
of a high throughput phenotypic screening workflow. While the screening parameters 
described in this dissertation focus specifically on the use of an image- based approach 
to identify host miRNAs and compounds that modulate HIV replication, the HCS design 
and optimisation principles presented here can also be readily adapted to miRNA, 














Chapter 4: HCS uncovers novel host  miRNA-mediated 
modulation of HIV replication through the regulation of 
signalling networks that are functionally relevant to HIV 
4.1 Introduction 
 
In contrast to ~30 000 annotated human genes, there are currently only ~ 2000 
annotated human miRNAs (Kozomara, 2014). Despite their relatively small number, 
these endogenous molecules are master regulators of almost all cellular processes, 
through their roles as molecular guides within the endogenous RNAi network (see 
Chapter 1 for a complete review of miRNA biology). Briefly, a single miRNA may govern 
the expression of multiple functionally related genes, and facilitate cross-talk between 
both coding and  long noncoding RNA species (Yoon, 2014; Tan, 2015). Modulating the 
functional activity of a single miRNA can therefore result in complex physiological 
changes that are targeted to specific regulatory pathways and cellular processes (Tan, 
2015). This non-orthogonal but functionally convergent nature of miRNA-target 
interactions has thus positioned many miRNAs as molecular switches that govern key 
biological processes including cellular proliferation (miR-21; Selcuklu, 2009), 
inflammation (miR-155; Faraoni, 2009) and G1/S cell cycle transitions (miR-17-5p; 
Cloonan, 2008) to name a few.  
 
Genome-wide miRNA screening reagents provide researchers with a tool that is typically 
an order of magnitude smaller than traditional genome-wide siRNA libraries, and which 
also offers a potentially broader range of functional coverage which may not be readily 
achieved through single gene silencing strategies (Lemons, 2013). In addition most  
 
miRNA reagent libraries are available in two formats, as collections of double-stranded 
miRNA mimics and single stranded miRNA inhibitors. miRNA mimics are synthetic 
replicates of mature endogenous miRNAs, while miRNA inhibitors function as molecular 
decoys that inhibit endogenous miRNA-target interactions (see Chapter 2). Ectopic 
expression of these molecules can thus be utilised to either enhance or suppress the 
functional activity of a specific endogenous miRNA(s), thereby allowing for a two-
pronged screening approach to evaluate the functional relevance of specific miRNAs 
within a biological process of interest (Santhakumar, 2010).  
 
Research into host-pathogen interactions has revealed that  miRNAs are key mediators 
of viral infection with a number of host miRNAs reported to function as viral restriction or 
host-dependency factors (reviewed by Guo, 2014). A number of viruses have in turn also 
been reported to encode viral miRNAs of their own, that function to hijack the host RNAi 
network and promote viral replication (reviewed by Kincaid, 2012). Functional miRNA 
screens have been successfully utilized to identify a number of novel and broadly acting 
anti-viral host miRNAs in murine cellular models of infection (Santhakumar, 2010), as 
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well as human miRNAs that are relevant to influenza replication (Meliopoulos, 2012; 
Bakre, 2013), and even conserved functional targets among viral-encoded miRNAs 
(Cox, 2015). In addition to uncovering a wealth of novel information on complex 
signalling networks that govern host-viral interactions, miRNA-based HCS approaches 
have also demonstrated great potential for the identification of novel therapeutic targets. 
In fact, miRNAs themselves may be utilised as novel therapeutic agents (Lemons, 
2013). Related to HIV, less than 30 host miRNAs have currently been described as 
functionally relevant for HIV replication, and a large-scale functional evaluation of the 
roles that host miRNAs play in the replication dynamics of HIV is absent (reviewed by 
Klase, 2012 and Barichievy, 2015). To address this shortfall, the GHOST(3)-PSG3BAL 
infection assay and optimised HCS pipeline described in the previous chapter were used 
to screen a panel of miRNA mimics and inhibitors in order to characterize host miRNAs 





Figure 4.1 Validated miRNA-based HIV infection HCS pipeline  
A) GHOST(3) reporter cells expressing a Tat-sensitive GFP reporter construct were seeded into 
the inner 60 wells of µClear®  96 well imaging plates (grey circles) and forward transfected 24 
hours later, B) with a 25 nM final concentration of miRNA mimics or inhibitors. C) 48 hours post-

















~ R: "· ":-· 
















infection cells were fixed with formaldehyde solution and nuclei were counterstained with 2 nM of 
Hoechst, E) Four FOVs were acquired per well in both the 405 (Hoechst) and 488 (GFP) 
channels using an automated microscope system. GFP expression positively correlated with HIV 
replication, F) The acquired images were processed and 17 subcellular measurements (features) 
were extracted from each image in order to convert image-based data to numerical data, G) 
Statistical analyses, quality control filtering and data mining strategies were applied to the 
numerical dataset to identify miRNA reagents that significantly  enhanced or suppressed HIV 




A total of 1239 miRNA mimics and 1245 miRNA inhibitors mimics were screened in 
duplicate across 126 experimental plates. A reconstructed image of a single 
experimental plate is presented in Figure 4.2 below. Uninfected control wells and siCD4-
treated control wells were collectively utilized to define a positive control phenotype for 
image analysis (Figure 4.2). Approximately 7500 individual transfections reactions were 
manually executed along with ~6500 individual HIV infection reactions and ~7500 
fixation/nuclear staining reactions. More than 60 000 images were acquired over ~70 
hours of imaging time, and these images were then catalogued, processed and analysed 
over several months (see Chapter 3). miRNA screening results were separated into 
mimic and inhibitor datasets for image analysis. This was done to try and improve the hit 
recovery rate for miRNA inhibitors which generally produce much more subtle 
phenotypic effects. However, the overarching aim of identifying miRNA mimics and 





Figure 4.2 miRNA screen experimental plate layout  
A single composite image comprised of reconstructed images acquired in both the 405 (Hoechst) 
and 488 (GFP) channels is shown. Each well is represented by 4 FOVs. The black border 
represents the outer 36 wells that were not utilized for experimental reactions. Duplicate 
experimental control wells were located on rows B and E of each experimental plate and 
experimental samples (mimics/ inhibitors) were were always located on rows C, D, F and G. GFP 
reporter signal (green), nuclei stained with Hoechst (red). 
 
4.2.1 HCS Quality Control 
 
Visual inspection of graphical data outputs in HCstratomineR were utilised to perform a 
number of quality control verification steps. Briefly, cellular assay performance was 
quantified by Z’ factor analysis using the ‘inTotalGFP’ and ‘Total Cell Area’ feature 
scores. An ‘inTotalGFP’ Z’ factor value > 0.1 and a negative ‘Total Cell Area’ Z’ factor 
were indicative of acceptable assay performance. Plate rotations and well-specific 
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biases were also evaluated by distributions plots of ‘inTotalGFP’ and ‘Total Cell Area’ 
feature scores for all experimental wells/ plates. Individual datasets were generated for 
miRNA mimics and inhibitors for each replicate (n=2) and replicate datasets were 
analysed within a single screening experiment. 
4.2.1.1 Mimics 
 
The unprocessed ‘Total Cell Area’ scores (cell count parameter) demonstrated no clear 
variation between the phenotypic control samples, including the positive and negative 
controls and the internal infected and uninfected controls (Figure 4.3A). This was 
confirmed by the recovery of negative Z’ factor values for all experimental plates. 
Experimental treatments demonstrated a greater level of variation, indicative of miRNA 
mimic -associated effects on cell density (Figure 4.3A). The unprocessed ‘inTotalGFP’ 
scores (primary reporter assay feature) demonstrated a clear and significant variation 
between positive and negative control samples (Figure 4.3B). In addition, uninfected 
non-targeting miRNA controls as well as infected non-targeting miRNA control samples 
exhibited similar phenotypic classifications compared to their respective controls (Figure 
4.3B). A Z’ factor range between 0.3-0.6 was recovered for all experimental plates 
indicative of assay performance and data quality that was suitable for downstream 
analysis. To be clear, there was a significant difference between positive and negative 
control wells, based on total GFP expression. Similarly, wells containing virus and non-
targeting controls showed similar GFP expression to virus only wells, and these were 
significantly different from wells containing only non-targeting controls (Figure 4.3A ii). 
Distribution of the uninfected phenotypic controls confirmed that none of the 
experimental plates were acquired in the wrong orientation and well location based 
analysis (‘Frequent hitter’ analysis) confirmed that systematic errors had not significantly 
impacted the inTotalGFP-related phenotypic readout within experimental plates (Figure 
4.3C). Controls wells were observed to consistently produce specific and distinct GFP 
expression phenotypes, while experimental treatment wells did not (Figure 4.3C). In 
addition, no biased directional (column, row) or well-specific effects on GFP expression 
were observed across experimental well locations. The quality of the data obtained from 






Figure 4.3 Quality control for miRNA mimic screen data.  
A) Scatter plot of unprocessed ‘Total Cell Area’ scores for all experimental wells across two 
replicates. Significant variations in cell count were observed within experimental treatments 
(green), but not for experimental controls (red, yellow, blue, purple). B) Scatter plot of the 
unprocessed ‘inTotalGFP’ scores for all experimental wells (controls and treatments) across two 
replicates. A significant variation in GFP intensity was observed within miRNA treatments, and 
positive (yellow) and negative (red) controls exhibited discrete distributions which were 
recapitulated by infected (blue), and uninfected (purple) non-targeting miRNA controls. C) 
Visualization of frequent-hitter (Well-based) analysis by box plots revealed no directional or well 
specific biases for ‘inTotalGFP’ scores for experimental treatment wells, while control wells 
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As with the miRNA mimic dataset, unprocessed ‘Total cell area’ scores demonstrated no 
clear variation between phenotypic control samples for the miRNA inhibitor dataset and 
this was confirmed by the recovery of negative Z’ factor values for all experimental 
plates. However, the miRNA inhibitor-treated samples demonstrated little to no variation, 
indicating a low incidence of treatment-associated effects on cell viability (Figure 4.4A). 
The unprocessed ‘inTotalGFP’ scores demonstrated a clear and significant variation 
between the positive and negative control samples as expected (Figure 4.4B) and this 
was confirmed by a Z’ factor range between 0.2 and 0.8, which was recovered for all 
experimental plates. In addition the uninfected and infected samples containing non-
targeting miRNA controls exhibited similar phenotypes compared to positive and 
negative controls samples respectively (Figure 4.4B). miRNA inhibitor-treated samples 
again however displayed a poor GFP distribution range suggesting that, by in large, 
miRNA inhibitor treatments had no significant effects on GFP-reporter activity. Well 
location-based analysis also confirmed that technical errors had not significantly 
impacted the phenotypic readout across experimental plates (Figure 4.4C). Thus while 
the overall quality of the GHOST(3) miRNA inhibitor assay was acceptable, the dataset 





Figure 4.4 Quality control for miRNA inhibitor screen data.  
A) Scatter plot of the unprocessed Total cell area scores for all experimental wells (controls and 
treatments) across two replicates. No significant variations were observed within experimental 
treatments (green) or between experimental controls (red, yellow, blue, purple). B) Scatter plot of 
the unprocessed ‘inTotalGFP’ scores for all experimental wells (controls and treatments) across 
two replicates. Significant variations in GFP intensity were observed between experimental 
controls (positive (yellow), negative (red), infected (blue), and uninfected (purple) non-targeting 
miRNA controls). C) Visualization of frequent-hitter analysis by box plots based on inTotalGFP 
revealed no directional or well specific biases for experimental treatment wells, while control wells 
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4.2.2 Normalisation and Feature retention  
 
Features scores were normalized against negative control wells on a per plate basis. 
Normalized features trends were then evaluated through HCSR visualization tools and 
only certain features were retained for downstream analysis (feature reduction). 
Features that contributed to an accurate assessment of cell count/viability (Figure 4.5A), 
and features that distinguished between positive and negative control phenotypes 
(Figure 4.5B) were retained. In addition experimental treatment wells were confirmed to 
exhibit feature-specific distribution trends suggestive of a broad phenotypic range. 
Where applicable, specific data reduction methods were applied using PCA- or MDS- 
based data transformations (see Hit Selection in Chapter 3), and screen hits were then 
selected using different hit selection criteria.     
 
Similar distribution plots were generated and evaluated for all features and these 
distributions contributed to the selection of features for data reduction and hit selection.   
 
 
Figure 4.5 Normalised feature score distribution plots for mimic and inhibitor datasets 
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A) Distribution plots from mimic dataset, Total cell area distributions revealed a uniform 
distribution for all experimental treatments with no significant variations between positive (yellow) 
and negative control (red) samples. Additionally the majority of experimental treatments were 
observed to overlap with the distribution range of the experimental control samples, the 
inTotalGFP feature exhibited non-uniform and bimodal distribution patterns across all 
experimental treatments with clear variation between the positive (yellow) and negative (red) 
control samples as well as the infected (blue) and uninfected (purple) non-targeting miRNA 
control samples. Experimental treatments (green) samples were widely distributed across and 
beyond both the negative and positive control sample ranges. B) Distribution plots from inhibitor 
dataset. Total cell area distributions revealed a uniform distribution for all experimental 
treatments with no significant variations between positive (yellow) and negative control (red) 
samples. Additionally the majority of experimental treatments (green) overlapped with the 
distribution range of the experimental control samples, the inTotalGFP feature exhibited non-
uniform and bimodal distribution patterns across all experimental treatments with clear variation 
between the positive (yellow) and negative (red) control samples as well as the infected (blue) 
and uninfected (purple) non-targeting miRNA control samples. Experimental treatments (green) 
samples exhibited a uniform distribution within the negative control sample range. Distribution 
median (Dashed vertical line) 
 
4.3 Hit Selection  
 
miRNA mimics and inhibitors that either enhanced or suppressed PSG3BAL replication 
within GHOST(3) cells were recovered by multiple hit selection methods (see Chapter 3, 
Hit selection methods). Briefly, where applicable data reduction by either 
multidimensional scaling (MDS) or principal component analysis (PCA) was utilized to 
generate factors which summarised the relationships between specific sets of features 
(Figure 4.6 A). Only factors that were descriptive of the phenotypic variation between the 
positive and negative control phenotypes were then applied to hit selection (Figure 4.6 
B). The phenotypic distance between experimental treatments was calculated using 
either the positive (-STP) or negative (-DFN) controls as reference points and a 
phenotypic distance threshold (p<0.1) was used to identify putative hits (Figure 4.6 C). 
All miRNA mimics and inhibitors that resulted in a >60% decrease in cell viability (‘Total 
cell area’) compared to negative control wells were excluded from hit selection and GFP-
related thresholds were applied to generate final hit lists. Notably, while HIV-suppressive 
and HIV replication -enhancing miRNA mimics were readily recovered by different hit 
selection methods, miRNA inhibitors that induced significant functional effects on HIV 




Figure 4.6 Data reduction-based hit selection 
A) Polar plot summarising the correlative relationships between specific features. B) Data 
distribution plot generated for the factor present in (A), a non-uniform and bimodal distribution 
pattern was observed for all experimental treatments with clear variation between the positive 
(yellow) and negative (red) control samples as well as the infected (blue) and uninfected (purple) 
non-targeting miRNA control samples, Experimental treatments (green) samples were widely 
distributed across the negative and positive control sample ranges. C) Distance plot, the 
phenotypic distance of all experimental treatments are plotted in reference to the negative 
controls (NEG), experimental treatments that exhibited significant phenotypic distance from the 
negative controls in both replicates (average p<0.1) were classified as putative hits.   
 
4.3.1 Suppressed HIV replication  
Mimics  
 
GFP ranking identified 46 miRNA mimics that resulted in a >55% reduction in GFP-
reporter signal compared to negative control wells. The percentage of total reagents (all 
mimics) identified as hits (hit rate) using this approach was thus 3.7%. Two-factor PCA-
DFN hit selection recovered 17 HIV-suppressive miRNA mimics (hit rate = 1.3%) that 
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were phenotypically distinct from negative control wells (p<0.1) and which also resulted 
in a >55% reduction in GFP-reporter signal as compared to negative control wells. PCA-
STP hit selection using the same 2 factors resulted in identification of 12 miRNA mimics 
(hit rate = 0.96%) that were phenotypically similar (p<0.1) to positive control wells. None 
of the hits recovered by PCA-STP were recovered by PCA-DFN, and only 3 of the 12 
hits recovered by PCA-STP were also recovered by GFP ranking (hsa-mir-940, hsa-mir-
650 and hsa-mir-192), see Figure 4.7 below. PCA-STP thus resulted in identification of 9 
unique hits. 16 of the 17 hits recovered by PCA-DFN were also recovered by GFP 
ranking, with hsa-mir-646 being the only unique hit identified by PCA-DFN (Figure 4.7). 
In contrast to PCA-DFN, 28 of the 46 hits recovered by GFP ranking were unique to that 
hit selection method (Figure 4.7). Only PCA-STP and GFP ranking hit lists were retained 




Figure 4.7 Overlap in HIV-suppressive hits recovered by different hit selection methods. 
Number of miRNA mimics recovered as HIV-replication suppressing agents by ‘GFP ranking’, 
‘PCA-DFN’ and ‘PCA-STP’ hit selection methods, * denotes number of unique hits identified by 
each method. 
 
The majority of hits identified by GFP ranking were randomly validated by visual 
inspection (Figure 4.6). Variable but consistently significant phenotypes of suppressed 
HIV replication (reduced GFP expression) were observed right from top ranked hits 
(Figure 4.8A) down to the lowest ranked hit, hsa-mir-1231 (Figure 4.8B). Variations in 
cell number were also observed, and many hits exhibited lower cell numbers compared 
to negative controls although always within an acceptable range (>40%, Figure 4.8). 
These observations further validated GFP ranking as a functional hit selection method 









Figure 4.8 Visual inspection of GFP ranking-derived miRNA mimic hits for suppressed HIV 
replication 
A) Top 5 miRNA mimic hits identified by GFP ranking hit selection as compared to negative 
control images (NEG) acquired from the same plate. B) Lower ranked miRNA mimic hits 
identified by GFP ranking as compared to NEG. Images represent unprocessed composite 
images acquired in the 405 and 488 channels.  GFP-reporter signal (green), nuclei stained with 
Hoechst (red), scale bars = 20 µm. 
A. Plate specific Negative Control HIV-suppressive miRNA mimic hits B. Plate specific Negative Control HIV-suppressive miRNA mimic hits 
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4.3.2 Enhanced HIV replication 
 
Having identified miRNA mimics that suppressed HIV replication, similar methods were 
then used to identify mimics that enhanced HIV replication. MDS-DFN identified 6 
miRNA mimics (hit rate = 0.48%) that were phenotypically distinct from negative control 
wells (p <0.1), and which resulted in >70% increase in GFP reporter signal (mir-378*, 
mir-141*, mir-2277-5p, mir-3679-3p, mir-4318 and mir-200*). PCA-DFN recovered 4 
miRNA mimics (hit rate = 0.32%), while GFP ranking classified 28 miRNA mimics (hit 
rate = 2.2%), including all of the hits identified by both other methods. Visual inspection 
of these hits revealed three consistent phenotypic trends: enhanced infection rates (e.g. 
mir-2277-5p), enhanced GFP-reporter activity (mir-378*) or both (mir-200b*). In contrast 
to the reduced cell numbers that were observed for many of the HIV suppressive hits, 
HIV enhancing miRNA mimics did not exhibit any noticeable effects on cell viability 
(Figure 4.10). However, a trend of aberrant cell morphology (shape or size) was noted 
for many HIV enhancing hits, such as mir-891b (rank #9) and mir-34c-3p (rank #28). 
Overall, 28 miRNA mimics identified by GFP ranking were thus retained for further 
investigation and pathway analysis (Table A4.2, Appendix IV). Notably, none of the 






Figure 4.10 Visual profiles of HIV replication-enhancing miRNA mimic hits identified by 
GFP ranking hit selection.  
Consistent phenotypes related to increased GFP-reporter activation and(or) increased numbers 
of infected cell were observed for the miRNA mimics identified by this method. Images represent 
unprocessed composite images acquired in the 405 and 488 channels. GFP-reporter signal 











4.4 Hit triage  
 
High content image analysis and data mining recovered 53 miRNA mimics and 4 miRNA 
inhibitors that suppressed HIV replication. Similarly, 27 miRNA mimics were found that 
enhance HIV replication. Together, this gave a total of 84 host miRNAs that are 
functionally relevant for HIV replication, thereby expanding the current repertoire of HIV-




Figure 4.11 Summary of contribution to current knowledge on HIV replication modulating 
human miRNAs 
 
4.4.1 miRNA hits and prior art 
 
Four of the miRNA hits described here (hsa-miR-124-3p, hsa-miR-138-5p, hsa-miR-
378a-5p, hsa-miR-19b-2-5p) were previously demonstrated to functionally modulate HIV 
replication (reviewed by Barichievy, 2015). Specifically, miR-138 was predicted to target 
multiple sites in the HIV genome corresponding to Env, Pol and Tat mRNAs (Houzet, 
2012). miR-378 was predicted to target Vpu (Hariharan, 2005), miR-19b was predicted 
to target the Tat-associated PCAF/p300 complex (Triboulet, 2007), and miR-124-3p 
(previously miR-124a) was described to increase HIV replication through suppression of 
TASK1 (Farberov, 2015). While the HIV suppressive phenotype recovered for miR-138 
supported previous findings (Houzet, 2012), the remaining phenotypes did not. This 
suggests that alternative mechanisms of miRNA action may be modulating HIV 
replication, within the confines of the assays described in this study. Notably, only 2 of 
the recovered hits (miR-138 and miR-378) were described to directly target sites on the 
HIV genome (Hariharan, 2005; Houzet, 2012). Furthermore, miRDB-based (mirdb.org) 
miRNA binding analysis revealed that none of the recovered miRNA were predicted to 
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interact with the humanised GFP variant (GenBank U50963.1) expressed by GHOST(3) 
cells. These observations would suggest that the majority of enhanced or suppressed 
HIV replication phenotypes recovered by HCS were a result of miRNA-mediated effects 
on HIV replication and not as a result of miRNA-mediated modulation of GFP mRNA. 
 
Chemokine C-C motif ligand 4 (CCL4/MIP1ß), a well characterized antagonist of CCR5 
and HIV replication (Guan, 2002), is also an experimentally validated target of miR-378-
5p (Skalsky, 2012). Thus miRNA-378-5p suppression of CCL4 may account for the 
enhanced HIV replication phenotype in this study. Likewise, a number of experimentally 
validated targets of miR-19b-2-5p are enriched within the TGFß and cell cycle pathways, 
and current literature have posited these to be highly relevant to HIV replication, thus 
suggesting alternative by which miR-19b-2-5p may influence HIV replication (Table A4.4, 
Appendix IV). The HIV replication enhancing function of miR-124-3p was previously 
related to its’ ability to downregulate TASK1, a viral restriction factor (VRF) which 
disrupts Vpu-mediated virion release (Farberov, 2015). TarBase analysis of miR-124-3p 
targets revealed a low association score for TASK1 (KCNK3), with only microarray 
expression data to support the miR-124/TASK1 association. In contrast, one of the 
highest scored targets for miR-124-3p, confirmed by immunoprecipitation, was the TAR 
RNA binding protein (TRBP1). TRBP1 facilitates HIV replication through inhibition of the 
antiviral activity of PKR (Sanghvi, 2011), thus supporting the HIV-suppressive phenotype 
recovered for this miRNA in the current study. In addition, a number of  other host 
miRNAs previously associated with HIV replication were either identified as HIV-
suppressive hits but excluded due to toxicity (miR-15a and miR-92a-1), or were 
recovered as HIV-enhancing hits using more relaxed selection criteria (miR-125b, miR-
150, miR-204, miR-382). The recovery described here of a number of host miRNAs also 
previously shown to modulate HIV replication validates the robustness and fidelity of this 
study, and provides confidence that  the novel host miRNA-HIV interactions may be 
similarly robust.  
 
A poor concordance was observed between miRNA hits recovered by HCS and miRNAs 
previously reported to be differentially expressed following HIV infection (summarised in 
Hayes, 2011). However, this was expected because i) there are cell type-specific miRNA 
expression patterns noted by many independent expression-based studies (see Chapter 
1), and ii) differential expression of a miRNA is not necessarily indicative of its functional 
relevance within a given biological model (Salmena, 2011). Furthermore the HCS hit 
recovery model utilised in this study did not specifically exclude miRNAs based on tissue 
or cell-type expression patterns in order to characterise all host miRNAs with the 
potential to modulate HIV replication, not simply those expressed in HIV susceptible cell 
lines (e.g T lymphocytes, macrophages). With that in mind, it was nonetheless surprising 
that none of the 19 host miRNAs which regulate CD4 or the 15 host miRNAs which 
target CCR5  (as described using Tarbase v7.0) were recovered as HIV-suppressive hits 
in this study. This suggests that the level of CD4/CCR5-specific post-transcriptional 
repression mediated by each of these miRNAs is not sufficient to functionally inhibit HIV 
entry. This is plausible given that, i) GHOST(3) cells have been engineered to express 
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elevated levels of both CD4 and CCR5 receptors, and ii) host miRNAs have been 
described to target on average ~ 300 different host genes.  
  
Interestingly, a number of miRNA hits identified in this study were correlated with other 
models of viral infection, including Influenza virus and HCV. Specifically, miR-491 and 
miR-654 suppress Influenza virus replication in MDCK cells  (Liu, 2010), and both of 
these miRNAs were recovered as HIV-suppressive hits by HCS (Table A4.1, Appendix 
IV). In addition, miR-491 has been shown to suppress HCV replication in cultured 
hepatoma cells, in a PI3K-dependent manner (Ishida, 2011). Ectopic expression of a 
miR-34c-3p mimic enhanced Influenza virus replication in cultured cells (Bakre, 2013), 
and an enhanced viral replication phenotype was also recovered for HIV in this study. 
miR-141, which was recovered as an HIV replication-enhancing hit, is upregulated by 
Influenza infection and associated with viral-mediated regulation of TFGß signalling 
(Lam, 2013). This same miRNA is also induced by enterovirus infection and is required 
for viral propagation through the inhibition of host translation (Ho, 2011). In contrast to 
the reported attenuation of Influenza replication by miR-136 (Zhao, 2015), the current 
HCS recovered miR-136 exclusively in association with enhanced HIV replication (Table 
A4.2, Appendix IV). The HIV suppressive hit, miR-124, was described to be 
epigenetically silenced by HCV infection (Zeng, 2012), while the HIV suppressive hit, 
miR-138, was found to regulate CDK13, a host factor essential for Influenza virus 
replication (Bakre, 2013). miR-192 was recovered as an HIV-suppressive hit which has 
also been described as a tumor suppressor that negatively regulates ZEB2 and 
nucleotide excision repair (NER) processes in response to P53 induction (Kim, 2011; 
Xie, 2011). Suppression of NER processes has been linked to carcinogenic viruses such 
HTLV-I and HCV but a direct role for miR-192 in viral infection has yet to be elucidated 
(Xie, 2011). Additionally miR-192 has been described to regulate cycle progression, 
promoting P53-dependent G1 and G2  cell cycle arrest (Bo, 2008; Georges, 2008). The 
results of this study therefore represent the first account of a functional role for miR-192 
in the modulation of HIV replication. These observations further bolster confidence in the 
novel findings of this study, and suggests that a specific subset of host miRNAs may 
exhibit pan-viral modulating activity although this warrants further investigation.  
 
4.4.2 miR-200 and miR-34 families and HIV 
 
Strikingly, 3 of the 5 members from the miR-200 family, namely hsa-miR-141-5p, hsa-
miR-200a-5p and hsa-miR-200b-5p, were recovered as hits for the enhanced viral 
replication phenotype, while a fourth member, hsa-miR-200c, was marginally excluded 
based on hit selection criteria. Analysis of their sequences revealed a high degree of 
homology (90%) between miR-200a-5p, miR-200b-5p and miR-141-5p but not miR-
200c-5p (Figure 4.12A), and mirPath analysis revealed 8 genes that were regulated by 
all three miRNAs (Figure 4.12B). STITCH 4.0 protein-protein interaction analysis 
revealed a significant (p<0.05) KEGG enrichment for both P53 and cell cycle associated 
factors for these genes (Figure 4.12C), and gene ontology (GO) analysis revealed a 
139 
significant (p<0.05) correlation with ‘enzyme linked receptor protein signaling pathway’ 
and ‘regulation of DNA replication’. This was unsurprising given the previous association 
of miR-200 family members and P53 (Kim, 2011). 
 
The miR-200 family consists of two separate polycistronic pri-miRNA transcripts, miR-
200a/200b/429 and miR-141/200c, which regulate epithelial to mesenchymal transition 
(EMT) and tumour metastasis by targeting the transcription factors ZEB1 and 
ZEB2(reviewed by Mongroo, 2010). As mentioned, the miR-200 family have also been 
implicated as P53-regulated miRNAs (Kim, 2011) that negatively regulate WNT 
signalling leading to EGFR-directed anti-cancer therapy resistance(Mongroo, 2010). 
While miRNAs of the miR-200 family were previously described to be downregulated in 
murine models of HIV-associated nephropathy (Cheng, 2013), there has until now been 
no functional data supporting a direct relationship between the miR-200 family and HIV 
replication. The results of this study therefore posit a novel functional role for this miRNA 
family in HIV replication, potentially through P53 signalling, cell cycle regulation and(or) 
ZEB1/2 (Kim, 2011; Figure 4.12).  
 
 
Figure 4.12 miR-200 family associated with enhanced HIV replication. 
 
A) Alignment of miR-200a-5p, miR-200b-5p, miR-141-5p and miR-200c-5p sequences with 
mismatches shown in black. B) Host factors regulated by miR-200a-5p, miR-200b-5p and miR-
B.----~ 
A. t: AAt:Aci:ccccccuAAi:cAuc cA miR-200c 
CAUCl:UACC CCACACUCC l:GGA miR-200a 
CAUCUJACUCCGCAC CAUUGGA miR-20Qb 













141-5p. C) Protein interaction map for common gene targets of miR-200a-5p, miR-200b-5p and 
miR-141-5p.  
 
The miR-34 family of miRNAs (miR-34a/b/c) have been well characterised as tumour 
suppressors that are direct targets of P53 transcriptional activity, and which regulate a 
myriad of host factors to suppress cellular proliferation and induce apoptosis in response 
to DNA damage and other genotoxic stressors (reviewed by Hermeking, 2010). miR-
34a-3p was recovered as an HIV suppressive hit by HCS, while miR-34c-3p was 
recovered as an HIV replication enhancing hit. The molecular mechanisms associated 
with miR-34c-3p function have not been completely elucidated but it may act in part 
through suppression of eIF4E (Liu, 2015) and modulation of Myc (reviewed by Cannell, 
2010). miR-34a-3p modulates macrophage activation, TGFß-mediated apoptotic signals 
(Guennewig, 2013), and also negatively regulates XIAP, ß-catenin and the negative 
regulator of ß-catenin, AXIN2 (Tarbase v7.0). In addition, mir-34a-3p has been 
implicated as a critical mediator of the P53/P63-OCT4 axis associated with human cell 
transformation (Ng, 2014). While ‘miR-34a’ has been described to be induced by Tat and 
promote LTR activation through suppression of SIRT1 (Zhang, 2012), this has been  
associated with miR-34a-5p and not the -3p arm of the miR-34a precursor (Guennewig, 
2013). Likewise, no functional association between miR-34c-3p and HIV replication has 
been described in the current literature, although ectopic expression miR-34c-3p was 
found to significantly enhance Influenza virus replication, potentially through upregulation 
of Polo-Like kinase 1 (PLK; Bakre, 2013). The results of this study represent the first 
account of experimental evidence establishing a functional role for miR-34a-3p and miR-
34c-3p in the modulation of HIV replication.  
 
4.4.3 Top ranked hits 
 
miR-506 was the top ranked hit by GFP expression for suppressed HIV replication 
(Figure 4.8) and miRpath analysis revealed 89 experimentally validated targets for this 
miRNA.  In addition miR-506 was shown to be downregulated in chronically infected 
PBMCs, although a direct functional association between HIV replication and miR-506 
was not described (Hayes, 2011). Protein-protein interaction analysis of the 
experimentally validated targets of miR-506 revealed a significant enrichment for Erbb 
(EGFR)-mediated signalling (Figure 4.13) and this was confirmed by KEGG analysis 
(p>0.05). Of interest, the second highest ranked HIV-suppressive hit, miR-124, was 
previously also identified as a critical regulator of EGFR-mediated control of cell cycle 
(Uhlmann, 2012).  
 
The top ranked hit recovered for enhanced HIV replication was miR-378-5p (Figure 
4.10), for which mirPath analysis revealed 441 experimentally validated targets. Protein 
interaction and subsequent KEGG analysis revealed a significant (p<0.05) enrichment 






Figure 4.13 Protein interaction network for miR-506 and its associated targets 
Protein interactions were predicted using STITCH 4.0 and derived from various sources including,  
genomic context, high throughput experiments, and conserved co-expression. Thickness of lines 






4.5 Pathways analysis  
 
Given the relatively large size of the recovered hit pool (~90 reagents), miRNA-target 
prediction and pathway analyses were used to ratify the data and identify functional 
trends. mirPath, a web-based miRNA pathway analysis tool, was utilized to identify 
specific functional pathways enriched within each of the hit classes. miRNA names were 
based on miRBASE v.20 nomenclature and those miRNA sequences that were excluded 
from the miRBASE v.20 database were also excluded from pathway analysis. miRPath 
analysis was based on experimentally validated miRNA-target interactions listed in 
Tarbase v.7.0, or using microT-CDS v.5.0 target prediction when experimentally 
validated targets were not available (Vlachos, 2015).  
 
Fifty-two of the 53 miRNAs (mimics) associated with suppressed viral replication were 
used in pathway analysis and experimentally validated targets were available for 34 of 
these. The total number of experimentally validated targets per miRNA ranged from 
between 25 genes (for mir-483-5p) to 1962 genes (for mir-124, now mir-124-3p), with an 
average of ~300 genes per miRNA. Likewise, twenty-seven of the 28 miRNAs (mimics) 
associated with enhanced viral replication were retained during pathway analysis. 
Experimentally validated targets were available for 22 of these, with target number per 
miRNA ranging from 3 for mir-3679-3p to 1769 for mir-22-3p. Pathway analysis yielded 
62 functional pathways that significantly (p<0.05) correlated with miRNA target genes 
recovered for the suppressed HIV replication phenotype (Table A4.3, Appendix IV) and 
48 functional pathways that significantly (p<0.05) correlated with the enhanced HIV 
replication phenotype (Table A4.4, Appendix IV). These pathways were ranked 
according to the number of miRNAs associated with each pathway and the top 30 
pathways recovered for the suppressed (Figure 4.14) and the enhanced (Figure 4.15) 
HIV replication phenotypes are presented below. 
 
‘Proteoglycans in cancer’ was revealed as the highest ranked pathway associated with 
the suppressed HIV replication phenotype (48 miRNAs targeting 138 genes). ‘Pathways 
in cancer’ was ranked second (48 miRNAs targeting 252 genes) and ‘Focal Adhesion’ 
third, with 48 miRNAs targeting 138 genes (Figure 4.14). A large overlap (~90%) was 
observed for the miRNAs associated with each of these pathways, and 40-56% overlap 





Figure 4.14 Top 30 functional pathways associated with suppressed HIV replication.  
Pathways were identified by mirPath v.3.0 and ranked according to the number of miRNA hits 
associated with each pathway. 
 
 
The PI3K signalling pathway was the highest ranked pathway associated the enhanced 
HIV replication phenotype with 26 miRNAs targeting 124 genes (Figure 4.15). 
‘Proteoglycans in cancer’ was ranked second (24 miRNAs targeting 96 genes) and 
‘Focal Adhesion’ third, with 24 miRNAs targeting 96 genes (Figure 4.15).  
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Figure 4.15 Top 30 functional pathways associated with enhanced HIV replication.  
Pathways were identified by mirPath v.3.0 and ranked according to the number of miRNA hits 
associated with each pathway.   
 
4.5.1 Pathways associated with both enhanced and suppressed HIV 
replication  
 
Interestingly, pathway analysis recovered 38 functional pathways which were enriched 
within both ‘suppressed’ and ‘enhanced’ HIV replication phenotypes (Table 4.1). These 
findings posit the cellular networks associated with these pathways as central mediators 
of HIV-host interactions. Unsurprisingly a number of these pathways have well 
characterized functional relevance to HIV replication and viral infection in general 
including the Erbb, TGFß, P53 and WNT signalling pathways (Brass, 2008; Konig, 2008; 
Friedrich, 2011). Contrastingly, mirPath analysis also recovered pathways which have 
not been well characterised with regards to HIV replication, including the hippo signalling 
pathway, thus placing these as potentially novel mediators of HIV-host interactions. A 
comparison of the functional targets identified for suppressed and enhanced HIV 
replication within a single pathway also provided an ideal opportunity to recover specific 
miRNA targets preferentially associated with each HIV replication phenotype, and this 
comparison was completed for the viral carcinogenesis, cell cycle, regulation of actin 























Table 4.1 Functional pathways associated with both enhanced and suppressed HIV 
replication 
Functional pathways recovered by mirPath* 
Adherens junction Neurotrophin signaling pathway 
Bacterial invasion of epithelial cells Oocyte meiosis 
Bladder cancer p53 signaling pathway 
Cell cycle Pancreatic cancer 
Central carbon metabolism in cancer Pathways in cancer 
Chronic myeloid leukemia Prion diseases 
Colorectal cancer Prostate cancer 
ECM-receptor interaction Protein processing in endoplasmic reticulum 
Endometrial cancer Proteoglycans in cancer 
Epstein-Barr virus infection Regulation of actin cytoskeleton 
ErbB signaling pathway Renal cell carcinoma 
Fatty acid biosynthesis Shigellosis 
Focal adhesion Signaling pathways regulating pluripotency of 
stem cells 
FoxO signaling pathway Small cell lung cancer 
Glioma TGF-beta signaling pathway 
Hepatitis B Thyroid hormone signaling pathway 
Hippo signaling pathway Transcriptional misregulation in cancer 
Insulin signaling pathway Viral carcinogenesis 
Melanoma Wnt signaling pathway 




Pathway analysis recovered 46 HIV-suppressive miRNAs (Table A4.5, Appendix IV) and 
23 HIV replication enhancing miRNAs (Table A4.6, Appendix IV) which regulate host 
factors enriched within the viral carcinogenesis pathway. To date, this represents the 
most comprehensive list of host miRNAs that functionally modulate HIV replication, 
potentially through regulation of host factors classically associated with both viral 
replication and carcinogenesis (Wang, 2015).  Carcinogenesis refers to the process 
whereby a normal cell is systematically re-programmed at the genetic, epigenetic and 
cellular level by specific mutations or environmental factors, ultimately resulting in 
uncontrolled cell division and escape from apoptosis (Hanahan, 2011). In addition, 
certain viruses can also transform host cells into a cancerous state and this process is 
known as viral carcinogenesis (Butel, 2000; Chen, 2014). A number of carcinogenic 
human viruses have been described including HCV, HBV, Epstein-Barr virus (EBV), 
Human papilloma virus (HPV), HTLV-I and Kaposi’s sarcoma-associated herpesvirus 
(KSHV). Furthermore, viral infections are estimated to account for 15-20% of all cancers 
globally (Bregnard, 2014). HIV has traditionally been indirectly associated with cancer 
phenotypes as HIV-mediated depletion of the  immune response results in a higher 
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susceptibility to carcinogenic pathogens like KSHV and HPV (reviewed by da Silva, 
2011). However, it has also been suggested that HIV infection itself may indeed be 
oncogenic (Nakai-Murakami, 2007; reviewed by Pierangeli, 2015). mirPath analysis 
revealed a strong concordance between host factors enriched within HCV, HBV, EBV, 
HPV, HTLV-I and KSHV infection and the miRNA hits recovered by HCS (Figure A4.2, 
Appendix IV). The high degree of overlap in functional targets between such ‘true’ 
oncogenic viruses and HIV supports the ‘viral cooperation’ model of tumorigenesis 
(reviewed by da Silva, 2011), and is also indicative of the highly conserved mechanisms 
exploited by various human viruses (Wang, 2015).  
 
Indeed, the majority of the protein targets recovered for enhanced HIV replication hits 
were also associated with suppressed viral replication hits (Figure A4.2). In addition, 18 
host proteins were exclusively associated with enhanced viral replication hits (Table 
A4.7, Appendix IV) including JAK1 and STAT5B, while 59 host factors were exclusively 
associated with suppressed HIV replication hits (Table A4.8, Appendix IV) including 
Protein Kinase-R (PKR), BAD, Retinoblastoma protein (Rb), IKBα, NFKß, Lyn and PCAF. 
All of these proteins have been previously associated with HIV replication and therefore 
represent strong functional targets related to miRNA-mediated modulation of HIV 
replication. PKR is activated by P53 following HIV infection and directly interacts with 
Tat, thereby suppressing Tat-mediated transcription (Clerzius, 2011; Yoon, 2015). HIV 
Nef suppresses the proapoptotic activity of BAD via p21 activated kinase (PAK) in a 
PI3K-dependent manner (Wolf, 2001), while the induction of Rb (RB1) in HIV-infected 
monocytes has been associated with resistance to apoptosis and enhanced cell survival 
in response to immune activation (Gekonge, 2012). The SRC kinase Lyn, facilitates 
CCR5-mediated activation of ERK and TNFα production in macrophages, in response to 
HIV gp120 (Tomkowicz, 2006). P300/CBP-associated factor (PCAF) is a well 
characterised coactivator of Tat transcriptional activity (Zeng, 2005) that is also a 
documented target for miRNA-mediated modulation of HIV replication (Triboulet, 2007). 
IKBα and NFKß signalling are linked to viral persistence and resistance to apoptosis in 
HIV-infected monocytes and macrophages (reviewed by Le Douce, 2010). JAK1 was 
recovered by genome-wide siRNA screening as a putative HIV-HDF (Zhou, 2008) and 
STAT5 protein is downregulated in response to HIV infection (Pericle, 1998). A number 
of HLA variants (HLA-B, HLA-C, HLA-F) were also identified within the suppressed viral 
replication hits, and miRNA-mediated regulation of HLA-C in particular has been 
associated with the natural restriction of HIV replication (Kulkarni, 2011). Finally, HDACs 
have well described effects on HIV latency and transcriptional activation of the HIV LTR 




Pathways analysis recovered 46  HIV-suppressive miRNA hits (Table A4.9, Appendix IV) 
and 22 HIV replication enhancing miRNA hits (Table A4.10, Appendix IV) associated 
with regulation of cell cycle. Similarly to the trend previously observed for viral 
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carcinogenesis, approximately 90% of proteins associated with enhanced HIV replication 
hits were also associated with suppressed viral replication hits, and only 7 host proteins 
were exclusively associated with enhanced viral replication hits (Table A4.11, Appendix 
IV). In contrast, 27 host factors were exclusively associated with suppressed HIV 
replication hits (Table A4.12, Appendix IV). 
 
In support of previous HIV-related findings (Brass, 2008; reviewed by Friedrich, 2011; 
Romani, 2015) P53 and its associated factors (HDM2, Retinoblastoma protein (Rb), 
various CDKs (CDK1,2 4,6), Cdc25A, PCNA, Wee-1, the mini chromosome 
maintenance (MCM) complex and 14-3-3 were also identified here, either for enhanced 
or suppressed HIV replication phenotypes (Figure 4.16). Notably, regulation of the 
ATM/ATR- CHK1/CHK2 DNA damage signalling cascade was recovered for enhanced 
replication and not suppressed viral replication (Figure 4.16). ATR-mediated activation of 
CHK1 specifically, has been associated with the DNA-binding activity of Vpr and Vpr-
induced cell cycle arrest (Lai, 2005; Bregnard, 2014). miRNA-regulation of SMAD4 was 
also recovered exclusively for the enhanced HIV replication hits (Figure 4.16). SMAD4 
directly interacts with HIV Tat to inhibit LTR transactivation and Tat-mediated 
transcription (Coyle-Rink, 2002; Abraham, 2003). Two members of the Inhibitors of 
CDK4 (INK4) family of cyclin-dependent kinase inhibitors (CKIs), namely CDKN2A (p16) 
and CDKN2D (p19), were exclusively associated with suppressed HIV replication hits 
(Figure 4.16). The INK4 family of CKIs specifically regulate the activity of CDKs 4 and 6, 
and inhibition of CDK6 specifically inhibits HIV reverse transcription through regulation of 
the cell cycle via VRF and SAMHD1 (Pauls, 2014). Similarly, proliferating cell nuclear 
antigen (PCNA) was exclusively associated with suppressed HIV replication hits (Figure 
4.16). PCNA expression correlates with HIV infection in mononuclear phagocytes 
(Fischer-Smith, 2004), and was also shown to be upregulated in response to HIV gp120 
(Singhal, 2000). Finally multiple components of the anaphase promoting complex 
(ANAPC 1,4,13) as well as cyclins B1 (CCNB1) and D3 (CCND3) were also exclusively 
associated with suppressed HIV hits. ANAPC is associated with site selection during HIV 
integration (Ocwieja, 2011), while CCNB1 directly interacts with Tat in order to influence 
cell cycle (Zhang, 2012), and CCND3 interacts with CDK6 to inhibit the activity of 
SAMHD1 and promote HIV replication in primary macrophages (Ruiz, 2015). 
Interestingly, no clear bias was observed towards factors associated with a specific cell 
cycle stage (Figure 4.16) even though HIV replication has been reported to result in G2M 
cell cycle arrest (reviewed by Bregnard, 2014). These findings suggest that specific 
networks of host miRNAs, including those described by this study, are capable of 
modulating HIV replication through regulation of cell cycle related factors, including P53. 
Notably, a large overlap was observed between the miRNA hits enriched for cell cycle 




Figure 4.16 miRNA targets associated with cell cycle pathways and enhanced HIV 
replication.  
Host genes targeted by miRNA hits (orange), host genes not targeted by miRNA hits (green), 





A number of functional pathways uncovered by mirPath were inherently associated with 
processes related to cytoskeletal remodelling, including ‘Regulation of actin 
cytoskeleton’, ‘Adherens junctions’ and ‘Bacterial invasion of epithelial cells’. The host 
factors associated with these pathways were best summarised within the ‘Regulation of 
actin cytoskeleton’ pathway (Figure A4.3, Appendix IV). Briefly, miRNA modulation of 
receptor (e.g EGFR, TGFRβ) and cytoplasmic kinase (e.g src, c-abl) driven signaling 
cascades (e.g MEK/ERK, PI3K/AKT, MAPK) that are typically associated with various 
processes such as endocytosis, actin-mobilization and intracellular trafficking, were 
found to be enriched within both the suppressed and enhanced HIV replication hit pools 
(Figure A4.2, Appendix IV). 60 host factors were exclusively recovered for the 
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suppressed HIV replication phenotype (Table A4.13, Appendix IV) including, APC, 
ROCK1, MAP2K1, MAPK3 while 24 host factors were recovered for the enhanced HIV 
replication phenotype only, including ARHGEF4, PDGFß, VAV2 and VAV3 (Table A4.14, 
Appendix IV). Many of these proteins have also been described to mediate cytoskeletal 
interactions during early stages of HIV infection, including viral entry and nuclear 
trafficking (reviewed by Stolp, 2011). mirPath analysis recovered 45 HIV-suppressive 
miRNA hits (Table A4.15, Appendix IV) and 25 HIV replication enhancing miRNA hits 
that were associated with the ‘Regulation of actin cytoskeleton’ pathway (Table A4.16, 
Appendix IV). The results of this study therefore represent the first body of experimental 
work to functionally relate discrete subsets of host miRNAs associated with cytoskeletal 
rearrangements to the modulation of HIV replication.  
 
Hippo signalling pathway 
 
Unlike many of the other functional pathways recovered by mirPath analysis, functional 
significance of the Hippo signalling pathway with regards to viral infection and HIV 
replication remains poorly characterised (Larsson, 2013). The Hippo signalling cascade 
was first described in Drosophila Melanogaster where it was shown to control cell growth 
and apoptosis in organ size regulation (reviewed by Pan, 2010). In humans the pathway 
is comprised of a core kinase cascade that causes phosphorylation of YAP/TAZ and its 
cytoplasmic retention by 14-3-3 as part of contact inhibition and stress-induced 
apoptosis in mammalian cells (Pan, 2010). Dysregulation of hippo kinase activity and the 
nuclear accumulation of YAP/TAZ  generally results in the expression of anti-apoptotic 
proteins like survivin (Pan, 2010; Vigneron, 2010). Conversely the specific nuclear 
association of YAP with p73 results in expression of proapoptotic genes like PUMA. 
Forty-six HIV-suppressive miRNA hits (Table A4.17, Appendix IV) and 22 HIV replication 
enhancing miRNA hits (Table A4.18, Appendix IV) were collectively linked to the 
regulation of 175 genes associated with the Hippo signalling pathway. Similarly to 
previous analyses, approximately 90% of the host factors recovered were common 
between both enhanced and suppressed HIV replication hit lists. Only 6 host genes were 
exclusively recovered for enhanced HIV replication hits (Table A4.19, Appendix IV), 
while 55 host genes were exclusively recovered for suppressed HIV replication (Table 
A4.20, Appendix IV) including the central kinases Mst1/2, SAV1 and their binding 
proteins RASSF6 and RASSF1 (Figure 4.17). These host factors have previously not 
been directly associated with HIV replication and these findings thus suggest a 
potentially novel role for the hippo central kinase cascade in the regulation of HIV 
replication. 
 
The Hippo signalling cascade intersects with many additional pathway members 
including transcriptional coactivators of YAP, TEAD homologs, TCF/LEF associated 
factors, Smad4, as well as a number of genes associated with the WNT and BMP 
signalling pathways (Figure 4.17). Genes associated with P53 signalling including TP73 
and TP53BP2 were uncovered for suppressed HIV hits only (Figure 4.17). Collectively, 
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these genes are important as many have established roles in the HIV life cycle. WNT 
signalling negatively regulates HIV replication (reviewed by Al-Harthi, 2012) and Nef has 
been posited as a potential antagonist of WNT signalling that competes for ß-catenin 
receptor binding (Weiser, 2013). Tat downregulates transcription of BMP receptor 2 
(Caldwell, 2006) and P73 negatively regulates the transcriptional and apoptotic effects of 
Tat in human astrocytes (Saunders, 2005). Contrastingly, the role of the hippo kinase 
cascade and the differential regulation of YAP/TAZ transcriptional activity in response to 
HIV infection remains poorly characterised. Chronic HIV infection correlates with 
increased expression of CTLA4 and induction of the transcriptional repressor, BLIMP-1 
in CD8+ cells and this may occur through CTLA4-mediated activation (reviewed by 
Larsson, 2013). The results of the work presented here suggest, for the first time, that 
there is a direct role for the Hippo central kinase cascade, YAP/TAZ, and their 
associated transcriptional coactivators in the differential modulation of HIV replication 
(Figure 4.17). In addition given that many other pathways associated with cellular 
proliferation and apoptosis are widely exploited by many other human viruses, the hippo 
signalling pathway may also be similarly involved. Thus, the Hippo signalling -associated 
host miRNAs identified by HCS and described here represent a unique target list 












Figure 4.17 Enhanced HIV replication miRNA hit targets associated with the Hippo and 
intersecting signalling pathways.  
Host genes targeted by miRNA hits (orange), host genes not targeted by miRNA hits (green), 
viral proteins (white), selected proteins differentially regulated for HIV-suppression phenotype 
(red ring). 
 
4.5.2 Pathways associated exclusively with enhanced HIV replication  
 
The enhanced HIV replication phenotype yielded 10 unique pathways (Table 4.2) 
including the PI3K/AKT, HIF-1 and spliceosome pathways. Considering that miRNA-
induced perturbation of these pathways resulted exclusively in enhanced HIV replication, 
this would suggest that specific host factors/signals within these pathways may exert an 
inhibitory effect  on HIV replication. The functional relevance of PI3K signalling has been 
well characterised for a number of viruses (reviewed by Ehrhardt, 2009). The pathway 
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has also been specifically linked to alternative splicing of HIV transcripts (Hillebrand, 
2014), and signalling events related to HIV entry (Herbein, 2010). The relevance of the 
of the HIF-1 and spliceosome pathways are discussed in greater detail below. 
 
Table 4.2 Functional pathways associated exclusively with enhanced HIV replication 
phenotypes 
Functional pathways recovered by mirPath 
PI3K-Akt signaling pathway Spliceosome 
Endocytosis Lysine degradation 
mRNA surveillance pathway Alanine, aspartate and glutamate metabolism 
Salmonella infection 2-Oxocarboxylic acid metabolism 




Modulation of host RNA splicing machinery by HIV has been well characterised 
(reviewed by Stoltzfus, 2006) and was also discussed in Chapter 1. Briefly, various 
members of the Ser-Arg (SR) and heterogeneous ribonucleoproteins (hnRNPs) family 
have been associated with splicing of HIV transcripts, and suppression of such factors, 
like CDK13, lead to increased viral replication (Berro, 2008). Furthermore, spliceosome-
associated processes, including the host mRNA surveillance pathway, which was also 
recovered for the enhanced HIV replication phenotype,  have been described to naturally 
restrict retroviral replication (reviewed by Mocquet, 2015), including that of HIV (Liu, 
2011). HCS and pathway analysis revealed 18 host miRNAs (Table 4.3) targeting 57 
genes within the spliceosome pathway including various hnRNPs, SR proteins, specific 
spliceosome-related small nuclear RNAs, and their associated proteins (Figure 4.18). 
These findings represent the first account of a subset of host miRNAs that specifically 
enhance HIV replication, potentially through modulation of spliceosome-associated 
factors.  
 
Table 4.3 HIV replication-enhancing miRNA hits associated with the Spliceosome pathway 
miRNA (mirBase v.20) 
hsa-miR-1260a  hsa-miR-378a-5p  
hsa-miR-1260b  hsa-miR-4318  
hsa-miR-136-3p  hsa-miR-550a-3p  
hsa-miR-141-5p  hsa-miR-576-3p  
hsa-miR-188-5p  hsa-miR-587  
hsa-miR-200a-5p  hsa-miR-625-3p  
hsa-miR-22-3p  hsa-miR-668-3p  
hsa-miR-3171  hsa-miR-675-3p  




Figure 4.18 miRNA targets associated with Spliceosome pathway and enhanced HIV 
replication.  
Host genes targeted by miRNA hits (orange), host genes not targeted by miRNA hits (green). 
 
HIF-1 signalling pathway 
 
HIF-1 is a heterodimeric transcription factor comprised of two subunits, HIF-1α and HIF-
1ß (reviewed by Semenza, 2007). HIF-1α is negatively regulated by a prolyl hydroxylase 
domain protein (PHD) under normal cellular conditions, but this suppression is relieved 
in response to various environmental stressors, including hypoxia. Through its 
interaction with transcriptional coactivators like p300 and Creb binding protein (CBP), 
HIF-1 is able to regulate the transcription of  hundreds of genes, including many genes 
related to cellular proliferation and apoptosis (Semenza, 2007). HIF-1 signalling is 
induced in response to a Vpr-mediated oxidative stress response, and has also been 
linked to persistent HIV infection in macrophages (Deshmane, 2011; Barrero, 2013). 
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Additionally, activation of the HIF-1 signalling pathway results in the upregulation of 
stromal cell-derived factor 1 (SDF-1) a well characterised inhibitor of HIV entry and 
replication (Bleul, 1996; Xiang, 2004). HCS and pathway analysis recovered 20 host 
miRNAs (Table 4.4) targeting 47 genes enriched within the HIF-1 and oxidative stress 
signalling pathway (Figure 4.19). In support of the previous association between HIV and 
HIF-1 signalling, these findings represent the first description of a specific subset of host 
miRNAs that functionally enhance HIV replication, potentially through the HIF-1 
signalling pathway.   
 
Table 4.4 HIV replication-enhancing miRNA hits associated with the HIF-1 pathway 
miRNA (mirBase v.20) 
hsa-miR-1260a  hsa-miR-34c-3p  
hsa-miR-1260b  hsa-miR-378a-5p  
hsa-miR-1271-5p  hsa-miR-3938  
hsa-miR-141-5p  hsa-miR-4318  
hsa-miR-188-5p  hsa-miR-550a-3p  
hsa-miR-19b-2-5p  hsa-miR-576-3p  
hsa-miR-218-1-3p  hsa-miR-587  
hsa-miR-22-3p  hsa-miR-625-3p  
hsa-miR-3171  hsa-miR-668-3p  




Figure 4.19 miRNA targets associated with HIF-1 signalling pathway and enhanced HIV 
replication.  
Host genes targeted by miRNA hits (orange), host genes not targeted by miRNA hits (green), 
viral proteins (white). 
 
4.5.3 Pathways associated exclusively with suppressed HIV 
replication  
 
Twenty-four functional pathways were exclusively associated with the suppressed  HIV 
replication phenotype (Table 4.5) including the MAPK, mTOR, TNF and sphingolipid 
signalling pathways. The functional relevance of the MAPK signalling pathway has been 
extensively characterised for HIV replication (Jacqué, 1998). Likewise the  mTOR 
(Nicoletti , 2011) and TNF (Westendorp, 1995) signalling pathways have also been 
previously associated with HIV replication, while sphingolipids have been described 
mediate a number of processes associated with HIV entry and HIV-mediated signal 
transduction (reviewed by Rawat, 2005). Surprisingly, while the BER (Espeseth, 2011) 
and NHEJ (Genovesio, 2011) DNA repair pathways have been previously associated 
with HIV replication by functional genomic screens, only the homology directed repair 
(HDR) pathway was recovered by mirpath analysis as being exclusively associated with 
04)6612(_11(15 
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the suppressed HIV replication phenotype and this finding is discussed in greater detail 
below.  
 
Table 4.5 Functional pathways associated exclusively with suppressed HIV replication 
phenotype 
Functional pathways recovered by mirPath 
Acute myeloid leukemia HTLV-I infection 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 
MAPK signaling pathway 
Axon guidance mTOR signaling pathway 
cGMP-PKG signaling pathway N-Glycan biosynthesis 
Choline metabolism in cancer Non-small cell lung cancer 
Estrogen signaling pathway Progesterone-mediated oocyte maturation 
Fatty acid elongation Sphingolipid metabolism 
Fatty acid metabolism Sphingolipid signaling pathway 
Fc gamma R-mediated phagocytosis Thyroid cancer 
Glycosaminoglycan biosynthesis - chondroitin 
sulfate / dermatan sulfate 
Thyroid hormone synthesis 
GnRH signaling pathway TNF signaling pathway 
Homologous recombination Vasopressin-regulated water reabsorption 
 
Homology directed repair 
 
A number of viral lifecycles, including that of HIV, are dependent on manipulation of host 
DNA damage repair pathways, and deregulation of host P53 signaling networks that 
determine cell fate in response to DNA damage (reviewed by Chen, 2014 and Bregnard, 
2014).  
 
The homologous DNA repair (HDR) pathway is a host DNA repair process generally 
associated with the repair of double strand breaks (DSBs) following resectioning of 
damaged DNA into 3’ single strand structures that then ‘invade’ a homologous DNA 
strand, using it as a template for the repair process (reviewed by Jasin, 2013). Fifteen 
host miRNAs associated with suppressed HIV replication (Table 4.6) were reported to 
regulate 21 host proteins involved in the homologous repair of DSBs (Figure 4.20). 
Specifically, factors involved in resectioning (RAD50, Nbs1), strand invasion (RAD51, 
RPA, BRCA2) and resolution of the adjoining strands (BLM, TOP3) correlated with 
suppressed HIV replication (Figure 4.20). This functional association of HDR, specifically 
the activity of RAD51, with HIV replication supported previous findings (Nakai-Murakami, 
2006; Cosnefroy, 2012). Specifically, enhanced activation of RAD51 and DNA repair 
suppressed HIV infection through inhibition of HIV integrase (Cosnefroy, 2012), while 
Vpr-induced DNA damage in turn enhanced activation of RAD51 and HDR (Nakai-
Murakami, 2007).  In addition, a number of other host DNA damage repair pathway 
genes were also shown to be required for HIV replication by multiple independent 
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siRNA-based screens (Brass, 2008; Konig, 2008, Zhou, 2008, Espeseth, 2011). Notably, 
the miRNAs uncovered in this study represent a novel subset that are associated with 
HDR and HIV replication (Table 4.6; Figure 4.20). 
 
Table 4.6  HCS miRNA hits associated with HDR 
miRNA (mirBASE v.20)* 
hsa-miR-124-3p  hsa-miR-383-5p  
hsa-miR-1295a  hsa-miR-4256  
hsa-miR-192-5p  hsa-miR-4270  
hsa-miR-2110  hsa-miR-4314  
hsa-miR-3179  hsa-miR-497-5p  
hsa-miR-3190-5p  hsa-miR-889-3p  
hsa-miR-342-5p  hsa-miR-940  
hsa-miR-3616-5p   




Figure 4.20 HCS miRNA hit targets that are enriched within the HDR pathway.  
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4.6 HIV infection promotes a cancer-like phenotype in GHOST(3) 
cells 
 
A rigorous bioinformatics-based investigation revealed some common ‘functional 
outputs’ with regards to pathways recovered by mirPath analyses for miRNAs 
associated with functional modulation of HIV replication. These included evasion of 
apoptosis, regulation of cell cycle and host DNA repair pathways, as well as modulation 
of signalling pathways associated with cellular proliferation (e.g MAPK, PI3K, TNF, 
Erbb). A number of these processes are functionally relevant to cancer-like phenotypes 
and a possible link between HIV infection and cancer was further underscored by 
enrichment of multiple tissue-specific carcinomas as well as recovery of the viral 
carcinogenesis pathway by mirPath analysis. The viral carcinogenesis pathway in 
particular revealed a high degree of overlap between HIV and a number of oncogenic 
viruses, specifically in terms of their host-pathogen interaction profiles (Figure A4.2, 
Appendix IV).  
 
The HDR pathway was exclusively recovered for suppressed HIV replication and 
signaling networks classically associated with the host cell response to DNA damage 
were enriched within many of the recovered pathways. HIV integrase and Vpr have both 
been associated with the induction of double strand DNA breaks and activation of the 
host DNA damage response (Craigie, 2001; Nakai-Murakami, 2007). Furthermore, HIV 
infection has previously been described to promote aberrant cell survival in both cultured 
cell lines and primary macrophages in response to DNA damage-inducing agents  and 
other forms of genotoxic stress (Col, 2005; reviewed by Cummins, 2013), potentially 
through the P53-inhibitory effects of viral Tat and Nef proteins (Greenway, 2002; Col, 
2005). Finally, HIV gp120 has also been well characterized as an activator of apoptotic 
signalling pathways through its interaction with various cell surface receptors, although 
these apoptotic signals are counterbalanced by the pro-survival activity of specific viral 
(e.g Vpr) and host (e.g MAPK) proteins (Cummins, 2013).  
 
Inhibition of P53 and aberrant cell survival in spite of high levels of DNA damage are 
molecular phenotypes associated with hallmarks of cancer (reviewed by Hanahan, 
2011). The close functional relationship between cancer-like molecular phenotypes and 
HIV replication posited by HCS pathway analysis is thus well supported by prior art 
although this relationship has not yet been specifically characterised in GHOST(3) cells. 
A series of validation experiments were thus undertaken to further evaluate the potential 
relationship between HIV infection and cancer-like phenotypes in cultured GHOST(3) 






4.6.1 HIV infection deregulates P53 transcriptional activity 
 
The tumour suppressor P53 is widely regarded as the ‘gatekeeper’ of genome integrity 
and cell survival as a result of its ability induce to apoptosis or cell cycle arrest in 
response to various environmental stresses including DNA damage (reviewed by Levine, 
2009). P53 is specifically inactivated in many cancers, and by many viruses, resulting in 
abnormal cell survival and proliferation despite high levels of DNA damage and genomic 
instability (Chen, 2014). The CDKN1A gene, which encodes p21, is a direct 
transcriptional target of P53 and p21 is a well characterised downstream effector of P53-
mediated cell cycle arrest and apoptosis (Nowsheen, 2012).   
 
qPCR analysis revealed that TP53 transcript levels were significantly downregulated 
following HIV infection of GHOST(3) cells both at 24 hpi (46%) and 48 hpi (89%; Figure 
4.19A, p<0.05). Likewise a corresponding 70% and 79% downregulation was observed 
for CDKN1A at 24 hpi and 48 hpi respectively (Figure 4.19B). These findings suggest 
that HIV infection functionally inhibits P53 at the transcriptional level and that this effect, 
together with the reported P53-inhibitory effects of viral proteins like Tat and Nef, 
together contribute to suppressed transcriptional activity of P53 and its transcriptional 
target CDKN1A (Figure 4.21). As mentioned previously, dysregulation of TP53 signalling 
is one of the hallmarks of cancer and these findings thus support the notion that HIV 




Figure 4.21 Relative TP53 and CDKN1A expression levels in response to HIV infection. 
qPCR analysis showing A) relative TP53 expression 24 and 48 hpi in infected GHOST(3) cells, 
and B) relative CDKN1A expression levels 24 hpi and 48 hpi in infected GHOST(3) cells. 
Expression levels were normalized against the reference gene HPRT, * = p<0.05, n=3.  
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4.6.2 Stable or de novo HIV infection as a determinant of GHOST(3) 
cell survival in response to DNA damage 
 
Another hallmark of cancer is aberrant cell survival in spite of high levels of DNA 
damage (Hanahan, 2011). Double strand breaks (DSBs) represent one of the most 
lethal forms of genotoxic stress and even single unrepaired break can lead to dire 
consequences including mutagenesis and cell death (reviewed by Nowsheen, 2012). 
DSBs are readily detected by DNA damage sensors such as the MRN complex, which 
then activates Ataxia Telangiectasia Mutated (ATM) or Ataxia Telangiectasia and Rad3 
Related (ATR) kinases leading to histone protein H2AX serine 139 phosphorylation (γ-
H2AX) at sites proximal to the DSB (Kuo, 2008; Nowsheen, 2012). Activated γ-H2AX 
then recruits DNA repair factors to DSB sites (Kuo, 2008). γ-H2AX foci thus represent 
biomarkers for DSBs, where a single foci is generally representative of a single DSB 
(Kuo, 2008). The effect of HIV infection on GHOST(3) cell survival in response to DNA 
damage was assessed by indirect immunofluorescence and imaging following 
chemically-induced DSBs, and γ-H2AX was used to visualize DNA damage (Figure 
4.22). Such damage was induced by VP16 (Etoposide) which is a topoisomerase II 
inhibitor that causes stalled replication forks and accumulation of DSBs, which 
eventually result in P53-mediated cell cycle arrest and apoptosis (Arriola, 1999; Jamil, 
2015).  
 
ICC revealed that GHOST(3) cells naturally exhibit multiple γ-H2AX foci per cell 
indicative of persistent DNA-damage or stalled replication forks, which are a common 
phenotype in immortalised cell lines (Figure 4.22). A 24 hour treatment with 10 µM 
Etoposide resulted in a significant increase in γ-H2AX foci but did not have a significant 
effect on cell viability (Figure 4.22). In contrast, 48 hour treatment with 10 µM Etoposide 
resulted in significantly elevated levels of γ-H2AX foci as compared to the untreated 
controls (Figure 4.22) and a corresponding broad cytotoxicity (>95% loss of cell viability). 
HIV infection alone generally resulted in moderately elevated levels of γ-H2AX foci, 
especially in infected cells, as compared to untreated control cells (Figure 4.22). This 
was in agreement with previous findings which demonstrated that Vpr induces DSBs 
(Nakai-Murakami, 2007), but also suggested that HIV exposure may induce DSBs in 
bystander cells not stably infected by HIV.  
 
A highly noteworthy phenotype was observed when viral infection and Etoposide 
treatment were combined. GHOST(3) cells infected with HIV for 24 hours that were then 
treated with 10 µM Etoposide for 24 hours showed higher levels of γ-H2AX as compared 
to untreated control cells, with only a moderate effect on cell viability (Figure 4.22). A 
similar experiment using HIV-infected GHOST(3) cells but treated with 10uM Etoposide 
for 48 hours resulted in the highest level of γ-H2AX foci observed for any treatment, yet 
cell viability still generally exceeded ~20% (Figure 4.22). Intriguingly, the surviving 
population was dominated by cells exhibiting high levels of LTR transactivation (Figure 
4.22), suggesting that integrated virus is able to protect host cells from additional lethal 
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DNA damage.  This protective phenotype was readily reversed when the order of 
reagents was changed such that GHOST(3) cells received 10uM Etoposide for 24 hours 
prior to infection for 24 hours. In this case, broad scale cytotoxicity was observed (Figure 
4.22). Likewise, simultaneous exposure of GHOST(3) cells to HIV and Etoposide (10 
µM) for 48hr exhibited a similar cytotoxic effect as a 48 hr Etoposide only treatment 
(Figure 4.22).  
 
 
Figure 4.22 GHOST(3) cell survival in response to HIV infection and chemically-induced 
DNA damage. 
Survival of GHOST(3) cells in response to Etoposide only or infection only treatment, or in 
response to HIV infection followed by 24 or 48 hours of Etoposide treatment, or simultaneous 
treatment with both HIV and Etoposide. Nuclei counterstained with Hoechst (blue), activated y-





H2AX (red), activated LTR-GFP reporter (green). Images represent overlays of single FOVs, 
acquired at 40x from the 405, 488 and 550 excitation channels. Scale bars = 10µm. 
 
 
ICC-based validation experiments thus revealed two contrasting effects on GHOST(3) 
cell viability in response to DNA damage and HIV infection. Firstly, exposing GHOST(3) 
cells to Etoposide either prior to or during HIV infection sensitized cultured cells towards 
apoptosis (Figure 4.22). This effect was clearly related to HIV exposure, as the same 
Etoposide treatment conditions (10µM, 24hrs) did not induce broad scale cytotoxic 
effects in the absence of virus (Figure 4.22). The induction of DNA damage has 
previously been described to enhance HIV replication, specifically integration (Koyama, 
2013), thus suggesting that these pro-apoptotic phenotypes may involve more complex 
mechanisms associated with the consequences of Etoposide treatment rather than just 
the induction of DSBs alone. Furthermore, DNA damage induced by Etoposide can be 
repaired within 3hr in cultured cells following the withdrawal of Etoposide (Arriola, 1999), 
thus suggesting that the apoptotic effect related to HIV exposure was likely initiated 
within the first 3 hours of virus addition, implicating early interaction events between HIV 
virions and the host cell. This would posit the HIV entry process, and specifically the 
interaction between HIV gp120 and cell surface proteins, as a prime candidate for the 
apoptotic ‘trigger’ associated with this phenotype.  
 
Secondly, while prolonged Etoposide treatment (48hr) was highly toxic in HIV-naive 
GHOST(3) cells, stably infected GHOST(3) cells exposed to the same treatment course 
were significantly more resistant to Etoposide-induced apoptosis, despite exhibiting 
extremely high levels of DNA damage (Figure 4.22). This observation thus provides 
direct evidence that stable or chronic HIV infection promotes an aberrant cell survival 
phenotype in GHOST(3) cells. This is line with previous findings which reported HIV-
mediated attenuation of apoptosis in response to both Etoposide and UV -induced DNA 
damage in T cells and primary macrophages (Schindler, 2005; Cummins, 2013). The 
observation that similar phenotypes were recovered in primary PBMCs and 
macrophages, again suggests that the GHOST(3) infection assay is able to robustly 
recapitulate critical and physiologically relevant HIV-associated molecular phenotypes. 
These findings thus, in addition to confirming the functional trends recovered by HCS 
and pathway analysis, also posit that functional associations and miRNA hits recovered 
by HCS are indeed physiologically relevant.  
 
4.6.3 Transcriptional activity of P53 may influence HIV-DNA damage 
associated cell survival phenotypes 
 
Etoposide has previously been described to inhibit the P53-suppressor, HDM2, at both 
the protein and transcriptional level, resulting in nuclear localisation and transcriptional 
activation of P53, as denoted by an upregulation of CDKN1A (Arriola, 1999). 
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Additionally, Nef-mediated destabilization of P53 transcriptional activity enhanced cell 
survival in response to UV-induced DSBs (Greenway, 2002). qPCR analysis was thus 
used to evaluate the potential role of P53 transcriptional activity in relation to the 
phenotypes described in Figure 4.22 above. In accordance with previous data (Figure 
4.21) TP53 expression analysis revealed a significant downregulation of TP53 24 hours 
after HIV infection (~40%) which was similar to that observed for 3hr (~42%) and 24hr 
(~49%) Etoposide treatments (Figure 4.23A). A 24hr HIV exposure followed by 24 hr 
Etoposide treatment (10µM) also exhibited a significant downregulation of TP53 (~28%), 
while a 3hr Etoposide treatment administered 24hr post-infection did not exhibit a 
significant (p>0.05) effect on TP53 expression levels (Figure 4.23A).  
 
An evaluation of CDKN1A expression levels for the same set of treatments revealed that 
3hrs of Etoposide treatment did not have a significant effect on CDKN1A transcript 
levels, although 24hrs of Etoposide treatment resulted in a significant 250% increase in 
CDKN1A transcript levels (Figure 4.23B). In accordance with previous results, CDKN1A 
was confirmed to be significantly downregulated (~38%) 24hr post infection, while cells 
infected with HIV for 24 hrs and then exposed to Etoposide for 24 hrs showed significant 
(~60%) upregulation in CDKN1A (Figure 4.21B). Likewise CDKN1A was observed to 
significantly upregulated by ~240% following a short (3hr) Etoposide treatment of HIV-




Figure 4.23 Relative TP53 and CDKN1A expression levels in response to combinations of 
HIV infection and Etoposide treatment. 
qPCR analysis of mRNA transcript levels on GHOST(3) cells exposed to Etoposide alone or, HIV 
alone, as well as HIV-infected cells exposed to Etoposide for various time courses. A) Relative 
TP53 expression and B) relative CDKN1A expression. Expression levels were normalized 
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qPCR analysis of TP53 and CDKN1A expression levels in response to HIV infection and 
chemically-induced DNA damage revealed that 24hrs of Etoposide treatment was able 
to significantly induce CDKN1A expression levels, through a process independent of 
TP53 transcription. This is in line with previous findings that describe elevated CDKN1A 
expression following Etoposide treatment (Arriola, 1999; Jamil, 2015). Intriguingly, while 
3hrs of Etoposide treatment alone did not induce a significant increase in CDKN1A 
expression, the same treatment in a population of infected GHOST(3) cells resulted in a 
2.4 fold increase in CDKN1A expression compared to untreated cells, and a ~3 fold 
increase compared to the 24 hpi treatment.  
 
Notably, P53 transcriptional activity is actively suppressed during HIV infection (Figure 
4.23B, Greenway, 2002) suggesting that Etoposide treatment partially alleviates HIV-
mediated suppression of P53 transcriptional activity, resulting in a rapidly amplified 
transcriptional response. In addition, the ‘re-activation’ of P53 transcriptional activity in 
response to Etoposide treatment of infected cells may contribute to the moderate toxicity 
observed (Figure 4.22).  
 
Intriguingly, the variations in CDKN1A expression did not correspond with concordant 
variations in TP53 expression highlighting that the interaction of these factors is complex 
and multi-layered, occurring at transcriptional and translational levels. Activation of P53 
transcriptional activity, through the inhibition of HDM2 by Nutlin-3 treatment (10µM, 24hr; 
Vassilev, 2004) prior to HIV exposure did not have a significant impact on HIV replication 
or cell viability (Appendix IV, Figure A4.4), suggesting that simply elevating levels of P53 
prior to HIV exposure may not be enough to sensitise GHOST(3) cells to apoptosis or 
significantly impact HIV replication. In accordance with the prior art these data suggest 
that HIV-mediated modulation of P53 transcriptional activity plays an important role in 
aberrant cell survival phenotypes recovered in response to DNA damage following HIV 
infection (reviewed by Cummins, 2013). These findings thus further support the cancer-
like phenotype    
 
4.7 LincRNA-p21 plays a role in the modulation of HIV replication 
and GHOST(3) cell survival in response to DNA damage 
 
LincRNA-p21 was first described as a P53-induced long noncoding transcript which was 
actively transcribed in response to chemically-induced DNA damage (Huarte, 2010). 
LincRNA-p21 acts as a pro-apoptotic factor that mediates transcriptional repression of 
hundreds of P53 target genes through its association with heterogeneous nuclear 
ribonucleoprotein K, hnRNP-K (Huarte, 2010). Given the close association between P53 
transcriptional activity and many of the functional trends and phenotypes recovered by 
miRNA-based HCS, specifically those related to DNA damage and apoptosis, an 
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Figure 4.25 Putative associations between lincRNA-p21 and miRNA HCS hits 
A) Predicted miRNA binding sites that map to various regions of the human lincRNA-p21 
transcript, and which correspond to HIV-suppressive HCS hits. ‘=’ denotes a single miRNA 
binding site, miR-637 (black), miR-2110 (blue), miR-3189 (purple), miR-654-5p (green). B) Visual 
profiles of miRNA mimic treatments recovered by HCS for each of the mimics in A. Plate-specific 
negative control images are included on the left of each miRNA treatment image. Images 
represent overlays of images acquired from a single FOV in the 405 and 488 channels, nuclei 
counterstained with Hoechst (red), LTR-GFP reporter activity (green). Images acquired at 20x, 
scale bars = 20µm. 
 
 
These findings suggest a potential role for LincRNA-p21 in HIV replication, where 
miRNA-mediated modulation of LincRNA-p21 targeted to specific, concise regions may 
strongly inhibit HIV replication (Figure 4.25). miRNA-lincRNA interactions can result in a 
broad range of functional effects including lincRNA cleavage, modifications to the 
secondary structure of lincRNAs, perturbations of lincRNA binding dynamics, as well as 
cross-talk between lincRNAs and mRNAs which may fine tune gene expression 
(Salmena, 2011; Yoon, 2014).  
 
Although a more comprehensive investigation into the proposed miRNA-lincRNA-p21 
interactions is clearly required to definitively validate these interactions, some additional 
experimental data was generated. Specifically, siRNA-mediated knockdown of lincRNA-
p21 was used to identify whether the observed HIV-suppressive phenotypes were 
related to functional silencing of lincRNA-p21. A 25 nM siRNA treatment resulted in 
significant downregulation (83%, p<0.05) of lincRNA-p21 transcript levels 24 hours post 
transfection (Figure A.4.5, Appendix IV). However, microscopy revealed that this did not 
have a significant effect on HIV replication in si-lincRNA-p21 transfected/infected 
GHOST(3) cells as compared to infected control cells (Figure 4.26). Interestingly though, 
siRNA-treatment did have a significant effect on cell viability in response to si-lincRNA-
p21 transfected/Etoposide treated cells (10µM, 48hr). In this case, siRNA-mediated 
A. LincRNA-p21 partial sequence 
Ont lOOOnt 1956nt 
- - == 
0-lSOnt 790-950nt 1600-l 700nt 
B. 
miR-637 miR-2110 miR-3189 miR-654-Sp 
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knockdown of lincRNA-p21 attenuated the cytotoxic phenotype previously noted for this 




Figure 4.26 Effects of siRNA-mediated knockdown of lincRNA-p21 on HIV replication and 
GHOST(3) cell survival. 
A) Untreated cells, B) Cell infected with HIV for 48 hours, MOI=0.5., C) Cells transfected with 
25nM si-lincRNA-p21 (25nM) for 24 hours, then infected with HIV for 48 hours, MOI=0.5., D) 
Cells transfected with 25nM si-lincRNA-p21 for 24 hours, then Etoposide treated for  (10µM, 48 
hours). Nuclei counterstained with Hoechst (blue), activated y-H2AX (red), activated LTR-GFP 
reporter (green). Images represent overlays of single FOVs, acquired at 40x from the 405, 488 
and 550 excitation channels. Scale bars = 10µm. 
 
Overall, as the functional silencing of lincRNA-p21 by siRNAs did not impact HIV 
replication, this suggested that the phenotypes recovered for miRNAs predicted to bind 
lincRNA-p21 may be due to modification of the lincRNA’s protein/DNA/RNA binding 
interactions, and not simply its degradation. Furthermore, the enhanced GHOST(3) cell 
survival phenotype observed for si-lincRNA-p21 transfected/Etoposide treated cells 
reinforces the role of lincRNA-p21 in DNA-damage-induced apoptosis. In the context of 
pathogenic infection, such as that of HIV, these data also revealed that viral 
manipulation of host non-coding RNAs is a powerful mechanism to avoid a terminal 
outcome such as apoptosis. 
 
4.8 Validation of HCS miRNA hits against an X4-tropic HIV 
variant 
 
The depletion of CD4+ T cell populations during late stages of chronic HIV infection have 
been associated with a switch in HIV co-receptor usage and emergence of X4-tropic 
viral strains that utilise CXCR4 co-receptors as opposed to CCR5 (Gorry, 2005). Co-
receptor binding by HIV gp120 results not only in fusion events, but also in the activation 
of downstream signalling cascades which prime host cells, making them more 
permissive to HIV replication (Wu, 2009). A panel of 6 HIV-suppressive and 2 HIV 
replication enhancing miRNA mimics were thus screened against the X-4 tropic viral 
variant, HIV Gag-iGFP (Hubner, 2007), in order to determine whether viral tropism was a 
discriminating factor in the phenotypes recovered for these specific miRNA mimics by 
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HCS. As with HCS, GHOST(3) cells were transfected with a 25 nM final concentration of 
miRNA mimics 48 hour prior to infection and cells were fixed, stained and imaged 48 hpi 
(Figure 4.27). An siRNA targeted to the CD4 receptor was utilized as a positive control 
for suppressed HIV replication, while a mock transfection was utilised as a negative 
control (Figure 4.27A). HIV Gag-iGFP was identified as a syncytia-inducing strain, as 
indicated by large multinucleate cellular bodies, which were also positive for GFP 
expression (Figure 4.27A). Syncytia are induced by specific variants of Env, the cell 
surface expression of which, results in membrane fusion events between neighbouring 
cells (Watkins, 1997).  
 
The highest ranked HIV-suppressive hit recovered by HCS, miR-506, significantly 
inhibited both syncytia formation and GFP signal output (Figure 4.27B). Likewise, similar 
effects were observed for miR-637 and miR-124-3p (Figure 4.27B). Furthermore, in 
accordance with the phenotype recovered by HCS, exogenous expression of miR-2110 
resulted in a cytotoxic phenotype where the majority of surviving cells were not positive 
for GFP (Figure 4.27B). Exogenous expression of miR-138 on the other hand exhibited 
an opposing effect, where only HIV-infected cells seemingly survived (Figure A4.6 A, 
Appendix IV). In contrast to its HIV-suppressive effect on PSG3BAL infection, miR-193-3p 
treatment did not have a significant effect on HIV Gag-iGFP replication (Figure A4.6 A, 
Appendix IV).  
 
 
Figure 4.27 HIV-suppressive miRNA hits with conserved anti-HIV activity against an X4-
tropic HIV variant. 
A) Phenotypic control experiments included mock transfected/infected GHOST(3) cells (left), and 
siCD4-treated/infected GHOST(3) cells (right), B) Examples of HIV-suppressive hits recovered by 
HCS with demonstrated activity against the X4-tropic variant HIV Gag-iGFP. Images represent 
overlays of single FOVs acquired at 20x in the 405 and 488 excitation channels. Nuclei 




These data suggest that a CCR5-related mechanism was at play for the HIV-
suppressive phenotypes recovered for both miR-138-5p and miR-193-3p. Four of the 6 
HIV-suppressive miRNA hits evaluated exhibited more broadly-acting anti-HIV activity, 
i.e. against both R5 and X4 -tropic HIV variants, suggesting that their mechanism of 
action is independent of viral tropism. Likewise, the HIV replication-enhancing miRNA 
mimic hit, miR-34c-3p, exhibited a similar phenotype following X4-tropic HIV infection, 
while miR-1200 exhibited a higher rate of syncytia formation as compared to negative 
controls (Figure A4.6 B, Appendix IV). These findings thus confirmed pan-tropic HIV 
replication modulating activity for the majority of miRNAs evaluated, but also suggested 
that at least a small proportion of miRNA hits recovered by HCS may be sensitive to HIV 
viral tropism. A more comprehensive investigation of the impact of viral tropism on the 





HCS recovered 53 miRNA mimics and 4 miRNA inhibitors as potential VRFs while 28 
miRNA mimics were revealed to specifically enhance HIV replication. Additionally 
subsequent validation experiments suggested that the majority of these HIV replication 
modulating effects may be independent of HIV viral tropism. miRNA target prediction 
and subsequent pathway analysis recovered 62 functional pathways associated with 
suppressed HIV replication, and 48 functional pathways associated with enhanced HIV 
replication. Of these, 38 functional pathways were associated with both replication 
phenotypes. Furthermore, 23 function pathways were exclusively associated with 
suppressed HIV replication and 9 exclusively with enhanced HIV replication. Details of 






Figure 4.28 Functional pathways associated with enhanced and suppressed HIV 
replication.  
A total of 70 functional pathways were recovered by mirPath analysis. A panel of 38 pathways 
were recovered for both enhanced and suppressed HIV replication phenotypes, while 24 
pathways were associated exclusively with suppressed viral replication, and 10 pathways 
exclusively with the enhanced viral replication phenotype. Selected pathways of interest are 
presented for each panel.  
 
Viral carcinogenesis was one of the broader functional processes recovered by mirPath 
analysis and included a number of specific host signalling cascades and functional 
outcomes (Figure A4.2, Appendix IV). The high degree of overlap between host factors 
associated with viral carcinogenesis and those associated here with HIV infection 
suggests that the virus itself may elicit certain carcinogenic properties within infected 
cells, or that HIV replication is highly dependent on overlapping molecular cues and 
signalling events. Characterisation of host miRNAs that are able to modulate viral 
replication through the regulation of functional pathways associated with viral 
carcinogenesis could be a  lucrative research avenue for the discovery of host miRNAs 
with anti-HIV therapeutic potential (Wang, 2015). This study has specifically identified 47 
host miRNAs that directly affect HIV replication and which target host factors enriched 
within the viral carcinogenesis pathway. Therefore, these miRNAs may also have 
therapeutic benefit across a broader range of viral pathogens.  
 
The highest ranked pathway recovered by mirPath analysis for HIV suppressive 
miRNAs, ‘proteoglycans in cancer’ (reviewed by Connell, 2013) was also the second 
highest ranked hit recovered for the enhanced HIV replication phenotype. This pathway 
revealed a high degree of overlap with ‘viral carcinogenesis’ in terms of associated 
miRNAs, implicated genes and relevant signalling cascades. Of particular interest, a 
number of the membrane-bound proteoglycans associated with this pathway (e.g. 

























HIV gp120 and p17 in order to mediate HIV binding, entry and activation of T cells 
(Bobardt, 2004; Poiesi, 2008). This suggests a similar set of interactions occurred in the 
HCS described here. Likewise ‘regulation of the actin cytoskeleton’ was also recovered 
by pathway analysis for both enhanced and suppressed viral replication phenotypes and 
revealed a high degree of overlap with ‘proteoglycans in cancer’  and functional 
pathways associated with bacterial entry and endocytic processes. The miRNA hits 
associated with these pathways are therefore also likely related to the modulation of 
cellular signals and re-arrangements of the actin cytoskeleton that are required for HIV 
entry and nuclear localization of the HIV RTC (see Chapter 1). Indeed, these same 
factors may also modulate bacterial infection in human cells, underscoring the 
convergent evolution of intracellular pathogens. 
 
While most of the recovered signalling pathways have previously been widely associated 
with viral infection and even HIV replication specifically (Brass, 2008; Friedrich, 2011), 
the role of Hippo signalling in HIV infection remains poorly characterised and mostly 
unknown (Larsson, 2013). Hippo signalling has classically been associated with the 
regulation of apoptosis in response to contact inhibition and other environmental cues 
(reviewed by Pan, 2010) and thus aligns very well with the functional trend observed for 
other signalling pathways recovered here by mirPath analysis. The Hippo signalling 
pathway was recovered for both enhanced and suppressed viral replication phenotypes, 
portending its importance to HIV replication. Notably, data analysis revealed differential 
regulation of factors specifically associated with the hippo central kinase cascade and 
transcriptional activity of the Hippo effector proteins YAP/TAZ. This suggests that 
YAP/TAZ may either directly or indirectly influence transactivation of the HIV LTR. 
Intriguingly a recent study published only last year demonstrated that KSHV infection 
enhances the activation and transcriptional activity of YAP/TAZ (Liu, 2015). In the 
current study pathway analysis posited that KSHV and HIV may employ highly similar 
mechanisms of host subversion (Figure A4.2, Appendix IV). Furthermore, Vpr regulates 
the ability of 14-3-3 proteins to interact with their binding partners (Kino, 2005) and 14-3-
3 has been well characterized as the cytoplasmic ‘anchor’ for inactivated YAP/TAZ (Pan, 
2010). These findings thus support a model whereby HIV infection may modulate the 
Hippo signalling pathway in order to regulate the transcriptional activity of YAP/TAZ, and 
where Vpr is able to subvert Hippo-induced cytoplasmic retention of YAP/TAZ by 
interacting with 14-3-3 (Figure 4.29). Thus, the findings of this study, for the first time, 
propose a direct relationship between host miRNAs associated with the Hippo signalling 





Figure 4.29 Proposed model for Hippo signalling in HIV replication 
Typically, YAP/TAZ and 14-3-3 are negatively regulated via Hippo signalling. HIV infection 
dysregulates Hippo signalling to promote nuclear localisation of YAP/TAZ, in part through the 
interaction of Vpr with 14-3-3 in the cytoplasm, as well as association of YAP/TAZ with specific 
DNA-binding partners in the nucleus to modulate HIV LTR activation. miRNA hits recovered for 
both enhanced and suppressed HIV replication phenotypes directly regulate Hippo kinases, 
YAP/TAZ, 14-3-3 and the transcriptional coactivators of YAP/TAZ. Circular arrowheads indicate 
an hypothetical interaction with likely but unknown biological effect. 
 
 
The homologous recombination directed repair (HDR) pathway was recovered 
exclusively for the suppressed HIV replication phenotype, implying that dysregulation of 
host DNA repair processes related to double strand breaks (DSBs) prior to HIV exposure 
may inhibit viral replication. Integration of the HIV genome into that of its host occurs via 
HIV integrase-mediated DSBs and subsequent ligation which in turn is mediated by host 
DNA repair machinery (see Chapter 1). Vpr has also been shown to induce DSBs and 
activation of the ATM/ATR-CHK host DNA damage response, specifically HDR and 
Rad51 activation (Nakai-Murakami, 2007). In addition the non-homologous end joining 
(NHEJ) and BER DNA repair pathways have previously been implicated in HIV 
replication by functional genomic screens (Espeseth, 2011; Genovesio, 2011). Ectopic 
expression of the Tat-interacting protein, Pur-alpha, suppressed Rad51 foci formation in 
response to DSBs, while  expression of Tat was found to enhance Rad51 expression 
and HDR in response to DSBs (Wang, 2008). The human DNA damage response is 
closely related to cell cycle and P53-mediated signalling and both these functional 
pathways were also recovered by mirPath analysis. Current knowledge has thus 
positioned the host DNA repair pathway as a critical juncture in HIV-host interactions 
and this was confirmed by miRNA-based HCS and pathway analysis. Fifteen HDR-
related miRNAs were recovered by HCS and a number of Rad51 homologs were 
enriched as validated targets of those. These miRNAs may therefore represent potential 
therapeutic agents that are able to inhibit HIV replication through modulation of HDR and 
Cytoplasm 










further posit HDR and Rad51 as potential targets for the treatment of HIV (Cosnefroy, 
2012).  
 
Importantly, experimental validation confirmed a functional relationship between the 
DNA damage response and HIV replication in GHOST(3) cells which was initially 
predicted by mirPath analysis. In accordance with prior art, HIV infection induced a 
cancer-like survival phenotype in cultured cells in response to lethal levels of chemically-
induced DSBs. Surprisingly, priming of GHOST(3) cells with a DNA damage-inducing 
agent either prior to or during HIV exposure dramatically sensitized host cells towards 
apoptosis in response to HIV. This HIV-specific toxicity phenotype was further deduced 
to be associated with viral entry. Furthermore, miRNA-mediated modulation of the DNA 
damage-associated long noncoding transcript, lincRNA-p21, was proposed as a novel 
mechanism related to specific ‘suppressed HIV replication’ phenotypes recovered by 
HCS, with these phenotypes presumably resulting from miRNA-mediated perturbation of 
lincRNA-p21 transcriptional and(or) protein binding activity.   
 
The EGFR-mediated signaling cascade was also prevalent within many of the larger 
functional networks uncovered by pathway analysis. The Erbb signalling pathway 
specifically was also identified within the top 30 pathways associated with both 
suppressed and enhanced HIV replication phenotypes (Table A4.3; A4.4). EGFR 
signalling has been well characterised in many carcinomas where constitutive activation 
of Erbb signalling results in aberrant cellular proliferation and resistance to apoptosis 
(reviewed by Normanno, 2006). In addition, nuclear localisation of EGFR (nEGFR) has 
been shown to promote enhanced DNA damage repair and resistance to both radiation 
and chemotherapeutic-based treatment strategies through its association with DNA-PKs 
(Liccardi, 2011). Furthermore, EGFR signalling has been associated with the entry 
strategies of many viruses, including influenza, where RNAi-mediated suppression of 
EGFR was demonstrated to inhibit viral entry and replication (Meliopoulos, 2012). Of 
particular relevance, the rearrangement and subsequent activation of receptor tyrosine 
kinases (RTKs), like EGFR, within the cell membrane in response to influenza 
attachment was found to induce downstream signals that were required for viral entry by 
endocytosis, ultimately resulting in accumulation of viral particles and RTKs within late 
endosomes (Meliopoulos, 2012). Similar roles for EGFR signalling have also been 
described for other viruses including hCMV, HCV and vaccinia virus (reviewed by Grove, 
2011). In terms of HIV replication, Env, Nef and Tat have been predicted to directly 
interact with a number of host factors enriched within the Erbb signalling pathway 
(Evans, 2009). In addition Tat upregulates TGF-alpha production in an EGF-dependent 
manner (Nabell, 1994), while Gag expression inhibits EGFR degradation resulting its 
accumulation within late endosomes which correlated with enhanced MAPK signalling 
(Valiathan, 2004). Despite all this data, the functional relevance of EGFR signalling 
during early stages of HIV infection and its potential role in the HIV-induced DNA 
damage response are not well characterised, although it seems likely that EGFR-
mediated signalling may play a similar role in HIV entry as described for other viruses. 
This is particularly significant given that the current study has now identified a unique 
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subset of host miRNAs that are able to functionally modulate HIV replication, at least in 
part, through regulation of the Erbb signalling pathway.    
 
Notably, the panel of HIV replication modulating miRNAs described in this study likely do 
not represent an exhaustive list of host miRNAs that are capable of modulating HIV 
replication. Indeed, the use of the GHOST(3) assay limited the scope of this study to 
factors that influence HIV replication upto the point of LTR transactivation only. A 
functional evaluation of host miRNAs that specifically impact the later stages of the viral 
replication cycle would thus, in combination with the findings of this study, provide a 
more comprehensive overview of the HIV-modulating capacity of the human miRNAome. 
The poor functional performance of miRNA inhibitor panels is a common trend that has 
been well documented and is likely also a contributing factor to the poor characterization 
of human miRNAs that function as HIV-HDFs. A more intensive validation and 
optimisation approach geared specifically at miRNA inhibitor uptake and functional 
impact would thus be advisable for all future screening projects. Specifically the use of 
methodologies like RNAseq and qPCR may be utilised to validate the efficacy of miRNA 





Many years of research have posited miRNAs as critical mediators of the molecular 
interface between pathogen and host, and these small regulatory molecules have also 
been described to exhibit broad functional control over almost all cellular processes 
(reviewed by Huang, 2011; Tan, 2015). A number of studies have reported perturbations 
in host miRNA expression profiles in response to HIV infection but the functional 
relevance of these variations and the potential of each host miRNA to modulate 
replication dynamics of HIV have not been well characterized. Indeed, less that 30 host 
miRNAs have been described to functionally modulate replication (reviewed by 
Barichievy, 2015). In addition, HCS has emerged as a powerful tool delineate functional 
relevance of the host miRNAome within various cellular models of pathology, including 
viral infection (Santhakumar, 2010; Meliopoulos, 2012; Lemons, 2013). The principal aim 
of this study was therefore to utilise a HCS-based approach to characterize the 
functional relevance of host miRNAs in HIV replication. 
 
This study represents the first known description of a large scale functional screen to 
identify specific host miRNAs that modulate HIV replication and its findings have, i) 
successfully demonstrated the utility of a novel HCS pipeline developed for this study, ii) 
led to the identification of 85 novel host miRNAs that regulate HIV (Figure 4.30) and iii) 
facilitated the identification of 70 host functional processes and pathways upon which 
HIV replication is highly dependent and thus potentially susceptible to therapeutic 
intervention (Figure 4.30). Specifically, this study has identified 53 host miRNAs as novel 
potential VRFs and 5 host miRNAs as potential HDFs. Furthermore, 28 host miRNAs 
were specifically identified that enhance HIV replication. Notably, novel functional roles 
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were uncovered for the miR-200 family of miRNAs and the Hippo signalling pathway as 
potential mediators of HIV-host interactions. Normal activity of the PI3K, spliceosome, 
mRNA surveillance and HIF-1 functional pathways were associated with suppression of 
HIV replication. Conversely successful HIV replication was found to be highly dependent 
on the normal activity of HDR, MAPK, TNF and mTOR pathways.  
 
Furthermore, HIV-modulating miRNAs recovered by this study constitute valuable 
intellectual property which could be exploited for commercial purposes. Specifically, HIV-
suppressive miRNAs recovered by this study may be exploited as therapeutic agents for 
prevention and(or) treatment of HIV infection. HIV replication-enhancing miRNAs on the 
other hand may provide a valuable clinical resource for the activation and eradication of 
latent viral reservoirs, or serve as functional tools to increase yields of virus in cell 
culture-based vaccine production models. Finally, a number of functional pathways and 
miRNA targets identified in this study are also prevalent targets of pharmaceutical 
agents used to treat various pathologies. Many of these compounds may thus also 
exhibit anti-HIV properties and represent prime candidates for drug repurposing as novel 
ARVs. The overall outcomes of this study therefore represent a significant and novel 
contribution to current HIV research efforts, and will likely also provide a platform for 








Figure 4.30 Summary of HCS and pathway analysis 
HCS identified 53 host miRNAs that suppressed viral replication and 28 host miRNAs 
that enhanced HIV replication. Of these, 9 functional pathways were associated 
exclusively with the natural suppression of HIV replication (red blocks) and 23 functional 
pathways were found to support HIV replication (green blocks). In addition, 39 functional 
pathways were associated with both enhanced and suppressed viral replication 
phenotypes (purple blocks). 
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Chapter 5: miRNA-informed HCS uncovers novel anti-
HIV activity for pharmaceutical compounds and reveals 




HCS and pathway analysis recovered 88 host miRNAs that potentially regulate >5000 
host genes across 70 functional pathways to influence HIV replication (Chapter 4). The 
relatively large number of hits recovered and potential complexity and cost associated 
with a comprehensive miRNA-target validation approach (discussed in Chapter 3) 
prompted pursuit of an alternative hit validation strategy. To this end, a series of 
orthogonal compound-based validation screens were undertaken to determine whether 
small molecule inhibitors targeted to specific functional processes recovered by mirPath 
analysis (Chapter 4) could i) recapitulate the observed miRNA-related HIV replication 
phenotypes, and ii) identify novel anti-HIV therapeutic applications for these compounds 
 
Many of the functional processes recovered by mirPath analysis converged on HIV-
mediated subversion of host pathways related to cellular proliferation, apoptosis, DNA 
damage repair and cell cycle (see Chapter 4). In addition a high number of host factors 
related to viral carcinogenesis were recovered thus portending a close relationship 
between HIV infection and a cancer-like molecular phenotype in infected GHOST(3) 
cells. This relationship was subsequently confirmed by experimental data demonstrating 
deregulated P53 transcriptional activity and aberrant cell survival in response to DNA 
damage in HIV-infected GHOST(3) cells,  as compared to uninfected controls (Chapter 
4).  
 
The summation of these observations suggested that modulation of cancer-associated 
functional targets may potentially impact the replication dynamics of HIV. Thus, the HCS 
workflow utilised in Chapter 4 was specifically adapted for compound-based screening 
(see Chapter 3) that included a panel of small molecule inhibitors, and a number of FDA-
approved chemotherapeutic compounds, to assess their anti-HIV activity.  
 
These screens were executed in three formats referred to as ‘pre-HIV exposure’, ‘post-
HIV exposure’ and’ Drug Only’ (Figure 5.1). The divergent effects observed for 
Etoposide treatment administered either prior to or following HIV exposure was the 
primary motivation for these different screening formats as it revealed that the 
phenotypic outcome of pharmaceutical intervention may vary between pre- and post-HIV 




Figure 5.1 Experimental plan for compound screening formats 
GHOST(3) cells were seeded in µClear 96 well plates at a density of 5000 cells/well at 0 hr for all 
screen formats. Cells were treated with drugs 24hr post-seeding for pre-HIV exposure screens. 
Cells were then exposed to PSG3BAL  for 48hr before being processed for imaging. In the post-
HIV exposure screen format, 24hr following seeding, cells were exposed to PSG3BAL for 48hr. 
Cells were then treated with compounds for 24hr before sample processing. In the Drug Only 
screen format, cells were treated with compounds for 24hr before being processed for imaging. 
A) Cells were fixed in 4% PFA and nuclei were counterstained with Hoechst. B) Plates were 
imaged on the IXU system,  4 FOVs were acquired per well at 20x for the 405 and 488 excitation 
channels. C) Images were transformed into numerical data through feature extraction, and D) the 
numerical data was processed and analysed within the HCStratomineR data mining tool to 
identify compounds that produced phenotypes of interest.    
 
 
Two  targeted compound libraries (Kinase Inhibitor set and Oncology set) comprising a 
total of 293 small molecules were screened at three concentrations each (100nM, 1µM 
and 10 µM) across the three screening formats. This allowed for characterization of the 
following functional classes of  small molecules: i) those that protect host cells against 
HIV infection or suppress HIV replication when administered prior to HIV exposure, ii) 
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sensitise host cells to apoptosis specifically in response to HIV exposure/infection, and 
iv) those that can no longer induce apoptosis due to the presence of HIV (Figure 5.2). 
Approximately 11 000 individual experimental wells, including ~7000 individual infection 
reactions, were prepared by hand, and more than 90 000 images were acquired and 
analysed to identify small molecules of interest. 
   
 
 
Figure 5.2 Functional hit classes identified by small molecule drug screening and high 
content image analysis. 
i) Small molecules that protect host cells against HIV infection in the pre-HIV exposure screen 
format. ii) Small molecules that suppress LTR activation in the post-HIV exposure screen 
format. iii) a. Small molecules that were not toxic in the drug only screen but exhibited toxicity in 
the post-HIV exposure screen format. b. Small molecules that were not toxic in the drug only 
screen format but sensitized cells to apoptosis following HIV exposure in the pre-HIV exposure 
screen format.  iv) Compounds that exhibited toxic effects in the drug only screen format but not 
in the pre- or post-HIV exposure screen formats. HIV infected cells (green), uninfected cells or 
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5.2.1 HCS quality control  
 
As with miRNA screen-derived data, visual inspection of graphical data outputs in 
HCstratomineR were utilised to perform a number of quality control verification steps for 
the various compound screens. Briefly, where applicable performance of the cellular 
assay was quantified by Z’ factor analysis using ‘inTotalGFP’ and ‘Total Cell Area’ 
feature scores. In addition, plate rotations and well-specific biases were evaluated by 
distribution plots of ‘inTotalGFP’ and ‘Total Cell Area’ feature scores for all experimental 
wells/plates. Individual datasets were generated for each replicate (n=2 for Drug only 
screens and n=3 for all other screens), from each screen format, across each drug 
concentration (100nM, 1µM, 10µM) and for each compound library. Replicate datasets 
were then analysed for a single screening experiment with each concentration, screen 
format and drug panel treated as separate screens during image analysis. GHOST(3) 
cells treated with an appropriate dilution of DMSO only were utilized as negative 
controls. Similarly to the screen discussed in Chapter 3, Maraviroc and Raltegravir 
(ARV) treatments (10 µM) were utilized here as  positive phenotypic controls for 
suppressed HIV replication.  
 
Distribution plots for the 10 µM Kinase Inhibitor drug panel screen in the ‘pre-HIV 
exposure’, ‘post-HIV exposure’ and ‘drug only’ formats are presented and discussed 
below, while corresponding plots for the Oncology drug panel screen are presented in 
Appendix V in the interest of brevity. The pre-HIV exposure kinase datasets revealed no 
significant variation between positive and negative controls as a function of average cell 
density per well (Total Cell Area), with a negative Z’ factor range obtained for all 
experimental plates (Figure 5.3 A). Experimental treatment wells exhibited a broad 
distribution below the average distribution range of phenotypic controls, implying that 
specific compound treatments may have had a negative effect on cell viability (Figure 
5.3A). Well location-based analysis spanning all experimental plates and replicates 
revealed that no plate rotations or well-specific directional biases had impacted the cell 
seeding step (Figure 5.3B), and all positive and negative control well locations exhibited 
a consistent and tight distribution range across all experimental plates and replicates.  
 
Most of the experimental well locations exhibited distribution trends similar to that of the 
phenotypic control well locations, but a number of experimental well locations also 
exhibited broad distributions indicative of functional effects of specific compounds on 
cellular density/viability (Figure 5.3B). Scatterplots based on ‘inTotalGFP’ scores 
revealed significant variability between distribution ranges of the negative and positive 
phenotypic controls across all replicates, and this was confirmed by an acceptable Z’ 
factor range of between 0.3-0.5 for all experimental plates (Figure 5.3B). In addition 
experimental treatments exhibited broad distribution ranges exceeding the upper and 
lower distribution limits of negative control wells (Figure 5.3C). This suggested that a 
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number of  experimental treatments had variable effects on GFP reporter signal output. 
Well location-based analysis confirmed consistent and distinct distribution ranges for 
well locations corresponding to the positive and negative controls (Figure 5.3 D). No 
directional biases or plate rotation-related effects were noted and a number of well 
locations corresponding to specific experimental treatments exhibited broad distribution 
ranges suggestive of fluctuations in the GFP reporter activity related to treatment with 
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Figure 5.3 Unprocessed data distribution plots for all replicates of ‘pre-HIV exposure’ 
Kinase Inhibitor panel (10µM). 
A) Scatterplot representing the distribution of individual experimental controls and treatments 
across three screen replicates in relation to the extracted Total Cell Area feature scores. No 
significant variability in Total Cell Area was noted between positive (green) and negative (red) 
controls. Experimental treatments (blue) exhibited a broad distribution range that extended 
beyond the lower limits of phenotypic controls suggesting strong treatment-related effects on cell 
density. B) Box plot representing the average Total Cell Area scores obtained for specific well 
locations across all experimental plates and replicates. Negative (red) and positive (green) control 
well locations exhibited consistent distribution ranges that were not distinct from each other. Well 
locations corresponding to experimental treatments exhibited broader distribution ranges. C) 
Scatterplot representing the distribution of individual experimental control and treatment wells 
across three screen replicates in relation to the extracted ‘InTotalGFP’ feature scores. Positive 
(green) and negative (red) controls exhibited distinct distribution ranges from each other. 
Experimental wells (blue) exhibited broader distribution ranges beyond the lower limits of 
negative controls suggestive of treatment-related effects LTR reporter activity. D) Box plot 
representing the average ‘InTotalGFP’ scores obtained for specific well locations across all 
experimental plates and replicates. Negative (red) and Positive (green) control well locations 
exhibited consistent and distinct distribution ranges. Well locations corresponding to experimental 
treatments exhibited broader distribution ranges.    
   
 
The second dataset, that of the post-HIV exposure screen, showed negative Z’ factor 
values for experimental plates in relation to Total Cell Area feature scores. These values 
were not as high as those obtained for the pre-HIV exposure dataset, suggesting a 
higher level of variability was present between positive and negative control phenotypes 
in the post-HIV exposure screen (Figure 5.4A). This variance was however non-
significant (based on Z’ factor values). An acceptable Z’ factor range between 0.3 and 
0.7 was obtained for all experimental plates in relation to ‘InTotalGFP’ scores. This was 
confirmed by visual inspection of the data distribution trends, which revealed a clear 
separation between positive and negative controls  as well as a broad distribution range 
for  experimental treatments (Figure 5.4 C). Well location-based analysis confirmed that 
directional biases and plate rotations had not impacted the dataset, and phenotypic 
control well locations exhibited consistent and tight distributions (Figure 5.4D). Notably, 
the effect of compounds treatments as a function of distribution range was not as 
prominent in the post-HIV exposure screen format compared to the pre-exposure 
dataset (Figure 5.3), suggesting that HIV infection may attenuate the general functional 




Figure 5.4 Unprocessed data distribution plots for all replicates of ‘post-HIV exposure’ 
Kinase Inhibitor panel (10µM). 
A) Scatterplot representing the distribution of individual experimental controls and treatments 
across screen replicates in relation to the extracted Total Cell Area feature scores. The positive 
(green) and negative (red) controls exhibited noticeable but non-significant variation in their 
respective distribution ranges. Experimental wells (blue) exhibited a broad distribution range 
suggestive of treatment-related effects on cell density. B) Box plot representing average Total 
Cell Area scores obtained for specific well locations across all experimental plates and replicates. 
Negative (red) and positive (green) control well locations exhibited consistent and tight 
distribution ranges. Well locations corresponding to experimental treatments exhibited broad 
distribution ranges. C) Scatterplot representing the distribution of individual experimental control 
and treatment wells across screen replicates in relation to the extracted ‘InTotalGFP’ feature 
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scores. Positive (green) and negative (red) controls exhibited distinct distribution ranges. 
Experimental wells (blue) revealed broader distribution ranges, mostly beyond the lower limits of 
the negative controls suggestive of negative treatment-related effects on LTR reporter activity. D) 
Box plot representing average InTotalGFP scores obtained for specific well locations across all 
experimental plates and replicates. Negative (red) and positive (green) control well locations 
exhibited consistent and distinct distribution ranges. Well locations corresponding to experimental 
treatments exhibited broader distribution ranges exceeding those of the negative controls.  
 
For the last compound screen, that of the Drug Only dataset, Total Cell Area distribution 
plots were utilised to monitor general data distribution trends (Figure 5.5A) and to 
confirm that plate rotations and directional biases had not impacted individual datasets 




Figure 5.5 Unprocessed data distribution plots for all replicates of ‘Drug Only’ Kinase 
inhibitor panel (10µM) based on Total Cell Area feature scores 
A) Scatterplot representing the distribution of individual negative controls and treatments across 
three screen replicates in relation to the extracted Total Cell Area feature scores. Negative 
controls (red) did not differ in their distribution ranges. Experimental treatments (green) exhibited 
a broad distribution range. B) Box plot representing the average Total Cell Area scores obtained 
for specific well locations across all experimental plates and replicates. Negative control well 
locations (red) exhibited consistent and tight distribution ranges irrespective of their positions on 
experimental plates. Well locations corresponding to experimental treatments (green) exhibited 
broad distribution ranges, with no clear pattern or bias.  
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Overall, similar distribution trends were observed for all 10 µM datasets (Appendix V, 
Figures A5.1-A5.3), with the exception that a larger number of compounds exhibited 
strong cytotoxic effects on GHOST(3) cell viability in the ‘pre-HIV exposure’ and ‘drug 
only’ screen formats. As with the Kinase Inhibitor panel dataset however, this effect was 
attenuated in the post-HIV exposure screen format (Appendix V). In addition, data 
quality including Z’ factor analysis and visual inspection of data distribution profiles were 
verified for all screening-derived datasets.  
 
5.2.2 Normalisation and feature retention for hit selection 
 
Extracted feature scores were normalized against those of the negative controls on a per 
plate basis for all compound screens. Normalized feature plots were then evaluated by 
visual inspection  to identify features that were descriptive of the variability between 
positive and negative control phenotypes for ‘pre-HIV exposure’ and ‘post-HIV exposure 
screens’. All features acquired in the Hoechst channel were considered for ‘Drug only’  
toxicity analysis. Features which did not meet these criteria, or exhibited missing values, 
or skewed distributions, were excluded from subsequent analyses.  
 
A general dose response phenotype was observed for normalized Total Cell Area and 
InTotalGFP feature plots for all three compound concentrations (10 µM, 1 µM and 100 
nM) across all screen formats and for both drug panels. Normalized feature plots 
recovered for the Kinase Inhibitor drug panel screens are presented in Figure 5.6 as an 
example. Briefly, a number of compounds exhibited significant effects on cell density 
(Figure 5.6A) and GFP reporter signal output (Figure 5.6B) at the 10 µM concentration 
as evident by the non-uniform distribution patterns recovered for experimental 
treatments (blue bars). This effect was noticeably diminished at 1 µM (reduced variability 
within experimental treatment distributions) and was mostly abrogated at 100 nM 
treatments, as evident by the uniform distribution patterns recovered for experimental 
treatments and Negative controls (Figure 5.6). This concentration-dependent response 
was best exemplified by the Total Cell Area plots obtained for the Drug Only screen 
format (Figure 5.6C).  
 
In addition, normalized Total Cell Area feature plots revealed overlapping distribution 
patterns for positive and negative controls at each of the concentrations screened in 
both pre- and post-HIV exposure formats (Figure 5.6A). Conversely normalized 
InTotalGFP plots revealed a clear bimodal distribution and separation of positive and 
negative controls across all screen formats and treatment concentrations (Figure 5.6B). 
Initially, the 10 µM InTotalGFP distribution plots for both the pre- and post-HIV exposure 
formats were noticeably ‘left-shifted’ with respect to the median cut off in each plot, with 
this effect most pronounced in the post-HIV treatment (Figure 5.6B). This was 
attributable to a single compound that was highly autofluorescent thus resulting in an 
elevated and outlying GFP signal readout which distorted the distribution of these plots 
(Figure 5.6B). As a further point of interest,  the 10 µM post-HIV experimental treatments 
187 
exhibited a significantly more uniform distribution when compared to the 10 µM pre-HIV 
experimental treatments, implying that HIV infection may in general attenuate the 
functional impact of compounds on cell viability (Figure 5.6A).  Overall, similar trends 
were recovered for the normalized Oncology drug panel feature plots and these are 




Figure 5.6 Normalized feature plots for Kinase Inhibitor drug panel screens 
A) Normalized Total Cell Area distribution plots for pre-HIV and post-HIV treatment screens at 10 
µM, 1 µM and 100 nM compound concentrations. B)  Normalized InTotalGFP distribution plots for 
pre-HIV and post-HIV treatment screens at 10 µM, 1 µM and 100 nM compound concentrations. 
C) Normalized Total Cell Area distribution plots for Drug only screens at 10 µM, 1 µM and 100 nM 
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5.2.3 Hit Selection and triage  
 
Normalized feature scores were subjected to MDS or PCA-based data reduction in order 
to create factors that best summarised the relationships between them. Unique factors 
were generated for each screening dataset although they followed a general trend with 
regards to the screen format. Factors utilized in analysis of the Kinase Inhibitor drug 
panels screened at 10 µM are presented in Appendix V, Figure A5.5 as an example. 
Factor-based analysis was then applied to experimental datasets and either PCA-DFN 
or MDS-DFN based hit selection methods were applied to identify compounds that 
produced phenotypes of interest (Figure 5.2). Briefly, the combined phenotypic distance 
scores between replicates were used to define compounds that exhibited phenotypic 
profiles which were significantly (p<0.05) distant from negative controls. These 
compounds were then ranked by combined InTotalGFP scores, to identify compounds 
that suppressed LTR activity (>50%), or by combined Total Cell Area scores to identify 
compounds that were highly toxic (Combined Total Cell Area score < 0.1).  
 
The pre-HIV and post-HIV exposure screen formats thus allowed for identification of i) 
compounds that could suppress HIV LTR activity, and ii) compounds that were toxic in 
either screen format.  The ‘Drug only’ screen format allowed for establishment of 
baseline toxicity effects for all compounds, and the toxic hits recovered by this screen 
format were used in a comparative analytical approach to differentiate between 
compounds that were broadly cytotoxic and those that had toxic effects specifically in 
response to HIV exposure/infection (HIV-specific toxicity). In addition identification of 
compounds that were highly toxic in the ‘Drug only format’ but not in the HIV exposure 
screen formats allowed for the recovery of compounds whose natural apoptotic activity 
was attenuated by HIV infection (Mitigated toxicity).  
 
The hits recovered for each drug panel were then combined to obtain discrete lists of 
compounds related to each functional class of interest (Figure 5.7). Briefly, high content 
image analysis recovered 8 unique compounds which significantly suppressed LTR 
reporter activity in the ‘pre-HIV exposure’ screen format (Figure 5.7, Red), and 5 
compounds that exclusively suppressed reporter activity in the ‘post-HIV exposure’ 
screen format (Figure 5.7, Blue). Only four compounds (Ponatinib, SNS-032 and two 
versions of Flavopiridol) suppressed HIV replication in both the pre-HIV exposure and 
post-HIV exposure screen formats. Six compounds were recovered for the mitigated 
toxicity phenotype and 2 of these, NVP-TAE684 and Dactinomycin, were also recovered 
as HIV-suppressive hits in the ‘post-HIV exposure’ screen format (Figure 5.7, Grey). The 
largest number of hits was recovered for the HIV-specific toxicity phenotype where 28 
compounds were found to specifically sensitize host cells to apoptosis in response to 
HIV exposure/infection (Figure 5.7, Green). Four of these 28 compounds were also 
recovered as HIV-suppressive hits in the post-HIV exposure screen format, namely A-




Figure 5.7. Compound screen hits recovered by HCS and grouped by phenotypic class 
 
Suppressed HIV replication hits 
 
Visual inspection was utilized to confirm the recovered hit classifications and examples 
of HIV-suppressive hit phenotypes from the pre- and post-HIV exposure screen formats 
are presented in Figure 5.8 below. Briefly, Ponatinib suppressed HIV replication in both 
screens, while BIBF1120 and Temozolomide were recovered as hits exclusively for the 
pre-HIV screen format (Figure 5.8 A-D). Likewise A-674563 and NVP-TAE684 were 
recovered as HIV-suppressive hits in the post-HIV exposure screen format only (Figure 
5.8 E & F).  
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Figure. 5.8 Examples of HIV-suppressive compounds recovered by HCS for pre- and post-
HIV exposure treatments.  
Hits characterised within this functional class exhibited significantly reduced GFP expression 
compared to the appropriate plate-specific negative control (DMSO only). A-C: HIV-suppressive 
phenotype recovered for the pre-HIV exposure screen format. D-E: HIV-suppressive phenotype 
recovered for the post-HIV exposure screen format. ‘DMSO only’ images were obtained from a 
negative control well on the same experimental plate as the compound treatments. Images 
represent an overlay of acquisitions from the 405 and 488 excitation channels from a single FOV. 
GFP/LTR activation (green), nuclei counterstained with Hoechst (red). Scale bars = 20 µm. 
 
Ponatinib was one of the most promising novel anti-HIV drug candidates recovered by 
HCS as it exhibited significant suppression of HIV replication in both the pre- and post-
HIV exposure screen formats with little to no effect on GHOST(3) cell viability (Figure 5.8 
A & D).  Ponatinib is a potent inhibitor of the oncogenic BCR-ABL fusion protein that has 
also been described to inhibit SRC kinases and various receptor kinases including 
PDGFR, VEGFR and FGFR (Frankfurt, 2013). Ponatinib received accelerated approval 
from the FDA in 2012 but is currently limited to treatment of patients who cannot be 
treated with other tyrosine kinase inhibitors (TKIs), including patients with malignancies 
harbouring a T315I TKI resistance mutation (Gainor, 2015). The significant HIV-
suppressive activity of ponatinib suggests an important role for BCR, ABL and SRC 
kinase signalling activity in progressive HIV replication, Indeed, SRC kinases have been 
previously associated with cell to cell transfer of HIV from dendritic cells to T 
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lymphocytes and the subsequent endocytic processes governing viral entry (Gilbert, 
2007). Likewise ABL kinases have been implicated as HDFs which mediate actin 
rearrangements during HIV entry, specifically the membrane fusion step (Harmon, 
2010). This is also supported by miRNA pathway analysis which identified regulation of 
the actin cytoskeleton and a number of cytoplasmic kinases as functional targets 
associated with miRNA-mediated modulation of HIV replication (Chapter 4).  
 
While the HIV-entry associations described for Ponatinib targets may explain the 
associated phenotype in the pre-HIV-exposure screen format, the HIV-suppressive 
effect of Ponatinib in the post-HIV exposure screen format cannot be explained by 
inhibition of viral entry. Instead, this latter phenotype suggests a potential role for BCR, 
ABL and SRC kinases in transactivation of the viral LTR or alternatively, that the HIV-
suppressive activity of Ponatinib may be related to its functional effect on other targets, 
including viral proteins. BIBF1120, also known as Nintedanib (marketed as Vargatef) is 
an FDA-approved kinase inhibitor with documented activity against VEGFR, PDGFR and 
FGFR (Hilberg, 2008). Notably these specific receptor kinases are also targets of 
Ponatinib, suggesting a potentially conserved mechanism of action related to inhibition 
of these receptor kinase signaling cascades and the suppressed viral replication 
phenotypes recovered for both Ponatinib and BIBF1120 (Figure 5.7). Temozolomide on 
the other hand is an FDA-approved DNA alkylating agent that induces DNA damage and 
apoptosis in a mismatch repair-dependent manner (Zhang, 2012). Notably, the apoptotic 
activity of Temozolomide is antagonised by HDR, specifically the activity of RAD51 and 
BRCA2 (Quiros, 2011) which were all implicated in miRNA-mediated suppression of HIV 
replication (Chapter 4). Furthermore, Temozolomide has previously been described to 
enhance the chemotherapeutic activity of BCR-ABL inhibitors (Milano, 2009), thus 
suggesting that it may also represent a promising candidate for combination therapy with 
Ponatinib or BIBF1120 for the suppression of HIV replication.   
  
A-674563 is an AKT inhibitor (Okuzumi, 2010) which induces caspase-3/9 activation and 
apoptosis through functional inhibition of AKT and sphingosine kinase 1 (Xu, 2016).  
TAE684, also known as NVP-TAE684, was first described as an inhibitor of the ALK1 
receptor tyrosine kinase (RTK), which is associated with the TGFß signalling pathway 
(Galkin, 2007). In addition, Leucine-rich repeat kinase 2 (LRRK2) was described as a 
functional target of TAE684 activity (Smith, 2005). Exclusive recovery of both A-674563 
and TAE684 in the post-HIV exposure screening format suggests that AKT and TGFß -
mediated signalling is more relevant for sustained transactivation of the HIV LTR 
following viral integration as opposed to earlier stages of the viral life cycle. Notably, the 
TGFß signaling pathway and many of its associated factors were also recovered by 





Suppressed HIV replication hits below 10 µM 
 
Only 4 compounds were observed to exhibit significant HIV-suppressive activity at 1 µM 
(Figures 5.9 and 5.10) while no compounds were found to be effective at 100 nM. Three 
of these compounds, (SNS-032, Flavopiridol HCl and Flavopiridol) were highly toxic in 
the 10 µM screens, but exhibited HIV-suppressive phenotypes with attenuated 
cytotoxicity at 1 µM (Figure 5.9). SNS-032 is a CDK inhibitor with documented efficacy 
against CDK9 and is currently under phase I clinical investigation (Chen, 2009). 
Flavopiridol, also known as Alvocidib, is a pan-CDK inhibitor currently under phase II 
clinical trials for the treatment of various lymphomas. Flavopiridol, has been previously 
shown to suppress HIV replication through inhibition of CDK9/P-TEFb (Chao, 2000), and 
both SNS-032 and Flavopiridol have been reported to exhibit similar IC50s for inhibition 
of CDK9 (Ali, 2009; Chen, 2009). It is therefore plausible that both the HIV-suppressive 
and toxic phenotypes recovered for these compounds across all screen formats are 
related to inhibition of host transcriptional processes, specifically CDK9 (P-TEFb)-
mediated  transcription, which is also required for stable activation of the HIV LTR 
(Chao, 2000). The two variants of Flavopiridol provided within the Kinase Inhibitor drug 
panel were located on separate experimental plates and their concordant recovery by 
high content analysis further highlights the robustness and fidelity of the analytical 
approach used as well the technical accuracy with which experimental treatments were 




Figure. 5.9 Compounds with anti-HIV activity at 1 µM.  
A) Cytotoxic (10 µM) and HIV-suppressive (1 µM) phenotypes recovered for SNS-032 treatment 
in the pre-HIV exposure screen format. B) Cytotoxic (10 µM) and HIV-suppressive (1 µM) 
phenotypes recovered for Flavopiridol HCl treatment in the pre-HIV exposure screen format. A) 
Cytotoxic (10 µM) and HIV-suppressive (1 µM) phenotypes recovered for Flavopiridol (Alvocidib) 
treatment in the pre-HIV exposure screen format. DMSO only images were obtained from a 
negative control well on the same experimental plate as the compound treatments. Images 
represent an overlay of acquisitions from the 405 and 488 excitation channels from a single FOV. 
GFP/LTR activation (green), nuclei counterstained with Hoechst (red). Scale bars = 20 µm. 
 
The fourth compound that exhibited anti-HIV activity at 1 µM was Dactinomycin which is 
a DNA-intercalating, RNA synthesis inhibitor originally isolated from Streptomyces 
bacteria and which has received FDA-approval as a chemotherapeutic agent (reviewed 
by Bensaude, 2011). In addition, Dactinomycin treatment induces DSBs and γ-H2AX 
activation (Bensaude, 2011). In connection with HIV, Dactinomycin primes T cell 
populations for reactivation of latent viral reservoirs in response to TNF stimulation 
(Shishido, 2012). Intriguingly, the same study also demonstrated that while 
Dactinomycin enhanced LTR activation in latent reservoirs it exhibited an opposing, 
inhibitory effect on LTR activity in actively infected cell populations (Shishido, 2012). 
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Furthermore these HIV-replication modulating phenotypes were independent of the 
transcription-inhibiting effects of Dactinomycin suggesting an alternative unknown 
mechanism of action associated with the observed phenotypes (Shishido, 2012). The 
results obtained by HCS revealed a strong concordance with the phenotypes reported 
by Shishido and colleagues (Shishido, 2012), as Dactinomycin treatment suppressed 
HIV replication in the post-HIV exposure screen format (Figure 5.10), and induced 
modest but significant LTR activation in the HIV-naive Drug Only screen format, albeit 
with high levels of toxicity (Figure 5.10). These observations suggest that the molecular 
mechanisms associated with HIV replication in primary T lymphocytes may be 
conserved within the GHOST(3)-PSG3BAL infection assay, thus further strengthening 




Figure. 5.10 Effects of Dactinomycin treatment in Drug Only and post-HIV exposure screen 
formats.  
A) Dactinomycin-induced suppression of HIV replication in 10 µM and 1 µM post-HIV treatments. 
B) Dactinomycin induced toxicity and LTR-GFP stimulation in 10 µM and 1 µM Drug Only 
treatments. DMSO only images were obtained from a negative control well on the same 
experimental plate as the compound treatments. Images represent an overlay of acquisitions 
from the 405 and 488 excitation channels from a single FOV. GFP/LTR activation (green), nuclei 
counterstained with Hoechst (red). Scale bars = 20 µm. 
 
 
Dactinomycin has also previously been described to suppress HPV replication, reverse 
HPV-mediated suppression of P53, and promote apoptosis in HPV infected cells through 
nuclear accumulation and transcriptional activation of P53 (Hietanen, 2000). Given the 
highly similar host interaction profiles described for HIV and HPV infection by miRNA 
pathway analysis, it is likely that the same P53-related mechanisms may contribute to 
Dactinomycin-associated HIV phenotypes recovered by HCS, particularly those related 
10 µM 
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to cell survival. Indeed similar cell survival phenotypes were also recovered for the DNA 
damage inducing agent Etoposide in the Drug Only, post-HIV and pre-HIV treatments 
with the exception that Etoposide did not suppress HIV replication in the ‘post-HIV’ 
treatment (Chapter 4). Like Dactinomycin, Etoposide promotes nuclear localization and 
activation of P53, via suppression of MDM2 (Arriola, 1999). The apoptotic phenotypes 
induced by both Dactinomycin and Etoposide in HIV-naive GHOST(3) cell populations 
are thus likely dependent on P53. Inactivation of P53 during HIV infection by both Nef-
dependent and independent mechanisms (Greenway, 2002; Schindler, 2005), including 
downregulation of TP53 transcript levels (Chapter 4), is therefore likely a contributing 
factor in the Mitigated Toxicity phenotypes recovered for many post-HIV treatments, 
including that of Dactinomycin and Etoposide. Furthermore, P53 has been described to 
activate the HIV LTR  (Sawaya, 1998) suggesting that activation of the GHOST(3) LTR-
GFP reporter construct in the ‘Drug Only’ Dactinomycin treatment may also be 
associated with enhanced P53 transcriptional activity. 
HIV-specific toxicity 
 
The largest contingent of hits was comprised of compounds that sensitized or ‘primed’ 
host cells towards apoptosis in response to HIV exposure or infection. Examples of 3 
compounds that induced HIV-specific toxicity in the pre-HIV exposure screen format are 
presented in Figure 5.11 below. Briefly, in the pre-HIV exposure screen format, cells 
exposed to 10 µM of Pelitinib (Figure 5.11A), Abiraterone (Figure 5.11B) or A-674563 
(Figure 5.11C) showed significant cytotoxicity, as denoted by diminished Hoechst signal 
(i.e. lower cell numbers), compared to relevant plate-specific negative controls (Figure 
5.11). Notably, this highly cytotoxic phenotype was not recovered for the same 
compounds in the Drug Only screen format (Figure 5.11). These data clearly suggested 
that certain compounds, when applied in isolation are not toxic to cells, but when added 





Figure. 5.11 Example of compound hits associated with HIV-specific toxicity in the pre-HIV 
exposure screen format.  
A) 10 µM Pelitinib treatment resulted in significant cytotoxicity in the pre-HIV exposure format but 
not in the Drug Only format. B) Similarly 10 µM Abiraterone treatment resulted in significant 
cytotoxicity in the pre-HIV exposure format but not in the Drug Only format, and the same was 
observed for C) 10 µM A-674563 treatment. DMSO only images were obtained from a negative 
control well on the same experimental plate as compound treatments. Images represent an 
overlay of acquisitions from the 405 and 488 excitation channels from a single FOV. GFP/LTR 
activation (green), nuclei counterstained with Hoechst (red). Scale bars = 20 µm. 
 
 
As mentioned previously, A-674563 is an inhibitor of AKT signalling, while Pelitinib is an 
irreversible EGFR inhibitor that is currently under phase II clinical trials with documented 
activity against SRC, STAT3, AKT and ERK1/2 (Nunes, 2004). Abiraterone (marketed as 
Zytiga) is an FDA-approved inhibitor of the enzyme 17 alpha-hydroxylase/C17,20 lyase 
(CYP17A1) and functions as an antagonist of androgen receptor (AR) signalling for the 
treatment of prostate cancer (Schweizer, 2012). The nuclear localisation and 
transcriptional activation of AR promotes cell survival and proliferation, and may be 
activated in an androgen-independent manner through RTK-mediated (e.g HER-2) 






inhibition of host factors associated with pro-survival signalling pathways like ERBB, 
MAPK and AKT may therefore sensitise host cells to apoptosis in response to HIV 
infection. Compounds that exhibit these phenotypic trends may prime host cells into a 
pro-apoptotic or stressed state where the genotoxic stress associated with HIV infection 
then irreversibly initiates an apoptotic response which cannot be subverted by a non-
established viral  infection.  
 
HIV-induced cell survival 
 
Small molecules that exhibited significant cytotoxic effects in the Drug Only screen 
format but not the post-HIV exposure screen format were of particular interest, as these 
contrasting cytotoxic outcomes suggest that HIV is able to specifically subvert the pro-
apoptotic activity of these small molecules. Only six small molecules were recovered for 
this functional class by HCS and two of these, NVP-TAE684 and Dactinomycin (Figure 
5.10), also suppressed HIV replication in the post-HIV exposure screen format. Two 
examples of hits relevant to this functional class are represented in Figure 5.12 below. 
Briefly, significant cytotoxic effects of both Fludarabine phosphate and NVP-TAE684 
were readily denoted by diminished Hoechst signal (i.e. lower cell numbers) in the Drug 
Only screen format (Figure 5.12 A & B). However, the same treatment time and 
compound concentrations exhibited significantly diminished cytotoxic effects when 
administered 48hr after HIV exposure (Figure 5.12 A & B). These data clearly suggest 
that HIV is able to mitigate or subvert, perhaps even lessen, the cytotoxic effects of 









Figure. 5.12 Example of compound hits associated with HIV-mitigated toxicity in the post-
HIV exposure screen format.  
A) 10 µM Fludarabine treatment resulted in significant cytotoxicity in the Drug Only treatment but 
not in the post-HIV screen format. B) Similarly, 10 µM NVP-TAE684 treatment resulted in 
significant cytotoxicity in the Drug Only treatment but not in the post-HIV screen format. DMSO 
only images were obtained from a negative control well on the same experimental plate as 
compound treatments. Images represent an overlay of acquisitions from the 405 and 488 
excitation channels from a single FOV. GFP/LTR activation (green), nuclei counterstained with 
Hoechst (red). Scale bars = 20 µm. 
 
Fludarabine is an FDA-approved nucleoside analog, marketed as Oforta, which is 
traditionally used for the treatment of various lymphomas (Christopherson, 2014). This 
drug is incorporated into the DNA of actively dividing cells and results in inhibition of 
transcription, accumulation of DNA breaks, as well as nuclear and mitochondrial 
localisation of activated P53 (Christopherson, 2014). As mentioned previously NVP-
TAE684 inhibits ALK and TGFß-mediated signalling (Galkin, 2007). These findings 
suggest that HIV is able to subvert apoptotic signals mediated through the P53 and 
TGFß signalling pathways and this is in accordance with miRNA HCS data which 
recovered a close functional relationship between these specific pathways and the 
modulation of HIV replication. Additionally these findings also lend further support the 
proposed role of  HIV-induced downmodulation of P53 transcriptional activity in the 
aberrant cell survival phenotypes previously noted for Etoposide treatment following HIV 
infection (Chapter 4). 
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5.2.4 Pathway analysis 
 
Based on the hits selected from the various screen formats, compound-protein and 
protein-protein interaction analyses were then performed in order to evaluate higher-
order processes associated with each functional class of hits. These enrichment and 





STITCH analysis recovered interactions between CDKs 1, 2, 4, 5, 7 and 9 in association 
with the HIV suppressive phenotype in the pre-HIV exposure screen format (Figure 
5.13). Specifically, the posttranslational modification of  a number of CDKs by CDK7 and 
vice versa was recovered. This is in accordance with the central role of CDK7 in the 
CDK-activating complex (CAK), which regulates cell cycle progression (Obaya, 2002) 
and has also been implicated as Tat-associated factor that mediates LTR transactivation 
(Cujec, 1997). These findings thus posit the pharmacological inhibition of multiple CDKs 
as a potential strategy for the treatment of HIV and has recovered specific small 
molecules that are eble to exert anti-HIV effects through this specific mechanism of 
action (Figure 5.13). In addition the inhibition of  EGFR-SRC signalling and VEGFA and 
the activation of PTGS2 were also associated with the HIV suppressive phenotype by 
STITCH analysis. VEGFA has been described to be upregulated in response to HIV 
infection (Korgaonkar, 2008), while PTGS2 has been implicated as an inhibitor of HIV 
replication (Whitney, 2011). The functional inhibition of EGFR-SRC signaling was 
strongly implicated in miRNA-based modulation of HIV replication by HCS (Chapter 4) 
and the potential role of EGFR in HIV replication is discussed in greater detail in section 
5.2.5. KEGG analysis revealed a significant (p<0.05) enrichment for the cell cycle, 
VEGFR, ERBB, adherens junction, endocytosis and MAPK signalling pathways, along 
with regulation of the actin cytoskeleton. All of these functional pathways were also 
found to be enriched by pathway analysis for miRNA mimics that suppressed HIV 
replication (Chapter 4). This observation further highlights the significant concordance 
between certain functional targets identified by miRNA screening and the 
pharmacological activity of specific small molecules that both suppress HIV replication. 
Notably, as these targets were all identified in a pre-HIV exposure format, their effect on 
HIV is likely exhibited early on during infection positing these molecules as prime 






Figure 5.13 STITCH analysis for pre-HIV exposure compound hits 
The pharmacological inhibition of, and molecular interactions between, various CDKs as well as a 
signalling network comprised of EGFR, SRC, VEGFA and PTGS2 were the most prominent 
functional clusters recovered for compounds hits associated with suppressed HIV replication in 
the pre-HIV screen format. Posttranslational modification (pink), activation (green arrowhead), 
inhibition (flat red arrowhead), catalysis (purple), binding (blue), effect on gene expression 
(yellow),  interaction (grey). 
 
In addition Ponatinib, Flavopiridol and Cisplatin stimulate expression of Breast Cancer 
Resistance Protein (BCRP), also known as ABCG2 (Figure 5.13). The ATP-binding 
cassette (ABC) family of transporters regulate absorption and bioavailability of small 
molecules including lipids and drugs (reviewed by Szakacs, 2008). BCRP is specifically 
induced by Tat in T lymphocytes (Zhou, 2016), and elevated BCRP expression has been 
linked to AIDS progression and failure of ARV treatment (Wang, 2003; Zhang, 2014). 
Furthermore, ABCG2 has been described as a direct transcriptional target of EGFR 
(Huang, 2011). Together, these findings posit BCRP-mediated drug resistance as an 
additional potential mechanism of HIV-induced cell survival in response to toxic 
compounds. However, while Cisplatin, Ponatinib and Flavopiridol may represent viable 
candidates for drug repurposing as novel anti-HIV therapeutics, these compounds are 
susceptible to BCRP-mediated drug resistance. Taking a cue from HIV-specific 
regimens, a combination therapy that includes BCRP-inhibition, may provide a more 









In the post-HIV exposure format, STITCH analysis again recovered CDKs 1, 2, 4, 5, 7 
and 9 as well their interaction with CCND1 and either the activation or posttranslational 
modification of P53 (Figure 5.14). The posttranslational modification of P53 is 
intrinsically related to its stability, nuclear localization and transcriptional activity 
(reviewed by Meek, 2009). Notably the posttranslational modification of P53 
transcriptional activity was implicated in the aberrant cell survival phenotype recovered 
for Etoposide treatments in Chapter 4. EGFR-mediated signalling occupied a 
significantly less prominent role in the post-HIV treatment as compared to the pre-HIV 
treatment, suggesting that EGFR-mediated signals may be more relevant during the 
earlier stages of viral replication i.e. prior to stable LTR transactivation. STITCH analysis 
also suggested that inhibition of P53 posttranslational modification by CDKs may exert a 
strong influence on LTR transactivation in stably infected cells. If so, these interactions 
represent potentially attractive targets for therapeutic intervention. Indeed, Tat has been 
proposed to interact with cyclin-CDK complexes including CDKs 2, 7 and 9, and 
pharmacological inhibition of CDKs has previously been proposed as a potential strategy 
to inhibit HIV replication (Maddukuri, 2003). However, the majority of compounds 
recovered by this study have not been directly or specifically associated with suppressed 
HIV replication, meaning additional data is required to gain confidence in these 
connections. In contrast, KEGG analysis revealed a significant (p<0.05) enrichment for 
the cell cycle, P53, Wnt and MAPK signalling pathways which were also recovered by 
miRpath analysis (Chapter 4). This latter piece of data once again generates confidence 
in the use of orthogonal assays to identify HIV-related host functional pathways that 





Figure 5.14 STITCH analysis for post-HIV exposure compound hits 
The pharmacological inhibition of, and molecular interactions between, various CDKs, CCND1 
and P53 comprised the most prominent functional cluster associated with suppressed HIV 
replication in the post-HIV exposure screen format. Notably, a signalling network comprised of 
EGFR, SRC, VEGFA and PTGS2 were the most prominent functional clusters recovered. 
Posttranslational modification (pink), activation (green arrowhead), Inhibition (flat red arrowhead), 




The most conserved mechanism associated with the HIV-specific toxicity phenotype was 
related to pharmacological inhibition of RTKs (ERBBs, PDGFRs, KIT, RET, FLT3) which 
exhibited convergent downstream interactions with cytoplasmic kinases such as BCR, 
LCK, ABL1 and SRC (Figure 5.15). The functional inhibition of these RTKs and(or) the 
inhibition of their binding to each other correlated with HIV-induced toxicity. Notably, LCK 
(P56) activity is modulated by gp120 (Hubert, 1995), and LCK has also been linked to 
Tat-mediated regulation of NF-kß and apoptosis (Manna, 2000). The fact that the 
majority of these compounds only exhibited HIV-specific toxicity in the pre-HIV exposure 
screen format further suggests that these toxic phenotypes are associated with a host 
cell ‘priming effect’. In other words, pharmacological inhibition of RTK signalling 
cascades seems to sensitize host cells to apoptosis, specifically in response to HIV 
exposure. Further investigation is required in order to determine exactly which stage of 
the viral life cycle, and  which viral proteins may serve as the ‘trigger’ for such an 
apoptotic switch. In addition, the large scale toxic effects recovered for these compound 
'post-HIV exposure' 
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treatments, compared to negative control images, appear to extend beyond only the 
infected cell population (Figure 5.11). This represents an interesting outcome that may 
be related to the broad-scale pyroptotic responses in uninfected bystander cells which is 
induced by stalled HIV replication in infected cells (Doitsh, 2014). Again, validation of 
such a relationship requires further investigation. Overall, the compounds recovered for 
the HIV-specific toxicity phenotype may constitute promising therapeutic candidates, for 
the prevention of de novo infections during chronic HIV infection, and also as post-
exposure prophylactic treatments to counteract the establishment of viral reservoirs 
following acute exposure to HIV. Finally, KEGG analysis revealed a significant (p<0.05) 
enrichment for the ERBB, focal adhesion, endocytosis, cytokine-cytokine, adherens 
junction and MAPK signalling pathways. The recovery of these specific pathways 
supports the role of RTK-mediated signalling in the survival of compound-treated cells 
exposed to HIV. The KEGG results also suggest that actin-associated rearrangements, 
potentially during viral entry, may serve as the molecular triggers for apoptosis, although 




Figure 5.15 STITCH analysis for HIV-specific toxicity-associated compound hits 
HIV-specific toxicity 
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The pharmacological inhibition of a number of RTKs and their convergent signalling through 
cytoplasmic kinases was highly enriched within this hit class. Posttranslational modification (pink), 
activation (green arrowhead), inhibition (flat red arrowhead), catalysis (purple), binding (blue), 
effect on gene expression (yellow),  interaction (grey). 
 
 
The prosurvival effect of stable HIV replication in cell types such as macrophages has 
been described as a major barrier to the eradication of viral reservoirs by conventional 
therapeutic strategies (Cummins, 2013). The panel of HCS hits recovered for the HIV-
specific toxicity hit class thus represent a potentially valuable therapeutic resource for 
combination therapy as these compounds have been demonstrated to specifically 





KEGG analysis revealed a significant (p<0.05) enrichment for Toll-like receptor, Hepatitis 
C, JAK/STAT and Influenza A-associated signalling pathways for compounds related to 
the mitigated toxicity phenotype (Figure 5.17). Enrichment of pathways associated with 
Influenza A and Hepatitis C suggest that the mitigated toxicity phenotype may be  
conserved between various human viruses, warranting further investigation. In addition 
STITCH analysis suggested that HIV is able to overcome apoptosis induced by the 
activation of TLRs and P53 and the inhibition and(or) posttranslational modification of 
STAT3, IL6, AKT and ESR. IL6 mediates anti-apoptotic activity through upregulation of 
MCL1 (Lin, 2001), and inhibition of STAT3 promotes apoptosis in various malignancies 
(Siddiquee, 2008). Furthermore, inhibition of TLR8 has been linked to enhanced 
apoptotic effects through negative regulation of the ERK1/2 and NF-kß signaling 
cascades (Tang, 2015). Given the strong relationship between these factors and HIV-
mediated regulation of apoptosis, these interactions may also play a role in HIV-induced 
apoptosis during the later stages of viral replication and represent therapeutically 
relevant targets specifically in long-lived viral reservoirs like macrophages.  
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Figure 5.17 STITCH analysis for compound hits associated with the mitigated toxicity 
phenotype 
RTK and cytoplasmic kinase-associated drug targets were noticeably omitted from this hit class, 
while inhibition of STAT3, IL6 and TLR signalling were identified as target points that HIV could 
overcome to promote cell survival, potentially through a P53-related process. Posttranslational 
modification (pink), activation (green arrowhead), inhibition (flat red arrowhead), catalysis 
(purple), binding (blue), effect on gene expression (yellow), interaction (grey). 
 
5.2.5 Potential role for EGFR during the early stages of viral 
replication  
 
Small molecule inhibitors of RTKs, including EGFR, and their associated cytoplasmic 
effector kinases featured prominently in the compound hits and enrichment analyses for 
the HIV-specific toxicity and pre-HIV exposure screen formats (Figure 5.13 and Figure 
5.15). Based on this, potential relationships between EGFR and HIV replication were 
thus explored.  
 
Microscopy revealed higher EGFR (ERBB1) expression levels in uninfected control 
treatments as compared to infected samples, with EGFR levels observed to be 
significantly diminished 24 hpi and even more so at the 48 hpi time point (Figure 5.18A). 
Conversely qPCR analysis revealed EGFR transcript levels to be non-significantly 
upregulated 24 hpi, with a significant (p<0.05) 2 fold upregulation noted at the 48 hpi 




time point (Figure 5.18B i). These observations suggest that EGFR protein and transcript 
levels are differentially modulated at distinct time points following HIV infection. 
Surprisingly, in contrast to immunofluorescence data, Western Blotting revealed a 
significant (p<0.05) upregulation of cytoplasmic EGFR 9hr (60%) and 24hr (200%) post-
infection (Figure 5.16B ii). In accordance with immunofluorescence data however, 
Western Blotting also confirmed a significant (p<0.05) downregulation of cytoplasmic 
EGFR 48 hpi (Figure 5.18B ii). Similar trends were recovered for EGFR levels detected 
from whole cell lysate (Appendix V, Figure A5.6 A), while only a degraded EGFR-
product was clearly detectable in the nuclear fractions from all experimental samples 
(Appendix V, Figure A5.6 B).  
 
A possible explanation for the discordance between ICC and Western Blot analyses at 
specific time points following infection is that antibody binding sites may have been 
occluded in the 24 hpi time point and were thus not accessible for detection by 
immunofluorescence. The dissociation steps associated with sample processing for 
Western Blot analysis would, in contrast, have exposed this binding site. In addition, the 
discordance between EGFR transcript and protein levels 48 hpi by HIV suggests either a 
translational block or rapid degradation of EGFR at this time point, but additional data is 
required to confirm this.  
 
 
Figure 5.18 Modulation of EGFR following HIV infection 
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A) EGFR-specific immunocytochemistry, EGFR expression and localisation i) in untreated 
GHOST(3) cells, ii) cells observed 24 hpi with HIV or iii) 48 hpi with HIV. Nuclei stained with 
Hoechst (blue), anti-EGFR (red), scale bars = 15µM. Frames represent independent FOVs B) 
Quantification of EGFR expression by i) qPCR analysis showing EGFR expression levels 24 hpi 
and 48 hpi relative to HPRT expression (n=3, *= p<0.05), and ii) Western Blot analysis showing 
relative EGFR expression 9, 24 and 48 hpi as compared to untreated control cells. ß-Actin was 
used a loading control, * = p<0.05.  
 
 
Upregulation of EGFR protein levels 9 hpi suggests that HIV entry and infection events 
preceding viral integration, which typically occur ~16 hpi, may  result in either 
stabilization or direct upregulation of EGFR. This effect appears to be potentiated 
following viral integration as EGFR levels increase further at 24 hpi. Notably, the 
discrepancy in EGFR detection levels between immunofluorescence and Western Blot 
datasets at 24 hpi also suggests that an EGFR binding interaction that is relevant to HIV 
replication may be at play during this early time point. This would be in accordance with 
previous findings that have reported the colocalization of viral particles and RTKs within 
late endosomal structures following Influenza A, HCV and hCVM infection (Grove, 2011; 
Meliopoulos, 2012). These observations thus suggest a potential role for EGFR during 
the early stages of HIV infection, up to and including 24 hpi.  
 
Strikingly, EGFR levels are significantly downregulated (as detected by both ICC and 
Western Blotting) at 48 hpi thus suggesting that EGFR activity may be dispensable 
during the later stages of infection that correspond with stable transactivation of the HIV 
LTR and subsequent GFP expression (Figure 5.16). These results are in strong 
agreement with STITCH analysis, which suggested that RTK-mediated signalling may 
play important roles in determining the outcome of successful HIV infection (Figure 5.13) 
and the propagation of a prosurvival cellular response during early stages of infection 
(Figure 5.15). This hypothesis is supported by data showing that HIV is able to both 
enhance the stability of EGFR and induce EGFR-mediated activation of pro-survival 
signalling pathways (Valiathan, 2004). Finally, a number of miRNAs that target factors 
associated with the EGFR signalling pathway were recovered as HIV-replication 
modulating hits during primary miRNA screens, thereby providing further evidence of a 
role for EGFR-mediated signalling during early stages of viral replication.   
 
5.2.6 Validation of anti-HIV compound phenotypes against X4 tropic 
viral variants 
 
An additional validation of the potential physiological relevance of phenotypes recovered 
by HCS was undertaken by evaluating the anti-HIV activity of a small subset of 
compound hits against an X4 tropic HIV variant. Six compound hits were validated 
against the X4-tropic variant, HIV Gag-iGFP. A simple validation approach was 
employed utilising the pre-HIV exposure experimental format only. GHOST(3) cells were 
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treated with either DMSO only (negative control), Raltegravir (positive control for 
suppressed replication) or specific compounds for 24 hours prior to HIV exposure at an 
MOI of 0.5.  
 
Raltegravir treatment significantly reduced syncytia formation, suppressed LTR-reporter 
activation, as well as virus-related GFP production as compared to the negative control 
phenotype (Figure 5.19 A & B). Treatment with a SRC-kinase inhibitor, Saracatinib, 
emulated the phenotypes recovered by HCS, resulting in minimal toxicity and 
suppressed HIV replication (Figure 5.19C). AT7519, which was recovered as an HIV-
specific toxicity hit by HCS, again revealed enhanced toxicity in response to HIV 
exposure, but also exhibited a strong HIV-suppressive phenotype akin to that of 
Raltegravir treatment in the surviving cell population (Figure 5.19D). Likewise A-674563, 
which exhibited HIV-specific toxicity in the pre-HIV exposure screen format and HIV-
suppressive activity in the post-HIV exposure screen format, also resulted in high levels 
of HIV-specific toxicity with the surviving cells seemingly protected against HIV infection 
(Figure 5.19E). GSK2126458 which was recovered as an HIV-suppressive hit in the 
post-HIV exposure screen format by HCS, revealed a strong HIV-specific toxicity 
response to  HIV Gag-iGFP exposure (Figure 5.19F).  
 
Intriguingly, both of the EGFR inhibitors, WZ4002 and Gefitinib, which exhibited HIV-
suppressive and HIV-specific toxicity phenotypes respectively in HCS, did not exhibit 
similar divergent phenotypes compared to negative controls in X4-tropic validation 
experiments (data not shown). This suggests that R5- and X4-tropic HIV variants may 
utilise/initiate discrete downstream signaling effectors that promote distinct vulnerabilities 
to therapeutic intervention, with EGFR activity likely being specifically required by R5-
tropic viruses. In addition this observation also suggests that the anti-HIV activities 
recovered for both WZ4002 and Gefitinib by HCS, may be related to viral entry.  
 
Overall, the observation that the majority of compounds tested against the X4 variant 
recapitulated the anti-HIV activity initially recovered by HCS, suggests that there are also 
a number of common vulnerabilities between R5 and X4 HIV variants. It is therefore 
likely that a greater number of compounds hits recovered by HCS may also exhibit pan-
antiviral activity against both X4 and R5-tropic variants of HIV, although this remains to 
be tested. Clearly, a more extensive validation of all compound hits recovered by HCS, 
may yield further information on discrete host-pathogen interactions and therapeutic 




Figure 5.19 Compound hit activity against an X4-tropic viral strain in GHOST(3) cells 
GHOST(3) phenotypes associated with 10 µM compound treatments prior to X4-tropic HIV 
exposure for 48 hours. A) DMSO-treated/HIV-infected controls, B) Raltegravir-treated/HIV-
infected controls, C) Saracatinib-treated/HIV-infected, D) AT7519-treated/HIV-infected, E) A-
674563-treated/HIV-infected, F) GSK2126458-treated/HIV-infected cells. Images represent 
overlays acquired from a single FOV at 40x, LTR-reporter (green), nuclei counterstained with 
Hoechst (red), scale bars = 20 µm. 
 
 
Closer inspection of the HIV-suppressive phenotypes recovered for Saracatinib (Figure 
5.20), A-674563 (Appendix V, Figure A5.7 A) and AT7519 (Figure A5.7 B) revealed the 
presence of punctate GFP spots either on the cell surface or within the cytoplasm of 
cells that did not exhibit activation of the LTR reporter or a syncytial phenotype (Figure 
5.20). These GFP ‘spots’ are indicative of the capsid-linked GFP molecules generated 
by HIV Gag-iGFP virions, and a similar phenotype was observed for the majority of cells 
that received Raltegravir treatment (Figure 5.20). Given that Raltegravir inhibits HIV 
integration  specifically, this implies that Saracatinib may also prevent HIV integration, or 
possibly even earlier stages of the HIV replication cell cycle following viral entry. The 
number of GFP spots recovered for cells treated with Saracatinib was noticeably 
attenuated in comparison to the number of spots acquired per cell for Raltegravir 
treatment (Figure 5.20). This implies that fewer virions were able to enter cells in the 
presence of Saracatinib and/or that virions which did enter the cell were inhibited prior to 
or at HIV integration (Figure 5.20). Together, this suggests a multiple inhibitory effect for 
Saracatinib at various stages during the HIV replication cycle. The HIV-specific toxicity 
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phenotypes recovered for A-674563 (Appendix V, Figure A5.7 A) and AT7519 (Appendix 
V, Figure A5.7 B) also suggest that these phenotypes are similarly related to either viral 
entry or integration. Further kinetic and temporally-focused validation experiments are 




Figure 5.20 Enlarged images from HIV-tropism validation experiments 
Upper) 10 µM Saracatinib-treated/HIV-infected cells. Lower) 10 µM Raltegravir-treated/HIV-
infected cells. White arrows indicate examples of cells where HIV capsid/virions are present in 
either the cytoplasm on at the surface of cells that are not stably infected with HIV. Pink arrows 
indicate examples of stably infected cells. Images represent overlays acquired from a single FOV 
at 40x, non-integrated virus (punctate green spots)/ integrated HIV (diffuse green), nuclei 





The principle aim of the compound screens conducted here was to determine whether 
functional inhibition of certain molecular targets recovered by primary miRNA screening 
could be recapitulated by a targeted panel of small molecules. Indeed, compound-based 
screening  revealed a high level of concordance with many of the functional pathways 
and specific targets initially recovered by the primary miRNA screen. This observation 
bolsters confidence in the HIV-host interactions proposed by miRNA pathway analysis, 
and posits miRNA-advised secondary compound screening as a robust validation 
strategy.   
 
In addition, a combined overview of miRNA and small molecule-based HCS data 
suggests a convergence on RTK-mediated signalling, and its direct downstream 
effectors, as a central vulnerability during early HIV replication which could be exploited 
for therapeutic gain. Intriguingly, this could occur either via inhibition of HIV replication or 
by priming host cells such that they undergo apoptosis following exposure to HIV. The 
use of multiple screening formats also highlighted a clear distinction between phenotypic 
outcomes as a function of the timing of compound addition (either before or after stable 
HIV infection). Furthermore, distinct and prioritised therapeutic targets could be identified 
for each case, which may not have been possible if one format had been used 





Figure 5.21 Prioritised host targets for treatment of HIV infection  
Targets recovered for experimental formats where A) host cells were treated with relevant 
compounds prior to HIV exposure, or B) stably infected populations of host cells were treated with 
relevant compounds. 
 
A strong concordance between previously described phenotypes related to HIV 
replication was also noted for a number of compounds (e.g. Flavopiridol, Dactinomycin). 
However, the majority of compound-related phenotypes characterised here represent 
the first description of their potential anti-HIV properties. This body of work therefore 
represents a significant contribution to potential anti-HIV therapies directed against 
endogenous, i.e. host targets. Furthermore, as a large number of the compounds 
recovered here have either already obtained FDA-approval or are currently under clinical 
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Overlapping functional targets and phenotypic outputs related to specific miRNAs and 
small molecules also represent a potentially valuable resource, as such 
miRNA/compound combinations could complement current therapeutic regimens. For  
example, Tarbase v7.0 identified hsa-miR-491-5p as the highest scored experimentally 
validated miRNA regulator of SRC-kinase and a miR-491-5p mimic was identified as an 
HIV hit suppressive by HCS. In addition miR-491-5p mediated suppression of SRC 
kinase in a bone marrow-derived cell line similar to that of the GHOST(3) parental cell 
line (Balakrishnan, 2014). Together, these findings strongly support the anti-HIV activity 
of miR-491-5p via regulation of SRC kinase in GHOST(3) cells.  
 
A number of other compounds, including Ponatinib and Saracatinib, that also suppress 
SRC kinase activity showed similar HIV-suppressive phenotypes. Perhaps then, miR-
491-5p is able to augment or mimic the function of these FDA-approved drugs. Indeed, 
analogous relationships were identified for several miRNA mimics and compounds that 
both suppressed HIV replication. SNS-032 and miR-192-5p suppress CDK1 protein 
levels (Hafner, 2010), while miR 193-3 targets CDK1, CDK7 and CCND1 (Chen, 2010; 
Helwak, 2013, Balakrishnan, 2014) as do Flavopiridol and SNS-032. In addition, miR-
138-5p and miR-124 suppress CCND1 (Karginov, 2013) and CDK2 (Nakamachi, 2009) 
respectively, and these proteins are also targeted by A-674563 and SNS-032. The 
miRNA to targeted compound HCS approach presented in this study therefore 
represents a valuable strategy to identify alternative/complementary miRNA-based 
therapies with the same functional effect as commercially available drugs. 
 
It should also be noted that the poor concordance between compound effects observed 
for 10 µM screens and treatments at lower concentrations was in accordance with data 
from the Broad Institute’s Cancer Cell Line Encyclopedia (CCLE) database (Barretina, 
2012). The average IC50 for pharmaceutical agents in GHOST(3) parental cells, HOS, 
was ~8 µM (Barretina, 2012), implying that concentrations > 8µM may be required to 
induce observable functional effects within populations of cultured GHOST(3) cells. This 
hypothesis is supported by the HCS data presented in this study, which revealed that 
only a single compound, Dactinomycin, was able to induce concordant anti-HIV 
phenotypes at both 10 µM and 1 µM concentrations (Figure 5.10). The majority of drug-
induced toxicity effects in the Drug Only screen format were also observed to be 
significantly diminished, or absent at the lower concentrations screened (Figure 5.6). 
Intriguingly, Etoposide (which was included in the Oncology compound library set) did 
not induce a toxic phenotype in response to pre-treatment with HIV as observed in the 
experimental work described in the previous chapter. Given the poor long-term stability 
of many compounds, even at -20˚C, it is plausible that this aliquot of Etoposide was no 
longer efficacious.   
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Similarly to the miRNA screens, functional readouts from the compounds screens 
presented in this study were limited to the identification of compounds that could impact 
HIV replication up to the point of LTR transactivation. However, the novel multi-format 
screening approach utilised here, significantly expanded the use of the GHOST(3) assay 
system and was extremely useful in the discrimination of specific compound-induced 
effects that may have been missed by traditional single format screens. The application 
of such a ‘three-pronged’ screening approach may thus prove equally useful in various 
other models of pathogenic infection.  
 
In conclusion, the compound-based screens described within this chapter effectively 
validated many of the HIV-host interactions identified by miRNA screening, and also 
demonstrated the significant utility of the established HCS pipeline for screening small 
molecules and compounds. The data generated by these screens have contributed a 
significant amount of new knowledge to HIV-host interactions and have revealed novel 
HIV-associated functionality for many FDA-approved therapies, which could be readily 
repurposed for the treatment of HIV. Finally, the novel multi-format screening approach 
and retrospective comparison of miRNA and compound phenotypes to identify miRNA-
based alternative therapies, represent potentially valuable approaches for future drug 
























Chapter 6: Concluding Remarks 
 
Two decades since its discovery, HIV remains a disease for which there is neither a cure 
nor vaccine. The estimated cost associated with lifetime HIV treatment for a single 
patient  is ~560 000 US dollars (Nakagawa, 2015), and this is a limiting factor to 
treatment accessibility in many developing regions hardest hit by the HIV/AIDS 
pandemic, including South Africa (UNAIDS, 2014). In addition, a number of drug-
resistant variants of HIV have been identified (Wittkop, 2011) thereby necessitating the 
development of novel HIV therapies which are not only more cost-effective but also 
provide a stronger barrier against viral escape by simple mutagenesis. Host-directed 
therapy thus represents an attractive research avenue for the discovery of novel 
therapeutic strategies against HIV, but this approach also requires comprehensive 
knowledge of HIV-host interactions in order to identify suitable therapeutic targets. The 
combination of high throughput screening and RNAi interference technologies have 
emerged as powerful  tools to delineate complex biological systems, including host-
pathogen interactions (Lemons, 2013). Functional genomics screens specifically, have 
previously led to the identification of over 1000 host genes as novel host dependency 
factors (HDFs) that were required for successful HIV replication (Brass, 2008; Konig, 
2008; Zhou, 2008). In comparison, the roles of the noncoding component of the human 
genome, including the host miRNAome, in modulation of HIV replication has remained 
comparatively poorly characterized (Barichievy, 2015).  
 
The principal aims of this study were to establish, optimise and then utilise a high 
content phenotypic screening (HCS) workflow in order to characterise host miRNAs that 
were functionally relevant to HIV replication. To this end, a cell-based assay was 
optimised and validated for high throughput processing and bespoke image analysis and 
data mining pipelines were developed to facilitate efficient quantification of HIV 
replication from image-based datasets (Chapter 3). A panel of 1239 miRNA mimics and 
1245 miRNA inhibitors were screened in duplicate in order to identify host miRNAs that 
could either significantly enhance or suppress HIV replication (see Chapter 4). A total of 
7 560 individual experimental reactions yielded ~ 60 000 images, which following image 
analysis and data mining recovered 84 host miRNAs that were functionally relevant to 
HIV replication. Specifically, 53 mimics suppressed HIV replication and 28 miRNA 
mimics significantly enhanced HIV replication. In addition, 4 miRNA inhibitors also 
exhibited anti-HIV activity. These findings represent the largest single contribution to 
current knowledge on host miRNAs that functionally modulate HIV replication 
(Barichievy, 2015), and have expanded the number of host miRNAs demonstrated to 
functionally modulate HIV replication by well over two-fold.  
 
miRNA-based therapeutics have recently gained a lot of momentum, and ongoing 
clinical evaluations of the first-in-class miRNA mimic-based therapy, MRX34 (Bouchie, 
2013) and the first miRNA inhibitor-based therapy, Miravirsen (Janssen, 2013), suggest 
that these modalities may become increasingly relevant as new technologies enabling 
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their targeted delivery continue to evolve. The HIV-suppressive miRNA mimics 
recovered by HCS may therefore represent valuable therapeutic agents that could 
potentially either complement or replace current ARV therapies. Similarly, the miRNAs 
associated with enhanced viral replication phenotypes may prove useful in the activation 
of latent reservoirs of HIV. Additionally HIV-replication enhancing agents may prove 
valuable in improving viral protein yields for cell culture-based vaccine production and 
other commercial research applications.   
 
An in silico approach to miRNA target validation and  pathway analysis recovered a 
number of host pathways and processes previously associated with HIV replication 
(Chapter 4), but for which potential miRNA-mediated regulators were previously 
unknown. The outcomes of this study have thus, for the first time, provided specific 
panels of hosts miRNAs related to these host pathways with demonstrated HIV 
replication-modulating capabilities. Notably, these miRNAs have experimentally 
validated targets enriched within functional pathways previously associated with HIV 
replication including the  MAPK, PI3K, TNF, cell cycle, P53 and DNA damage repair 
pathways to name a few. Pathway analysis also recovered novel HIV relevance for host 
pathways such as the Hippo signaling pathway, where the Hippo central kinase cascade 
and its downstream transcriptional effectors YAP/TAZ were implicated in miRNA-
mediated modulation of HIV replication. Subsequent validation experiments also 
revealed novel HIV-related functional relevance for the long noncoding transcriptional 
target of P53, lincRNA-p21. Specifically, lincp21 was posited as a potential host factor 
associated with miRNA-mediated suppression of HIV replication, and the outcome of cell 
survival in response to DNA damage.  
 
Furthermore, pathway analysis suggested a central convergence in processes 
associated with the evasion of apoptosis, regulation of cellular replication and 
modulation of host DNA repair factors. These molecular processes are typically 
associated with carcinogenesis and subsequent validation experiments demonstrated 
deregulated P53 transcriptional activity and aberrant cell survival in response to 
Etoposide-induced DNA damage in stably infected cells. This was in accordance with 
previous descriptions of oncogenic effects associated with HIV infection in various 
cellular models including primary macrophages (reviewed by Cummins, 2013). The 
concept of HIV preventing apoptosis in infected cells may at first seem counterintuitive 
given that HIV pathogenesis is known to result in the death/depletion of host T cell 
populations (Doitsh, 2014). This apoptotic effect has been further demonstrated to occur 
in both productively infected cells, through caspase-3 activation (Garg, 2006), and in 
abortive infections through caspase-1 activation and pyroptosis (Doitsh, 2014). However, 
during the early stages of viral infection (0-48 hpi) preceding virion release and 
apoptosis, HIV requires host cells to survive in order to produce sufficient amounts of 
virions and viral proteins. Many of these viral proteins, such Vpr, may induce genotoxic 
responses (e.g. DSBs) within infected host cells, especially at high concentrations 
(Andersen, 2006). HIV would therefore need to actively mitigate innate apoptotic 
responses induced by HIV replication events in order to prevent premature termination 
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of viral replication as a result of host cell death. This theory is supported by data showing 
viral subversion of key host factors associated with the apoptotic response, such as Nef-
induced destabilization of P53 (Greenway, 2002).  
 
Current knowledge thus suggests that HIV infection may induce a transient protective 
phenotype within infected T cells until sufficient levels of viral proteins are produced 
where increasing levels of genotoxic stress eventually overwhelm or release HIV-
mediated subversion of apoptosis. A similar replicative strategy has also been noted for 
other intracellular pathogens including Brucella abortus, which promotes apoptosis in 
human macrophages, but only after sufficient periods of bacterial replication (Cha, 
2013). Furthermore longer-term aberrant cell survival phenotypes have been described 
for HIV-infected primary macrophages and monocyte populations in response to DNA 
damage-induced apoptosis, suggesting that this cancer-like survival phenotype is highly 
conserved for HIV infection but may vary in duration in a cell-type specific manner 
(Cummins, 2013).   
 
Strikingly however, validation experiments also revealed a potential vulnerability in the 
HIV replicative cycle which was related to the differential cell survival phenotypes 
recovered for Etoposide treatments. Specifically, while stably infected cells were 
resistant to Etoposide-induced apoptosis, the priming of host cells with Etoposide prior to 
or during HIV exposure resulted in broad cytotoxic effects that were specific to HIV 
treatments. The HIV infective state of a host cell was thus identified as a major 
determinant of cell survival in response to DNA damage and this suggested that HIV 
may exhibit temporally distinct phenotypic responses to host-directed therapeutic 
intervention. These findings posited the priming approach as a potentially effective 
strategy to counteract de novo HIV infection.  
 
A secondary compound-based screening approach was selected to validate the pathway 
associations recovered by miRNA-based HCS and to further explore the divergent cell 
survival phenotypes associated with HIV exposure either prior to or following 
establishment of stable HIV infection. The newly established HCS workflow was adapted 
for compound screening (Chapter 3) and a novel multi-format screening and 
comparative analytical approach was utilised to screen 392 small molecules directed to 
the functional targets recovered by miRNA-based HCS (Chapter 5). Compounds 
generated anti-HIV phenotypes including those that induced apoptosis specifically in 
response to HIV infection/exposure and those that could suppress HIV replication in 
stably infected cells or prime host cells to resist HIV replication. Compound-based HCS 
recovered a total of 41 compounds that exhibited anti-HIV activity at a hit rate of ~10%, 
which would ordinarily be considered extremely high but in this case served as a 
validation of the utility of miRNA-based screening in advising targeted drug discovery. 
Interestingly, HIV was also observed to effectively attenuate the apoptotic activity of a 
specific subset of compounds, but only when compound treatments were administered 
to cell populations with an established HIV infection. In addition, a number of compounds 
were also found to prime uninfected host cells towards apoptosis specifically in response 
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to HIV exposure. These findings confirmed the phenotypes recovered for Etoposide-
based validation experiments presented in Chapter 4, and recovered a number of novel 
functional targets which may be exploited to limit the spread of de novo HIV infection.    
 
Drug-target interaction and enrichment analyses revealed a strong concordance 
between the anti-HIV phenotypes recovered by compound screening and functional 
targets recovered by miRNA-based HCS (Figure 6.1). Notably tyrosine kinase receptor-
mediated signalling and its associated downstream effectors emerged as a central 
functional target for the modulation of HIV replication and HIV-associated cell survival by 
targeted pharmacological inhibition. Specific clusters of functional targets were also 
prioritized for the priming of HIV-naive cells to apoptosis in response to HIV exposure, 
suppression of HIV replication in stably infected cells and suppression of HIV replication 
or infection in HIV-naive cell populations primed with specific compounds. Given that the 
majority of compounds described to exhibit anti-HIV activity by this study are either 
under clinical investigation, or have already been granted FDA-approval, this positions 
these compounds as ideal candidates to be repurposed as anti-HIV therapies. 
Furthermore, convergent functional targets and phenotypic effects on HIV replication 
described for specific compounds and miRNAs suggests that these miRNAs could either 
be complementary therapies utilized to lower functional drug concentrations, or 
replacement therapies with similar functional properties as commercially available drugs. 
Further investigation is required to confirm that the HIV-associated phenotypes 




Figure 6.1 Concordance between miRNA and compound based HCS 
Example of concordance between miRNA and compounds based HCS where functional targets 
that exhibited anti-HIV activity in the form of suppressed viral replication or HIV-specific toxicity 
are presented, double strand breaks (DSB). 
 
In summation, this study has established a robust HCS workflow, which has been 
demonstrated to be suitable for both RNAi and compound-based phenotypic screening. 
Additionally, the outcomes of the miRNA screens presented here represent a significant 
novel contribution to current knowledge on HIV-host miRNA interactions, and have 
uncovered novel putative HIV-based therapeutic applications for a large panel of host 
miRNAs. Furthermore  a cancer-like molecular phenotype was characterized in HIV-
infected cells populations, which may be therapeutically relevant and exploitable during 
the early stages of HIV infection. The multiformat compound screening approach was 
also able to identify novel anti-HIV activity for a number of therapeutically-relevant 
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exploited for the treatment and(or) prevention of HIV replication. Comparative analysis 
between miRNA and compounds screens revealed a number of miRNAs that may 
potentially be utilised as alternative or complementary therapies to specific commercially 
active drugs. The findings of this study may thus contribute to the development of future 
therapies against HIV, and represents a substantial contribution towards current 



































Figure A2.1 Example of RNA quality evaluation by electrophoresis 
RNA isolated from GHOST(3) cells and evaluated prior to utilisation in cDNA synthesis. 
Acceptable RNA quality as is indicated by intact 28S and 18S bands. 1) RNA ladder, 2) 
GHOST(3) cells only, 3) GHOST(3) cells 24 hpi, 4) GHOST(3) cells 48 hpi, 5) GHOST(3) cells- 
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Table A2.1 List of compounds in Oncology FDA-approved compound library 
Methotrexate Daunorubicin hydrochloride Vorinostat 
Busulfan Streptozocin Estramustine phosphate 
sodium 
Thioguanine Arsenic trioxide Capecitabine 
Mercaptopurine Azacitidine Exemestane 
Mechlorethamine hydrochloride Cladribine Gefitinib 
Allopurinol Ifosfamide Erlotinib hydrochloride 
Dactinomycin Cisplatin Fulvestrant 
Chlorambucil Tretinoin Arimidex 
Thiotepa Teniposide Letrozole 
Melphalan Doxorubicin hydrochloride Celecoxib 
Triethylenemelamine Bleomycin sulfate Zoledronic acid 
Altretamine Paclitaxel Dasatinib 
Quinacrine hydrochloride Decitabine Everolimus 
Aminolevulinic acid hydrochloride bendamustine hydrochloride Pazopanib HCl 
Fluorouracil Etoposide Imatinib mesylate 
Plicamycin Dexrazoxane Lapatinib ditosylate 
Pipobroman Tamoxifen citrate Nilotinib 
Cyclophosphamide Pentostatin Sorafenib tosylate 
Mitomycin Sirolimus Lenalidomide 
Floxuridine Carboplatin Ixabepilone 
Hydroxyurea Valrubicin Raloxifene hydrochloride 
Uracil mustard Oxaliplatin Abiraterone 
Mitotane Mitoxantrone Sunitinib (free base) 
Dacarbazine Amifostine Depsipeptide 
Methoxsalen Fludarabine phosphate pralatrexate 
Vinblastine sulfate Temozolomide Vismodegib 
Cytarabine hydrochloride Imiquimod PF-2341066 
Thalidomide Carmustine AG-013736 
Vincristine sulfate Clofarabine Carfilzomib 
Megestrol acetate Vinorelbine tartrate Vandetanib 
Procarbazine hydrochloride Topotecan hydrochloride Vemurafenib 
Lomustine Gemcitabine hydrochloride Cabazitaxel 
Nelarabine Irinotecan hydrochloride Bortezomib 








Table A2.2  List of compounds in Kinase Inhibitor compound library* 
BMS-599626 (AC480) SNS-032 (BMS-387032) WYE-125132 
Erlotinib HCl AZD7762 SB 431542 
Gefitinib (Iressa) Aurora A Inhibitor I Linifanib (ABT-869) 
Neratinib (HKI-272) Barasertib (AZD1152-HQPA) AEE788 (NVP-AEE788) 
PD153035 HCl CCT129202 Afatinib (BIBW2992) 
Pelitinib (EKB-569) ENMD-2076 Lapatinib Ditosylate (Tykerb) 
Vandetanib (Zactima) MLN8237 (Alisertib) JNJ-7706621 
WZ3146 Telatinib (BAY 57-9352) WYE-687 
WZ4002 PHA-680632 BEZ235 (NVP-BEZ235) 
WZ8040 SNS-314 GSK1059615 
Axitinib VX-680 (MK-0457, Tozasertib) AG-490 
BIBF1120 (Vargatef) ZM-447439 Tofacitinib citrate (CP-690550 
citrate) 
BMS 794833 AS703026 Crenolanib (CP-868596) 
NVP-BHG712 AZD6244 (Selumetinib) GSK1838705A 
Cediranib (AZD2171) AZD8330 KX2-391 
OSI-420 (Desmethyl Erlotinib) BIX 02188 NVP-BSK805 
CYC116 BMS 777607 PCI-32765 (Ibrutinib) 
R935788 (Fostamatinib disodium, 
R788) 
CI-1040 (PD184352) PF-00562271 
Imatinib (Gleevec) PD318088 DCC-2036 (Rebastinib) 
Imatinib Mesylate PD0325901 LDN193189 
KRN 633 PD98059 Flavopiridol hydrochloride 
Masitinib (AB1010) U0126-EtOH (UO126 EtOH)  AS-604850 
MGCD-265 LY2228820 WAY-600 
Motesanib Diphosphate BIRB 796 (Doramapimod) TG101209 
Amuvatinib (MP-470) SB 202190 GDC-0980 (RG7422) 
OSI-930 SB 203580 A-769662 
Pazopanib HCl VX-702 TAK-901 
Sorafenib (Nexavar) VX-745 AMG 900 
Sunitinib Malate (Sutent) GDC-0879 ZM 336372 
TSU-68 CX-4945 PH-797804 
Foretinib (GSK1363089, XL880) PLX-4720 AZD8931 
Danusertib (PHA-739358) RAF265 (CHIR-265) Tivozanib (AV-951) 
AT9283 SP600125 Ki8751 
Saracatinib (AZD0530) Phenformin hydrochloride Vatalanib dihydrochloride 
(PTK787) 
Bosutinib (SKI-606) AS-605240 Ponatinib (AP24534) 
Dasatinib (BMS-354825) GDC-0941 SU11274 
Nilotinib (AMN-107) LY294002 Flavopiridol (Alvocidib) 
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Quercetin (Sophoretin) PIK-293 Hesperadin 
NVP-ADW742 PIK-90 Raf265 derivative 
Quizartinib (AC220) PIK-93 AZ 960 
Tandutinib (MLN518) TG100-115 Mubritinib (TAK 165) 
KW 2449 TGX-221 PP242 
CI-1033 (Canertinib) XL147 Apatinib (YN968D1) 
CP-724714 XL765 CAL-101 (GS-1101) 
Regorafenib (BAY 73-4506) ZSTK474 PIK-294 
JNJ-38877605 AZD8055 BI6727 (Volasertib) 
PF-04217903 Everolimus (RAD001) BIX 02189 
Crizotinib (PF-02341066) Ku-0063794 BKM120 (NVP-BKM120) 
Cyt387 Rapamycin (Sirolimus) IC-87114 
SGX-523 Temsirolimus (Torisel) Deforolimus (Ridaforolimus) 
TAE684 (NVP-TAE684) WYE-354 KU-55933 
SB 525334 PP-121 GSK2126458 
R406 PIK-75 PI-103 
R406(free base) CHIR-99021 (CT99021) GSK1120212 (Trametinib) 
XL-184 free base (Cabozantinib) Indirubin WP1130 
BI 2536 SB 216763 TAK-733 
GSK461364 KU-60019 AZD5438 
HMN-214 MK-2206 dihydrochloride OSI-027 
ON-01910 LY2603618 (IC-83) NU7441(KU-57788) 
AT7519 AT7867 A-674563 
BS-181 HCl PF-05212384 (PKI-587) AS-252424 
PD 0332991 HCl AZD1480 PF-04691502 
PHA-793887 CCT128930  
Roscovitine (Seliciclib, CYC202) LY2784544  
Enzastaurin (LY317615) A66  




A3.1 miRNA library reconstitution 
 
Briefly, all 96 well master plates containing lyophilized pellets were centrifuged at 500 x 
g for 5 minutes at 4 °C in a Microfuge 22R refrigerated benchtop microcentrifuge 
(Beckman Coulter Incorporated, USA) before use. 250 µL of 1x Dharmacon™ siRNA 
buffer (GE Healthcare, USA) was dispensed per well into all wells of a master plate, 
excluding columns 1 and 12 . The contents of each well were mixed by repeat pipetting 
(100 µL volume three times) and the plates were then sealed with Rotilabo® AllumaSeal 
II™ sterile adhesive seals (Carl Roth GmbH + Co. KG, Germany), and placed on a 
Stuart® SSM5 microtitre plate shaker (medium setting) for 30 minutes at room 
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temperature (Bibby Scientific Limited, UK). The master plate was re-centrifuged at  500 x 
g for 5 minutes at 4 °C, the seal was removed and the contents of each well were mixed 
by repeat pipetting (50  µL volume three times). A volume of 50 µL was then aspirated 
from each well and 15 µL of each reagent was dispensed into corresponding wells in 
each of 3 pre-labelled daughter plates. The daughter plates and the master plate were 
then sealed with Rotilabo® AllumaSeal II™ sterile adhesive seals (Carl Roth GmbH + 
Co. KG, Germany) and placed into storage at - 20 ˚C. Plates and individual wells had to 
be sealed in order to prevent reagent loss and cross-contamination during long term 
storage. Rotilabo® AllumaSeal II™ sterile adhesive seals (Carl Roth GmbH + Co. KG, 
Germany) seals were specifically selected for plate storage due to their increased 
stability at low temperatures thus facilitating library storage at -80 ˚C and transport on 
dry ice should this be required at any stage. Likewise, Corning® 96 Well Clear V-Bottom 
Polypropylene microplates (Corning®, UK) were selected as the daughter plate type due 
to their increased stability at -80 ˚C as compared to standard polystyrene microplates. 
miRNA master and daughter plates were stored in dedicated non-cycling freezers at -20 
˚C. Reconstitution and daughtering of the entire miRIDIAN library was staggered and 
completed over the course of a week. Master and daughter plates were always 
centrifuged at ~500 x g for 5 minutes at 4 °C prior to use. 
 
 
A3.2 Compound libraries 
 
As with the miRNA library, all master and daughter plates removed from storage were 
always briefly centrifuged at ~500 x g for 5 minutes at 4 °C prior to use. All compound 
library dilution, re-formatting and daughtering steps were completed by hand using 
Lambda™ Plus 12 channel micropipettes (Corning®, UK) in a BSL-2 biosafety cabinet. 
 
A3.3 Cell seeding protocol  
 
Cell seeding was the first experimental step in the screening workflow of both miRNA 
and compound screens. The process of seeding a relatively constant volume and 
density of cells across multiple 96 well experimental plates was achieved by first 
detaching GHOST(3) cells from their culture vessels and resuspending them in a low 
volume of culture media. The number of cells present was calculated using a TC10™  
automated cell counter (Bio-Rad, USA), to ensure consistency of cell counting across 
multiple seeding events and to reduce the time spent on this step. The required cell 
dilution was generated in an appropriate volume in a sterile Pierce® reagent reservoir 
(Thermo Fisher Scientific, USA), and dispensed across experimental plates using a 
multichannel micropipette. The reagent reservoir was agitated by hand and the solution 
was always repeat pipetted before each aspiration step.  
 
When a multiwell plate (room temperature) is placed into an incubator, a transient 
temperature gradient is created from outside of the plate to the inner wells as the plate 
reaches 37 ˚C. This temperature gradient can result in differential cell attachment 
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patterns across the wells of a multiwell plate which can in turn distort downstream 
experimental readouts (Lundholt, 2003). All experimental screen plates were therefore 
incubated at room temperature for ~ 20 mins prior to being placed in a cell culture 
incubator. This allowed cells to settle evenly across all experimental wells thus mitigating 
the potential effects of resulting temperature gradients on cellular densities. GHOST(3) 
cells were seeded at a constant density of 5000 cells/well for miRNA screens and 6000 
cells/well for compound screens. Specific seeding volumes were selected for both 
miRNA and compound screens in order to minimise downstream liquid handling steps. 
For example, by seeding GHOST(3) cells in 80 µL of culture media for the miRNA 
screens, the volume of media in each well did not need to be adjusted prior to the 
transfection step. In addition to reducing the required treatment time this design principle 
also reduced the overall cost of the screen by reducing the number of filtered 
micropipette tips required. During large-scale screens, omission a single pipetting step 
from a workflow process can have a huge impact on the requirement of consumables 
and can therefore also affect the total cost of the screen. This design principle was 
applied to all screening-related experimental steps where possible.  
 
 
A3.4 HCS GHOST(3)-PSG3BAL infection protocol 
 
PSG3BAL viral stocks were diluted in infection media and then dispensed into a sterile 
reagent reservoir. Culture media was removed from each well on an experimental plate 
using a multichannel micropipette. 50 µL of HIV-naive infection media was added to 
each uninfected control well using a single channel micropipette. 50 µL of diluted 
PSG3BAL solution was dispensed into all infected control wells and all experimental wells 
using a multichannel micropipette. The reagent reservoir was agitated by hand before 
each dispensing step. Infection reactions utilized in both miRNA and compound screens 
were executed in final reaction volumes of 50 µL, in order to increase the probability of 
virion to cell contact events. GHOST(3) cells were exposed to PSG3BAL at an MOI of 0.5 
for both miRNA and compound screens and cell cultures were always exposed for 48 
hours before the infectious media was removed. 
 
A3.5 HCS liquid handling practices  
 
All liquid transfer steps following cell seeding were carefully executed so as not to 
disturb adherent cells at the bottom of each experimental well (Figure A3.1) by following 





Figure A3.1 Aspiration and dispensing techniques utilized in HCS workflow.  
A) Solutions were aspirated from wells by angling the experimental plate and positioning 
micropipette tips at the bottom each well. B) Solutions were dispensed into experimental wells by 
angling the experimental plate and placing the micropipette tip against the wall of the well.  
 
 
A3.6 GHOST(3) infection assay validation 
 
GHOST(3) infection time course in order to determine suitable infection time point for HCS assay. 
48hpi was observed to be the shortest time course that produced significant reporter activation 
following infection.  
 
 
Figure A3.2 GHOST(3) reporter signal relative to infection time course  
GFP-reporter signal readout in uninfected cells (cells only), 24hr post infection, 48hr post infection 
and 72hr postinfection. Cells infected at MOI of 0.5 with PSG3BAL. GFP-reporter signal (green), 





















Figure A4.1 Visual profiles of HIV-suppressive hits identified by PCA-STP hit selection.  
Hits that did not exhibit desirable phenotypes following visual inspection were excluded from 
further analysis (pink miRNA name and rank). Images represent unprocessed composite images 
acquired in the 405 and 488 channels. GFP-reporter signal (green), nuclei stained with Hoechst 
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Table A4.3 Pathways enriched for suppressed HIV replication 
Pathway Number of genes Number of miRNAs 
Proteoglycans in cancer 138 48 
Pathways in cancer 252 48 
Focal adhesion 138 48 
HTLV-I infection 163 47 
Regulation of actin cytoskeleton 127 47 
MAPK signaling pathway 150 47 
Hippo signaling pathway 112 46 
Viral carcinogenesis 132 46 
Epstein-Barr virus infection 128 46 
Protein processing in endoplasmic 
reticulum 
109 45 
Insulin signaling pathway 90 45 
Transcriptional misregulation in cancer 107 45 
cGMP-PKG signaling pathway 104 44 
Signaling pathways regulating 
pluripotency of stem cells 
87 44 
FoxO signaling pathway 88 43 
Adherens junction 56 42 
Neurotrophin signaling pathway 82 42 
Wnt signaling pathway 90 42 
Sphingolipid signaling pathway 74 42 
Estrogen signaling pathway 73 41 
Thyroid hormone signaling pathway 78 41 
Cell cycle 86 40 
TNF signaling pathway 76 40 
Axon guidance 81 40 
ErbB signaling pathway 62 40 
Oocyte meiosis 74 40 
Choline metabolism in cancer 66 40 
TGF-beta signaling pathway 52 39 
Chronic myeloid leukemia 56 38 
Prostate cancer 67 38 
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Bacterial invasion of epithelial cells 57 38 
Hepatitis B 94 38 
Glioma 44 38 
Fc gamma R-mediated phagocytosis 59 38 
ECM-receptor interaction 55 37 
Renal cell carcinoma 48 37 
Pancreatic cancer 54 35 
Melanoma 49 35 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
42 35 
p53 signaling pathway 45 35 




Small cell lung cancer 60 34 
Shigellosis 46 34 
Colorectal cancer 50 33 
mTOR signaling pathway 48 33 
Endometrial cancer 42 33 
Central carbon metabolism in cancer 42 33 
Acute myeloid leukemia 44 32 
Bladder cancer 32 31 




Thyroid hormone synthesis 44 29 
Sphingolipid metabolism 30 29 
N-Glycan biosynthesis 32 27 
Thyroid cancer 22 24 
Prion diseases 15 22 
Fatty acid metabolism 29 22 
Fatty acid elongation 15 15 
Homologous recombination 21 15 
Glycosaminoglycan biosynthesis - 
chondroitin sulfate / dermatan sulfate 
15 12 








Table A4.4  Pathways enriched for enhanced HIV replication 
KEGG pathway #genes #miRNAs 
PI3K-Akt signaling pathway 124 26 
Proteoglycans in cancer 96 24 
Focal adhesion 96 24 
Regulation of actin 
cytoskeleton 
88 24 
Pathways in cancer 149 24 
Viral carcinogenesis 89 23 
Protein processing in 
endoplasmic reticulum 
76 23 
Hippo signaling pathway 63 22 
Oocyte meiosis 56 22 
Cell cycle 66 22 
Hepatitis B 64 22 
Thyroid hormone signaling 
pathway 
54 22 
Endocytosis 83 22 
Transcriptional misregulation in 
cancer 
70 22 
Adherens junction 41 21 
Central carbon metabolism in 
cancer 
31 21 
mRNA surveillance pathway 42 21 
Signaling pathways regulating 
pluripotency of stem cells 
55 21 
Salmonella infection 37 21 
Small cell lung cancer 37 21 
Prostate cancer 45 20 
ErbB signaling pathway 40 20 
Colorectal cancer 32 20 
FoxO signaling pathway 53 20 
HIF-1 signaling pathway 47 20 
Neurotrophin signaling pathway 51 20 
TGF-beta signaling pathway 36 19 
Chronic myeloid leukemia 41 19 
Renal cell carcinoma 33 19 
p53 signaling pathway 31 19 
Insulin signaling pathway 59 19 
Wnt signaling pathway 57 19 
Pancreatic cancer 36 18 
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Spliceosome 57 18 
Melanoma 32 18 
Epstein-Barr virus infection 82 18 
Glioma 33 17 
Bacterial invasion of epithelial 
cells 
35 17 
Shigellosis 32 17 
Lysine degradation 22 16 
Endometrial cancer 24 16 
ECM-receptor interaction 33 14 
Bladder cancer 21 14 
Alanine, aspartate and 
glutamate metabolism 
17 13 





biosynthesis - keratan sulfate 
7 7 
Fatty acid biosynthesis 2 3 
 
 
Table A4.5 HIV-suppressive miRNA hits associated with viral carcinogenesis*   
hsa-miR-1185-5p  hsa-miR-3200-3p  hsa-miR-520d-5p  
hsa-miR-1231  hsa-miR-342-5p  hsa-miR-624-3p  
hsa-miR-124-3p  hsa-miR-34a-3p  hsa-miR-650  
hsa-miR-1269a  hsa-miR-3605-5p  hsa-miR-654-5p  
hsa-miR-127-5p  hsa-miR-3616-3p  hsa-miR-671-3p  
hsa-miR-1270  hsa-miR-3616-5p  hsa-miR-889-3p  
hsa-miR-1273e  hsa-miR-3622a-5p  hsa-miR-892b  
hsa-miR-1306-3p  hsa-miR-3691-5p  hsa-miR-940  
hsa-miR-135b-3p  hsa-miR-3918   
hsa-miR-138-5p  hsa-miR-4256   
hsa-miR-192-5p  hsa-miR-4270   
hsa-miR-193b-5p  hsa-miR-431-3p   
hsa-miR-2110  hsa-miR-4314   
hsa-miR-3166  hsa-miR-450b-3p   
hsa-miR-3173-3p  hsa-miR-483-5p   
hsa-miR-3179  hsa-miR-491-5p   
hsa-miR-3189-3p  hsa-miR-497-5p   
hsa-miR-3190-5p  hsa-miR-506-3p   
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hsa-miR-3192-5p  hsa-miR-518a-5p    
*miRNA (mirBASE v.20), miRNAs are ranked numerically 
 
 
Table A4.6 HIV replication enhancing miRNA hits associated with viral carcinogenesis* 
hsa-miR-1260a  hsa-miR-34c-3p  
hsa-miR-1260b  hsa-miR-378a-5p  
hsa-miR-1271-5p  hsa-miR-3938  
hsa-miR-136-3p  hsa-miR-4318  
hsa-miR-141-5p  hsa-miR-550a-3p  
hsa-miR-188-5p  hsa-miR-576-3p  
hsa-miR-200a-5p  hsa-miR-587  
hsa-miR-200b-5p  hsa-miR-625-3p  
hsa-miR-218-1-3p  hsa-miR-649  
hsa-miR-22-3p  hsa-miR-668-3p  
hsa-miR-3171  hsa-miR-891b  
hsa-miR-335-3p   
*miRNA (mirBASE v.20), miRNAs are ranked numerically 
 
Table A4.7 miRNA targets exclusively associated with enhanced viral replication that also 
coincide with members of the viral carcinogenesis pathway 
Gene symbols (KEGG identifiers) 
CCNE2 HIST1H4L H2BFM SRF 
CHEK1 HPN HDAC6 STAT5B 
DNAJA3 JAK1 HDAC8 TRAF3 
GTF2A2 PIK3R1 HIST1H4A  
GTF2H1 PIK3R3 SP100  
 
Table A4.8 miRNA targets exclusively associated with viral carcinogenesis and 
suppressed HIV replication 
Gene symbols (KEGG identifiers) 
ATF4 GRB2 HIST1H4E PIK3CA 
ATF6B GTF2H2 HIST1H4H PIK3CB 
BAD GTF2H3 HIST1H4J PIK3R5 
CCNA1 HDAC10 HIST2H2BE PSMC1 
CCND3 HDAC11 HIST2H4A RANBP1 
CCR8 HDAC5 HLA-B RB1 
CDC42 HIST1H2BB HLA-C RBL2 
CDKN2A HIST1H2BF HLA-F SKP2 
CREB1 HIST1H2BH KAT2A SND1 
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CREB3 HIST1H2BI KAT2B SNW1 
CREB3L1 HIST1H2BJ KRAS TBPL1 
DLG1 HIST1H2BL LYN TRAF2 
EGR2 HIST1H2BO MAPK3 TRAF5 
EGR3 HIST1H4B NFKB1 USP7 
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Figure A4.2 miRNA targets associated with viral carcinogenesis and enhanced HIV 
replication.  
A) Summary of viral-host interactions relevant to HCV, HBV and EBV. B) Summary of the viral-
host interactions relevant to HPV, HTLV-I and KSHV. Host genes targeted by miRNA hits 
(orange), host genes not targeted by miRNA hits (green), viral proteins (white), proteins 
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Table A4.9 HIV-replication suppresive miRNA hits associated with cell cycle  
miRNA (mirBase v.20)* 
hsa-miR-1231  hsa-miR-431-3p  hsa-miR-4314  
hsa-miR-124-3p  hsa-miR-3190-5p  hsa-miR-450b-3p  
hsa-miR-127-5p  hsa-miR-3192-5p  hsa-miR-483-5p  
hsa-miR-1270  hsa-miR-3200-3p  hsa-miR-491-5p  
hsa-miR-1295a  hsa-miR-342-5p  hsa-miR-497-5p  
hsa-miR-1306-3p  hsa-miR-34a-3p  hsa-miR-506-3p  
hsa-miR-135b-3p  hsa-miR-3605-5p  hsa-miR-518a-5p  
hsa-miR-138-5p  hsa-miR-3616-3p  hsa-miR-520d-5p  
hsa-miR-145-3p  hsa-miR-3616-5p  hsa-miR-624-3p  
hsa-miR-192-5p  hsa-miR-3622a-5p  hsa-miR-650  
hsa-miR-193b-5p  hsa-miR-3691-5p  hsa-miR-654-5p  
hsa-miR-2110  hsa-miR-3918  hsa-miR-671-3p  
hsa-miR-3166  hsa-miR-3927-3p  hsa-miR-889-3p  
hsa-miR-3173-3p  hsa-miR-4256  hsa-miR-892b  
hsa-miR-3179  hsa-miR-4270  hsa-miR-940  
hsa-miR-3189-3p    
 
 
Table A4.10 HIV-replication enhancing miRNA hits associated with cell cycle  
miRNA (mirBase v.20) 
hsa-miR-378a-5p  hsa-miR-1271-5p  
hsa-miR-141-5p  hsa-miR-891b  
hsa-miR-22-3p  hsa-miR-576-3p  
hsa-miR-34c-3p  hsa-miR-200a-5p  
hsa-miR-188-5p  hsa-miR-218-1-3p  
hsa-miR-335-3p  hsa-miR-19b-2-5p  
hsa-miR-550a-3p  hsa-miR-668-3p  
hsa-miR-625-3p  hsa-miR-3171  
hsa-miR-1260b  hsa-miR-200b-5p  
hsa-miR-4318  hsa-miR-3938  
hsa-miR-1260a  hsa-miR-136-3p  
 
Table A4.11 miRNA hits exclusively associated with cell cycle and enhanced HIV 
replication 
Gene symbols (KEGG identifiers) 
ATR CDC6 CUL1 TFDP2 







Table A4.12 miRNA hits exclusively associated with cell cycle and suppressed HIV 
replication 
Gene symbols (KEGG identifiers) 
ANAPC1 CDC14B FZR1 PTTG2 
ANAPC13 CDC27 MAD2L1 RB1 
ANAPC4 CDKN2A MAD2L2 RBL2 
CCNA1 CDKN2D ORC1 SKP2 
CCNB1 DBF4 ORC5 TFDP1 
CCND3 E2F4 PCNA TTK 





Figure A4.3 Cytoskeletal-associated functional processes enriched for miRNA hits that 
suppress HIV replication. 
Regulation of the actin cytoskeleton including signalling cascades related to focal adhesions, 
stress fibres, cellular extensions and adherens junctions. Genes targeted by miRNA hits (orange), 
genes not targeted by miRNA hits (green), bacterial protein (white).  
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Table A4.13 miRNA hits exclusively associated with regulation of actin cytoskeleton and 
suppressed HIV replication 
Gene symbols (KEGG identifiers) 
APC FGF18 MYLK 
ARAF FGF23 MYLK4 
ARHGEF1 FGF7 NCKAP1 
ARPC4 FGFR1 PAK3 
ARPC5L GNA12 PIK3CA 
BDKRB1 GNA13 PIK3CB 
BDKRB2 ITGA1 PIK3R5 
CDC42 ITGA10 PIP4K2C 
CHRM2 ITGA3 PIP5K1B 
CYFIP2 ITGAL PPP1CA 
DIAPH2 ITGAX PPP1R12B 
DOCK1 ITGB3 PTK2 
F2R ITGB4 RAC2 
FGD1 KRAS ROCK1 
FGF1 LIMK1 RRAS 
FGF10 LIMK2 RRAS2 
FGF11 MAP2K1 SLC9A1 
FGF12 MAPK3 SSH2 
FGF14 MYL2 TIAM1 
FGF16 MYL9 WASL 
 
 
Table A4.14 miRNA hits exclusively associated with regulation of actin cytoskeleton and 
enhanced HIV replication 


















Table A4.15 HIV-suppressive miRNA hits associated with regulation of the  actin 
cytoskeleton pathway* 
hsa-miR-1231  hsa-miR-431-3p  hsa-miR-483-5p  
hsa-miR-124-3p  hsa-miR-3190-5p  hsa-miR-491-5p  
hsa-miR-127-5p  hsa-miR-3192-5p  hsa-miR-497-5p  
hsa-miR-1270  hsa-miR-3200-3p  hsa-miR-506-3p  
hsa-miR-1295a  hsa-miR-342-5p  hsa-miR-518a-5p  
hsa-miR-1306-3p  hsa-miR-34a-3p  hsa-miR-520d-5p  
hsa-miR-135b-3p  hsa-miR-3605-5p  hsa-miR-624-3p  
hsa-miR-138-5p  hsa-miR-3616-3p  hsa-miR-650  
hsa-miR-145-3p  hsa-miR-3616-5p  hsa-miR-654-5p  
hsa-miR-192-5p  hsa-miR-3622a-5p  hsa-miR-671-3p  
hsa-miR-193b-5p  hsa-miR-3691-5p  hsa-miR-889-3p  
hsa-miR-2110  hsa-miR-3918  hsa-miR-892b  
hsa-miR-3166  hsa-miR-3927-3p  hsa-miR-940  
hsa-miR-3173-3p  hsa-miR-4256   
hsa-miR-3179  hsa-miR-4270   
hsa-miR-3189-3p  hsa-miR-4314   
*miRNA (mirBASE v.20), miRNAs are ranked numerically 
 
Table A4.16 HIV replication enhancing miRNA hits associated with regulation of the actin 
cytoskeleton pathway* 
hsa-miR-1260a  hsa-miR-335-3p  
hsa-miR-1260b  hsa-miR-34c-3p  
hsa-miR-1271-5p  hsa-miR-378a-5p  
hsa-miR-136-3p  hsa-miR-3938  
hsa-miR-141-5p  hsa-miR-4318  
hsa-miR-188-5p  hsa-miR-550a-3p  
hsa-miR-200a-5p  hsa-miR-576-3p  
hsa-miR-200b-5p  hsa-miR-587  
hsa-miR-218-1-3p  hsa-miR-625-3p  
hsa-miR-22-3p  hsa-miR-649  
hsa-miR-2277-5p  hsa-miR-668-3p  
hsa-miR-3171  hsa-miR-891b  













Table A4.17 HIV-suppressive miRNA hits associated with the Hippo signalling pathway* 
hsa-miR-1231  hsa-miR-3605-5p  
hsa-miR-124-3p  hsa-miR-3616-5p  
hsa-miR-1269a  hsa-miR-3622a-5p  
hsa-miR-127-5p  hsa-miR-3691-5p  
hsa-miR-1270  hsa-miR-383-5p  
hsa-miR-1273e  hsa-miR-3918  
hsa-miR-1295a  hsa-miR-3927-3p  
hsa-miR-1306-3p  hsa-miR-4256  
hsa-miR-135b-3p  hsa-miR-4270  
hsa-miR-138-5p  hsa-miR-431-3p  
hsa-miR-145-3p  hsa-miR-4314  
hsa-miR-192-5p  hsa-miR-483-5p  
hsa-miR-193b-5p  hsa-miR-491-5p  
hsa-miR-2110  hsa-miR-497-5p  
hsa-miR-3166  hsa-miR-518a-5p  
hsa-miR-3173-3p  hsa-miR-520d-5p  
hsa-miR-3179  hsa-miR-624-3p  
hsa-miR-3189-3p  hsa-miR-650  
hsa-miR-3190-5p  hsa-miR-654-5p  
hsa-miR-3192-5p  hsa-miR-671-3p  
hsa-miR-3200-3p  hsa-miR-889-3p  
hsa-miR-342-5p  hsa-miR-892b  
hsa-miR-34a-3p  hsa-miR-940  
*miRNA (mirBASE v.20), miRNAs are ranked numerically 
 
Table A4.18 HIV-replication enhancing miRNA hits associated with the  Hippo signalling 
pathway* 
hsa-miR-625-3p  hsa-miR-1271-5p  
hsa-miR-218-1-3p  hsa-miR-378a-5p  
hsa-miR-34c-3p  hsa-miR-587  
hsa-miR-335-3p  hsa-miR-3938  
hsa-miR-668-3p  hsa-miR-4318  
hsa-miR-22-3p  hsa-miR-136-3p  
hsa-miR-1260b  hsa-miR-891b  
hsa-miR-576-3p  hsa-miR-550a-3p  
hsa-miR-1260a  hsa-miR-200a-5p  
242 
hsa-miR-141-5p  hsa-miR-200b-5p  
hsa-miR-188-5p  hsa-miR-2277-5p  




Table A4.19 miRNA hits exclusively associated with Hippo signalling and enhanced HIV 
replication 
Gene symbols (KEGG identifiers) 
FZD8 AXIN2 BMP7 
SMAD4 PPP2R1A WNT7B 
 
 
Table A4.20 miRNA hits exclusively associated with Hippo signalling and suppressed HIV 
replication 
Gene symbols (KEGG identifiers) 
WTIP TCF7L2 ID2 CRB2 
WNT9A TCF7L1 ID1 CRB1 
WNT8B TCF7 GLI2 CCND3 
WNT7A STK3 GDF6 BMPR1B 
WNT5B SNAI2 FZD7 BMPR1A 
WNT4 SAV1 FZD5 BMP6 
WNT3 RASSF6 FZD1 BMP5 
WNT2B RASSF1 FGF1 BMP2 
WNT16 PPP2CB DVL3 BBC3 
TP73 PPP1CA DVL2 APC 
TP53BP2 NF2 DVL1  
TGFBR2 LLGL2 DLG4  
TEAD4 LLGL1 DLG3  
TEAD3 LIMD1 DLG1  





Figure A4.4 Effect of Nutlin-3 treatment on HIV replication 
GHOST(3) cells, were treated with either variable concentrations of the MDM2-inhibitor Nutlin-3 
or DMSO for 24hr prior to HIV exposure. Cells were fixed, processed and imaged at 48 hpi. 
Images were  acquired on the IXU at 20x,  n=2. 
 
Figure A4.5 siRNA-mediated knockdown of lincRNA-p21 
qPCR analysis of LincRNA-p21 transcript levels 24 hr post-transfection with si-LincRNA-p21 
(25nM). Expression levels normalized against reference gene HPRT, * = p<0.05, n=3.   
 
 

































Figure A4.6 HCS HIV-suppressive miRNA hits that did not inhibit HIV Gag-iGFP replication 
A) HIV-suppressive miRNA hits that were not effective against X4-tropic HIV variant, B) HIV 
replication enhancing hit, miR-34c-3p, exhibited elevated GFP signal output. miR-1200 (which 
was below the hit selection cut off) exhibited a heightened rate of syncytia formation (circularised 
polynucleated structures). Images represent overlays of single FOVs acquired at 20x in the 405 
and 488 excitation channels. Nuclei counterstained with Hoechst (red), HIV iGag-GFP/ LTR 





Oncology drug panel: 10 µM raw data plots 
 
Specific well locations within the oncology screen datasets exhibited seemingly biased 
distributions as a direct result of the small number of experimental plates (n = 3), and the drug-
associated cellular toxicities of many compounds in the oncology panel (Figure A5.1 & A5.3).. 
The biased distribution plots were confirmed by a comparison of the pre- and post-HIV exposure 





HIV and ‘drug only’ datasets, resulting in reformed distribution plots (Figure A5.2).  Apart from this 
issue, the general data distribution trends were very similar to those of the Kinase panel drug 




Figure A5.1 Unprocessed data distribution plots for all replicates of ‘pre-HIV exposure’ 
Oncology panel (10µM). 
A) Scatterplot representing the distribution of individual experimental controls and treatments 
across three screen replicates in relation to the extracted Total Cell Area feature scores. No 
significant variability in Total cell area was noted between the positive (green) and negative (red) 
controls. Experimental treatments (blue) exhibited a broad distribution range, notably below the 
Raw Data:pre-HIV Oncology Set screen 
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lower limits of phenotypic controls. B) Box plot representing the average Total Cell Area scores 
obtained for specific well locations across all experimental plates and replicates. Negative (red) 
and positive (green) control well locations exhibited consistent distribution ranges that were not 
distinct from each other. Well locations corresponding to experimental treatments  exhibited 
broader distribution ranges exceeding those of the phenotypic controls. C) Scatterplot 
representing the distribution of individual experimental control and treatment wells across three 
screen replicates in relation to the extracted inTotalGFP feature scores. Positive (green) and 
negative (red) controls exhibited distinct distribution ranges from each other. Experimental wells 
(blue) exhibited broader distribution ranges below the lower limits of negative controls. D) Box 
plot representing the average InTotalGFP scores obtained for specific well locations across all 
experimental plates and replicates. Negative (red) and positive (green) control well locations 
exhibited consistent and distinct distribution ranges. Well locations corresponding to experimental 





Figure A5.2 Unprocessed data distribution plots for all replicates of ‘post-HIV exposure’ 
Oncology panel (10µM). 
A) Scatterplot representing the distribution of individual experimental controls and treatments 
across three screen replicates in relation to the extracted Total Cell Area feature scores. The 
positive (green) and negative (red) controls exhibited noticeable but nonsignificant variation in 
their respective distribution ranges. Experimental wells (blue) exhibited a broad distribution range 
beyond the upper and lower limits of phenotypic controls. B) Box plot representing the average 
Total Cell Area scores obtained for specific well locations across all experimental plates and 
replicates. Negative (red) and positive (green) control well locations exhibited consistent and tight 
distribution ranges. Well locations corresponding to experimental treatments exhibited broad 
distribution ranges exceeding those of phenotypic controls. C) Scatterplot representing the 
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distribution of individual experimental control and treatment wells across three screen replicates 
in relation to the extracted inTotalGFP feature scores. Positive (green) and negative (red) controls 
exhibited distinct distribution ranges. Experimental wells (blue) revealed broader distribution 
ranges, mostly below the lower limits of negative controls. D) Box plot representing the average 
InTotalGFP scores obtained for specific well locations across all experimental plates and 
replicates. Negative (red) and positive (green) control well locations exhibited consistent and 
distinct distribution ranges. Well locations corresponding to experimental treatments exhibited 





Figure A5.3 Unprocessed data distribution plots for all replicates of ‘Drug Only’ Oncology 
panel (10µM) based on Total Cell Area feature scores 
A) Scatterplot representing the distribution of individual negative controls and treatments across 
three screen replicates in relation to the extracted Total Cell Area feature scores. Negative 
controls located on the left (red) and right (red) halves of experimental plates did not differ in their 
distribution ranges. Experimental treatments (green) exhibited a broad distribution range, 
predominantly below the lower limits of negative controls. B) Box plot representing the average 
Total Cell Area scores obtained for specific well locations across all experimental plates and 
replicates. Negative control well locations (red and blue) exhibited consistent and tight distribution 
ranges irrespective of their positions on experimental plates. Well locations corresponding to 
experimental treatments (green) exhibited broad distribution ranges exceeding those of 
phenotypic controls, with biased distributions for specific well locations.  
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Figure A5.4 Normalised feature plots for Oncology drug panel screens 
A) Normalised Total cell Area distribution plots for pre-HIV and post-HIV treatment screens at 10 
µM, 1 µM and 100 nM treatment concentrations. B)  Normalised inTotalGFP distribution plots for 
pre-HIV and post-HIV treatment screens at 10 µM, 1 µM and 100 nM treatment concentrations. 
C) Normalised Total cell Area distribution plots for Drug only screens at 10 µM, 1 µM and 100 nM 
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Figure A5.5 Example of factors utilised for hit selection in Kinase 10 µM drug panel 
screens. 
Single factor indicators PCA-based data reduction (A,C) while two factors indicate an MDS-based 




Figure A5.6 EGFR western blot analysis.  
A) Replicate Western Blot gels stained for EGFR obtained from cytoplasmic and B) whole cell 
lysate fractions. C) Similar Western blot data obtained from nuclear fraction. Histone H3 was 
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Figure A5.7 Additional enlarged images from HIV-tropism validation experiments 
Upper) 10 µM A-674563 treatment phenotype. Lower) 10 µM AT7519 treatment. White arrows 
indicate examples of cells where HIV capsid/virions are present in either the cytoplasm, or at the 
cell surface. Pink arrows indicate examples of stably infected cells. Images represent overlays 
acquired from a single FOV at 40x, GFP-HIV capsid/ LTR-reporter (green), nuclei counterstained 
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